<?xml version='1.0' encoding='UTF-8' ?>
<Trials_downloaded_from_ICTRP>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12554217
    </Internal_Number>
    <TrialID>NCT05538299
    </TrialID>
    <Last_Refreshed_on>3 October 2022
    </Last_Refreshed_on>
    <Public_title>Silicosis Treatment, Action, Screening and Surveillance in Rwanda Trials
    </Public_title>
    <Scientific_title>Silicosis Prevalence and Related Knowledge, Attitudes and Practices Among Mine Workers in Rural Rwanda
    </Scientific_title>
    <Acronym>STARSS
    </Acronym>
    <Primary_sponsor>Samuel Hatfield
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220908
    </Date_registration3>
    <Date_registration>08/09/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05538299
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 31, 2022
    </Date_enrollement>
    <Target_size>995
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Innocent Kamali;Robert Tumusime;Robert Tumusime
    </Contact_Lastname>
    <Contact_Email>;rtumusime@pih.org;rtumusime@pih.org
    </Contact_Email>
    <Contact_Tel>;250788597448;
    </Contact_Tel>
    <Contact_Affiliation>Partners in Health;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Miners with greater than 1 year of potential exposure to respirable crystalline silica&#x0D;&lt;br&gt;             within the defined catchment area of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  non-mining (administrative, low risk of exposure) workers within the WOLFRAM (mining&#x0D;&lt;br&gt;             company) catchment area&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Silicosis;Silicotic Fibrosis (Massive) of Lung
    </Condition>
    <Intervention>Behavioral: questionnaire, KAP
    </Intervention>
    <Primary_outcome>Silicosis Prevalence
    </Primary_outcome>
    <Secondary_outcome>Questionnaire Validation;Knowledge, Action, Prevelence
    </Secondary_outcome>
    <Secondary_ID>IMB-sil1
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12602940
    </Internal_Number>
    <TrialID>PACTR202208726145272
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Improving Cervical Cancer Screening and Patient Navigation Using the Smartphone-Enhanced VIA (SEVIA) Program
    </Public_title>
    <Scientific_title>Accelerated Adoption of Improved Technology in Cervical Cancer Prevention and Patient Navigation: Smartphone-Enhanced VIA (SEVIA) Program                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Queens University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220824
    </Date_registration3>
    <Date_registration>24/08/2022
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=23945
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>44 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>01/12/2022
    </Date_enrollement>
    <Target_size>4000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously,Randomised,Stratified allocation where factors such as age, gender, center, or previous treatment are used in the stratification,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Phase-3
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>Melinda
    </Contact_Firstname>
    <Contact_Lastname>Chelva
    </Contact_Lastname>
    <Contact_Address>98 Stuart Street
    </Contact_Address>
    <Contact_Email>16mc3@queensu.ca
    </Contact_Email>
    <Contact_Tel>6477461491
    </Contact_Tel>
    <Contact_Affiliation>Graduate Student
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Includes women aged 30-65 years or 25-65 years if HIV+.&#x0D;&lt;br&gt;Includes women attending their local reproductive health facility for routine care, including cervical cancer screening as part of a screening campaign, or who were receiving care in an HIV clinic.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Includes women younger than 25 and older than 65 years old.
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Cancer;Cancer
    </Condition>
    <Intervention>;Enhanced Usual Care;Nurse Navigation;App Navigation;Community Navigation
    </Intervention>
    <Primary_outcome>Completion of designated screening and treatment pathway (‘navigation passport’) in the SEVIA platform for each client based on HIV status, +/-HPV DNA status and type of cervical lesion.;Increased awareness for health care providers and RBC of overdiagnosis and overtreatment due to unsupported VIA in Bugesera district.;SEVIA-assisted VIA integrated into district health services.;More women with pre-cancerous lesions are accurately detected and treated.;Reduced LTFU among women receiving SEVIA-based navigation compared to standard screening practices.;Decrease in women with recurrent or residual disease.
    </Primary_outcome>
    <Secondary_outcome>Mixed-methods evaluation of implementation outcomes including acceptability, adoption, feasibility, fidelity, and cost of SEVIA program integration compared with current standard of care.
    </Secondary_outcome>
    <Source_Support>Southeastern Ontario Academic Medical Association;TogetHER Cervical Cancer Grant from Bio Ventures for Global Health
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>06/06/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>info@rnecrwanda.org
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Rwanda National Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+250788592004
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>info@rnecrwanda.org
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12529083
    </Internal_Number>
    <TrialID>NCT05516056
    </TrialID>
    <Last_Refreshed_on>12 September 2022
    </Last_Refreshed_on>
    <Public_title>ERAS After Cholecystectomy in Kigali, Rwanda
    </Public_title>
    <Scientific_title>Enhanced Recovery After Surgery Program in a Low and Middle-income Country: Feasibility, Safety, Patient's Acceptance, Reduction of the Length of Hospital Stay, Bed Turnover and Cost Benefits for Laparoscopic Cholecystectomy at CHUK
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Olivier Detry MD PhD
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220818
    </Date_registration3>
    <Date_registration>18/08/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05516056
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>16 Years
    </Inclusion_agemin>
    <Inclusion_agemax>100 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2022
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Olivier Detry, MD PhD;Martin Nyundo, MD;Martin Nyundo, MD
    </Contact_Lastname>
    <Contact_Email>;nyundomartin@gmail.com;nyundomartin@gmail.com
    </Contact_Email>
    <Contact_Tel>;+250788418727;+250788418727
    </Contact_Tel>
    <Contact_Affiliation>University of Liege;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All adult patients undergoing scheduled elective laparoscopic cholecystectomy in CHUK,&#x0D;&lt;br&gt;             Rwanda&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signed informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  acute cholecystitis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ASA IV patients&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  absence of consent&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>ERAS;Gall Bladder Disease
    </Condition>
    <Intervention>Other: ERAS clinical pathway
    </Intervention>
    <Primary_outcome>Length of hospital stay;Rate of Postoperative complications
    </Primary_outcome>
    <Secondary_outcome>Cost of laparoscopic cholecystectomy;Patient satisfaction measured with the Satisfaction Likert Scale (SLS)
    </Secondary_outcome>
    <Secondary_ID>EC/CHUK/074/2021
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Rwanda
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12354810
    </Internal_Number>
    <TrialID>NCT05405400
    </TrialID>
    <Last_Refreshed_on>13 June 2022
    </Last_Refreshed_on>
    <Public_title>The Sugira Muryango Longitudinal &amp; Spillover Study
    </Public_title>
    <Scientific_title>Understanding Longer-term Effects of a Father-engaged, Play-based Home Visiting Intervention to Promote Early Childhood Development and Prevent Violence in Rwanda: The Sugira Muryango Longitudinal &amp; Spillover Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Boston College
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220527
    </Date_registration3>
    <Date_registration>27/05/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05405400
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>3 Months
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 20, 2022
    </Date_enrollement>
    <Target_size>3082
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Theresa S Betancourt, ScD, MA;Theresa S Betancourt, ScD, MA
    </Contact_Lastname>
    <Contact_Email>;theresa.betancourt@bc.edu
    </Contact_Email>
    <Contact_Tel>;617-552-8406
    </Contact_Tel>
    <Contact_Affiliation>Boston College;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Participated in the Sugira Muryango CRT in 2018-19 (Trial Registration Number NCT02510313).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Family inclusion criteria for the CRT were:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  living in the Rubavu, Ngoma or Nyanza District of Rwanda&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  being VUP-eligible (according to the Rwandan government)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  having at least one child aged 6-36 months living in the home&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  having at least one caregiver who was willing to discuss and enhance their caregiving&#x0D;&lt;br&gt;             practices by interacting with a home-visiting coach (a community-based volunteer or&#x0D;&lt;br&gt;             CBV).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Further caregiver inclusion criteria were:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  was aged 18 or older and cared for child(ren)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  lived in the same household as the child(ren). For the current Longitudinal Study,&#x0D;&lt;br&gt;             inclusion criteria for families are&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  having participated in the prior CRT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  living in Ngoma, Nyanza, or Rubavu districts&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  having at least one child who participated in the CRT and who is currently living in&#x0D;&lt;br&gt;             the household.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion criteria for younger siblings are:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  aged 3 months or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  was not eligible to participate in the original CRT due to age (below 6 months or not&#x0D;&lt;br&gt;             yet born at the time of CRT).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion criteria for older siblings are:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  aged 12 years or younger&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  lived in the household but was not eligible to participate in the original CRT due to&#x0D;&lt;br&gt;             age (above 36 months at the time of CRT)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  currently lives in the household that participated in the CRT.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Other than not meeting inclusion criteria, specific family exclusion criteria for the CRT&#x0D;&lt;br&gt;        were:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  caregiver(s) having severe cognitive impairments which precluded their ability to&#x0D;&lt;br&gt;             speak to the research questions under study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  families or caregivers being in the midst of crisis (e.g., a caregiver(s) with active&#x0D;&lt;br&gt;             suicidal attempts or psychosis). Families with ongoing crises or disabilities were&#x0D;&lt;br&gt;             excluded from the study and were referred to appropriate services.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  These exclusion criteria remain the same for the current Longitudinal study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Siblings will be excluded from sampling for the spillover study if the primary&#x0D;&lt;br&gt;             caregiver has been away from the household for six months or more.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cognitive Change;Growth; Stunting, Nutritional;Language;Depression;Behavior;Violence;Parenting
    </Condition>
    <Primary_outcome>"Home Observation Measurement of the Environment" infants/toddlers survey and early childhood survey;"Ages &amp; Stages Questionnaire - 3";"Mullen Scale of Early Learning";"Kaufman Assessment Battery for Children-2";"Wechsler Preschool &amp; Primary Scale of Intelligence";"International Development &amp; Early Learning Assessment" stimulating care and play module;"Multiple Indicator Cluster Survey" child discipline module;Combined module based on "Multiple Indicator Cluster Survey" and "ISPCAN Child Abuse Screening Tool";DHS "Intimate Partner Violence" survey;"Child Behavior Checklist"
    </Primary_outcome>
    <Secondary_outcome>"Observation of Mother-Child Interactions";"The Role of Play in Children's Learning";"Parental Acceptance-Rejection Questionnaire";DHS/Promundo "Father Engagement &amp; Financial Decision-Making" survey;"Gender Equitable Men" scale;"Multiple Indicator Cluster Survey (5)" WASH module;World Health Organization "Infant and Young Child Feeding Practices" survey;"Hopkins Symptom Checklist (25)";"Enrollment in early education" survey;"Child Enrollment in Formal Education" survey;"Service utilization" survey;Anthropometric measures: height in centimeters;"Preschool Self-Regulation Assessment";"Infant Behavior Questionnaire";"Early Childhood Behavior Questionnaire";"Early Grade Reading Assessment";"Center for Epidemiological Studies Depression Scale";"Gender Equitable Men" scale;Anthropometric measures: weight in kilograms;Anthropometric measures: standardized height-for-weight;Anthropometric measures: standardized height-for-age;Anthropometric measures: middle upper arm circumference in centimeters
    </Secondary_outcome>
    <Secondary_ID>22.198.01
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Rwanda;FXB-Rwanda;LEGO Foundation;The ELMA Foundation;Echidna Giving;Wellspring Philanthropic Fund;United States Agency for International Development (USAID)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12635082
    </Internal_Number>
    <TrialID>ISRCTN16610902
    </TrialID>
    <Last_Refreshed_on>31 October 2022
    </Last_Refreshed_on>
    <Public_title>Improving antenatal care using WHO recommendations: an implementation research study in Africa and India
    </Public_title>
    <Scientific_title>Implementation research on the WHO Antenatal Care Guidelines adapted to country context for improved quality of care – India &amp; Burkina Faso, and implementation research on the WHO Antenatal Care Guidelines adapted to country context: Enhanced quality service delivery through a digitalized module – Rwanda &amp; Zambia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>World Health Organization
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220527
    </Date_registration3>
    <Date_registration>27/05/2022
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN16610902
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>17/06/2022
    </Date_enrollement>
    <Target_size>37440
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>A mixed methods stepped-wedge cluster randomized design implementation trial with nested cohort study (Prevention)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Burkina Faso;India;Rwanda;Zambia
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Health-workers at selected facilities.&lt;br&gt;                2. Women presenting for their first ANC contact who provide consent.&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Health facilities where the management does not agree to participate in the study.&lt;br&gt;                2. Pregnant women who do not provide consent (all study components).&lt;br&gt;                3. Health workers who do not consent (qualitative components).&lt;br&gt;                4. Women who do not reside in the catchment area of selected health care facilities. (India)&lt;br&gt;                5. Women who also sought ANC services from non-public health platforms like private sector providers (Rwanda).&lt;br&gt;                6. For the cohort study component in Burkina Faso and India, women at more than 16- or 20-weeks gestation, respectively, will be excluded.&lt;br&gt;                7. For the cohort study, women with pre-identified complications will be excluded.&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>antenatal care &lt;br&gt;Pregnancy and Childbirth
    </Condition>
    <Intervention>&lt;br&gt;                The study has two main intervention layers:&lt;br&gt;                1. The first layer is the ANC package adapted by each country or state (in India the study will be conducted in Assam and Tamil Nadu states only),&lt;br&gt;                2. The second layer are the co-interventions to support the implementation of the ANC package.&lt;br&gt;&lt;br&gt;                A logic model was developed to specify the components of the co-interventions being&lt;br&gt;                investigated, and how they are proposed, or hypothesized, to ‘work’ to bring about changes in ANC service delivery (including improving implementation of the adapted ANC guidelines) and uptake. This was done by drawing on a model of behaviour change - the Capability Opportunity Motivation-Behaviour (COM-B). The model was employed to conceptualize and describe the behaviour change targeted by the co-interventions. COM-B purports that there are three necessary conditions for a desired behaviour to occur: 1) the person’s psychological and physical ability to perform it (capability - i.e. having the necessary knowledge and skills), 2) their reflective and automatic mechanisms which “energize” or prevent it (motivation - i.e. strong intention to perform the behaviour, perceived importance, priority, advantages and disadvantages) and 3) the external social and environmental Opportunity which enable or inhibit it (opportunity - i.e. available resources, team culture and working, norms). The logic model for the present study specifies which&lt;br&gt;                barriers and enablers (identified in a Qualitative Evidence Synthesis from the Cochrane review) within each domain of Capability, Opportunity, Motivation the selected co-interventions aim to address.&lt;br&gt;&lt;br&gt;                The updated national/state ANC packages are based on the WHO 2016 
    </Intervention>
    <Primary_outcome>&lt;br&gt;                Quantitative data (adherence &amp; early initiation of ANC)&lt;br&gt;                The primary outcomes or indicators of interest, which will be measured for assessing the impact of national/state specific packages, vary across each country:&lt;br&gt;                1. Syphilis testing at first contact/during pregnancy&lt;br&gt;                2. ANC 1 within 12 weeks&lt;br&gt;                3. 8 ANC contacts&lt;br&gt;                4. IFA consumption for 90+ days&lt;br&gt;                5. Hemoglobin (Hb) screened at first ANC contact&lt;br&gt;                6. Total number of ANC contacts&lt;br&gt;                7. BP measurement at 1st contact&lt;br&gt;&lt;br&gt;                Qualitative data (acceptability)&lt;br&gt;                Additionally, the research team will develop measures based on qualitative data gathered from health workers and women, to gauge acceptability of the national/state-ANC package and its component. To understand whether the adapted state-specific ANC packages are acceptable to and create value for women as well as health care providers, we will collect and analyze qualitative data. Qualitative components will entail in-depth interviews and focus group discussions with purposively identified participants from stakeholder groups. The stakeholder groups that are relevant for this study objective vary across each country:&lt;br&gt;                1. Pregnant women who seek ANC at selected facilities or within the selected facilities' catchment areas.&lt;br&gt;                2. Husbands or mothers-in-law (household decision maker) from the selected catchment areas.&lt;br&gt;                3. Selected community representatives or champions for maternal health.&lt;br&gt;                4. Health workers providing ANC services at selected facilities or within catchment area of the selected facilities.&lt;br&gt;                5. Health facility managers of selected facilities&lt;br&gt;                6. Health workers providing ANC services at selected facilities using the ANC digital tool&lt;br&gt;                7. Community health workers rendering services within catchment area of selected health facilities.&lt;br&gt;                8. Government health officials (program managers) managing the maternal health program at district/state or national level.&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                The secondary outcomes or indicators of interest, which will be measured for assessing the impact of national/state-specific packages, vary across each country (for India and Burkina Faso, some of these outcomes will be measured from the embedded cohort study only):&lt;br&gt;                1. Ultrasound scan before 24 weeks&lt;br&gt;                2. HB check at 1st contact&lt;br&gt;                3. Tested/screened for maternal infections early in pregnancy&lt;br&gt;                4. BP, and weight checked at least once during pregnancy/in each trimester&lt;br&gt;                5. IFA consumption for 90+ days&lt;br&gt;                6. Preventive anthelminthic treatment&lt;br&gt;                7. Gestational weight gain during pregnancy&lt;br&gt;                8. Tested for GDM in pregnancy&lt;br&gt;                9. Screening for Anemia at ANC 1&lt;br&gt;                10. Screening for Malnutrition at ANC 1&lt;br&gt;                11. &gt;8 ANC contacts&lt;br&gt;                12. 4 ANC contacts&lt;br&gt;                13. IPTp treatment for malaria (all three doses)&lt;br&gt;                14. Women diagnosed with maternal infections (HIV, malaria, TB, hepatitis) initiated on treatment&lt;br&gt;                15. Women diagnosed with GDM in pregnancy initiated on treatment&lt;br&gt;&lt;br&gt;                Training and supervision needs will be documented and evaluated through the monitoring of the co-interventions. The implementation of the updated national/state level ANC package of interventions will further document the implementation of the programme to understand to what extent the co-interventions were performed as intended and factors that inhibited or promoted effectiveness. Project officers will conduct facility readiness assessments at all the study sites using a standard process evaluation form for monitoring at the beginning of each study period. The evaluation form will include items for measuring the readiness of study facilities in terms of drugs, equipment, laboratory reagents, testing kits, etc., in addition to training and supervision needs. This will be done through analysis of data that will be collected for monitoring the implementation of adapted packages using an adapted version of WHO Programme Reporting Standards.&lt;br&gt;&lt;br&gt;                Costing data will also be gathered during the cohort study exit interviews with pregnant women. The cost per contact will be estimated through exit interviews with beneficiaries captured, as part of the main evaluation. Direct costs are anticipated to include all out of pocket costs incurred in seeking ANC, including consultation fees, transportation costs, medicine and other supply costs. Indirect costs will additionally be assessed including wages lost and child-care costs as a result of time spent seeking ANC. Additionally, economic costs incurred by implementing partners will be tracked prospectively.&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;A66008
    </Secondary_ID>
    <Source_Support>Bill and Melinda Gates Foundation
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>
                    1. Approved 21/06/2021, Ethical Review Committee of the World Health Organization (WHO, Avenue Appia 20, 1211 Geneva, Switzerland; +41 22 791 21 11; ercsec@who.int), ref: A66008

                    Other approvals gained from:
                    2. Research Project Review Panel (RP2) of the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP)
                    3. Burkina Faso’s Ministry of Health’s 
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>15/08/2024
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12536838
    </Internal_Number>
    <TrialID>NCT05414786
    </TrialID>
    <Last_Refreshed_on>19 September 2022
    </Last_Refreshed_on>
    <Public_title>A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644)
    </Public_title>
    <Scientific_title>A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) in HIV-1 Uninfected Adults in Good General Health
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>International AIDS Vaccine Initiative
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220526
    </Date_registration3>
    <Date_registration>26/05/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05414786
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>50 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 26, 2022
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 1
    </Phase>
    <Countries>Rwanda;South Africa;Rwanda;South Africa
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Healthy adults as assessed by a medical history, physical examination, and laboratory&#x0D;&lt;br&gt;             tests who are at least 18 years at the time of screening and less than 51 years at the&#x0D;&lt;br&gt;             time of first IP administration;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Willing to comply with the requirements of the protocol and be available for follow-up&#x0D;&lt;br&gt;             for the planned duration of the study;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. In the opinion of the PI or designee and based on Assessment of (informed consent)&#x0D;&lt;br&gt;             Understanding (AOU) results, has understood the information provided and potential&#x0D;&lt;br&gt;             impact and/or risks linked to IP administration and participation in the study;&#x0D;&lt;br&gt;             written informed consent will be obtained from the participant before any&#x0D;&lt;br&gt;             study-related procedures are performed;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Willing to undergo HIV testing, risk reduction counselling and receive HIV test&#x0D;&lt;br&gt;             results;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. All women of reproductive potential who are engaging in sexual activity that could&#x0D;&lt;br&gt;             lead to pregnancy must commit to use an effective method of contraception at least 4&#x0D;&lt;br&gt;             weeks prior to the first IP administration and for 4 months following the last IP&#x0D;&lt;br&gt;             administration. Effective contraception includes:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Intrauterine device&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Hormonal contraception, including contraceptive implant or injectable&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Successful vasectomy in the male partner (considered successful if a woman&#x0D;&lt;br&gt;                  reports that a male partner has documentation of azoospermia by microscopy [1&#x0D;&lt;br&gt;                  year ago], or a vasectomy more than 2 years ago with no resultant pregnancy&#x0D;&lt;br&gt;                  despite sexual activity post vasectomy)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Not of reproductive potential, such as having undergone hysterectomy, bilateral&#x0D;&lt;br&gt;                  oophorectomy or tubal ligation, postmenopausal (=45 years of age with amenorrhea&#x0D;&lt;br&gt;                  for at least 2 years, or any age with amenorrhea for at least 6 months and a&#x0D;&lt;br&gt;                  serum follicle stimulating hormone (FSH) level &gt;40 IU/L), surgically sterile&#x0D;&lt;br&gt;                  Note: More restrictive measures may be required by the study sites.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. All participants born female who are not heterosexually active at screening must agree&#x0D;&lt;br&gt;             to utilize an effective method of contraception if they become heterosexually active&#x0D;&lt;br&gt;             as outlined above;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. All participants born female must be willing to undergo urine pregnancy tests at time&#x0D;&lt;br&gt;             points indicated in the Schedule of Activities (SOAs) (APPENDIX A or APPENDIX B);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. All sexually active participants born male, regardless of reproductive potential, must&#x0D;&lt;br&gt;             be willing to use an effective method of contraception (such as consistent condom use)&#x0D;&lt;br&gt;             from the day of the first IP administration until at least 4 months after the last IP&#x0D;&lt;br&gt;             administration; Note: For Center for Family Health Research (CFHR) site, males in&#x0D;&lt;br&gt;             monogamous relationships whose partners are on a documented and effective&#x0D;&lt;br&gt;             contraceptive method will be exempt from this requirement.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Willing to forgo donations of blood, or any other tissues during the study and, for&#x0D;&lt;br&gt;             those who test HIV-positive due to IP-induced antibodies, until the anti-HIV antibody&#x0D;&lt;br&gt;             titers become undetectable.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Positive test for HIV-1 or HIV-2 infection;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Any clinically relevant abnormality on history or examination, including history of&#x0D;&lt;br&gt;             immunodeficiency or autoimmune disease; use of systemic corticosteroids (the use of&#x0D;&lt;br&gt;             topical or inhaled steroids is permitted), immunosuppressive, anticancer,&#x0D;&lt;br&gt;             antituberculosis or other medications considered significant by the Investigator&#x0D;&lt;br&gt;             within the previous 6 months; Note: The following exceptions are permitted and will&#x0D;&lt;br&gt;             not exclude study participation: use of corticosteroid nasal spray for rhinitis,&#x0D;&lt;br&gt;             topical corticosteroids for an acute uncomplicated dermatitis; or a short course&#x0D;&lt;br&gt;             (duration of 10 days or less, or a single IP administration) of corticosteroid for a&#x0D;&lt;br&gt;             non-chronic condition (based on Investigator clinical judgment) at least 2 weeks prior&#x0D;&lt;br&gt;             to enrolment in this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Any clinically significant acute or chronic medical condition that is considered&#x0D;&lt;br&gt;             progressive or in the opinion of the Investigator makes the participant unsuitable for&#x0D;&lt;br&gt;             participation in the study;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. History of substance abuse or alcohol abuse;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Reported behaviour that puts the participant at risk for HIV infection within 6 months&#x0D;&lt;br&gt;             prior to screening, as defined by:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Unprotected sexual intercourse with a known HIV-infected person, a partner known&#x0D;&lt;br&gt;                  to be at high risk for HIV infection or a casual partner (i.e., no continuing&#x0D;&lt;br&gt;                  established relationship)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Engaged in sex work&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Frequent excessive daily alcohol use or frequent binge drinking, or any other use&#x0D;&lt;br&gt;                  of illicit drugs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  History of newly acquired syphilis, gonorrhea, non-gonococcal urethritis, herpes&#x0D;&lt;br&gt;                  simplex virus-2, chlamydia, pelvic inflammatory disease, trichomonas,&#x0D;&lt;br&gt;                  mucopurulent cervicitis, epididymitis, proctitis, lymphogranuloma venereum,&#x0D;&lt;br&gt;                  chancroid, or hepatitis B-or hepatitis C;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Two or more sexual partners&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. If female, pregnant or planning a pregnancy during the period of enrolment until 4&#x0D;&lt;br&gt;             months after the last IP administration; or lactating;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Bleeding disorder that was diagnosed by a physician (e.g., factor deficiency,&#x0D;&lt;br&gt;             coagulopathy or platelet disorder that requires special precautions) Note: A&#x0D;&lt;br&gt;             participant who states that he or she has easy bruising or bleeding but does not have&#x0D;&lt;br&gt;             a formal diagnosis and has IM vaccinations and blood draws without any adverse&#x0D;&lt;br&gt;             experience is eligible;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Infectious disease diagnosis: chronic hepatitis B-infection (HBsAg-positive),&#x0D;&lt;br&gt;             hepatitis C infection (HCV Ab-positive), or active syphilis (screening and&#x0D;&lt;br&gt;             confirmatory tests);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. History of splenectomy;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Any of the following abnormal laboratory parameters listed below at screening:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Hematology&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Hemoglobin &lt;12.0 g/dl or &lt;7.5 mmol/L&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Absolute Neutrophil Count (ANC) - =1,000/mm3 or &lt; 1.0 x 109 cells/L&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Absolute Lymphocyte Count (ALC) - =650/mm3 or &lt; 0.65 x 109 cells/L&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Platelets - &lt;125,000 cells/mm3 or &lt;125 x 109 cells/L Chemistry&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Creatinine - &gt;1.1 x upper limit of normal (ULN)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  AST - &gt;1.25 x ULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  ALT - &gt;1.25 x ULN Urinalysis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Clinically significant abnormal dipstick confirmed by microscopy:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             • Protein = 1+ or more Blood = 2+ or more (not due to menses) and &gt;10 RBCs per high&#x0D;&lt;br&gt;             power field When available, the screening laboratory tests will be reviewed by the&#x0D;&lt;br&gt;             study physician. Screening laboratory test(s) may
    </Inclusion_Criteria>
    <Condition>HIV-1-infection
    </Condition>
    <Intervention>Biological: eOD-GT8 60mer mRNA Vaccine (100µg)
    </Intervention>
    <Primary_outcome>Evaluate the safety and tolerability of eOD-GT8 60mer mRNA Vaccine
    </Primary_outcome>
    <Secondary_ID>IAVI G003
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>AURUM Tembisa Clinical Research;Center for Family Health Research;Moderna, Inc
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12285130
    </Internal_Number>
    <TrialID>ISRCTN11199072
    </TrialID>
    <Last_Refreshed_on>23 May 2022
    </Last_Refreshed_on>
    <Public_title>Evaluation of the impact of Community-Based Sociotherapy on social dignity among beneficiaries dealing with the consequences of genocide in Rwanda
    </Public_title>
    <Scientific_title>A cluster randomized controlled trial evaluating the impact of Community-Based Sociotherapy on social dignity among beneficiaries dealing with the consequences of genocide in Rwanda                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>University of Rwanda
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220513
    </Date_registration3>
    <Date_registration>13/05/2022
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN11199072
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/06/2022
    </Date_enrollement>
    <Target_size>1200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Two-level cluster randomized controlled trial (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: According to target categories in sociotherapy program, the selected respondents will either be a genocide survivor, perpetrator, bystanders, their descendants, and leaders in districts where sociotherapy is being implemented. The evaluation will include both male and female respondents and respondents of all ages above 18 years old.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                Everyone who is recruited by the sociotherapist for eventual participation is eligible unless they are unable to communicate.&lt;br&gt;                In addition, those who have gone through Community-Based Sociotherapy in previous programs will not be eligible.&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Mental health and psychosocial wellbeing &lt;br&gt;Mental and Behavioural Disorders
    </Condition>
    <Intervention>&lt;br&gt;                This study uses a two-level cluster randomized controlled trial design with person-level outcomes and treatment delivered at the cluster level. It will be a two-arm study. The allocation fraction will be 1:1 intervention and control. One arm will serve as a control (control) while the other will receive the Community-Based Sociotherapy (CBS) treatment (case).  Recruitment of participants will be performed by CBS facilitators. Out of the total number of groups that are recruited by CBS facilitators, eighty groups will be randomly selected following a computer-generated random sequence.  The eighty groups will then be randomly allocated to case or control. Data will be collected just before and after the intervention. The data collectors will not be blinded on allocation to case and control, and neither will the study participants, as in reality study participants become aware to which group they belong and they typically share this with the data collectors.&lt;br&gt;&lt;br&gt;                CBS is a group therapeutic approach and involves genocide survivors, perpetrators, bystanders, their descendants, and leaders. In this approach, sociotherapy groups of fifteen people that live in the same neighborhood meet weekly for approximately three hours over a period of fifteen weeks guided by CBS facilitators. In sociotherapy groups people speak primarily about problems in present-day everyday life. When these problems mirror the past, the past may also be addressed.  The case group will receive the full CBS treatment. The control group will receive no treatment whatsoever (but will be put on a waiting list). Allocation in case and control will be done on a cluster level and will be computer-generated.&lt;br&gt;
    </Intervention>
    <Primary_outcome>Social dignity as measured by a total score of Social Dignity Scale before and after the CBS intervention (baseline and 15 weeks)
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                Measured before and after the CBS intervention (baseline and 15 weeks):&lt;br&gt;                1. Sociodemographic characteristics measured using a sociodemographic questionnaire&lt;br&gt;                2. Personal wellbeing measured using the WHO (Five) Well-Being Index&lt;br&gt;                3. Perceived social support measured using the Multidimensional Scale of Perceived Social Support&lt;br&gt;                4. Traumatic events measured using the Life Events Trauma Questionnaire&lt;br&gt;                5. PTSD symptoms measured using the PTSD CheckList for DSM-5&lt;br&gt;                6. Mental disorders measured using the Self-reporting Questionnaire (SRQ-20)&lt;br&gt;                7. RECONCILIATION measured using a self-designed reconciliation scale&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;Nil known
    </Secondary_ID>
    <Source_Support>Community Based Sociotherapy Rwanda
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 14/04/2022, Institutional Review Board (IRB) of the College of Medicine and Health Sciences at the University of Rwanda (PO Box 3286, Kigali, Rwanda; no telephone number provided; researchcenter@ur.ac.rw), ref: 269/CMHS IRB/2022
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>11/11/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12455276
    </Internal_Number>
    <TrialID>NCT05364138
    </TrialID>
    <Last_Refreshed_on>15 August 2022
    </Last_Refreshed_on>
    <Public_title>Evaluating Scaleup of an Adapted Breast Cancer Early Diagnosis Program in Rwanda
    </Public_title>
    <Scientific_title>Evaluating Scaleup of an Adapted Breast Cancer Early Diagnosis Program in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Brigham and Women's Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220329
    </Date_registration3>
    <Date_registration>29/03/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05364138
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 15, 2022
    </Date_enrollement>
    <Target_size>3096
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Lydia Pace, MD, MPH;Lydia Pace, MD, MPH;Vincent Cubaka, MD
    </Contact_Lastname>
    <Contact_Email>;lpace@bwh.harvard.edu;
    </Contact_Email>
    <Contact_Tel>;4154657223;
    </Contact_Tel>
    <Contact_Affiliation>Brigham and Women's Hospital;
    </Contact_Affiliation>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12594757
    </Internal_Number>
    <TrialID>CTRI/2022/03/041310
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>An adaptive randomized active-controlled open-label sequential&#x0D;
cohort multicenter study to evaluate the efficacy safety&#x0D;
tolerability and pharmacokinetics of intravenous cipargamin&#x0D;
(KAE609) in adult and pediatric participants with severe&#x0D;
Plasmodium falciparum malaria
    </Public_title>
    <Scientific_title>An adaptive, randomized, active-controlled, open-label, sequential&#x0D;
cohort, multicenter study to evaluate the efficacy, safety,&#x0D;
tolerability, and pharmacokinetics of intravenous cipargamin&#x0D;
(KAE609) in adult and pediatric participants with severe&#x0D;
Plasmodium falciparum malaria (KARISMA Ã¢â?¬â?? KAE609Ã¢â?¬â?¢s Role in&#x0D;
Severe Malaria) - NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Novartis Healthcare Pvt Ltd
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220323
    </Date_registration3>
    <Date_registration>23-03-2022
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=49651
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>01-04-2022
    </Date_enrollement>
    <Target_size>192
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized, Parallel Group, Active Controlled Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Open Label
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Rwanda;Democratic Republic of the Congo;Gabon;India;Nigeria;Burkina Faso;Kenya;Malawi;Mozambique;Tanzania;Uganda
    </Countries>
    <Contact_Firstname>Murugananthan K
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Novartis Healthcare Private Limited 7th floor , Inspire BKC G Block, BKC Main Road Bandra Kurla Complex Bandra (East), Mumbai India Mumbai MAHARASHTRA  India 
    </Contact_Address>
    <Contact_Email>murugananthan.k@novartis.com
    </Contact_Email>
    <Contact_Tel>9122250243544
    </Contact_Tel>
    <Contact_Affiliation>Novartis Healthcare PVTLTD
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Cohort 1: Participants aged Ã¢â?°Â¥ 12 years with moderately severe malaria as defined in &lt;br/ &gt;&#x0D;&lt;br&gt;Barnes et al 2004 (prostration and/or repeated vomiting) without presence of other signs of &lt;br/ &gt;&#x0D;&lt;br&gt;severe malaria (Section 16.4) and with high P. falciparum parasitemia (60,000-250,000 &lt;br/ &gt;&#x0D;&lt;br&gt;parasites per Ã?Â¼l). &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;Subsequent Cohorts 2 to 5: Participants diagnosed with severe malaria as defined in &lt;br/ &gt;&#x0D;&lt;br&gt;Section 16.4 (modified version of severe malaria criteria in WHO 2014) and P. &lt;br/ &gt;&#x0D;&lt;br&gt;falciparum parasite count of Ã¢â?°Â¥ 5000 per Ã?Â¼l &lt;br/ &gt;&#x0D;&lt;br&gt;Cohort 2: Participants aged Ã¢â?°Â¥ 12 years &lt;br/ &gt;&#x0D;&lt;br&gt;Cohort 3: Participants aged 6 -  &lt;12 years &lt;br/ &gt;&#x0D;&lt;br&gt;Cohort 4: Participants aged 2 -  &lt; 6 years &lt;br/ &gt;&#x0D;&lt;br&gt;Cohort 5: Participants aged Ã¢â?°Â¥6 months -  &lt;2 years &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;2. Written informed consent form must be obtained prior to any study related procedure. If &lt;br/ &gt;&#x0D;&lt;br&gt;the participant is unable to read and write or otherwise incapable of signing an informed &lt;br/ &gt;&#x0D;&lt;br&gt;consent, then a witnessed consent according to local ethical standards is permitted &lt;br/ &gt;&#x0D;&lt;br&gt;(formally documented and witnessed, ideally via an independent trusted witness). &lt;br/ &gt;&#x0D;&lt;br&gt;Participants aged  &lt; 18 years, who are capable of providing assent, must provide assent &lt;br/ &gt;&#x0D;&lt;br&gt;with parental/legal guardian consent or as per local ethical guidelines. The participant or &lt;br/ &gt;&#x0D;&lt;br&gt;parent/legal guardian (in case of pediatric participants) is able to understand and comply &lt;br/ &gt;&#x0D;&lt;br&gt;with protocol requirements, instructions and protocol-stated restrictions for their child and &lt;br/ &gt;&#x0D;&lt;br&gt;is likely to complete the study as planned.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1 Mixed plasmodium infections &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;2 Treatment with any antimalarial drug (including quinine or artemisinin derivative) or any antibiotic with known antimalarial activity within 12 hours of screening &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;3 Known underlying illness, surgical or medical condition not related to ongoing episode of malaria which might jeopardize the patientÃ¢â?¬â?¢s health &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;4 Known or suspected case of active infections or concurrent febrile illness such as HIV, TB, Typhoid, COVID-19 etc. &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;5 Known h/o ECG abnormalities indicating significant risk to safety of participants-Clinically significant cardiac arrhythmias-H/o familial long QT syndrome or Torsades de Pointes-QTcF  &gt; 450 ms in males and QTcF  &gt; 460 ms in females &lt;br/ &gt;&#x0D;&lt;br&gt; aged  Ã¢â?°Â¥ 12 years old and QTcF  &gt; 450 ms in females aged  &lt; 12 years &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;6 Severe malnutrition Ã¢â?¬â?? In accordance with WHO guidelines  &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;7 Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;8 Participants taking prohibited medications as per protocol &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;9 Pregnant or nursing (lactating) women &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;10 Female of child bearing potential and sexually active males unless they are using one of the highly effective contraception methods (refer protocol section 5.2) during dosing and one week after last IV dose &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;Exclusion criteria for Cohort 1: &lt;br/ &gt;&#x0D;&lt;br&gt;1. ALT  &gt; 5 x the upper limit of normal range (ULN), regardless the level of total &lt;br/ &gt;&#x0D;&lt;br&gt;bilirubin &lt;br/ &gt;&#x0D;&lt;br&gt;2. ALT  &gt; 3 x ULN and total bilirubin is  &gt; 3 mg/dL &lt;br/ &gt;&#x0D;&lt;br&gt;3. Body weight of  &lt; 35 kg or  &gt; 75 kg &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;Exclusion criteria for Cohort 2: &lt;br/ &gt;&#x0D;&lt;br&gt;1. Body weight of  &lt; 35 kg or  &gt;75 kg &lt;br/ &gt;&#x0D;&lt;br&gt;2. Participants diagnosed as moderately severe malaria due to repeated vomiting without &lt;br/ &gt;&#x0D;&lt;br&gt;presence of any of the symptoms of severe malaria. &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;Exclusion criteria for Cohorts 3 to 5: &lt;br/ &gt;&#x0D;&lt;br&gt;1. Body weight of  &lt; 5 kg &lt;br/ &gt;&#x0D;&lt;br&gt;2. Participants diagnosed as moderately severe malaria due to repeated vomiting without &lt;br/ &gt;&#x0D;&lt;br&gt;presence of any of the symptoms of severe malaria.
    </Exclusion_Criteria>
    <Condition>Health Condition 1: B508- Other severe and complicated Plasmodium falciparum malaria&#x0D;

    </Condition>
    <Intervention>Intervention1: KAE609 20 mg: Minimum of two doses; q24h (to be administered at 0 hour and 24 hours) and not exceeding three doses (Dose 3 at 48 hours) followed by oral medication (CoartemÃ?Â® bid for 3 days)&lt;br&gt;Intervention2: KAE609 40 mg: Minimum of two doses; q24h (to be administered at 0 hour and 24 hours) and not exceeding three doses (Dose 3 at 48 hours) followed by oral medication (CoartemÃ?Â® bid for 3 days)&lt;br&gt;Control Intervention1: Artesunate 60 mg/vial: 0, 12, and 24 h and q24h for maximum 8 doses (7 days) according to label and until oral medication (CoartemÃ?Â® bid for 3 days) can be given according to label&lt;br&gt;
    </Intervention>
    <Primary_outcome>To assess the efficacy of IV cipargaminTimepoint: Variable: A binary outcome indicating Ã¢â?°Â¥ 90% reduction in P. falciparum parasite at 12 hours (H12) after first IV dose as compared to baseline.
    </Primary_outcome>
    <Secondary_outcome>To assess clinical outcomeTimepoint: Proportion of participants with clinical success over time. Clinical success at 48 hours is considered as the key secondary endpoint,for the secondary estimand.;To assess the presence/absence of individual signs of severe malariaTimepoint: Proportion of participants with individual signs of severe malaria over time;To assess the risk of hemolysisTimepoint: Proportion of participants developing hemolysis (early and delayed) after treatment;To assess the risk of long term neurological sequelaeTimepoint: Proportion of participants with neurological sequelae at Day 29;To evaluate parasite clearance dynamicsTimepoint: Proportions of participants with Ã¢â?°Â¥ 90% parasite reduction at 24 and 48 hours &lt;br/ &gt;&#x0D;&lt;br&gt;PCE slope half-life &lt;br/ &gt;&#x0D;&lt;br&gt;Time to P. falciparum parasite clearance (PCT) &lt;br/ &gt;&#x0D;&lt;br&gt;P. falciparum parasite reduction ratios (PRR) at 12, 24 and 48 hours &lt;br/ &gt;&#x0D;&lt;br&gt;Proportion of participants with recrudescence and reinfection by Day 29 &lt;br/ &gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>CKAE609B12201 Version 00 dated 14 October 2020
    </Secondary_ID>
    <Source_Support>Novartis Pharma AG, Novartis Campus 4056 Ã¢â?¬â? Basel, Switzerland
    </Source_Support>
    <Ethics_review_status>Not Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;29/01/2021;27/11/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>IEC-CWS HOSPITAL INSTITUTIONAL ETHICS COMMITTEE-Dr Sanjib;Institute ethics comittee,AIIMS-Dr Sunil;Nirmal Hospital Ethics Committee, Dr Nirmal C
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12441767
    </Internal_Number>
    <TrialID>ISRCTN23303832
    </TrialID>
    <Last_Refreshed_on>5 August 2022
    </Last_Refreshed_on>
    <Public_title>Validation of Kinyarwanda versions of questionnaires in patients with epilepsy and healthy volunteers
    </Public_title>
    <Scientific_title>Validation of the Kinyarwanda version of WHO-QOL, QOLIE10P, WG-SS, Rosenberg Self-Esteem Scale, Equitytool and Epilepsy Stigma Scale in patients living with epilepsy and healthy volunteers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>Ghent University Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220309
    </Date_registration3>
    <Date_registration>09/03/2022
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN23303832
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>09/02/2022
    </Date_enrollement>
    <Target_size>760
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Cross-sectional validation study (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda;Saint Helena
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 15 years and above&lt;br&gt;2. Signed informed consent &lt;br&gt;3. Able to understand and respond to questionnaires&lt;br&gt;4. For PwE: definite clinical diagnosis of epilepsy established by treating physician&lt;br&gt;5. For volunteers: in case of the presence of a chronic condition such as asthma or hypertension, adequate treatment is actively used with complete control of the condition&lt;br&gt;6. Willing to perform a retest assessment if randomly selected
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Presence of a condition leading to the inability to write or speak&lt;br&gt;2. Subject currently enrolled in a clinical trial involving the use of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study, or in an exclusion period following recent trial involvement&lt;br&gt;3. For volunteers: the presence of any acute infectious disease or the sequelae thereof&lt;br&gt;4. For volunteers: the presence of any chronic condition resulting in current disability or presence of a neoplastic disorder&lt;br&gt;5. For volunteers: the presence of any previous trauma resulting in a current disability
    </Exclusion_Criteria>
    <Condition>Epilepsy &lt;br&gt;Nervous System Diseases &lt;br&gt;Epilepsy
    </Condition>
    <Intervention>This is a cross-sectional validation study in PwE, with a comparator group of volunteers not affected by epilepsy. The study will be conducted in a staggered design with two phases:&lt;br&gt;&lt;br&gt;Phase 1. 75 PwE and 50 volunteers will be enrolled. &lt;br&gt;&lt;br&gt;Interim Analysis &lt;br&gt;An interim database lock will be performed. Exploratory and confirmatory analyses will be performed on item and construct of the questionnaires in order to early detect poor factor loading. In case of insufficient factor loading, the expert panel that signed off on the final Kinyarwanda version will convene to discuss possible reasons for poor factor loading related to the relevance of the item, inappropriate translation, or incorrect cross-cultural adaptation. The panel will provide any of the following recommendations: remove the item, recruit an additional sample of 50 PwE and 50 HV and reanalyzed or continue the trial.&lt;br&gt;&lt;br&gt;Phase 2:&lt;br&gt;Continued recruitment until both cohorts are completed. Retest will be performed in a randomly selected sample of 15% of PwE and volunteers&lt;br&gt;&lt;br&gt;This study validates multiple questionnaires in a single study. The use of more than one questionnaire will facilitate the process. For example, the WHO-QOL economic domain will correlate with the Equitytool but not with other questionnaires. On the other hand, the Epilepsy Stigma Scale may correlate with the Rosenberg Self-esteem scale. To obtain adequate validity comparisons such as convergent and discriminant validity, we deem all questionnaires needed. &lt;br&gt;&lt;br&gt;The PHQ9 is a screening tool for depression. As depression is common in PwE, the presence of depression may influence self-esteem and stigma scores. The PHQ9 was translated and validated into Kinyarwanda with good construct validity, internal and external validity (Cronbach alfa 0.87).&lt;br&gt;&lt;br&gt;The WHOQOL-B
    </Intervention>
    <Primary_outcome>Primary outcome measures will be recorded at a single timepoint (i.e. at baseline) for all subjects and at 10 days after baseline in a randomized retest sample:&lt;br&gt;&lt;br&gt;Construct validity:&lt;br&gt;1. Model parameters measured by factor loading range, and the Average Variance Extracted, the latter with a cut-off &gt;0.5&lt;br&gt;2. Confirmatory fit analyses analyzed with Chi-square fit (?2 and p-value; p&lt;0.05), Root Mean Square Error of Approximation (&lt;0.05), Tucker–Lewis’s index  (&gt;0.95)&lt;br&gt;3. Criterion validity analyzed by Pearson’s correlation; coefficients between item and its domain and among all domains (no cut-off)&lt;br&gt;4. Discriminatory validity measured by comparing patients with epilepsy to volunteers and by comparing high/low seizure frequency at baseline, presence of depression&lt;br&gt;5. External validity performed through comparison between scales&lt;br&gt;&lt;br&gt;Reliability:&lt;br&gt;1. Internal consistency measured by Cronbach’s alpha (&gt;0.7), and Composite Reliability (&gt;0.7)&lt;br&gt;2. Temporal stability measured by intra-class correlation (ICC) between the scores at two timepoints separated by 10 days (0,8 [good]; 0,9 [exceptional])
    </Primary_outcome>
    <Secondary_outcome>1. SSE factor model will be analyzed using model parameters and confirmatory fit analyses on a single timepoint measurement (i.e. at baseline)&lt;br&gt;2. Ceiling effects will be measured by analysis of variance (ANOVA) on a single timepoint measurement (i.e. at baseline)&lt;br&gt;3. The possible relationship between epilepsy, its resulting disability, depression, stigma, and self-esteem using the psychosocial model described by Trani, applied to PwE and healthy volunteers, will be based on  a single timepoint measurement (i.e. at baseline) and analyzed using: &lt;br&gt;3.1. Propensity score matching to correct for differences between subjects with and without disability &lt;br&gt;3.2. Structural equation models using the maximum likelihood procedure ?2 test as well as the comparative fit index (CFI significant for &gt;0.95), the root mean square error of approximation (RMSEA significant at &lt;0.05) and the Tucker-Lewis Index (TLI &gt;0.95)
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;1.2
    </Secondary_ID>
    <Source_Support>Fracarita Belgium
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 01/11/2021, Rwandan National Ethics Committee (Ministry of Health, PO Box 84, Kigali, Rwanda; +250 (0)255107884; info@rnecrwanda.org), ref: 925/RNEC/2021
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>31/03/2023
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12602667
    </Internal_Number>
    <TrialID>PACTR202203880375077
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Testing the effect of digital secondary school resources for informed health choices among secondary school students in Rwanda.
    </Public_title>
    <Scientific_title>Effects of Informed Health Choices secondary school resources on the ability of Rwandan students to think critically about health: protocol for a cluster-randomised trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>Andrew David Oxman
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220215
    </Date_registration3>
    <Date_registration>15/02/2022
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=21478
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>13 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>18 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>18/04/2022
    </Date_enrollement>
    <Target_size>3276
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Stratified allocation where factors such as age, gender, center, or previous treatment are used in the stratification,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>Laetitia 
    </Contact_Firstname>
    <Contact_Lastname>Nyirazinyoye
    </Contact_Lastname>
    <Contact_Address>KK 19 av
    </Contact_Address>
    <Contact_Email>ntirenganyal1@gmail.com
    </Contact_Email>
    <Contact_Tel>+250788683209
    </Contact_Tel>
    <Contact_Affiliation>Professor of Public Health
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Schools	&#x0D;&lt;br&gt;•	Public, private and government aided schools &#x0D;&lt;br&gt;•	Schools with electricity  &#x0D;&lt;br&gt;•	Schools using national competence-based curriculum&#x0D;&lt;br&gt;•	Schools with lower secondary school section &#x0D;&lt;br&gt;•	Schools with computers&#x0D;&lt;br&gt;•       Schools with projectors and Internet connection&#x0D;&lt;br&gt;•	Schools with over 100 students&#x0D;&lt;br&gt;•	Schools with over 10 teachers&#x0D;&lt;br&gt;•	School directors consenting for the school to participate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Students	&#x0D;&lt;br&gt;•	Senior two students&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Teachers	&#x0D;&lt;br&gt;•	Teachers teaching one of the following subjects: Biology and Health sciences, Physics, Chemistry and &#x0D;&lt;br&gt;        Mathematics&#x0D;&lt;br&gt;•	Teachers who have smartphone/computer&#x0D;&lt;br&gt;•	Teachers consenting to participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Schools&#x0D;&lt;br&gt;•	School that participated in the user testing and pilot of digital resources&#x0D;&lt;br&gt;•	International schools&#x0D;&lt;br&gt;•	Schools that provide special needs education&#x0D;&lt;br&gt;•	Schools that are difficult to reach i.e those with an estimated travel time of more than four hours from &#x0D;&lt;br&gt;        Kigali&#x0D;&lt;br&gt;Students&#x0D;&lt;br&gt;•	Students who choose not to participate 
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Critical thinking about health;Critical thinking about health
    </Condition>
    <Intervention>;Be smart about your health secondary school resources;Standard teaching of competence based curriculum with no additional resources
    </Intervention>
    <Primary_outcome>The primary outcome measure is the difference between the intervention and control schools in the proportion of children with a passing score.
    </Primary_outcome>
    <Secondary_outcome>The mean difference in the score (percent of correct answers) for the 18 questions that assess the students’ ability to apply the nine concepts covered by the be smart about your health secondary school resources;The difference in the proportion of students with a score indicating mastery of the concepts covered by the be smart about your health secondary school resources;The difference in the proportion of students that answered both questions correctly for each of the nine concepts covered by the be smart about your health secondary school resources;The difference in intended behaviours and self-efficacy;The difference in scores on standardised national examinations.;The difference in the proportion of teachers with a passing score and a mastery score, and the mean difference in the score for teachers
    </Secondary_outcome>
    <Source_Support>Research Council of Norway ;University of Rwanda Center of Excellence for Biomedical Engineering and Ehealth
    </Source_Support>
    <Secondary_Sponsor>Laetitia Nyirazinyoye
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>12/02/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>info@rnecrwanda.org
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Rwanda National Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+250788592004
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>info@rnecrwanda.org
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12594201
    </Internal_Number>
    <TrialID>CTRI/2022/01/039513
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Liquefied Petroleum Gas (LPG) stove intervention follow up study
    </Public_title>
    <Scientific_title>Assessing the 5-Year Effects of a 500-Day LPG Stove and Fuel intervention: the HAPIN Cohort Follow up study. - HAPIN 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Sri Ramachandra Institute of Higher Education and Research Deemed to be University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220118
    </Date_registration3>
    <Date_registration>18-01-2022
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=62130
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>01-02-2022
    </Date_enrollement>
    <Target_size>2250
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Outcome Assessor Blinded
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Guatemala;India;Rwanda
    </Countries>
    <Contact_Firstname>Dr Kalpana Balakrishnan
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Professor and Director &#x0D;
WHO Collaborating Center for Occupational&#x0D;
and Environmental Health &#x0D;
ICMR Center for Advanced Research on Environmental Health&#x0D;
Department of Environmental Health Engineering 1 Ramachandra Nagar&#x0D;
Porur
    </Contact_Address>
    <Contact_Email>kalpanasrmc@ehe.org.in
    </Contact_Email>
    <Contact_Tel/>
    <Contact_Affiliation>Sri Ramachandra Institute of Higher Education and Research - Deemed to be University
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Mother/Care-giver of participant child must have been previously enrolled as a participant in the India site of the multi-country HAPIN trial. Lives in study area, will remain in study area for next 12 months, and agrees to participate with informed consent.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: There are no exclusion criteria
    </Exclusion_Criteria>
    <Condition/>
    <Intervention/>
    <Primary_outcome>Child linear growth (HAZ, height-for-age z-score) &lt;br/ &gt;&lt;br&gt;Child development: CREDI &lt;br/ &gt;&lt;br&gt;Child development: MDAT &lt;br/ &gt;&lt;br&gt;Timepoint: 36, 48 and 60 months
    </Primary_outcome>
    <Secondary_outcome>Exposure Biomarkers for early biological effects in mothers and other adult women of the same households. Blood pressure changes in mothers and other adult women.Timepoint: 36, 42, 48, 54 and 60 months
    </Secondary_outcome>
    <Secondary_ID>NIL
    </Secondary_ID>
    <Source_Support>National Institutes of Health 9000 Rockville Pike Bethesda, Maryland 20892
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>08/10/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>IEC - Sri Ramachandra Institute of Higher Education and Research
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12621064
    </Internal_Number>
    <TrialID>NCT05247853
    </TrialID>
    <Last_Refreshed_on>24 October 2022
    </Last_Refreshed_on>
    <Public_title>HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV
    </Public_title>
    <Scientific_title>Long-Term Human Papillomavirus Vaccination Effectiveness and Immunity in Rwandan Women Living With and Without Human Immunodeficiency Virus
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Montefiore Medical Center
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220113
    </Date_registration3>
    <Date_registration>13/01/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05247853
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>28 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>November 3, 2021
    </Date_enrollement>
    <Target_size>2271
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Kathryn A Anastos, MD;Kathryn A Anastos, MD;Gad Murenzi, MD, MPH
    </Contact_Lastname>
    <Contact_Email>;kanastos@montefiore.org;gadcollins@gmail.com
    </Contact_Email>
    <Contact_Tel>;+1 (718) 515-2593;+250 788 589 085
    </Contact_Tel>
    <Contact_Affiliation>Albert Einstein College of Medicine;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Female&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  18-28 years. The age of inclusion criteria will likely be restricted as age-specific&#x0D;&lt;br&gt;             enrollment goals are met.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Physically and mentally able and willing to participate in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to provide written and signed or thumb printed, informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known to be living with HIV (i.e., enrolled in a treatment program), or consent to HIV&#x0D;&lt;br&gt;             testing to confirm HIV status.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have positive pregnancy test or report to be pregnant at the time of visit or less&#x0D;&lt;br&gt;             than 6 weeks post-partum (will be asked to make an appointment 6 or more weeks&#x0D;&lt;br&gt;             post-partum)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Report to be menstruating at the time of visit (will be asked to make new appointment)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of hysterectomy and no longer have a cervix&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of treatment for cervical abnormalities after cervical screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of cervical cancer&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Report no previous sexual activity&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV status is unknown, and date of birth is 12/31/1995 or earlier&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Because this study has age-specific enrollment goals for WLWH and HIV[-] women, once&#x0D;&lt;br&gt;             those enrollment goals are met for each study group, the respective cohorts will be&#x0D;&lt;br&gt;             closed and other eligible women will be excluded.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cervical Cancer;Human Papilloma Virus;Human Immunodeficiency Virus;HPV-Related Carcinoma
    </Condition>
    <Intervention>Procedure: Blood collection;Procedure: Oral, cervicovaginal and anal specimen collection;Procedure: Anoscopy &amp; Biopsy of Acetowhite Lesions;Procedure: Colposcopy &amp; Biopsy of Acetowhite Lesions;Procedure: Ablative Treatment;Procedure: LEEP (Loop Electrosurgical Excision Procedure)
    </Intervention>
    <Primary_outcome>Change in vaccine effectiveness of prophylactic HPV vaccine at 6 months;Change in long-term antibody responses to HPV vaccination at 6 months
    </Primary_outcome>
    <Secondary_outcome>Change in HPV natural history study at 6 months
    </Secondary_outcome>
    <Secondary_ID>1U54CA254568-01;2021-13087
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Cancer Institute (NCI);Rwanda Military Hospital;University of Rwanda
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11785716
    </Internal_Number>
    <TrialID>ISRCTN36459506
    </TrialID>
    <Last_Refreshed_on>4 January 2022
    </Last_Refreshed_on>
    <Public_title>Determining colorectal cancer features using a Rwandan population to lay a foundation and inform precise colorectal cancer clinical management
    </Public_title>
    <Scientific_title>Molecular and genetic profile of colorectal cancer in Rwanda                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>KU Leuven
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20211224
    </Date_registration3>
    <Date_registration>24/12/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN36459506
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/01/2019
    </Date_enrollement>
    <Target_size>300
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Mixed (retrospective and prospective) cross-sectional descriptive laboratory study (Diagnostic)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Histologically confirmed colorectal cancer&lt;br&gt;                2. Diagnosis made or reviewed at King Faisal Hospital (KFH) between 01/01/2019 and 29/02/2021, or prospectively from 21/03/2021 to 31/05/2021&lt;br&gt;                3. Adult&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients with colorectal masses that are not histologically confirmed
    </Exclusion_Criteria>
    <Condition>Colorectal cancer &lt;br&gt;Cancer
    </Condition>
    <Intervention>&lt;br&gt;                This is a mixed (retrospective and prospective) descriptive laboratory study of colorectal cancer patients who have undergone diagnosis either at King Faisal Hospital (KFH)  or at Rwanda Military Hospital (RMH) from 01/01/2019 to 29/02/2021, and prospectively from 21/03/2021 to 31/05/2021.&lt;br&gt;&lt;br&gt;                Retrospective data will be collected from the surgery logbooks and electronic medical records (EMR) of all colorectal cancer patients diagnosed at KFH meeting the selection criteria during the study period. Data will be entered directly into a Microsoft Excel data collection tool and stored on a password-protected laptop. A de-identified database will be established from the data collection tool and EMR data query results. All datasets will be password-protected and saved on a backup drive.&lt;br&gt;&lt;br&gt;                A commercial kit from Promega (MSI Analysis System, Version 1.2) will be used for MSI typing. Three categories of MSI status are observed by using Promega kit, MSI-H, MSI-L, and MSS. Laboratory studies will be done in the following steps:&lt;br&gt;                1. DNA extraction from paraffin-embedded CRC tissues and blood&lt;br&gt;                2. Amplification of microsatellites by PCR&lt;br&gt;                3. Capillary electrophoresis on an automated sequencer&lt;br&gt;                4. Data analysis using GeneMapper® software&lt;br&gt;                After completion of the run, DNA fragments will be analyzed using AlleleLink software provided by the manufacturer.&lt;br&gt;
    </Intervention>
    <Primary_outcome>MSI status, categorised as MSI-H, MSI-L, or MSS, measured using Promega (MSI Analysis System, Version 1.2) kit at a single time point
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Demographics measured from electronic medical records (EMR) at a single time point&lt;br&gt;                2. Family history measured from electronic medical records (EMR) at a single time point&lt;br&gt;                3. Clinical history, including treatment measured from electronic medical records (EMR) at a single time point&lt;br&gt;                4. Diagnostic method (colonoscopy + biopsy) measured from electronic medical records (EMR) at a single time point&lt;br&gt;                5. Location of tumor in the bowel  measured from electronic medical records (EMR) and surgery logbooks at a single time point&lt;br&gt;                6. Gross appearance measured from electronic medical records (EMR) at a single time point&lt;br&gt;                7. Histopathological type and grade measured from electronic medical records (EMR) at a single time point&lt;br&gt;                8. Lymphocytic infiltration measured from electronic medical records (EMR) at a single time point&lt;br&gt;                9. Signet-ring cell measured from electronic medical records (EMR) at a single time point&lt;br&gt;                10. Tumor stage measured from electronic medical records (EMR) at a single time point&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;Nil known
    </Secondary_ID>
    <Source_Support>Not applicable
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 03/11/2021, The University of Rwanda - the College of Medicine and Health Sciences (CMHS) Institutional Review Board (IRB) (P.O.Box 3286 Kigali, Rwanda; +250784575900; researchcenter@ur.ac.rw), ref: No 328/CMHSIRB/2021
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>29/07/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12602581
    </Internal_Number>
    <TrialID>PACTR202203582920839
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 and Novavax NVX-CoV2373 COVID-19 vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years with and without HIV infection in 3 African Countries (Kenya, Democratic Republic of Congo, and Rwanda).
    </Public_title>
    <Scientific_title>A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 and Novavax NVX-CoV2373 COVID-19 vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years with and without HIV infection in 3 African Countries (Kenya, Democratic Republic of Congo, and Rwanda).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Victoria Biomedical Research Institute
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20211213
    </Date_registration3>
    <Date_registration>13/12/2021
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=19319
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>13 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>18 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>04/04/2022
    </Date_enrollement>
    <Target_size>1950
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Permuted block randomization,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Phase-2
    </Phase>
    <Countries>Kenya;Congo;Rwanda
    </Countries>
    <Contact_Firstname>Lucas
    </Contact_Firstname>
    <Contact_Lastname>Otieno Tina
    </Contact_Lastname>
    <Contact_Address>Kisumu County Hospital
    </Contact_Address>
    <Contact_Email>Itina@vibriafrica.org
    </Contact_Email>
    <Contact_Tel>00254720597654
    </Contact_Tel>
    <Contact_Affiliation>Public enquiries 
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: To be eligible for the study, each HIV (+) participants must satisfy all of the following criteria:&#x0D;&lt;br&gt;1. Adolescent male or female aged = 12 to 17 years at screening and adult male or female aged = 18 to 64 years at screening (inclusive).&#x0D;&lt;br&gt;2. Written informed consent (and assent if adolescent), after review of the consent form and having adequate opportunity to discuss the study with an investigator or a qualified designee. For participants who cannot read or write, the consent must be witnessed by a literate third party not involved in study conduct.&#x0D;&lt;br&gt;3. Comply with study procedures, including potential home visits for COVID-19 follow-up.&#x0D;&lt;br&gt;4. Has completed a primary homologous vaccination series at least 3 months but no more than 6 months prior to enrollment. Vaccinations allowed include:&#x0D;&lt;br&gt;a) mRNA (Moderna mRNA-1273 or Pfizer/BNT) – primary series is 2 doses&#x0D;&lt;br&gt;b) Adenovector 26 (Janssen Ad26COVS1) – primary series is 1 dose;&#x0D;&lt;br&gt;c) Inactivated whole virus (Sinopharm-BIBP) – primary series is 2 doses;&#x0D;&lt;br&gt;5. Female participants of childbearing potential (defined as any female who has experienced menarche and who is NOT surgically sterile [i.e, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea at least 12 consecutive months or documented plasma follicle-stimulating hormone level =40 mIU/mL]) must agree to consistently use an effective method of contraception from enrolment and agree to continue adequate contraception until 12 weeks after vaccination:a. Condoms (male or female)&#x0D;&lt;br&gt;b. Diaphragm with spermicide&#x0D;&lt;br&gt;c. Cervical cap with spermicide&#x0D;&lt;br&gt;d. Intrauterine device&#x0D;&lt;br&gt;e. Oral or patch contraceptives&#x0D;&lt;br&gt;f. Hormonal Contraceptives implants or injection e.g., Norplant®, Depo-Provera®.&#x0D;&lt;br&gt;g. Abstinence, as a form of contraception, is acceptable if in line with the participant’s lifestyle.&#x0D;&lt;br&gt;NOTE: Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Theseprocedures and laboratory test results must be confirmed by physical examination, by participant recall of specific date and hospital/facility of procedure, or by medical documentation of said procedure.6. Medically stable at screening, as determined by the investigator (based on review of health status, vital signs, medical history, and targeted physical examination). Acceptable Vital signs as determined by the Principal Investigator or designee.&#x0D;&lt;br&gt;7. Receiving highly active antiretroviral therapy (HAART) and using the same regimen the past 8 weeks before screening. Changes in antiretroviral dosage within 8 weeks prior to entering the study are permitted. In addition, the exchange of pharmacological formulation (e.g., the conventional formulation for combination formulations) is allowed. If regimen has changed then the participant can be reconsidered for inclusion once the 8 weeks has passed.&#x0D;&lt;br&gt;8. An HIV-1 viral load &lt; 1000 copies/mL and/or CD4 Count = 200 cells/mm3 within 3 months before randomization. May be taken during screening or utilize medical testing from clinic.&#x0D;&lt;br&gt;9. Documentation of HIV test result by HIV rapid test or assay as per the Ministry of Health guidelines in the respective countries irrespective of HIV status.&#x0D;&lt;br&gt;Each HIV (-) participant must meet all the following criteria to be enrolled in this study:&#x0D;&lt;br&gt;1. Male or female aged = 18 to 64 years at screening, inclusive.&#x0D;&lt;br&gt;2. Willing and able to give informed consent prior to study enrolment and co
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Participants with any of the following criteria will be excluded:&#x0D;&lt;br&gt;1. Any ongoing, symptomatic acute illness requiring medical or surgical care or chronic illness of moderate or severe grade including HIV Stage III/IV or chronic illness/disease that is not stable (at the discretion of the investigator). Acute illness is a temporary exclusion for which the participant may be re-evaluated once they improve or recover.&#x0D;&lt;br&gt;2. Use of a heterologous COVID-19 primary series at the platform level (mRNA, Adenovector and inactivated vaccine).&#x0D;&lt;br&gt;3. Unstable or Severe Chronic disease inclusive of:&#x0D;&lt;br&gt;a. Hypertension (elevated blood pressure [SBP&gt;155mmHg or DBP&gt;100mmHg]). Note that participants can be retested once after resting or return on another day for retesting. Participants may also have anti-hypertensive medication adjusted and may be reassessed after at least 2 weeks.b. Congestive heart failure (CHF) stage 3 or greater or diagnosed cardiovascular disease that is not controlled using medication in the past 6 months.&#x0D;&lt;br&gt;c. Chronic obstructive pulmonary disease (COPD) with a history of an acute exacerbations repeated in the past 2 years. Note: If participant has been stable the last 6 months and are not Gold stage 3 or greater, they may be included.&#x0D;&lt;br&gt;d. Asthma stage 4 and/or unstable cases with asthma therapy adjustments in the past that 2 months.&#x0D;&lt;br&gt;e. Type 1 or any type 2 diabetes (adult onset) with an HbA1c &gt; 8.5 in the last 6 months. Any participant with diabetes is required to have an AIC value in last 6 months. Adolescents may not be diabetic.&#x0D;&lt;br&gt;f. Chronic kidney disease requiring dialysis or GFR &lt;30 (may use associated creatinine based on age and gender)&#x0D;&lt;br&gt;g. Chronic hepatic disease with evidence of hepatic compromise. Includes known Hepatitis B or C.&#x0D;&lt;br&gt;h. Chronic or serious neurological diseases (e.g. cerebrovascular disease (including transient ischemic attacks), autoimmune disorders, neurologic deterioration (including dementia), Guillain Barre syndrome)&#x0D;&lt;br&gt;4. Cognitive impairment – congenital or acquired&#x0D;&lt;br&gt;5. Participation in research involving an investigational product (drug/biologic/device) within 30 days prior to first study vaccination. Exception is if participant in a follow up safety phase and the investigation product has been given &gt; 6months previously.&#x0D;&lt;br&gt;6. Prior receipt of an Ebola vaccine i.e., Ad26.ZEBOV/MVA-BN-Filo vaccines.&#x0D;&lt;br&gt;7. Received any other vaccine within 4 weeks prior to first study vaccination or planned vaccination within 2 weeks after study vaccination (exception for mass vaccination campaigns). Participants may be revaluated after the window has passed.&#x0D;&lt;br&gt;8. Any autoimmune or immunodeficiency disease/condition (iatrogenic or congenital), excluding HIV. Note: Stable endocrine disorders that have a confirmed autoimmune etiology (e.g., thyroid, pancreatic), including stable diabetes are allowed.&#x0D;&lt;br&gt;9. Chronic administration (&gt;14 continuous days) of immunosuppressant, systemic glucocorticosteroids, or other immune-modifying drugs within 60 days prior to first study vaccination, excluding HAART. Note: An immunosuppressant dose of glucocorticoid is defined as a systemic dose = 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.10. Received immunoglobulin, blood-derived products, or other immunosuppressant drugs within 90 days prior to first study vaccination, excluding HAART.&#x0D;&lt;br&gt;11. Temporary exclusion: Acute respiratory and/or non-respiratory illness consistent with po
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;COVID-19;COVID-19
    </Condition>
    <Intervention>;Janssen Ad26COVS1;Novavax NVX CoV2373;Janssen Ad26COVS1;Novavax NVX CoV2373;Janssen Ad26COVS1;Novavax NVX CoV2373
    </Intervention>
    <Primary_outcome> To evaluate reactogenicity (solicited adverse events (AEs) Ad26.COV2S1 and NVX-CoV2372 following boosting.                                                                                                                                                                                                                                                                                                                                                                                                                                                       ;To evaluate Serious Adverse events related to vaccination of Ad26.COV2S1 or NVX-CoV2372 during the entire study.;To evaluate the immunogenicity of Ad26.COV2S1 and NVX-CoV2372 vaccines at day 28
    </Primary_outcome>
    <Secondary_outcome>To evaluate all unsolicited AEs post-vaccination through 28 days and treatment emergent adverse events through 85 days in all participants.;To evaluate safety in terms of adverse events of special interest (AESIs) following vaccination, for HIV (+) participants through end of study.;To describe severe adverse events through end of study in all participants.&#x0D;&lt;br&gt;;To compare the immunogenicity of heterologous boost in participants at Day 28 (IgG ELISA and neutralization);To compare the durability of response through end of study (IgG ELISA and neutralization);To evaluate mucosal immunogenicity of heterologous boost in participants at Day 28 (S-IgA ELISA).
    </Secondary_outcome>
    <Source_Support>Coalition for Epidemic Preparedness Innovation
    </Source_Support>
    <Ethics_review_status>Not approved;Not approved;Not approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;01/01/1900;01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>info.kenya@amref.org;info@rnecrwanda.org;matsiegpb@yahoo.fr
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>AMREF Ethics and Scientific Review Committee;Rwanda National Ethics Committee;National Committee of Health Ethics 
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>0054206994000;00250788592004;002425512117
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>info.kenya@amref.org;info@rnecrwanda.org;matsiegpb@yahoo.fr
    </Ethics_review_contact_email>
    <results_url_link>To be updated once available
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12508851
    </Internal_Number>
    <TrialID>ISRCTN17123528
    </TrialID>
    <Last_Refreshed_on>29 August 2022
    </Last_Refreshed_on>
    <Public_title>Translation of questionnaires on quality of life, disability, self-esteem, and stigma into Kinyarwanda (the language of Rwanda)
    </Public_title>
    <Scientific_title>A COVID-19 pandemic adapted framework for international collaboration on the cross-cultural translation of questionnaires on quality of life, disability, stigma, self-esteem, and wealth into Kinyarwanda using a mixed multistep approach with early involvement of patients living with epilepsy and healthy volunteers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>Ghent University Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20211115
    </Date_registration3>
    <Date_registration>15/11/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN17123528
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>06/07/2021
    </Date_enrollement>
    <Target_size>55
    </Target_size>
    <Study_type>Other
    </Study_type>
    <Study_design>International collaboration single-center study using a mixed approach (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                A) Patients with epilepsy (N=2) included in panel discussions&lt;br&gt;                1. Definite clinical diagnosis of epilepsy, defined as two epileptic seizures, unprovoked, with a minimum interval of 24 hours&lt;br&gt;                2. Able to read self-administered questionnaires and able to write&lt;br&gt;                3. Bilingual English and Kinyarwanda, preferably trilingual French, English, Kinyarwanda&lt;br&gt;                4. Able to attend/complete computer-assisted personal interviewing&lt;br&gt;                5. Willing to attend video conferencing and CASI&lt;br&gt;                6. = 18y of  age&lt;br&gt;                7. Providing signed informed consent&lt;br&gt;&lt;br&gt;                B) Healthy volunteers (N=2) included in panel discussions&lt;br&gt;                1. Able to read&lt;br&gt;                2. = 18y of  age&lt;br&gt;                3. Willing to attend video conferencing and CASI&lt;br&gt;                4. Provide signed informed consent&lt;br&gt;&lt;br&gt;                C) Volunteers (N=30) enrolled for assessment of similarity/comparability of the original version (OV) and Back translation (BT)&lt;br&gt;                1. Fluent in English&lt;br&gt;                2. Able to attend/complete CASI&lt;br&gt;                3. = 18y of  age&lt;br&gt;                4. Providing signed informed consent&lt;br&gt;&lt;br&gt;                D) Patients (N=5) for testing of prefinal version&lt;br&gt;                1. Definite clinical diagnosis of epilepsy, defined as two epileptic seizures, unprovoked, with a minimum interval of 24 hours&lt;br&gt;                2. Able to understand and respond to the questionnaire&lt;br&gt;                3. = 18y of  age&lt;br&gt;                4. Provide signed informed consent&lt;br&gt;&lt;br&gt;                E) Healthy Volunteers (N=5) for testing of prefinal version&lt;br&gt;                1. Able to understand and respond to the questionnaire&lt;br&gt;                2. = 18y of  age&lt;br&gt;                3. Provide signed informed consent&lt;br&gt;&lt;br&gt;                F) Healthcare Professional (N=5) for testing of prefinal version&lt;br&gt;                1. = 18y of  age&lt;br&gt;                2. Board-certified healthcare professional in Rwanda&lt;br&gt;                3. Fluent in Kinyarwanda&lt;br&gt;                4. Provide signed informed consent&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                A) PwE (N=2) included in panel discussions&lt;br&gt;                1. Presence of cognitive deficit hampering interview, comprehension of questions&lt;br&gt;                2. Presence of neurological deficit that hinders answering of questions, reading, or understanding&lt;br&gt;                3. Presence of hallucinations, psychosis&lt;br&gt;&lt;br&gt;                B) HVs (N=2) included in panel discussions&lt;br&gt;                1. Presence of any medical condition unless treatment provides total symptom control for at least 6 months or unless judged healthy by the enrolling investigator&lt;br&gt;                2. Presence of cognitive deficit, possibly hampering participation or reading, understanding or answering of questions,&lt;br&gt;                3. Presence of hallucinations, psychosis&lt;br&gt;&lt;br&gt;                C) volunteers (N=30) enrolled for assessment of similarity/comparability of the original version (OV) and Back translation (BT)&lt;br&gt;                1. Presence of physical condition hampering reading, understanding or answering&lt;br&gt;                2. Presence of hallucinations, psychosis&lt;br&gt;&lt;br&gt;                D) Patients (N=5) for testing of prefinal version&lt;br&gt;                1. Presence of cognitive deficit hampering interview, comprehension of questions&lt;br&gt;                2. Presence of neurological deficit that hinders answering of questions, reading or understanding&lt;br&gt;                3. Presence of hallucinations, psychosis&lt;br&gt;&lt;br&gt;                E) Healthy Volunteers (N=5) for testing of prefinal version&lt;br&gt;                1. Presence of any medical condition unless treatment provides total symptom control for at least 6 months or unless judged healthy by the enrolling investigator&lt;br&gt;                2. Presence of cognitive deficit, possibly hampering participation or reading, understanding or answering of questions,&lt;br&gt;                3. Presence of hallucinations, psychosis&lt;br&gt;&lt;br&gt;                F) Healthcare Profession (N=5) for testing of prefinal version&lt;br&gt;                1. Presence of any medical condition unless treatment provides total symptom control for at least 6 months or unless judged healthy by the enrolling investigator&lt;br&gt;                2. Presence of cognitive deficit, possibly hampering participation or reading, understanding or answering of questions&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Translation of questionnaire on (health-related) quality of life, self-esteem, disability, and stigma for Rwandan patients with epilepsy and volunteers &lt;br&gt;Not Applicable
    </Condition>
    <Intervention>&lt;br&gt;                Different samples of study subjects will be recruited during the project.&lt;br&gt;                A) Panel members enrolled in step 1 to 9, participate for the full study and will attend panel meetings and participate actively in a consensus discussion. In step 3, they complete once an online content validity assessment questionnaire, thorugh a computer-assisted self-interview.&lt;br&gt;                B) Healthy volunteer enrolled in step 6 for comparability/similarity assessment, complete once an online comparability/similarity questionnaire on all items, through a computer-assisted self-interview&lt;br&gt;                C) Patients or healthy volunteer enrolled in step 8 for for prefinal version testing, complete the Kinyarwanda versions of all questionnaires once and are subject to an in-depth interview for each item through a computer-assisted personal interview.&lt;br&gt;                D) Healthcare professional enrolled in step 8 for for prefinal version testing, complete the Kinyarwanda versions of all questionnaires once and and complete a user preference questionnaire thorugh a computer-assisted self-interview.&lt;br&gt;&lt;br&gt;                Step 1: Forward Translation: three forward translators provide translation from English to Kinyarwanda of all items, including response options.&lt;br&gt;                Step 2: Forward translation reconciliation: the expert panel creates a single Kinyarwanda translation based on the forward translations from step 1, reviews and approves the version&lt;br&gt;                Step 3:  Content Validity Assessment: the expert panel assesses all items of each questionnaire in terms of relevance both conceptually and culturally, using a content validity questionnaire&lt;br&gt;                Step 4: Final Forward translation: the expert panel reviews the content validity indices by it
    </Intervention>
    <Primary_outcome>Content Validity is measured using the item content validity index (I-CVI), Scale-CVI, proportional index and unanimity agreement score, at a single time point (step 3)
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Comparability and similarity is measured once in step 6 using a 7-point Likert scale, ranging from 'extremely comparable' to 'not at all comparable' and 'extremely similar to 'not at all similar'&lt;br&gt;                2. User preference for healthcare professionals is measured once in step 8 using a 4-point Likert scale in a non validated, study-specific user preference questionnaire&lt;br&gt;                3. Patient and volunteer testing assesses difficulty, emotional barriers, and understanding of all items for all questionnaires using a 4-item Likert scale completed by the interviewer and using the yes/no items completed by the interviewer from his/her observation at the end of the study&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;Nil known
    </Secondary_ID>
    <Source_Support>Fracarita Belgium
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 29/06/2021, CARAES Ndera Hospital Ethical Committee (CARAES Ndera hospital, P.O. Box 423 Kigali - Rwanda; +250 781 447 928; nderaethicscommittee@gmail.com), ref: 025/CNEC/2021
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/02/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12544150
    </Internal_Number>
    <TrialID>NCT05108831
    </TrialID>
    <Last_Refreshed_on>26 September 2022
    </Last_Refreshed_on>
    <Public_title>Dynamic CDSA to Manage Sick Children in Rwanda
    </Public_title>
    <Scientific_title>Dynamic Clinical Decision Support Algorithms to Manage Sick Children in Primary Health Care Settings in Rwanda
    </Scientific_title>
    <Acronym>DYNAMIC-RW
    </Acronym>
    <Primary_sponsor>Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20211015
    </Date_registration3>
    <Date_registration>15/10/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05108831
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>1 Day
    </Inclusion_agemin>
    <Inclusion_agemax>14 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 1, 2021
    </Date_enrollement>
    <Target_size>50000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Valerie D'Acremont, PhD;Valerie D'Acremont, PhD
    </Contact_Lastname>
    <Contact_Email>;Valerie.DAcremont@unisante.ch
    </Contact_Email>
    <Contact_Tel>;+41 61 284 8679
    </Contact_Tel>
    <Contact_Affiliation>Centre for Primary Care and Public Health;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presenting for an acute medical or surgical condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presenting for scheduled consultation for a chronic disease (e.g. HIV, TB, NCD,&#x0D;&lt;br&gt;             malnutrition)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presenting for routine preventive care (e.g. growth monitoring, vitamin&#x0D;&lt;br&gt;             supplementation, deworming, vaccination)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Caregiver unavailable, unable or unwilling to provide written informed consent (except&#x0D;&lt;br&gt;             for older children who can provide verbal assent with an adult witness during the&#x0D;&lt;br&gt;             consenting process)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Child Health
    </Condition>
    <Intervention>Device: ePOCT+
    </Intervention>
    <Primary_outcome>Percentage of children prescribed an antibiotic at initial consultation in the intervention group (ePOCT+) as compared to the control group (routine care)
    </Primary_outcome>
    <Secondary_outcome>Percentage of children cured at day 7 in the intervention group (ePOCT+) as compared to the control group (routine care);Percentage of children with one or more unscheduled re-attendance visits at any health facility by day 7;Percentage of children with severe clinical outcome (death or non-referred secondary hospitalization) by day 7;Percentage of children referred to hospital or inpatient ward at a health centre at initial consultation;Percentage of febrile children tested for malaria by RDT and/or microscopy at day 0;Percentage of malaria positive children prescribed an antimalarial at day 0;Percentage of malaria negative children prescribed an antimalarial at day 0;Percentage of children untested for malaria prescribed an antimalarial at day 0
    </Secondary_outcome>
    <Secondary_ID>No.752/RNEC/2020;Project_7F-10361.01.01;2020-02799
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Swiss Tropical &amp; Public Health Institute;Ecole Polytechnique Fédérale de Lausanne;Rwanda Biomedical Centre
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12505719
    </Internal_Number>
    <TrialID>NCT05056545
    </TrialID>
    <Last_Refreshed_on>29 August 2022
    </Last_Refreshed_on>
    <Public_title>Postpartum Family Planning Program in Rwanda
    </Public_title>
    <Scientific_title>Implementation and Evaluation of a Large-scale Postpartum Family Planning Program in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Emory University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210914
    </Date_registration3>
    <Date_registration>14/09/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05056545
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 1, 2022
    </Date_enrollement>
    <Target_size>21383
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Kristin Wall, PhD;Kristin Wall, PhD;Etienne Karita, MD
    </Contact_Lastname>
    <Contact_Email>;kmwall@emory.edu;ekarita@rzhrg-mail.org
    </Contact_Email>
    <Contact_Tel>;404-727-9088;+250 252 503 233
    </Contact_Tel>
    <Contact_Affiliation>Emory University;
    </Contact_Affiliation>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12282443
    </Internal_Number>
    <TrialID>NCT05063487
    </TrialID>
    <Last_Refreshed_on>23 May 2022
    </Last_Refreshed_on>
    <Public_title>Evaluation of HIV-1 Recent Infection Testing in Rwanda
    </Public_title>
    <Scientific_title>Evaluating the Impact of HIV-1 Recent Infection Testing on Incremental HIV Testing Yield and Adverse Events Linked to Return of Recent Infection Testing Results in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Columbia University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210913
    </Date_registration3>
    <Date_registration>13/09/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05063487
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 29, 2021
    </Date_enrollement>
    <Target_size>1466
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Suzue Saito, PhD;Gallican Rwibasira, MD;Suzue Saito, PhD
    </Contact_Lastname>
    <Contact_Email>;;ss1117@cumc.columbia.edu
    </Contact_Email>
    <Contact_Tel>;;212-304-7130
    </Contact_Tel>
    <Contact_Affiliation>Columbia University;Rwanda Biomedical Centre;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Aged =15 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be newly diagnosed with HIV&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to speak and understand English or Kinyarwanda&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Consented to be part of both case-based surveillance (CBS) (which includes PNS) and&#x0D;&lt;br&gt;             recency surveillance under the separate, approved CBS protocol.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Give voluntary written informed consent for data collection via semi-structured&#x0D;&lt;br&gt;             interview and survey instruments&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Give voluntary written informed consent for use of routinely collected data&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be female if they are received at the facility at the same time as their partner (for&#x0D;&lt;br&gt;             intimate partner violence objective only).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Opt out or do not consent, or are unable to consent to participate in semi-structured&#x0D;&lt;br&gt;             interviews and completion of survey instruments&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a history of testing HIV positive (i.e., not newly diagnosed with HIV)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Report antiretroviral drug (ARV) use for HIV management at any point during the HIV&#x0D;&lt;br&gt;             testing service (HTS) visit&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV Infections
    </Condition>
    <Intervention>Other: Return of recent classification;Other: Return of long-term classification
    </Intervention>
    <Primary_outcome>The HIV positive yield of index testing among the contacts of people newly diagnosed with HIV that test recent versus long-term.;The incidence of intimate partner violence associated with the return of recency testing results among people newly diagnosed with HIV that test recent versus long-term
    </Primary_outcome>
    <Secondary_ID>GG014256-18;AAAT5637
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Centers for Disease Control and Prevention;Ministry of Health, Rwanda
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12602454
    </Internal_Number>
    <TrialID>PACTR202110626944896
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
    </Public_title>
    <Scientific_title>Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Inovio Pharmaceuticals Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210910
    </Date_registration3>
    <Date_registration>10/09/2021
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=16121
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>44 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/12/2021
    </Date_enrollement>
    <Target_size>7116
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously,Randomised,Simple randomization using a randomization table created by a computer software program,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Phase-3
    </Phase>
    <Countries>Rwanda;Rwanda;Tunisia;Tunisia;Tunisia
    </Countries>
    <Contact_Firstname>Inovio
    </Contact_Firstname>
    <Contact_Lastname>Call Center
    </Contact_Lastname>
    <Contact_Address> 660 W Germantown Pike, Ste 110
    </Contact_Address>
    <Contact_Email>clinical.trials@inovio.com
    </Contact_Email>
    <Contact_Tel>12674404237
    </Contact_Tel>
    <Contact_Affiliation>Inovio
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Working or residing in an environment with high risk of exposure to SARS-CoV-2 for whom exposure may be relatively prolonged or for whom personal protective equipment (PPE) may be inconsistently used, especially in confined settings.&#x0D;&lt;br&gt;Phase 2 only: Screening laboratory results within normal limits for testing laboratory or are deemed not clinically significant by the Investigator.&#x0D;&lt;br&gt;Be post-menopausal or be surgically sterile or have a partner who is sterile or use medically effective contraception with a failure rate of &lt; 1% per year when used consistently and correctly from Screening until 3 months following last dose (Phase 2) or until last dose (Phase 3).
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Acute febrile illness with temperature higher than or equal to 100.4°F (38.0°C) or acute onset of upper or lower respiratory tract symptoms.&#x0D;&lt;br&gt;Positive serologic or molecular (Reverse transcription polymerase chain reaction (RT-PCR)) test for SARS-CoV-2 at Screening (this criterion applies to all Phase 2 participants and only applies after approximately 402 participants positive for SARS-CoV-2 serologic test are randomized in the Phase 3 segment of the study).&#x0D;&lt;br&gt;Pregnant or breastfeeding or intending to become pregnant or intending to father children within the projected duration of the trial starting from the Screening visit until 3 months following the last dose (Phase 2) or until last dose (Phase 3).&#x0D;&lt;br&gt;Known history of uncontrolled HIV based on a CD4 count less than 200 cells per cubic millimeter (/mm^3) or a detectable viral load within the past 3 months.&#x0D;&lt;br&gt;Is currently participating or has participated in a study with an investigational product within 30 days preceding Day 0.&#x0D;&lt;br&gt;Previous or planned receipt of an investigational (including Emergency Use Authorization (EUA) or local equivalent authorization) or licensed vaccine for prevention or treatment of COVID-19, middle east respiratory syndrome (MERS), or severe acute respiratory syndrome (SARS) (documented receipt of placebo in previous trial would be permissible for trial eligibility).&#x0D;&lt;br&gt;Respiratory diseases (e.g., asthma, chronic obstructive pulmonary disease) requiring significant changes in therapy or hospitalization for worsening disease during the 6 weeks prior to enrolment.&#x0D;&lt;br&gt;Immunosuppression as a result of underlying illness or treatment.&#x0D;&lt;br&gt;Lack of acceptable sites available for ID injection and EP.&#x0D;&lt;br&gt;Blood donation or transfusion within 1 month prior to Day 0.&#x0D;&lt;br&gt;Reported alcohol or substance abuse or dependence, or illicit drug use (excluding marijuana use).&#x0D;&lt;br&gt;Any illness or condition that in the opinion of the investigator may affect the safety of the participant or the evaluation of any study endpoint.&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;COVID-19;COVID-19
    </Condition>
    <Intervention>;INO 4800 Dose ;Placebo 
    </Intervention>
    <Primary_outcome>Phase 2: Change From Baseline in Antigen-specific Cellular Immune Response Measured by Interferon-gamma (IFN-?) Enzyme-linked Immunospot (ELISpot) Assay;Phase 2: Change From Baseline in Neutralizing Antibody Response Measured by a Pseudovirus-based Neutralization Assay;Phase 3: Percentage of Participants, (SARS-CoV-2 seronegative at baseline), With Virologically-confirmed COVID-19 Disease
    </Primary_outcome>
    <Secondary_outcome>Phase 2 and 3: Percentage of Participants With Adverse Events of Special Interest (AESIs);Phase 3: Percentage of Participants With Death From All Causes;Phase 3: Percentage of Participants, (SARS-CoV-2 seronegative at baseline), With Non-Severe COVID-19 Disease;Phase 3: Percentage of Participants, (SARS-CoV-2 seronegative at baseline), With Severe COVID-19 Disease;Phase 3: Percentage of Participants, (SARS-CoV-2 seronegative at baseline), With Death From COVID-19 Disease;Phase 3: Percentage of Participants, (SARS-CoV-2 seropositive at baseline), With Virologically-Confirmed SARS-CoV-2 COVID-19 Disease&#x0D;&lt;br&gt;;Phase 3: Change From Baseline in Antigen-specific Cellular Immune Response Measured by IFN-gamma ELISpot Assay;Phase 3: Change From Baseline in Neutralizing Antibody Response Measured by a Pseudovirus-based Neutralization Assay;Phase 2 and 3: Percentage of Participants With Solicited and Unsolicited Injection Site Reactions;Phase 2 and 3: Percentage of Participants With Solicited and Unsolicited Systemic Adverse Events (AEs);Phase 2 and 3: Percentage of Participants With Serious Adverse Events (SAEs)
    </Secondary_outcome>
    <Secondary_ID>INNOVATE   
    </Secondary_ID>
    <Source_Support> Inovio Pharmaceuticals Inc.
    </Source_Support>
    <Ethics_review_status>Not approved;Not approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>sameh.triki@rns.tn;info@rnecrwanda.org
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Comite de Protection Des Personnes Du Nord;National Ethics Committee Rwanda
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+21698266942;255107884
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>sameh.triki@rns.tn;info@rnecrwanda.org
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12593041
    </Internal_Number>
    <TrialID>CTRI/2021/08/035456
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Low dose magnesium sulphate for treatment of seizures in pregnancy
    </Public_title>
    <Scientific_title>A66014: Simplified Treatment for Eclampsia Prevention using Magnesium sulfate:  A phase III, randomized, open label, active controlled, multicountry, multicentre, non-inferiority trial of simplified magnesium sulfate regimen for eclampsia prophylaxis (The STEP-Mag Trial) - The STEP-Mag Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>World Health Organization
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210805
    </Date_registration3>
    <Date_registration>05-08-2021
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=56294
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>01-09-2021
    </Date_enrollement>
    <Target_size>12000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized, Parallel Group, Active Controlled Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Pre-numbered or coded identical Containers  Blinding and masking:Open Label
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Egypt;India;Kenya;Malawi;Nigeria;Rwanda;South Africa;Uganda
    </Countries>
    <Contact_Firstname>Dr Shivaprasad S Goudar
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Department of Physiology, KLE Academy of Higher Education and Research J N Medical College Nehru Nagar Belgaum Principal Investigator Womens and Childrens Health Research Unit Wing Belgaum 
    </Contact_Address>
    <Contact_Email>sgoudar@jnmc.edu
    </Contact_Email>
    <Contact_Tel>9448126371
    </Contact_Tel>
    <Contact_Affiliation>KLE Academy of Higher Education and Researchs J N Medical College
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Women meeting all of the following criteria: &lt;br/ &gt;&#x0D;&lt;br&gt;1. Be admitted with a diagnosis of pre-eclampsia and with clinical or laboratory indication(s) for magnesium sulfate treatment, as defined by any of the following: two readings of systolic blood pressure more than or equal to 160 mm Hg, or diastolic blood pressure more than or equal to 110 mm Hg along with more than or equal to 2+ proteinuria on urine dipstick; or the presence of symptoms, signs or laboratory findings suggestive of severe disease such as headache, visual disturbances, upper abdominal pain, pulmonary oedema, nausea and vomiting, hyperreflexia or clonus, elevated liver enzymes, raised serum creatinine, or thrombocytopenia. Women with HELLP syndrome, a severe form of pre-eclampsia characterized by Haemolysis, Elevated Liver enzymes, and Low Platelets (less than 100 cells per mcl) will be included if there is no clinical contraindication to IM injection.  &lt;br/ &gt;&#x0D;&lt;br&gt;2. Have not yet given birth but birth is planned or expected within the next 24 hours, or have given birth within the last 24 hours. &lt;br/ &gt;&#x0D;&lt;br&gt;3. Provide written informed consent before any trial-related procedures are carried out &lt;br/ &gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Women are not eligible if they fulfill any of the following exclusion criteria: &lt;br/ &gt;&#x0D;&lt;br&gt;1. Unable or unwilling to give informed consent (because the woman is too distressed or not capable to understand, confirm and give informed consent due to emergency or health condition, or does not wish to be randomized for whatever reason).   &lt;br/ &gt;&#x0D;&lt;br&gt;2. Less than 18 years of age. &lt;br/ &gt;&#x0D;&lt;br&gt;3. History of hypersensitivity to magnesium sulfate. &lt;br/ &gt;&#x0D;&lt;br&gt;4. Serious cardiovascular disorders (WHO classification III or IV or acute heart failure). &lt;br/ &gt;&#x0D;&lt;br&gt;5. Serious hepatic (encephalopathy or coma) or renal disease.  &lt;br/ &gt;&#x0D;&lt;br&gt;6. History of epilepsy. &lt;br/ &gt;&#x0D;&lt;br&gt;7. Myasthenia gravis or any muscular dystrophies. &lt;br/ &gt;&#x0D;&lt;br&gt;8. Coagulopathy. &lt;br/ &gt;&#x0D;&lt;br&gt;9. Have previously received magnesium sulfate for eclampsia prevention in the current pregnancy. &lt;br/ &gt;&#x0D;&lt;br&gt;10. Planned to receive magnesium sulfate regimen other than the regimens specified for the trial on account of other medical indication(s) (e.g. fetal neuroprotection). &lt;br/ &gt;&#x0D;&lt;br&gt;11. Known oliguria (less than 400mL urine in 24 hours) at the time of admission.
    </Exclusion_Criteria>
    <Condition>Health Condition 1: O159- Eclampsia, unspecified as to timeperiod&#x0D;

    </Condition>
    <Intervention>Intervention1: simplified regimen of Magnesium sulphate: Women in the intervention arm will receive the simplified regimen of two IM doses of 10g magnesium sulphate 12 hours apart&lt;br&gt;Control Intervention1: Active control arm: Women in the active control arm will receive either the standard IV (Zuspan) regimen consisting of IV injection of 4 g over 10-15 minutes as a loading dose, followed by a maintenance IV infusion of 1 g per hour for 24 hours (total dose 28g); or standard IM (Pritchard) regimen consisting of IV injection of 4 g over 10-15 minutes and IM injection of 10g as a loading dose, followed by a maintenance IM injection of 5 g every 4 hours for 24 hours (total dose 39g)&lt;br&gt;
    </Intervention>
    <Primary_outcome>Maternal eclamptic seizure (defined as occurrence of convulsions in a woman with features of pre-eclampsia that is unrelated to other neurological conditions)Timepoint: until the time of hospital discharge or transfer to a higher care unit or death
    </Primary_outcome>
    <Secondary_outcome>14. Indicators of severe neonatal morbidity (Apgar  less than 7 at 5 minutes, need for intubation at birth, ventilation, seizures, admission to neonatal intensive care or special care unit) &lt;br/ &gt;&#x0D;&lt;br&gt;15. Gestational age at birth, birthweight, small-for-gestational age &lt;br/ &gt;&#x0D;&lt;br&gt;16. Maternal satisfaction assessmentTimepoint: until the time of hospital discharge or transfer to a higher care unit or death;4. Indicators of severe maternal morbidity (respiratory arrest, cardiac arrest, coagulopathy, renal failure, liver failure, pulmonary oedema, and stroke) &lt;br/ &gt;&#x0D;&lt;br&gt;5. Maternal intensive care unit (ICU) admission &lt;br/ &gt;&#x0D;&lt;br&gt;6. Recurrence of seizures (for women with eclampsia)Timepoint: until the time of hospital discharge or transfer to a higher care unit or death;7. Maternal side effects of magnesium sulfate (nausea or vomiting, flushing of the skin, drowsiness, confusion, muscle weakness, problem at injection site Ã¢â?¬â?? pain, injection abscess with IM or IV administration)Timepoint: until the time of hospital discharge or transfer to a higher care unit or death;8. Mode of birth (caesarean section or vaginal birth) &lt;br/ &gt;&#x0D;&lt;br&gt;9. Induction of labour  &lt;br/ &gt;&#x0D;&lt;br&gt;10. Augmentation of labour &lt;br/ &gt;&#x0D;&lt;br&gt;11. Abruptio placenta &lt;br/ &gt;&#x0D;&lt;br&gt;12. Postpartum haemorrhage (estimated blood loss Ã¢â?°Â¥ 500 mL with vaginal birth or Ã¢â?°Â¥ 1000 mL with caesarean birth, treatment with additional uterotonics for haemorrhage, blood transfusion) &lt;br/ &gt;&#x0D;&lt;br&gt;13. Retained placentaTimepoint: until the time of hospital discharge or transfer to a higher care unit or death;Feasibility outcomes &lt;br/ &gt;&#x0D;&lt;br&gt;17. Recruitment rate (participants enrolled/centre/month) &lt;br/ &gt;&#x0D;&lt;br&gt;18. Indications for magnesium sulfate treatment &lt;br/ &gt;&#x0D;&lt;br&gt;19. Proportion of eligible participants consented &lt;br/ &gt;&#x0D;&lt;br&gt;20. Proportion of eligible and consented participants randomized &lt;br/ &gt;&#x0D;&lt;br&gt;21. Rates of participants receiving the allocated intervention &lt;br/ &gt;&#x0D;&lt;br&gt;22. Rates of adherence to treatment protocol for simplified and standard regimens &lt;br/ &gt;&#x0D;&lt;br&gt;23. Retention rates by allocation &lt;br/ &gt;&#x0D;&lt;br&gt;24. Incidence and completeness of primary outcome data  	Timepoint: until the time of hospital discharge or transfer to a higher care unit or death;Key secondary outcome &lt;br/ &gt;&#x0D;&lt;br&gt;1. Composite endpoint describing events related to maternal toxicity and consisting of one or more of the following: absent/reduced tendon reflexes, respiratory depression, use of calcium gluconate to counteract perceived/confirmed maternal toxicity, or stopping/reduced magnesium sulfate treatment in the event of perceived/confirmed maternal toxicityTimepoint: until the time of hospital discharge or transfer to a higher care unit or death;Other secondary outcomes &lt;br/ &gt;&#x0D;&lt;br&gt;2. Maternal death (all-cause and cause-specific) &lt;br/ &gt;&#x0D;&lt;br&gt;3. Death of baby before hospital discharge (stillbirth, perinatal death or neonatal death, for women enrolled before giving birth)Timepoint: until the time of hospital discharge or transfer to a higher care unit or death
    </Secondary_outcome>
    <Secondary_ID>A66014
    </Secondary_ID>
    <Source_Support>WHO/HRP and MSD for Mothers (Internal Pilot)
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>28/08/2021;13/10/2021;14/08/2021;03/08/2021;28/05/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Institutional Ethics Committee JJM Medical College Davangere;Institutional Ethics Committee of Gadag Institute of Medical Sciences, Gadag;Institutional Ethics Committee Raichur Institute of Medical Sciences;Institutional Ethics Committee SCB Medical College Cuttack;Institutional Ethics Committee, KLE Academy of Higher Education and Research, Belagavi
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12602393
    </Internal_Number>
    <TrialID>PACTR202107562417077
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled,  Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of  Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years and Older&#x0D;

    </Public_title>
    <Scientific_title>A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled,  Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of  Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years and Older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Livzon Mabpharm Inc
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210723
    </Date_registration3>
    <Date_registration>23/07/2021
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=16018
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>44 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/10/2021
    </Date_enrollement>
    <Target_size>22500
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously,Randomised,Stratified allocation where factors such as age, gender, center, or previous treatment are used in the stratification,Central randomisation by phone/fax
    </Study_design>
    <Phase>Phase-3
    </Phase>
    <Countries>Ghana;Ghana;Uganda;Uganda;Uganda;Uganda;Rwanda;Rwanda
    </Countries>
    <Contact_Firstname>Vincent 
    </Contact_Firstname>
    <Contact_Lastname>Mutabazi 
    </Contact_Lastname>
    <Contact_Address>KG 11 Avenue N47 PO Box 4560 
    </Contact_Address>
    <Contact_Email>mutabazivincent@gmail.com
    </Contact_Email>
    <Contact_Tel>250788302073
    </Contact_Tel>
    <Contact_Affiliation>Principal investigator 
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Voluntarily participate in this study and sign the informed consent form&#x0D;&lt;br&gt;Adults aged 18 years and older, male or female&#x0D;&lt;br&gt;According to the assessment of the investigator, the participant has a stable medical condition (which is defined as no significant changes in therapy or hospitalization caused by disease aggravation within 3 months before enrollment and are able to and willing to follow the requirements of the protocol&#x0D;&lt;br&gt;Males of reproductive potential and females of child-bearing potential voluntarily agree to take effective and acceptable contraceptive methods from the signing of informed consent form to 12 months after full-course immunization; females of child-bearing potential have negative pregnancy test at screening and at the day of vaccination 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria:  History of previous COVID19 infection &#x0D;&lt;br&gt;Positive result for RTPCR test in screening period, or specific antibody IgG or IgM meet the following conditions&#x0D;&lt;br&gt; If both IgG and IgM are negative the participant can be vaccinated without waiting for the RTPCR test results&#x0D;&lt;br&gt; History of severe acute respiratory syndrome SARS middle east respiratory syndrome MERS and other human coronavirus infections or diseases&#x0D;&lt;br&gt; History of severe allergy to any vaccine eg acute allergic reactions, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain etc or be allergic to any components of V01&#x0D;&lt;br&gt;Any confirmed or suspected immunosuppression or immunodeficiency condition known from medical history, including human immunodeficiency virus infection asplenia&#x0D;&lt;br&gt; Serious or uncontrolled cardiovascular diseases, nervous system disorders eg Guillain-Barre syndrome blood and lymphatic system disorders, immune system disorders, hepatorenal disorders, respiratory system disorders e g active tuberculosis, pulmonary fibrosis metabolic and skeletal systems disorders or malignant tumors except for skin basal cell carcinoma or in situ carcinoma of uterine cervix that has been cured more than 5 years&#x0D;&lt;br&gt; Hereditary hemorrhagic tendency or coagulation dysfunction, or a history of thrombosis or hemorrhagic disease, or requirement of continuous use of anticoagulants&#x0D;&lt;br&gt;Prior use of any medications to prevent COVID19 e g use of antipyretics without pyrexia and any other symptoms &#x0D;&lt;br&gt; History of vaccination against SARSCoV2 marketed or investigational&#x0D;&lt;br&gt; Received attenuated live vaccine within 28 days before the first vaccination or any other vaccines licensed or investigational within 14 days before the first vaccination&#x0D;&lt;br&gt; Injection of immunoglobulin and/or other blood products within 3 months before the administration of inves
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;severe acute respiratory syndrome coronavirus 2 SARS CoV 2;severe acute respiratory syndrome coronavirus 2 SARS CoV 2
    </Condition>
    <Intervention>;Placebo;Recombinant SARSCoV2 fusion protein vaccine V01
    </Intervention>
    <Primary_outcome>Primary Objectives&lt;br&gt;Efficacy:&lt;br&gt;To evaluate the efficacy of the recombinant SARS-CoV-2 fusion protein vaccine V-01 for the prevention of symptomatic RT-PCR-positive COVID-19 (mild or above severity) starting from at least 14 days (=15 days) after full-course immunization (completing all vaccinations)&lt;br&gt;Safety:&lt;br&gt;To evaluate the incidence of adverse events (AEs) of recombinant SARS-CoV-2 fusion protein vaccine (V-01) from the first vaccination to 28 days after full-course immunization;
    </Primary_outcome>
    <Secondary_outcome>Secondary Objectives:&#x0D;&lt;br&gt;Efficacy:&#x0D;&lt;br&gt;1. To evaluate the efficacy of the recombinant SARS-CoV-2 fusion protein vaccine (V-01) for the prevention of COVID-19 of severe&#x0D;&lt;br&gt;or above severity starting from at least 14 days 15 days) after full-course immunization;&#x0D;&lt;br&gt;? Definition of COVID-19 of severe or above severity (meeting any one of the following):&#x0D;&lt;br&gt;1) Tachypnea, respiratory rate = 30 breaths/min;&#x0D;&lt;br&gt;2) Oxygen saturation [SpO2]=93% at rest;&#x0D;&lt;br&gt;3) Arterial partial pressure of oxygen/fraction of inspired oxygen [PaO2/FiO2]=300mmHg (in the areas with altitude over 1000 meters, PaO2/FiO2 should be corrected according to the following formula: PaO2/FiO2×[760/atmospheric pressure (mmHg)]);&#x0D;&lt;br&gt;4) Progressive worsening of clinical symptoms; chest imaging showing significant lesion progression &gt; 50% within 24 to 48 hours (if any);&#x0D;&lt;br&gt;5) Respiratory failure and requiring mechanical ventilation;&#x0D;&lt;br&gt;6) Shock;&#x0D;&lt;br&gt;7) With other organ failure that requires intensive care unit (ICU) care.&#x0D;&lt;br&gt;2. To evaluate the efficacy of the recombinant SARS-CoV-2 fusion protein vaccine (V-01) for the prevention of symptomatic RT-PCR-positive COVID-19 (mild or above severity) starting from at least 14 days 15 days) after the first vaccination;&#x0D;&lt;br&gt;3. To evaluate the efficacy of the recombinant SARS-CoV-2 fusion protein vaccine (V-01) for the prevention of symptomatic RT-PCR-positive COVID-19 (mild or above severity) starting from at least 14 days 15 days) after full-course immunization in different age groups;&#x0D;&lt;br&gt;4. To evaluate the morbidity of suspected but not confirmed COVID-19 (negative or not detected);&#x0D;&lt;br&gt;5. To evaluate the mortality caused by COVID-19;&#x0D;&lt;br&gt;6. To evaluate the hospitalization rate caused by COVID-19;&#x0D;&lt;br&gt;Safety:&#x0D;&lt;br&gt;1. To evaluate the incidence of serious adverse events (SAEs) and adverse events of special interest (AESIs) occurred from the first dose of recombinant SARS-CoV-2 fusion protein vaccine (V-01) to 12 months after full-course immunization;
    </Secondary_outcome>
    <Source_Support>Livzon Mabpharm Inc
    </Source_Support>
    <Ethics_review_status>Not approved;Not approved;Not approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;01/01/1900;01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ethics@kintampo-hrc.org;aidan.kiseka@gmail.com;ing_valentine@yahoo.com
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Kintampo Health Research Centre Institutional Ethics Committee;the Research Ethics Committee of the Makerere University School of Public Health MUSPH;Rwanda National Ethics Committee RNEC
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>0556847860;256414321962;002502525510788
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ethics@kintampo-hrc.org;aidan.kiseka@gmail.com;ing_valentine@yahoo.com
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12517828
    </Internal_Number>
    <TrialID>ISRCTN45167024
    </TrialID>
    <Last_Refreshed_on>5 September 2022
    </Last_Refreshed_on>
    <Public_title>Eczema monitoring online via questionnaires
    </Public_title>
    <Scientific_title>Evaluation of the effect of symptom monitoring with patient-reported outcome measures on clinical outcomes in eczema: an online, parallel-group randomised controlled trial (EMO trial)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>University of Nottingham
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210629
    </Date_registration3>
    <Date_registration>29/06/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN45167024
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>14/09/2021
    </Date_enrollement>
    <Target_size>266
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Online parallel-group randomized controlled clinical trial (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe;Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Self-report or parent/carer report of eczema diagnosis by a healthcare professional&lt;br&gt;                2. Person aged 1 year or older&lt;br&gt;                3. Able and willing to provide informed consent&lt;br&gt;                4. If under 16 years old, a parent/carer needs to provide informed consent on behalf of the child&lt;br&gt;                5. Able to read and understand written English&lt;br&gt;                6. Have access to the internet and to an internet-enabled device&lt;br&gt;                7. POEM score of 3 or above at eligibility screening&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Unable/unwilling to provide informed consent&lt;br&gt;                2. Currently taking part in another eczema clinical trial&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Eczema &lt;br&gt;Skin and Connective Tissue Diseases &lt;br&gt;Dermatitis and eczema
    </Condition>
    <Intervention>This is a methodological trial and there will be no treatment intervention involved. The intervention will be the online Patient Oriented Eczema Measure (POEM) questionnaire. Eligible participants will be randomised online and assigned to either the intervention group or to the control group using the REDCap software. The randomisation schedule will be based on computer-generated codes using random permuted blocks of varying size, stratified by age and baseline disease severity. The PhD student will deal with participant queries, thus she will have access to group allocation, but the other trial team members and the trial statistician will remain blinded. Participants in the intervention group (weekly group) will be asked to complete the POEM questionnaire weekly for 8 weeks. The control group will not receive the intervention.
    </Intervention>
    <Primary_outcome>Eczema severity measured by the self-reported or proxy (parent/carer reported) POEM questionnaire score at baseline and 8 weeks
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Adherence to eczema treatment use, assessed in two ways:&lt;br&gt;                1.1. Eczema treatment use assessed by the emollient and topical corticosteroid use questionnaire over the last week from baseline to 8 weeks&lt;br&gt;                1.2. Eczema treatment use assessed by the overall eczema treatment use questionnaire 2 months prior to joining the study and at the end of the study at 8 weeks&lt;br&gt;                2. Missing data: the proportion of fully completed questionnaires at 8 weeks&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;EMO 120421
    </Secondary_ID>
    <Source_Support>University of Nottingham
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 23/04/2021, Faculty of Medicine &amp; Health Science Research Ethics Committee, University of Nottingham (Faculty Hub, Room E41, E Floor, Medical School, Queen's Medical Centre Campus, Nottingham University Hospitals, Nottingham, NG7 2UH, UK; +44 (0) 115 74 85060; FMHS-ResearchEthics@nottingham.ac.uk), ref: 239-0421
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>03/04/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12620165
    </Internal_Number>
    <TrialID>NCT04940039
    </TrialID>
    <Last_Refreshed_on>24 October 2022
    </Last_Refreshed_on>
    <Public_title>A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
    </Public_title>
    <Scientific_title>Clinical Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
    </Scientific_title>
    <Acronym>CASPAR
    </Acronym>
    <Primary_sponsor>Janssen-Cilag International NV
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210622
    </Date_registration3>
    <Date_registration>22/06/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04940039
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Years
    </Inclusion_agemin>
    <Inclusion_agemax>34 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 22, 2021
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Janssen-Cilag International NV Clinical Trial;Study Contact
    </Contact_Lastname>
    <Contact_Email>;Participate-In-This-Study@its.jnj.com
    </Contact_Email>
    <Contact_Tel>;844-434-4210
    </Contact_Tel>
    <Contact_Affiliation>Janssen-Cilag International NV;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of schizophrenia by Mini International Neuropsychiatric Interview&#x0D;&lt;br&gt;             (MINI)-Screen / MINI (Module K) that requires treatment initiation or a change in&#x0D;&lt;br&gt;             treatment to better address safety, efficacy, or adherence limitations of current&#x0D;&lt;br&gt;             treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Eligible for treatment in the Rwandan mental healthcare system&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  At least moderately ill as measured by the Clinical Global Impression - Severity of&#x0D;&lt;br&gt;             Schizophrenia (CGI-SS) scale for schizophrenia (rating of greater than or equal to&#x0D;&lt;br&gt;             [&gt;=] 4). This criterion needs to be re-confirmed at Visit 2&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has a primary caregiver who is willing to participate in this study (caregiver should&#x0D;&lt;br&gt;             be knowledgeable about the participant's condition, provide economic/cost of care&#x0D;&lt;br&gt;             information, and is expected to be with the participant for greater than [&gt;] 24 hours&#x0D;&lt;br&gt;             each week for the duration of the study)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A woman of childbearing potential must have a negative highly sensitive serum&#x0D;&lt;br&gt;             (beta-human chorionic gonadotropin [beta-hCG]) during screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to give consent to participate in a clinical study that includes treatment with&#x0D;&lt;br&gt;             risperidone and long-acting injectable (LAI) formulations of paliperidone palmitate.&#x0D;&lt;br&gt;             Participants must be willing to receive injections. The participant and the caregiver&#x0D;&lt;br&gt;             must sign their own informed consent form (ICF) indicating that he or she understands&#x0D;&lt;br&gt;             the purpose of, and procedures required for, the study and is willing to participate&#x0D;&lt;br&gt;             in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has a physical, mental, or legal incapacity that prevents a valid consent or capacity&#x0D;&lt;br&gt;             to complete about 12 months of treatment with antipsychotic medication and compliance&#x0D;&lt;br&gt;             with this study protocol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of organic brain syndromes, comorbid psychiatric and/or physical illnesses, or&#x0D;&lt;br&gt;             significant comorbid substance abuse that is likely to interfere with understanding of&#x0D;&lt;br&gt;             or compliance with study requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known allergies, hypersensitivity, or intolerance to risperidone or paliperidone&#x0D;&lt;br&gt;             palmitate or its excipients&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Received an investigational intervention including investigational vaccines or used an&#x0D;&lt;br&gt;             invasive investigational medical device within 30 days before the planned first dose&#x0D;&lt;br&gt;             of study intervention, or is currently enrolled in an investigational study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant, or breast-feeding, or planning to become pregnant while enrolled in this&#x0D;&lt;br&gt;             study or within 6 months after the last dose of study intervention&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Poor prior response to risperidone or paliperidone&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Schizophrenia
    </Condition>
    <Intervention>Drug: Risperidone 3 mg;Drug: Paliperidone Palmitate 50 mg eq.;Drug: Paliperidone Palmitate 75 mg eq.;Drug: Paliperidone Palmitate 100 mg eq.;Drug: Paliperidone Palmitate 150 mg eq.;Drug: Paliperidone Palmitate 175 mg eq.;Drug: Paliperidone Palmitate 263 mg eq.;Drug: Paliperidone Palmitate 350 mg eq.;Drug: Paliperidone Palmitate 525 mg eq.
    </Intervention>
    <Primary_outcome>Mean Change in Clinical Global Impression Severity of Schizophrenia (CGI-SS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [End of Study {EOS}])
    </Primary_outcome>
    <Secondary_outcome>Change in SQLS Score from Visit 2 (Week 1) to Visit 6 (Week 25);Number of Participants with Treatment-emergent Adverse Events;Number of Participants with Abnormalities in Clinical Laboratory Measures;Number of Participants with Abnormalities in Vital Signs;Number of Participants with Abnormalities in Electrocardiogram (ECG);Number of Participants with Abnormalities in Physical Examination;Number of Participants With Pregnancy Outcome as a Safety Measure;Mean Change in CGI-SS Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS]);Mean Change in CGI-SS Score from Visit 2 (Week 1) to Visit 6 (Week 25);Change in Personal and Social Performance (PSP) Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS]);Change in PSP Scale Scores from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS]);Change in PSP Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25);Change in Patient Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS]);Change in Patient Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS]);Change in Patient Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25);Change in Clinician Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS]);Change in Clinician Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS]);Change in Clinician Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25);Change in Schizophrenia Quality of Life Scale (SQLS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS]);Change in SQLS Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
    </Secondary_outcome>
    <Secondary_ID>R092670PSY4002;CR108924
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12602359
    </Internal_Number>
    <TrialID>PACTR202107499406828
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Role of Narrative Therapy Approach in Behavior Disorders Healing Process among Abandoned Children in Rwanda
    </Public_title>
    <Scientific_title>Role of Narrative Therapy Approach in Behavior Disorders Healing Process among Abandoned Children in Rwanda                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor/>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210619
    </Date_registration3>
    <Date_registration>19/06/2021
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=15954
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>12 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>09/03/2020
    </Date_enrollement>
    <Target_size>72
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously,Randomised,Dynamic (adaptive) random allocation such as minimization,Numbered containers
    </Study_design>
    <Phase>Phase-0
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>Emmanuel
    </Contact_Firstname>
    <Contact_Lastname>Biracyaza
    </Contact_Lastname>
    <Contact_Address>455 Kigali, Rwanda
    </Contact_Address>
    <Contact_Email>biracyazaemmaus@gmail.com
    </Contact_Email>
    <Contact_Tel>+250785686886
    </Contact_Tel>
    <Contact_Affiliation>District Manager
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: - Being children fostered in SOS Children’s villages of Kayonza, Kigali or Byumba; &#x0D;&lt;br&gt;- Being aged 6-12 years during the study period;&#x0D;&lt;br&gt;- Having at least one year fostered in SOS children’s villages;&#x0D;&lt;br&gt;- Children who did not attend Narrative Therapy for control group.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: - Children with severe psychiatric disorders or any other health conditions that would affect their judgment&#x0D;&lt;br&gt;- Children who denied providing assent &#x0D;&lt;br&gt;- Children whose mothers (guardians) refused their participation in this study
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Mental and Behavioural Disorders;Mental and Behavioural Disorders
    </Condition>
    <Intervention>;Narrative Therapy Approach ;Blinded
    </Intervention>
    <Primary_outcome>Children in Narrative Therapy group (experimental group) indicated a significant reduction of symptoms of psychological disorders and significant increase of psychological resilience.
    </Primary_outcome>
    <Secondary_outcome>-Our results that narrative therapy seems to contribute to a reduction of anxiety symptoms &#x0D;&lt;br&gt;-Narrative therapy contributed to a reduction of attention deficit hyperactivity disorders symptoms &#x0D;&lt;br&gt;- Narrative therapy seems to contribute to an increase of psychological resilience &#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Source_Support>Yes
    </Source_Support>
    <Secondary_Sponsor>University of Rwanda
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>23/12/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>researchcenter@ur.ac.rw
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>College of Medicine and Health Sciences Institutional Review Board at the University of Rwanda
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+250788563311
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>researchcenter@ur.ac.rw
    </Ethics_review_contact_email>
    <results_date_posted>21/06/2021
    </results_date_posted>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12373275
    </Internal_Number>
    <TrialID>ISRCTN12329547
    </TrialID>
    <Last_Refreshed_on>27 June 2022
    </Last_Refreshed_on>
    <Public_title>Trial of a digital depression management application: juli
    </Public_title>
    <Scientific_title>Randomised control trial of a digital depression management application: juli                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>University College London
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210608
    </Date_registration3>
    <Date_registration>08/06/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN12329547
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>21/06/2021
    </Date_enrollement>
    <Target_size>476
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Interventional placebo-controlled randomized controlled trial (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe;Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary
    </Countries>
    <Contact_Firstname>Bettina
    </Contact_Firstname>
    <Contact_Lastname>Dührkoop
    </Contact_Lastname>
    <Contact_Address>
                    Juli Health
                    23 Beach Ave
                
    </Contact_Address>
    <Contact_Email>bd@juli.co
    </Contact_Email>
    <Contact_Tel>+44 (0)20 7679 9736
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Depression with PHQ-8 score &gt;4 at baseline&lt;br&gt;                2. Age 18 to 65 years (inclusive)&lt;br&gt;                3. English speakers&lt;br&gt;                4. Have an iPhone&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. PHQ-8 &lt;5 at baseline&lt;br&gt;                2. Children&lt;br&gt;                3. Non-English speakers&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Depression &lt;br&gt;Mental and Behavioural Disorders &lt;br&gt;Depressive episode, unspecified
    </Condition>
    <Intervention>&lt;br&gt;                Participants will be randomly allocated using an online tool to receive the juli app or treatment as usual plus an attention placebo control app.&lt;br&gt;&lt;br&gt;                The participant will use the juli app for 8 weeks and complete a depression symptoms questionnaire every 2 weeks (four in total). Participants will also be asked to complete a wellbeing questionnaire at 4 and 8 weeks and a user satisfaction questionnaire at 8 weeks. These are all standardised questionnaires, commonly used for research (the 8-item Patient Health Questionnaire, the 12-item Short Form survey of health-related quality of life and the Mobile Health App Usability Questionnaire).&lt;br&gt;&lt;br&gt;                The full version of the app presents the participant with graphical displays of some data automatically generated from their phone and smartwatch. The types of data are:&lt;br&gt;                1. Sleep – time in bed and time asleep&lt;br&gt;                2. Activity – steps and flights of stairs climbed&lt;br&gt;                3. Heart rate variability – the variation in the time interval between heartbeats&lt;br&gt;                4. Workouts – periods of exercise&lt;br&gt;                5. Oxygen saturation&lt;br&gt;                6. Menstrual cycle&lt;br&gt;&lt;br&gt;                It also presents them with external data: weather, pollen count and air quality (provided via geolocation). It asks the participant to rate how they are feeling and answer questions about their mood on a daily basis. It allows them to set a medication reminder, and add notes to a journal. It presents them with correlations between these different types of data and helps them to identify things that make their mood better or worse.&lt;br&gt;&lt;br&gt;                Participants allocated to the dummy version of the app will be asked to rate how they are feeling on a daily basis, but will not
    </Intervention>
    <Primary_outcome>Depression symptoms measured using the eight-item Patient Health Questionnaire (PHQ-8) at 8 weeks
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Depression symptoms measured using the PHQ-8 at 2, 4 and 6 weeks&lt;br&gt;                2. Health-related quality of life measured using Short Form 12 (SF-12) Item at 4 and 8 weeks&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known
    </Secondary_ID>
    <Source_Support>Juli Health
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 07/06/2021, UCL Research Ethics Committee (Office of the Vice-Provost (Research), University College London, 2 Taviton St, London, WC1E 6BT, UK; +44 (0)20 7679 8717; ethics@ucl.ac.uk), ref: 19413/001
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/08/2023
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12373274
    </Internal_Number>
    <TrialID>ISRCTN87679686
    </TrialID>
    <Last_Refreshed_on>27 June 2022
    </Last_Refreshed_on>
    <Public_title>Trial of a digital asthma management application: juli
    </Public_title>
    <Scientific_title>Randomised controlled trial of a digital asthma management application: juli                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>University College London
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210608
    </Date_registration3>
    <Date_registration>08/06/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN87679686
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>21/06/2021
    </Date_enrollement>
    <Target_size>180
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Interventional placebo-controlled randomized controlled trial (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Bettina
    </Contact_Firstname>
    <Contact_Lastname>Dührkoop
    </Contact_Lastname>
    <Contact_Address>
                    juli Health
                    23 Beach Ave
                
    </Contact_Address>
    <Contact_Email>bd@juli.co
    </Contact_Email>
    <Contact_Tel>+44 (0)20 7679 9736
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Asthma with Asthma Control Test score&lt;20 at baseline&lt;br&gt;                2. Age 18 to 65 (inclusive)&lt;br&gt;                3. English speaker&lt;br&gt;                4. Have an iPhone&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Asthma Control Test&gt;19 at baseline&lt;br&gt;                2. Children&lt;br&gt;                3. Non-English speakers&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Reduction of asthma symptoms in adults with asthma &lt;br&gt;Respiratory &lt;br&gt;Asthma
    </Condition>
    <Intervention>&lt;br&gt;                Use of juli app vs treatment as usual (plus attention placebo control app).&lt;br&gt;&lt;br&gt;                juli app: Participants will be prompted to open the app each day via an automated alert. They will be asked to rate how they are feeling on a scale using 5 emojis and track number of shortness of breath episodes, rescue inhaler usage and night time waking with shortness of breath. The app will gather information via Apple HealthKit; sleep, activity, workouts, oxygen saturation. It will present this data to the participant and show associations with asthma symptoms. It will make recommendations about these parameters to guide healthy behaviours and will use external data sources (weather, air quality, pollen count) to guide these recommendations. The app has a medication reminder function that can be set by the participants to improve medication adherence. Participants are also encouraged to engage in journaling via the app, especially in relation to exacerbating or reliving factors for asthma symptoms.&lt;br&gt;&lt;br&gt;                Attention placebo control app: Participants will be prompted to open the app each day via an automated alert and rate how they are feeling on a scale using 5 emojis.&lt;br&gt;&lt;br&gt;                The participant will use the app for eight weeks and complete an asthma questionnaire every two weeks (four in total). Participants will also be asked to complete a well-being questionnaire at four and eight weeks and a user satisfaction questionnaire at eight weeks.&lt;br&gt;
    </Intervention>
    <Primary_outcome>Asthma symptoms measured using the Asthma Control Test at 8 weeks
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Asthma symptoms measured using the Asthma Control Test at 2, 4, and 6 weeks&lt;br&gt;                2. Short Form 12 Item health-related quality of life at 4 and 8 weeks&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;Nil known
    </Secondary_ID>
    <Source_Support>juli Health
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 07/06/2021, UCL Research Ethics (Office of the Vice-Provost (Research), University College London, 2 Taviton St, London, WC1E 6BT, UK; +44 (0)20 7679 8717; ethics@ucl.ac.uk), ref: 19413/001
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/08/2023
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11101804
    </Internal_Number>
    <TrialID>NCT04932239
    </TrialID>
    <Last_Refreshed_on>28 June 2021
    </Last_Refreshed_on>
    <Public_title>Effectiveness of Road Traffic Crashes First-aid Education Among Commercial Motorcyclists in Kigali-City, Rwanda
    </Public_title>
    <Scientific_title>Effectiveness of Road Traffic Crashes First-aid Education on Knowledge, Attitude, and Practice Among Commercial Motorcyclists in Kigali-City, Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Universiti Putra Malaysia
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210528
    </Date_registration3>
    <Date_registration>28/05/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04932239
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 15, 2021
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Single (Participant). 
    </Study_design>
    <Phase>Early Phase 1
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>SOH KIM LAM, Prof.;KULANTHAYAN KC MANI, Prof.;TWAGIRUMUGABE THEOGENE, Assoc. Prof.;Rosliza Abdul Manaf, Assoc. Prof.;UFASHINGABIRE MINANI CHRISTINE, PhD student;TWAGIRUMUGABE THEOGENE, Assoc.Prof.
    </Contact_Lastname>
    <Contact_Email>;;;;ufachristine@gmail.com;twagirumugabe@gmail.com
    </Contact_Email>
    <Contact_Tel>;;;;01169687293;+250788539904
    </Contact_Tel>
    <Contact_Affiliation>Universiti Putra Malaysia;Universiti Putra Malaysia;Butare university Teaching Hospital;Universiti Putra Malaysia;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be a citizen of Rwanda and a commercial motorcyclist working in one&#x0D;&lt;br&gt;             of the Districts, Gasabo, Nyarugenge, and Kicukiro.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must have the age of 18 years and above.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be able to read, write and speak Kinyarwanda (mother tongue)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must have at least a primary school level of education.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must have a motorcycle driving license.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Commercial motorcyclists with physical disabilities&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>First Aid Education for Road Traffic Crashes
    </Condition>
    <Intervention>Other: first aid education
    </Intervention>
    <Primary_outcome>Change of knowledge on road traffic crashes first aid;Change in attitudes on road traffic crashes first aid;Change in reported practice toward first aid provision
    </Primary_outcome>
    <Secondary_ID>JKEUPM-2021-173
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11033245
    </Internal_Number>
    <TrialID>NCT04912414
    </TrialID>
    <Last_Refreshed_on>14 June 2021
    </Last_Refreshed_on>
    <Public_title>Brief Family Therapy (BFT) for the Treatment of Psychosomatic Symptoms in Rwanda
    </Public_title>
    <Scientific_title>Brief Family Therapy (BFT) for the Treatment of Psychosomatic Symptoms in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Rwanda
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210526
    </Date_registration3>
    <Date_registration>26/05/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04912414
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>59 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 1, 2020
    </Date_enrollement>
    <Target_size>120
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Francoise Uwizeye, Mr.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Rwanda
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Being aged 18-59 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Being diagnosed Medically Unexplained Symptoms at least more than once with the&#x0D;&lt;br&gt;             similar symptoms.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Being with psychosomatic at least more than 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having no will to participate in the study;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Not signing the informed consents to participate&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Patient Engagement
    </Condition>
    <Intervention>Behavioral: Brief Family Therapy (BFT)
    </Intervention>
    <Primary_outcome>Psychosomatic Symptom Checklist (PSC-17)
    </Primary_outcome>
    <Secondary_ID>017/CMHS IRB/2020
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11576561
    </Internal_Number>
    <TrialID>NCT04861870
    </TrialID>
    <Last_Refreshed_on>8 November 2021
    </Last_Refreshed_on>
    <Public_title>Bandebereho 6 Year Follow up RCT in Rwanda
    </Public_title>
    <Scientific_title>Bandebereho Randomized Control Trial: Six Year Follow-up to Assess the Impact of a Gender-transformative Intervention With Couples to Promote Men's Engagement in Maternal, Newborn and Child Health, Caregiving and Healthier Couple Relations
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Promundo, United States
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210419
    </Date_registration3>
    <Date_registration>19/04/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04861870
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>35 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 15, 2021
    </Date_enrollement>
    <Target_size>2818
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Kate E Doyle;Ruti G Levtov;Fidele Rutayisire;Shamsi Kazimbaya;Felix Sayinzoga
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>Promundo-US;Prevention Collaborative;Rwanda Men's Resource Centre;Promundo-US;Rwanda Biomedical Centre
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria at baseline:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Men aged 21-35 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Living with a partner&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Expectant (or soon to be) father or father of young children under-5&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Living in an area with a group facilitator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria at baseline:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        - Participated in previous cycles of the same intervention&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Gender Relations;Violence;Child Development;Contraception;Prenatal Care;Partner Communication
    </Condition>
    <Intervention>Behavioral: MenCare+/Bandebereho fathers'/couples' group education
    </Intervention>
    <Primary_outcome>Women's experiences of intimate partner violence (physical &amp; sexual);Use of violence/harsh punishment against children;Observation-based child development measure;Child behavior assessment
    </Primary_outcome>
    <Secondary_outcome>Family planning;Antenatal care (ANC) service utilization;Antenatal care (ANC) accompaniment;Parenting behaviors with children;Parenting behaviors and adjustment;Time spent/gender division of caregiving/domestic tasks and paid work
    </Secondary_outcome>
    <Secondary_ID>RWN6YR
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Rwanda Men's Resource Centre
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12602285
    </Internal_Number>
    <TrialID>PACTR202104845356660
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Developing Triple Artemisinin Combination Therapies Trial in Africa
    </Public_title>
    <Scientific_title>A multi-centre randomised controlled non-inferiority trial to compare the efficacy, safety and tolerability of Triple Artemisinin-based Combination Therapies versus first-line ACTs + placebo for the treatment of uncomplicated Plasmodium falciparum malaria in Africa&#x0D;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210414
    </Date_registration3>
    <Date_registration>14/04/2021
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=15824
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>1 Month(s)
    </Inclusion_agemin>
    <Inclusion_agemax>23 Month(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/09/2020
    </Date_enrollement>
    <Target_size>3240
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Permuted block randomization,Sealed opaque envelopes
    </Study_design>
    <Phase>Phase-3
    </Phase>
    <Countries>Burkina Faso;Gambia;Guinea;Niger;Nigeria;Democratic Republic of the Congo;Rwanda;Tanzania
    </Countries>
    <Contact_Firstname>Mehul
    </Contact_Firstname>
    <Contact_Lastname>Dhorda
    </Contact_Lastname>
    <Contact_Address>420/6 Ratchawithi Road, Ratchathewi
    </Contact_Address>
    <Contact_Email>Mehul@tropmedres.ac
    </Contact_Email>
    <Contact_Tel>+6622036333
    </Contact_Tel>
    <Contact_Affiliation>Project Coordinator
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: • Male or female, aged =6 months to &lt;12 years (For Gambia, Rwanda sites only: =6 months)&#x0D;&lt;br&gt;• Ability to take oral medication&#x0D;&lt;br&gt;• Acute uncomplicated P. falciparum monoinfection&#x0D;&lt;br&gt;• Asexual P. falciparum parasitaemia: 1,000/µL to =10% parasitaemia, determined on a peripheral blood film (At Gambia, Rwanda sites only: For subjects =12 years – 1000/µL to 200,000/µL)&#x0D;&lt;br&gt;• Fever defined as = 37.5°C tympanic temperature or a history of fever within the last 24 hours&#x0D;&lt;br&gt;• Written informed consent by the subject or by the parent/guardian in case of children lower than the age of consent and assent if required (per local regulations)&#x0D;&lt;br&gt;• Willingness and ability of the subjects or parents/guardians to comply with the study protocol for the duration of the study&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: ?Signs of severe malaria (adapted from WHO criteria)&#x0D;&lt;br&gt;?Patients not fulfilling criteria for severe malaria but with another indication for parenteral antimalarial treatment at the discretion of the treating physician&#x0D;&lt;br&gt;?Haematocrit &lt;15% at screening (For Gambia, Rwanda sites only: For subjects =12 years – Haematocrit &lt;20% at screening)&#x0D;&lt;br&gt;?Subjects who have received artemisinin or a derivative within the previous 7 days OR lumefantrine or amodiaquine within the previous 14 days OR mefloquine or piperaquine within the previous 30 days&#x0D;&lt;br&gt;?In applicable countries: use of seasonal malaria chemoprophylaxis (SMC) within the last 14 days.&#x0D;&lt;br&gt;?Acute illness other than malaria requiring systemic treatment;&#x0D;&lt;br&gt;?Severe acute malnutrition (in Niger only – only those patients with Severe Acute Malnutrition and complications requiring inpatient nutritional treatment will be excluded)&#x0D;&lt;br&gt;?Known HIV infection&#x0D;&lt;br&gt;?Known tuberculosis infection&#x0D;&lt;br&gt;?For females: post-menarche (For Gambia, Rwanda sites only: females who are pregnant, trying to get pregnant or are lactating)&#x0D;&lt;br&gt;?History of allergy or known contraindication to any of the study drugs, including neuropsychiatric disorders and epilepsy&#x0D;&lt;br&gt;?Previous splenectomy&#x0D;&lt;br&gt;?Enrolment in DeTACT in the previous 3 months&#x0D;&lt;br&gt;?Participation in another interventional study in the previous 3 months
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Malaria;Malaria
    </Condition>
    <Intervention>;Artemether Lumefantrine;Artesunate Mefloquine;Artemether Lumefantrine Amodiaquine;Artesunate Mefloquine Piperaquine
    </Intervention>
    <Primary_outcome>42-day efficacy defined as PCR-corrected adequate clinical and parasitological response (ACPR).&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>For safety and tolerability: Incidence of adverse events and serious adverse events within the first 42 days including markers of hepatic, renal or bone marrow toxicity; cardiotoxicity, in particular QT or QTc-interval above 500 ms at timepoint H4 and H52/H64 and between these time points; change in haemoglobin concentration at day 3, 7, 28, stratified for G6PD status/genotype; proportion of subjects requiring retreatment due to vomiting within 1 hour after administration of the study drugs; proportion of subjects that reports completing a full course of observed TACT or ACT without withdrawal of consent or exclusion from study because of drug related serious adverse event ;For efficacy: 63-day PCR corrected and uncorrected efficacy; 42-day PCR uncorrected efficacy; parasite clearance half-life assessed by microscopy as primary parameter to determine parasite clearance; proportion of subjects with microscopically detectable P. falciparum parasitaemia at Day 3; fever clearance time (i.e. the time taken for the tympanic temperature to fall below 37.5 ºC in  patients who were febrile at inclusion); proportion of subjects with gametocytaemia during and after treatment stratified by presence of gametocytes at enrolment.&#x0D;&lt;br&gt;;For PK/PD interactions: Pharmacokinetic profiles and interactions (including Cmax and AUC) of artemisinin-derivatives and partner drugs in ACT and TACT treated subjects in correlation with pharmacodynamics measures of drug efficacy; day 7 plasma levels of partner drugs in correlation with treatment efficacy and treatment arm 
    </Secondary_outcome>
    <Source_Support>Foreign and Commonwealth Development Office 
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>25/04/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>oxtrec@admin.ox.ac.uk
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Oxford Tropical Research Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+44186528210
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>oxtrec@admin.ox.ac.uk
    </Ethics_review_contact_email>
    <results_url_link>https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/data-sharing
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10837047
    </Internal_Number>
    <TrialID>NCT04834999
    </TrialID>
    <Last_Refreshed_on>19 April 2021
    </Last_Refreshed_on>
    <Public_title>Validation of Instruments for Clinical Trial on Patients With Bipolar Disorder in Rwanda
    </Public_title>
    <Scientific_title>Validation and Transcultural Adaptation of Instruments Used in a Clinical Trial on Patients With Bipolar Disorder in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Aarhus
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210406
    </Date_registration3>
    <Date_registration>06/04/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04834999
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 15, 2021
    </Date_enrollement>
    <Target_size>500
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Per Kallestrup, Prof.;Caroline J Arnbjerg, Msc;Emmanuel Musoni Rwililiza, Msc
    </Contact_Lastname>
    <Contact_Email>;caroline.arnbjerg@ph.au.dk;rwimus@gmail.com
    </Contact_Email>
    <Contact_Tel>;+250786917224;+250788568244
    </Contact_Tel>
    <Contact_Affiliation>University of Aarhus;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Participants for validation of the YMRS and the MARS:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with a diagnosis of BD type I or II, that meets DSM-IV diagnostic criteria&#x0D;&lt;br&gt;             given by a trained psychiatrist&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Participants for validation of the ISMI-9:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A diagnosis of mental disorder that meets DSM-IV diagnostic criteria given by a&#x0D;&lt;br&gt;             trained psychiatrist&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Participants for validation of the MDQ:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient with a diagnosis of BD type I or II, or major depression that meets DSM-IV&#x0D;&lt;br&gt;             diagnostic criteria given by a trained psychiatrist&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Volunteers with no history or family history of the psychiatric disorder will be&#x0D;&lt;br&gt;             recruited as controls.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria for all participants:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Insufficient understanding of Kinyarwanda&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical evidence of substantial cognitive impairments.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Mental Disorder
    </Condition>
    <Intervention>Other: Validation of questionnaires in Kinyarwanda
    </Intervention>
    <Primary_outcome>Adaption and validation of the Rwandese version of the Mood Disorder Questionnaire for screening for Bipolar Disorder;Adaption and validation of the Rwandese version of the Medication Adherence Rating Scale (MARS).;Adaption and validation of the Rwandese version of The Internalized Stigma of Mental Illness Scale-9 (ISMI-9);Adaption and validation of the Rwandese version of the Young Mania Rating Scale
    </Primary_outcome>
    <Secondary_ID>AUUR2020DKRW_4
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Rwanda;Mental Health Centre Copenhagen
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12630910
    </Internal_Number>
    <TrialID>NCT04765384
    </TrialID>
    <Last_Refreshed_on>31 October 2022
    </Last_Refreshed_on>
    <Public_title>A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)
    </Public_title>
    <Scientific_title>An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants
    </Scientific_title>
    <Acronym>HORIZON 1
    </Acronym>
    <Primary_sponsor>Janssen Vaccines &amp; Prevention B.V.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210219
    </Date_registration3>
    <Date_registration>19/02/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04765384
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>45 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>August 27, 2021
    </Date_enrollement>
    <Target_size>51
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>United States;Brazil;South Africa;Brazil;South Africa;United States;Australia;Canada;Finland;Rwanda;Spain;United Kingdom
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Janssen Vaccines &amp; Prevention B.V. Clinical Trial
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Janssen Vaccines &amp; Prevention B.V.
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If on medication for a condition, the medication dose must have been stable for at&#x0D;&lt;br&gt;             least 4 weeks preceding vaccination&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be healthy as confirmed by medical history, physical examination,&#x0D;&lt;br&gt;             vital signs, and obstetric history performed at Screening. Participant may have&#x0D;&lt;br&gt;             underlying illnesses, as long as the symptoms and signs are medically controlled&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant will be at second or third trimester of pregnancy, that is, Week 16 to&#x0D;&lt;br&gt;             Week 38 of gestation (inclusive), at the time of vaccination, based on ultrasound at&#x0D;&lt;br&gt;             the time of screening (or not longer than 10 days prior to vaccination if performed&#x0D;&lt;br&gt;             elsewhere)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant agrees to not donate bone marrow, blood, and blood products from the first&#x0D;&lt;br&gt;             study vaccine administration until 3 months after receiving the last dose of study&#x0D;&lt;br&gt;             vaccine&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be willing to provide verifiable identification, has means to be&#x0D;&lt;br&gt;             contacted and to contact the investigator during the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant either received their last COVID-19 vaccination with an&#x0D;&lt;br&gt;             authorized/licensed COVID-19 vaccine (at least 4 months prior to first study&#x0D;&lt;br&gt;             vaccination) or is COVID 19 vaccine-naïve&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants with medical or obstetric histories that put them at higher risk for&#x0D;&lt;br&gt;             maternal or fetal complications (example, chronic pregnancy-related disorders, birth&#x0D;&lt;br&gt;             defects or genetic conditions during previous pregnancy)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant with abnormal pregnancy screening test (example, ultrasound fetal&#x0D;&lt;br&gt;             abnormalities, maternal blood screen)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has a history of malignancy within 2 years before screening (exceptions&#x0D;&lt;br&gt;             are squamous, basal cell carcinomas of the skin, carcinoma in situ of the cervix, or&#x0D;&lt;br&gt;             malignancy, considered cured with minimal risk of recurrence)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has a known or suspected allergy or history of anaphylaxis or other&#x0D;&lt;br&gt;             serious adverse reactions to vaccines or their excipients (including specifically the&#x0D;&lt;br&gt;             excipients of the study vaccine)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has a history of any serious, chronic, or progressive neurological&#x0D;&lt;br&gt;             disorders or seizures including Guillain-Barre syndrome, with the exception of febrile&#x0D;&lt;br&gt;             seizures during childhood&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has a positive diagnostic test result (polymerase chain reaction [PCR]&#x0D;&lt;br&gt;             based viral ribonucleic acid [RNA] detection) severe acute respiratory syndrome&#x0D;&lt;br&gt;             coronavirus-2 (SARS-CoV-2) infection at screening or Day 1 (if more than 4 days in&#x0D;&lt;br&gt;             between)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has a history of thrombosis with thrombocytopenia syndrome (TTS),&#x0D;&lt;br&gt;             including cerebral venous sinus thrombosis (CVST), or heparin-induced thrombocytopenia&#x0D;&lt;br&gt;             (HIT)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has a history of capillary leak syndrome (CLS)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>COVID-19 Prevention
    </Condition>
    <Intervention>Biological: Ad26.COV2.S
    </Intervention>
    <Primary_outcome>Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Vaccination or Until Resolution;Number of Participants with Solicited Systemic AEs for 7 Days After Vaccination or Until Resolution;Number of Participants with Unsolicited AEs;Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Adverse Events of Special Interest (AESIs);Number of Participants with Medically-attended Adverse Events (MAAEs);Number of Participants with AEs leading to Discontinuation;Serological Response to Vaccination as Measured by Enzyme-linked Immunosorbent Assay (ELISA) 28 Days After Vaccination
    </Primary_outcome>
    <Secondary_outcome>Group 4: Number of Adult Participants with Solicited Local AEs for 7 Days After Booster Vaccination or Until Resolution;Group 4: Number of Adult Participants with Solicited Systemic AEs for 7 Days After Booster Vaccination or Until Resolution;Group 4: Number of Adult Participants with Unsolicited AEs For 28 Days After Booster Vaccination;Group 4: Number of Adult Participants with SAEs Throughout the Study (From Booster Vaccination Until End of the Study [EOS]);Group 4: Number of Adult Participants with AESIs Throughout the Study (From Booster Vaccination Until EOS);Group 4: Number of Adult Participants with MAAEs Until 6 Months After Booster Vaccination;Number of Adult Participants with AEs leading to Discontinuation (During the Entire Study);Number of Adult Participants with Pregnancy Outcomes;Number of Adult Participants with Pregnancy Related AEs;Serological Response to Vaccination as Measured by ELISA and/or Equivalent Assay, at all Blood Collection Timepoints in Adult Participants;Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers, 28 Days After Vaccination in Adult Participants;Group 4: Serological Response to Booster Vaccination Measured by Binding (S-ELISA and/or Equivalent Assay) in Adult Participants;Group 4: Serological Response to Booster Vaccination Measured by Neutralizing (VNA) Antibody Titers in Adult Participants;Serological Response to Vaccination as Measured by ELISA and/or Equivalent Assay in Infants and Neonates;Serological Response to Vaccination as Measured by VNA Titers at Birth in Neonates and Infants;Number of Neonates and Infants with SAEs;Number of Neonates and Infants with AESIs;Number of Neonates and Infants with MAAEs;Number of Neonates and Infants with AEs leading to Study Discontinuation;Number of Neonates and Infants with or without any Complications, Anomalies and Deaths
    </Secondary_outcome>
    <Secondary_ID>2020-005330-14;VAC31518COV2004;CR108962
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10750449
    </Internal_Number>
    <TrialID>ISRCTN56646695
    </TrialID>
    <Last_Refreshed_on>22 March 2021
    </Last_Refreshed_on>
    <Public_title>Integrating self-affirmation content into a smoking cessation mobile app
    </Public_title>
    <Scientific_title>Integrating the use of self-affirmation content into a mobile app to promote quit attempts with text-based smoking cessation intervention messaging                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>National Cancer Institute
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210212
    </Date_registration3>
    <Date_registration>12/02/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN56646695
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>07/03/2018
    </Date_enrollement>
    <Target_size>500
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized 2 x 2 factorial design (integrated affirmation: affirmation texts present versus absent; baseline affirmation: questionnaire present versus absent) (Prevention)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Elizabeth
    </Contact_Firstname>
    <Contact_Lastname>Seaman
    </Contact_Lastname>
    <Contact_Address>600 Peachtree St NE #1000
    </Contact_Address>
    <Contact_Email>eseaman@cdcfoundation.org
    </Contact_Email>
    <Contact_Tel>+1 (0)4438524139
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                A randomly selected proportion of users who downloaded the free version of the Smoke Free-Quit Smoking Now mobile application during the study period (initially 10% and then increased to 30% to achieve recruitment goals) are shown a consent form and invited to participate in this study. Once participants who opted in completed the baseline assessment, their eligibility was determined. In order to participate, app users had to be:&lt;br&gt;                1. Adults (between the ages of 18-98)&lt;br&gt;                2. Selected a cessation date after the day they downloaded the app but not more than 14 days in the future&lt;br&gt;                3. Completed the baseline assessment&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Under 18 years or over 98 years old&lt;br&gt;                2. Selected a quit date more than 14 days in the future or more than 1 day in the past&lt;br&gt;                3. Paid for additional app features (Pro users)&lt;br&gt;                4. Did not complete the baseline assessment&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Smoking cessation among current smokers &lt;br&gt;Not Applicable
    </Condition>
    <Intervention>Two types of self-affirmation inductions (Integrated, Baseline) were added to a publicly available smoking cessation mobile application (Smoke-Free Quit Smoking Now). All users who met the inclusion criteria, provided consent to participate and completed a baseline assessment, were randomized to 1 of 4 conditions. Half of the participants were randomly assigned to complete a self-affirmation induction upon study entry. Orthogonally, half of the participants were randomly assigned to receive self-affirming text notifications during their quit attempt or to receive conventional notifications. The induction and the text notifications were fully automated, and all data were collected through self-assessments in the mobile application. Self-reported smoking cessation was assessed 1 month and 3 months following study entry.
    </Intervention>
    <Primary_outcome>Smoking cessation measured through self-assessments in the mobile application: past-week cessation at 1 month, past-month cessation at 1 month, past-week cessation at 3 months, and past-month cessation at 3 months
    </Primary_outcome>
    <Secondary_outcome>Optimism and baseline mood states (happiness, anger, anxiousness, hopefulness, sadness) measured through self-assessments in the mobile application at baseline 
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;17CN039
    </Secondary_ID>
    <Source_Support>National Cancer Institute
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 12/04/2018, the National Institutes of Health Intramural Institutional Review Board (Office of Human Subjects Research Protections, 6700B Rockledge Drive, Suite 4300, Bethesda, MD 20817, USA; +1 301 402 3713; irb@od.nih.gov), ref: #17CN039
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>06/03/2019
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12486752
    </Internal_Number>
    <TrialID>NCT04767217
    </TrialID>
    <Last_Refreshed_on>22 August 2022
    </Last_Refreshed_on>
    <Public_title>Malaria Therapeutic Efficacy Study, Rwanda
    </Public_title>
    <Scientific_title>Evaluation of the Efficacy of Artemether-lumefantrine and Dihydroartemisinin-piperaquine in Children With Uncomplicated Clinical Malaria in Rural Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Jhpiego
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210211
    </Date_registration3>
    <Date_registration>11/02/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04767217
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>59 Months
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 14, 2021
    </Date_enrollement>
    <Target_size>528
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Noella Umulisa, MD
    </Contact_Lastname>
    <Contact_Email>noella.umulisa@jhpiego.org
    </Contact_Email>
    <Contact_Tel>+250788539836
    </Contact_Tel>
    <Contact_Affiliation/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12206568
    </Internal_Number>
    <TrialID>NCT04742725
    </TrialID>
    <Last_Refreshed_on>2 May 2022
    </Last_Refreshed_on>
    <Public_title>A Study to Evaluate the Efficacy and Safety of Prothione™ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19)
    </Public_title>
    <Scientific_title>A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Prothione™ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Prothione, LLC
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210203
    </Date_registration3>
    <Date_registration>03/02/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04742725
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 25, 2021
    </Date_enrollement>
    <Target_size>231
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Laura Lile, MD,RPh;Vincent Mutabazi, MD;Albert Crum, MD
    </Contact_Lastname>
    <Contact_Email>;;
    </Contact_Email>
    <Contact_Tel>;;
    </Contact_Tel>
    <Contact_Affiliation>Innate FFAAP Medicines, L.L.C.;Research, Epidemiology and Training Programs: RASD Rwanda;Innate FFAAP Medicines, L.L.C.
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Potential subjects are required to meet all of the following criteria for enrollment into&#x0D;&lt;br&gt;        the study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male or female adult = 18 years of age at time of enrollment with mild to moderate&#x0D;&lt;br&gt;             symptoms caused by coronavirus 2019 confirmed infection with COVID-19 by PCR and one&#x0D;&lt;br&gt;             or more of the following:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Mild (uncomplicated) Illness:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Diagnosed with COVID-19 by a standardized RT-PCR assay AND&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Mild symptoms, such as fever, rhinorrhea, mild cough, sore throat, malaise,&#x0D;&lt;br&gt;                  headache, muscle pain, or malaise, but with no shortness of breath AND&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  No signs of a more serious lower airway disease AND RR&lt;20, HR &lt;90, oxygen&#x0D;&lt;br&gt;                  saturation (pulse oximetry) &gt; 93% on room air&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Moderate Illness:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Diagnosed with COVID-19 by a standardized RT-PCR assay AND&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  In addition to symptoms above, more significant lower respiratory symptoms,&#x0D;&lt;br&gt;                  including shortness of breath (at rest or with exertion) OR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Signs of moderate pneumonia, including RR = 20 but &lt;30, HR = 90 but less than&#x0D;&lt;br&gt;                  125, oxygen saturation (pulse oximetry) &gt; 93% on room air AND&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  If available, lung infiltrates based on X-ray or CT scan &lt; 50% present&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subjects with normal level of Vitamin B2; Note: If the result was below the normal&#x0D;&lt;br&gt;             range, based on clinical judgment by physician, appropriate treatment to be added to&#x0D;&lt;br&gt;             the subject treatment regimen as per standard of care. A B complex daily supplement&#x0D;&lt;br&gt;             will be supplied, if needed.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Subject (or legally authorized representative) provides written informed consent prior&#x0D;&lt;br&gt;             to initiation of any study procedures;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Understands and agrees to comply with planned study procedures; and&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Negative pregnancy test for female subjects. Women of child-bearing potential (WOCBP)&#x0D;&lt;br&gt;             and Women not of child-bearing potential are eligible to participate. Both women of&#x0D;&lt;br&gt;             child-bearing potential and women of no child-bearing potential should use an approved&#x0D;&lt;br&gt;             method of birth control and agrees to continue to use this method for the duration of&#x0D;&lt;br&gt;             the study (and for 30 days after taking the last dose of Prothione™ ).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Acceptable methods of contraception include abstinence, female subject/partner's use of&#x0D;&lt;br&gt;        hormonal contraceptive (oral, implanted, or injected) in conjunction with a barrier method&#x0D;&lt;br&gt;        (WOCBP only), female subject/partner's use of an intrauterine device (IUD), or if the&#x0D;&lt;br&gt;        female subject/partner is surgically sterile or 2 years post-menopausal. All male&#x0D;&lt;br&gt;        subjects/partners must agree to consistently and correctly use a condom for the duration of&#x0D;&lt;br&gt;        the study. In addition, subjects may not donate sperm for the duration of the study and for&#x0D;&lt;br&gt;        30 days after taking study drug.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Potential subjects meeting any of the following criteria will be excluded from enrollment:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subjects showing signs of acute respiratory distress syndrome (ARDS) or respiratory&#x0D;&lt;br&gt;             failure necessitating mechanical ventilation at the time of screening;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subjects who have history of receiving NAC, Prothione™ Capsules or GSH supplements in&#x0D;&lt;br&gt;             the past 30 days before the screening visit;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Subjects who have history of receiving corticosteroids (topical corticosteroid is&#x0D;&lt;br&gt;             excluded) in the past 30 days;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Subjects who are currently receiving Chemotherapy or Immunotherapy for the treatment&#x0D;&lt;br&gt;             of cancer;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Any uncontrolled active systemic infection requiring admission to an intensive care&#x0D;&lt;br&gt;             unit (ICU);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Subject with active Hepatitis B and Hepatitis C;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Subjects who are participating in other clinical trials;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Subjects that have had any Covid19 Vaccination;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Subjects who have a history of allergic reactions attributed to compounds of similar&#x0D;&lt;br&gt;             chemical or biologic composition to Prothione™ are not eligible;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Inability to provide informed consent or to comply with study requirements; and&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Subjects who are pregnant or breast-feeding.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Coronavirus Disease 2019 (COVID-19)
    </Condition>
    <Intervention>Drug: Placebo;Drug: Prothione™ (6g)
    </Intervention>
    <Primary_outcome>Time (days) to successful clinical recovery from positive RT-PCR for SARS-COV2 as indicated by two consecutive negative RT-PCR tests measured with three different measurements within a 24-36 hour period.
    </Primary_outcome>
    <Secondary_outcome>Change from Baseline to Day 29 in Serum 8-OHdG levels;Change in RBC intracellular Glutathione levels to Day 29;Quantitative change from Baseline (Screening Visit) to Day 29 oropharyngeal cell intracellular GSH levels;Time to clinical resolution (TTCR) defined as the time (days) from initiation of study treatment until reach a score of 0 at least in three of the following: o Fever o Myalgia o Dyspnea o Cough;Evaluate Cycle Threshold (Ct) numbers used in qualitative and quantitative RT-PCR for SARS-COV2 tests.;Clinical Improvement as assessed by change in symptom score from baseline (for fever, myalgia, dyspnea and cough).;Mortality at Day 29
    </Secondary_outcome>
    <Secondary_ID>TAL-PRO-001
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12602162
    </Internal_Number>
    <TrialID>PACTR202102626263606
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria - KAE609B12201(KARISMA)
    </Public_title>
    <Scientific_title>An adaptive, randomized, active-controlled, open-label, sequential cohort, multicenter study to evaluate the&#x0D;
efficacy, safety, tolerability, and pharmacokinetics of intravenous cipargamin (KAE609) in adult and pediatric&#x0D;
participants with severe Plasmodium falciparum malaria (KARISMA - KAE609's Role In Severe Malaria)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Novartis Pharma AG
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210122
    </Date_registration3>
    <Date_registration>22/01/2021
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=14630
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>2 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>5 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>28/06/2021
    </Date_enrollement>
    <Target_size>252
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Stratified allocation where factors such as age, gender, center, or previous treatment are used in the stratification,Central randomisation by phone/fax
    </Study_design>
    <Phase>Phase-2
    </Phase>
    <Countries>Democratic Republic of the Congo;Gabon;Cote Divoire;Cote Divoire;Nigeria;Rwanda;India;India;India;Uganda;Kenya;Mozambique
    </Countries>
    <Contact_Firstname>Marc
    </Contact_Firstname>
    <Contact_Lastname>Cousin
    </Contact_Lastname>
    <Contact_Address>Novartis Campus, Forum 3, Novartis Pharma AG
    </Contact_Address>
    <Contact_Email>marc.cousin@novartis.com
    </Contact_Email>
    <Contact_Tel>+41795704543
    </Contact_Tel>
    <Contact_Affiliation>Global Trial Director
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Cohort 1: Participants aged = 12 years with moderately severe malaria as defined in (prostration and/or repeated vomiting) without presence of other signs of severe malaria (and with high P. falciparum parasitemia (60,000-250,000 parasites per µl)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Subsequent Cohorts 2 to 5: Participants diagnosed with severe malaria as defined in modified version of WHO criteria and P. falciparum parasite count of = 5000 per µl&#x0D;&lt;br&gt;Cohort 2: Participants aged = 12 years&#x0D;&lt;br&gt;Cohort 3: Participants aged 6 - &lt; 12 years&#x0D;&lt;br&gt;Cohort 4: Participants aged 2 - &lt; 6 years&#x0D;&lt;br&gt;Cohort 5: Participants aged = 6 months - &lt; 2 years
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: To all Cohorts 1 to 5:&#x0D;&lt;br&gt;- Mixed Plasmodium infections&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;- Treatment with quinine or artemisinin derivative or any other antimalarial drug or any antibiotic with known antimalarial activity within 12 hours of screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;- Signs/symptoms of severe malnutrition in accordance with WHO guidelines: &#x0D;&lt;br&gt;1. Under 18 years: &lt;-3 Z-scores of WHO growth standard for weight-for-height/length (in children &lt; 5 years) or BMI for age (5-18 years), or very low mid-upper arm circumference (MUAC &lt; 115 mm in children &lt; 12 years, &lt; 160mm 12-18 years), or bilateral pitting edema&#x0D;&lt;br&gt;2. Over 18 years: BMI &lt; 16 kg/m2 or MUAC &lt; 160mm or bilateral pitting edema&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;- Known underlying illness, surgical or medical condition, which is not related to ongoing event of severe malaria and which might jeopardize the participant's health in case of participation in the study or which might alter the distribution, metabolism or excretion of study treatment. For example:&#x0D;&lt;br&gt;1. neurological or neurodegenerative disorders,&#x0D;&lt;br&gt;2. cardiac, renal, or hepatic disease, diabetes,&#x0D;&lt;br&gt;3. epilepsy, cerebral palsy,   &#x0D;&lt;br&gt;4. known or suspected to be HIV-1 positive and/or receiving antiretroviral treatment&#x0D;&lt;br&gt;5. malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases  &#x0D;&lt;br&gt;6.known or suspected cases of active infections or concurrent febrile illness such as TB, Typhoid, COVID-19 etc.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;for Cohort 1:&#x0D;&lt;br&gt;- ALT &gt; 5 x the upper limit of normal range (ULN), regardless the level of total bilirubin&#x0D;&lt;br&gt;- Total bilirubin is &gt; 3 mg/dL&#x0D;&lt;br&gt;- Body weight of &lt; 35 kg or &gt;75 kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;for Cohort 2:&#x0D;&lt;br&gt;- Body weight of &lt; 35 kg or &gt;75 kg&#x0D;&lt;br&gt;- moderately severe malaria due to repeated vomiting without presence of any of the symptoms of severe malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;for Cohorts 3 to 5:&#x0D;&lt;br&gt;- Body weight of &lt; 5 kg&#x0D;&lt;br&gt;- moderately severe malaria due to repeated vomiting without presence of any of the symptoms of severe malaria&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Malaria;Malaria
    </Condition>
    <Intervention>;IV KAE609;IV Artesunate
    </Intervention>
    <Primary_outcome>Percentage of participants achieving at least 90% reduction in Plasmodium falciparum (P. falciparum) at 12 hours [ Time Frame: Day 1 (12 Hours) ]&lt;br&gt;A blood draw will be performed at each collection time point for parasitemia assessment.
    </Primary_outcome>
    <Secondary_outcome>4.Percentage of participants with neurological sequelae at Day 29 [ Time Frame: Day 29 ]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Detailed neurological examination will be conducted and relevant medical history collected under the following categories to assess the extent of neurological signs and symptoms at baseline and to monitor the extent of neurological sequelae in follow-up visits:&#x0D;&lt;br&gt;a.Consciousness&#x0D;&lt;br&gt;b.Cranial Nerve Palsy&#x0D;&lt;br&gt;c.Motor system&#x0D;&lt;br&gt;d.Convulsions&#x0D;&lt;br&gt;e.Sense organs (Examination more useful at time of hospital discharge and in follow-up visits)&#x0D;&lt;br&gt;;1. Percentage of participants achieving clinical success over time [ Time Frame: Day 3 (48 Hours), Day 4 to Day 29 ]&#x0D;&lt;br&gt;Clinical success is a composite endpoint based on following criterias:&#x0D;&lt;br&gt;a.Is participant dead or alive&#x0D;&lt;br&gt;b.Presence of asexual parasites (yes/no)&#x0D;&lt;br&gt;c.Presence of any of the key signs of severe malaria (yes/no)&#x0D;&lt;br&gt;;2. Percentage of participants with individual signs of severe malaria over time [ Time Frame: Day 1 to Day 29 ]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Individual signs of severe malaria over time will be monitored for the presence of the following signs of severe malaria during the entire study duration:&#x0D;&lt;br&gt;a.Altered consciousness - Prostration or GCS &lt; 11 for participants &gt; 5 years / BCS &lt; 3 for participants =&lt; 5 years of age&#x0D;&lt;br&gt;b.Renal Impairment - Serum creatinine &gt; 3xULN or &gt; 3 mg/dL or need for renal replacement therapy&#x0D;&lt;br&gt;c.Acidosis - Serum lactate &gt; 4 mmol/L&#x0D;&lt;br&gt;d.Respiratory distress - present or absent&#x0D;&lt;br&gt;e.Severe anemia - Hb &lt; 5 g/dl or Hb &lt; 7g/dl in pediatric and adults respectively or need of blood transfusion&#x0D;&lt;br&gt;f.Jaundice - Serum bilirubin &gt; 3 g/dl&#x0D;&lt;br&gt;g.Hypoglycemia- plasma glucose &lt; 40 mg/dL&#x0D;&lt;br&gt;;3. Percentage of participants developing hemolysis (early and delayed) after treatment [ Time Frame: Day 8 and Day 29 ]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Development (early and delayed) of hemolysis after treatment are defined as follows:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Early Hemolytic anemia is defined as 10% or greater decrease in hemoglobin levels and an increase of LDH levels to &gt;390 U/L, or an increase of &gt;= 10% above baseline occurring up to Day 8 of the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Delayed hemolytic anemia might occur &gt; 7 days after initiation of parenteral study drug (IV artesunate or IV cipargamin) during the study period. The event is characterized by a 10% or greater decrease in hemoglobin levels accompanied by increase of LDH levels to &gt;390 U/L, or an increase of &gt;= 10% compared to the values measured at Day 8 of the study.&#x0D;&lt;br&gt;;5.Percentage of participants achieving at least 90% reduction in Plasmodium falciparum (P. falciparum) [ Time Frame: Day 2 (24 hours), Day 3 (48 hours) ]&#x0D;&lt;br&gt;A blood draw will be performed at each collection time point for parasitemia assessment;6.Time to parasite clearance (PCT) [ Time Frame: Day 1 (12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours) ]&#x0D;&lt;br&gt;Parasite Clearance Time (PCT) is defined as the time from the first dose until the first total and continued disappearance of asexual parasite forms which remained at least a further 24 hours;7.Time to fever clearance (FCT) [ Time Frame: Day 1 (12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours) ]&#x0D;&lt;br&gt;Fever Clearance Time (FCT) is defined as the time from the first dose until the first time the axillary body temperature decreased below and remained below 37.5°C axillary or 38.0°C oral/tympanic/rectal for at least a further 24 hours.;8.Percentage of participants achieving P. falciparum parasite reduction ratios (PRR) at 12, 24 and 48 hours [ Time Frame: Day 1 (12 hours), Day 2 (24 hours) and Day 3 (48 hours) ]&#x0D;&lt;br&gt;PRR is defined as the ratio of asexual parasite at baseline divided by asexual parasite at post-baseline. If the asexual parasite count at post-baseline is 0, the half value of detection limit will be used to calculate the ratio.;9.Percentage of participants with recrudescence and reinfection [ Time Frame: Day 29 ]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Time to event (recrudescence or reinfection) will be calculated from the time of first study medication to the date of first event if a patient experiences the event and be censored at the time of last parasite assessment if a patient does not experience the event due to whatever reason.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Reinfection is defined as appearance of asexual parasites after clearance of initial infection with a genotype different from those parasites present at baseline.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Recrudescence is defined as appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at baseline.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Reinfection and Recrudescence must be confirmed by PCR analysis.&#x0D;&lt;br&gt;;10.Time to recover from prostration [ Time Frame: Day 1 to Day 29 ]&#x0D;&lt;br&gt;To assess recovery of participants as measured by time (days and hours) to discharge from hospital or recovery from prostration compared to baseline.&#x0D;&lt;br&gt;;11.Time to switch to oral therapy [ Time Frame: Day 3 to Day 29 ]&#x0D;&lt;br&gt;Time to switch participants from IV therapy to Coartem (standard of drug for oral therapy) will be analyzed.;12.Time to discharge from hospital [ Time Frame: Day 3 to Day 29 ]&#x0D;&lt;br&gt;All participants will be hospitalized. Time (Days and Hours) to discharge from hospital will be analyzed.&#x0D;&lt;br&gt;;13.Number of Participants impacted on safety and tolerability assessments [ Time Frame: Day 1 to Day 29 ]&#x0D;&lt;br&gt;Adverse events (AE), Serious Adverse events (SAEs) will be collected from first dosing, Death including whether in-hospital death and routine laboratory assessments will be done up to last follow-up visit or until the event has resolved to baseline grade or better or the event was assessed stable by the investigator or the participant was lost to follow-up or withdrew consent.;14.Observed maximum plasma concentration (Cmax) of IV Cipargamin [ Time Frame: Day 1 - Day 8 ]&#x0D;&lt;br&gt;Blood samples will be collected for activity-based pharmacokinetics characterization. Cmax will be listed and summarized using descriptive statistics.;15.Time of maximum observed drug concentration occurrence (Tmax) of IV Cipargamin [ Time Frame: Day 1 - Day 8 ]&#x0D;&lt;br&gt;Blood samples will be collected for activity-based pharmacokinetics characterization. Tmax will be listed and summarized using descriptive statistics.&#x0D;&lt;br&gt;;16.Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of IV Cipargamin [ Time Frame: Day 1 - Day 8 ]&#x0D;&lt;br&gt;Blood samples will be collected for activity-based pharmacokinetics characterization. AUClast will be listed and summarized using descriptive statistics.;17.Area under the concentration time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) of IV Cipargamin [ Time Frame: Day 1 - Day 8 ]&#x0D;&lt;br&gt;Blood samples will be collected for activity-based pharmacokinetics characterization. AUC(0-inf) will be listed and summarized using descriptive statistics.;18.Area Under the plasma concentration-time Curve from the time 0 to the last observed quantifiable concentration (AUC(0-t)) of IV Cipargamin [ Time Frame: Day 1 - Day 8 ]&#x0D;&lt;br&gt;Blood samples will be collected for activity-based pharmacokinetics characterization. AUC(0-t) will be listed and summarized using descriptive statistics.;19.AUC(0-t) divided by the dose administered (AUC(0- t)/D) of IV Cipargamin [ Time Frame: Day 1 - Day 8 ]&#x0D;&lt;br&gt;Blood samples will be collected for activity-based pharmacokinetics characterization. AUC(0-t)/D will be listed and summarized using descriptive statistics.&#x0D;&lt;br&gt;;20.Terminal elimination half life (T^1/2) of IV Cipargamin [ Time Frame: Day 1 - Day 8 ]&#x0D;&lt;br&gt;Blood samples will be collected for activity-based pharmacokinetics characterization. The half-live will be listed and summarized using descriptive statistics.;21.Total systemic clearance for intravenous administration (CL) of IV Cipargamin [ Time Frame: Day 1 - Day 8 ]&#x0D;&lt;br&gt;Blood samples will be collected for activity-based pharmacokinetics characterization. CL will be listed and summarized using descriptive statistics.;22.volume of distribution during the terminal phase following intravenous elimination (Vz) of IV Cipargamin [ Time Frame: Day 1 - Day 8 ]&#x0D;&lt;br&gt;Blood samples will be collected for activity-based pharmacokinetics characterization. Vz will be listed and summarized using descriptive statistics.
    </Secondary_outcome>
    <Secondary_ID>CKAE609B12201
    </Secondary_ID>
    <Source_Support>Welcome Trust;European and Developing Countries Clinical Trials Partnership EDCTP
    </Source_Support>
    <Ethics_review_status>Not approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;07/12/2020;05/01/2021;28/01/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>cnergabon@gmail.com;lazarpoame@hotmail.com;info@uith.org;espsec_unikin@yahoo.fr
    </Ethics_review_contact_name>
    <Ethics_review_contact_address> Comite National Ethique pour la Recherche CNER;Comite Consultatif National de Bioethique de la Republique de Cote DIvoire;UITH ERC;Universite de Kinshasa
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+24105816968;+22502037504;+2348105657675;+243817493194
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>cnergabon@gmail.com;lazarpoame@hotmail.com;info@uith.org;espsec_unikin@yahoo.fr
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10420986
    </Internal_Number>
    <TrialID>ISRCTN95140761
    </TrialID>
    <Last_Refreshed_on>5 January 2021
    </Last_Refreshed_on>
    <Public_title>An international study to investigate rates of death and illness following surgery of the pancreas
    </Public_title>
    <Scientific_title>International Pancreatic Surgery Outcomes Study - PancreasGroup.org                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Royal Free London NHS Foundation Trust
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201203
    </Date_registration3>
    <Date_registration>03/12/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN95140761
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/01/2021
    </Date_enrollement>
    <Target_size>3500
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational cohort study (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United States Minor Outlying Islands;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Adults 18 years of age or older&lt;br&gt;                2. All indications (including benign and malignant)&lt;br&gt;                3. Open, laparoscopic or robotic&lt;br&gt;                4. Elective or emergency&lt;br&gt;                5. Partial or total pancreatectomies&lt;br&gt;                6. Pancreatic tumour enucleations&lt;br&gt;                7. Procedures with concomitant vascular or other organ resections&lt;br&gt;                8. Pancreatic duct drainage procedures (e.g. Frey, Puestow, or Beger)&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Pancreas or islet cell transplantation&lt;br&gt;                2. Transcutaneous or transgastric imaging-guided ablation (e.g. RFA) or electroporation (e.g. NanoKnife)&lt;br&gt;                3. Endoscopic (e.g. ERCP, stent or lithotripsy) procedures&lt;br&gt;                4. Endoscopic transgastric and surgical necrosectomies&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Patients with pancreatic disease requiring surgery &lt;br&gt;Surgery
    </Condition>
    <Intervention>Participants, agreeing to be part of this study, will be observed from the date of surgery until hospital discharge as well as 90 days after their operation. Fully anonymised data will be collected including the participant, their disease, operation characteristics as well as outcomes, such as events including death and illness.
    </Intervention>
    <Primary_outcome>Mortality rate 90 days postoperatively measured using patient records
    </Primary_outcome>
    <Secondary_outcome>Morbidity as defined by the Clavien-Dindo Classification and measured by the Comprehensive Complications Index ® (CCI®) at 90 days postoperatively measured using patient records
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;RFH287_20-21
    </Secondary_ID>
    <Source_Support>Royal Free Charity - Fiorina Fund
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>No ethics approval required. Registered and approved as an audit by the Royal Free Hospital Quality Governance Department with the ID number RFH287_20-21
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>31/03/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12551402
    </Internal_Number>
    <TrialID>NCT04675931
    </TrialID>
    <Last_Refreshed_on>3 October 2022
    </Last_Refreshed_on>
    <Public_title>To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
    </Public_title>
    <Scientific_title>An Adaptive, Randomized, Active-controlled, Open-label, Sequential Cohort, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Intravenous Cipargamin (KAE609) in Adult and Pediatric Participants With Severe Plasmodium Falciparum Malaria (KARISMA - KAE609's Role In Severe Malaria)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Novartis Pharmaceuticals
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201201
    </Date_registration3>
    <Date_registration>01/12/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04675931
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 7, 2022
    </Date_enrollement>
    <Target_size>252
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Congo;Côte D'Ivoire;India;Nigeria;Rwanda;Congo;Côte D'Ivoire;India;Nigeria;Rwanda;Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Novartis Pharmaceuticals;Novartis Pharmaceuticals
    </Contact_Lastname>
    <Contact_Email>;novartis.email@novartis.com
    </Contact_Email>
    <Contact_Tel>;+41613241111
    </Contact_Tel>
    <Contact_Affiliation>Novartis Pharmaceuticals;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cohort 1: Participants aged = 12 years with moderately severe malaria as defined in&#x0D;&lt;br&gt;             (prostration and/or repeated vomiting) without presence of other signs of severe&#x0D;&lt;br&gt;             malaria (and with high P. falciparum parasitemia (60,000-250,000 parasites per µl)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Subsequent Cohorts 2 to 5: Participants diagnosed with severe malaria as defined&#x0D;&lt;br&gt;                  in modified version of WHO criteria and P. falciparum parasite count of = 5000&#x0D;&lt;br&gt;                  per µl&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Cohort 2: Participants aged = 12 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Cohort 3: Participants aged 6 - &lt; 12 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Cohort 4: Participants aged 2 - &lt; 6 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Cohort 5: Participants aged = 6 months - &lt; 2 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria applying to all Cohorts 1 to 5:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mixed Plasmodium infections&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Treatment with quinine or artemisinin derivative or any other antimalarial drug or any&#x0D;&lt;br&gt;             antibiotic with known antimalarial activity within 12 hours of screening.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signs/symptoms of severe malnutrition in general accordance with WHO guidelines:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Under 18 years: &lt;-3 Z-scores of WHO growth standard for weight-for-height/length&#x0D;&lt;br&gt;                  (in children &lt; 5 years) or BMI for age (5-18 years), or very low mid-upper arm&#x0D;&lt;br&gt;                  circumference (MUAC &lt; 115 mm in children &lt; 12 years, &lt; 160mm 12-18 years), or&#x0D;&lt;br&gt;                  bilateral pitting edema&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Over 18 years: BMI &lt; 16 kg/m2 or MUAC &lt; 160mm or bilateral pitting edema&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known underlying illness, surgical or medical condition, which is not related to&#x0D;&lt;br&gt;             ongoing event of severe malaria and which might jeopardize the participant's health in&#x0D;&lt;br&gt;             case of participation in the study or which might alter the distribution, metabolism&#x0D;&lt;br&gt;             or excretion of study treatment. For example:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. neurological or neurodegenerative disorders,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. cardiac, renal, or hepatic disease, diabetes,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. epilepsy, cerebral palsy,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. known or suspected to be HIV-1 positive and/or receiving antiretroviral treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               5. malignancy of any organ system (other than localized basal cell carcinoma of the&#x0D;&lt;br&gt;                  skin or in situ cervical cancer), treated or untreated, within the past 5 years,&#x0D;&lt;br&gt;                  regardless of whether there is evidence of local recurrence or metastases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               6. known or suspected cases of active infections or concurrent febrile illness such&#x0D;&lt;br&gt;                  as TB, Typhoid, COVID-19 etc.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Additional exclusion criteria are as follows:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria for Cohort 1:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ALT &gt; 5 x the upper limit of normal range (ULN), regardless the level of total&#x0D;&lt;br&gt;             bilirubin&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Total bilirubin is &gt; 3 mg/dL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Body weight of &lt; 35 kg or &gt;75 kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria for Cohort 2:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Body weight of &lt; 35 kg or &gt;75 kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants diagnosed as moderately severe malaria due to repeated vomiting without&#x0D;&lt;br&gt;             presence of any of the symptoms of severe malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria for Cohorts 3 to 5:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Body weight of &lt; 5 kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants diagnosed as moderately severe malaria due to repeated vomiting without&#x0D;&lt;br&gt;             presence of any of the symptoms of severe malaria&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Severe Malaria
    </Condition>
    <Intervention>Drug: KAE609;Drug: IV Artesunate;Drug: Coartem
    </Intervention>
    <Primary_outcome>Percentage of participants achieving at least 90% reduction in Plasmodium falciparum (P. falciparum) at 12 hours
    </Primary_outcome>
    <Secondary_outcome>Percentage of participants achieving clinical success over time;Percentage of participants with individual signs of severe malaria over time;Percentage of participants developing hemolysis (early and delayed) after treatment;Percentage of participants with neurological sequelae at Day 29;Percentage of participants achieving at least 90% reduction in Plasmodium falciparum (P. falciparum);Time to parasite clearance (PCT);Time to fever clearance (FCT);Percentage of participants achieving P. falciparum parasite reduction ratios (PRR) at 12, 24 and 48 hours;Percentage of participants with recrudescence and reinfection;Time to recover from prostration;Time to switch to oral therapy;Time to discharge from hospital;Number of Participants impacted on safety and tolerability assessments;Observed maximum plasma concentration (Cmax) of IV Cipargamin;Time of maximum observed drug concentration occurrence (Tmax) of IV Cipargamin;Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of IV Cipargamin;Area under the concentration time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) of IV Cipargamin;Area Under the plasma concentration-time Curve from the time 0 to the last observed quantifiable concentration (AUC(0-t)) of IV Cipargamin;AUC(0-t) divided by the dose administered (AUC(0- t)/D) of IV Cipargamin;Terminal elimination half life (T^1/2) of IV Cipargamin;Total systemic clearance for intravenous administration (CL) of IV Cipargamin;volume of distribution during the terminal phase following intravenous elimination (Vz) of IV Cipargamin
    </Secondary_outcome>
    <Secondary_ID>217692/Z/19/Z;CKAE609B12201
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Wellcome Trust;European and Developing Countries Clinical Trials Partnership (EDCTP)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10836106
    </Internal_Number>
    <TrialID>NCT04648982
    </TrialID>
    <Last_Refreshed_on>19 April 2021
    </Last_Refreshed_on>
    <Public_title>Psychiatric Inpatient Discharge Data - Rwanda
    </Public_title>
    <Scientific_title>Psychiatric Inpatient Discharge Data - Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Aarhus
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201124
    </Date_registration3>
    <Date_registration>24/11/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04648982
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 1, 2020
    </Date_enrollement>
    <Target_size>1000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Per Kallestrup, Prof.;Caroline J Arnbjerg, Msc
    </Contact_Lastname>
    <Contact_Email>;caroline.arnbjerg@ph.au.dk
    </Contact_Email>
    <Contact_Tel>;+250786917224
    </Contact_Tel>
    <Contact_Affiliation>University of Aarhus;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All patients discharged from the inpatient psychiatric unit at Ndera Hospital, Rwanda&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  none&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Mental Disorder
    </Condition>
    <Intervention>Other: Admission to inpatient psychiatric unit
    </Intervention>
    <Primary_outcome>Diagnosis;Psychiatric comorbidity;Somatic comorbidity;Alcohol or drug addiction;Medical drug provided during this hospitalisation;Who made the referral;Number of previous hospitalisations;Insurance
    </Primary_outcome>
    <Secondary_ID>AUUR2020DKRW_2
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Rwanda;Mental Health Centre Copenhagen
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10836203
    </Internal_Number>
    <TrialID>NCT04671225
    </TrialID>
    <Last_Refreshed_on>19 April 2021
    </Last_Refreshed_on>
    <Public_title>Psychoeducation for Patients With Bipolar Disorder in Rwanda
    </Public_title>
    <Scientific_title>Psychoeducation for Patients With Bipolar Disorder in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Aarhus
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201124
    </Date_registration3>
    <Date_registration>24/11/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04671225
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 15, 2021
    </Date_enrollement>
    <Target_size>150
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Per Kallestrup, Prof.;Caroline J Arnbjerg, Msc
    </Contact_Lastname>
    <Contact_Email>;caroline.arnbjerg@ph.au.dk
    </Contact_Email>
    <Contact_Tel>;+250786917224
    </Contact_Tel>
    <Contact_Affiliation>University of Aarhus;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A diagnosis of BD type I or II that meets DSM-V diagnostic criteria given by a trained&#x0D;&lt;br&gt;             psychiatrist&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No episode in the preceding 4 weeks. Age = 18 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous participation in any structured psychological intervention&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Insufficient understanding of Kinyarwanda&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical evidence of substantial cognitive impairments.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Alcohol or drug-dependence&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Bipolar Disorder
    </Condition>
    <Intervention>Behavioral: Groups Psychoeducation;Behavioral: Waiting-list
    </Intervention>
    <Primary_outcome>Number of patients that relapse
    </Primary_outcome>
    <Secondary_outcome>Number of patient reporting improvement in medical adherence;Number of patient reporting reduction in self-stigma;Improvement of illness severity;Acceptability of the intervention
    </Secondary_outcome>
    <Secondary_ID>AUUR2020DKRW
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Rwanda;Mental Health Centre Copenhagen
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12635176
    </Internal_Number>
    <TrialID>ISRCTN13539303
    </TrialID>
    <Last_Refreshed_on>31 October 2022
    </Last_Refreshed_on>
    <Public_title>An international registry of coronavirus exposure in pregnancy
    </Public_title>
    <Scientific_title>International Registry of Coronavirus Exposure in Pregnancy (IRCEP)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Pregistry LLC
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20201030
    </Date_registration3>
    <Date_registration>30/10/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN13539303
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>08/06/2020
    </Date_enrollement>
    <Target_size>25000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Prospective observational study (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe;Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan
    </Countries>
    <Contact_Firstname>Diego;Sonia
    </Contact_Firstname>
    <Contact_Lastname>Wyszynski;Hernandez-Diaz
    </Contact_Lastname>
    <Contact_Address>
                    1801 Century Park East
                    25th Floor
                ;677 Huntington Avenue
    </Contact_Address>
    <Contact_Email>hello@pregistry.com;shernan@hsph.harvard.edu
    </Contact_Email>
    <Contact_Tel>+1 (747) 200-5468;+1 (617) 432-3942
    </Contact_Tel>
    <Contact_Affiliation>;
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Adult pregnant women with clinical confirmation of COVID-19 or tested for SARS-CoV-2 at any time during their pregnancy
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Subjects who do not meet the inclusion criteria
    </Exclusion_Criteria>
    <Condition>COVID-19 (SARS-CoV-2 infection) during pregnancy &lt;br&gt;Infections and Infestations &lt;br&gt;COVID-19 (SARS-CoV-2 infection)
    </Condition>
    <Intervention>&lt;br&gt;                The IRCEP will be an observational cohort study with prospective and retrospective components. Registration and participation via website or mobile app specially developed for the IRCEP will be voluntary. Women 18 years of age and older will be encouraged to enrol if at any time during pregnancy, they had a test performed for the coronavirus (regardless of the result) or if they had clinical confirmation of COVID-19 in the absence of a SARS-CoV-2 test. Women with confirmed COVID-19 via clinical or test methods will be included in the exposed group and women with a negative test will be included in the control group. Eligible women will be able to enrol at any time during gestation. Given the public health emergency due to the COVID-19 pandemic and the urgent need for data, the IRCEP will also enrol eligible women retrospectively during the first 180 days after delivery (if they delivered after December 2019).&lt;br&gt;&lt;br&gt;                As numbers accumulate, the natural history of COVID-19 during pregnancy will be reported stratified by days since COVID-19 confirmation at enrollment (i.e., from prospective if immediate to retrospective if enrolled after resolution) and the risk of pregnancy outcomes by COVID-19 exposure group will be reported stratified by trimester at enrollment. For the assessment of miscarriages, only participants enrolled during the first trimester will be included and the analyses will be stratified by gestational week at enrollment. For other outcomes, the primary analysis will include all enrollees. However, sensitivity analyses of 1) teratogenicity will be restricted to participants enrolled before an informative prenatal screening was done; 2) late-pregnancy outcomes (e.g. preeclampsia) will be restricted to participants enrolled before 
    </Intervention>
    <Primary_outcome>&lt;br&gt;                Measured by maternal self-report using online questionnaire at baseline:&lt;br&gt;                1. Pregnancy outcomes:&lt;br&gt;                1.1. Miscarriage (or spontaneous abortion)&lt;br&gt;                1.2. Elective termination&lt;br&gt;                1.3. Stillbirth&lt;br&gt;                1.4. Preterm delivery&lt;br&gt;                2. Birth outcomes (measured at additional time points up to 90 days):&lt;br&gt;                2.1. Major structural defects&lt;br&gt;                2.2. Neonatal death&lt;br&gt;                2.3. Admission into the Neonatal Intensive Care Unit&lt;br&gt;                2.4. Maternal obstetric complications&lt;br&gt;                2.5. Post-partum health&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                Measured by maternal self-report using online questionnaire:&lt;br&gt;                1. Head circumference (cm) at each time point from baseline to 90 days.&lt;br&gt;                2. Length at birth (cm)&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>NCT04366986;Nil known
    </Secondary_ID>
    <Source_Support>Pregistry LLC
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 08/06/2020, Institutional Review Board (IRB) of the Harvard T.H. Chan School of Public Health (90 Smith Street, 3rd Floor Boston, MA 02120, USA; +1 (617) 432-5132; kninsala@hsph.harvard.edu), ref: # IRB20-0622
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>30/04/2024
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12530559
    </Internal_Number>
    <TrialID>ISRCTN85785540
    </TrialID>
    <Last_Refreshed_on>12 September 2022
    </Last_Refreshed_on>
    <Public_title>Evaluating an app to help people quit smoking
    </Public_title>
    <Scientific_title>Effectiveness of an offer of the Smoke Free smartphone application for smoking cessation compared with no support: the App for Smoking ceSsation Evaluation Trial (ASSET)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>University College London
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20201015
    </Date_registration3>
    <Date_registration>15/10/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN85785540
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>20/08/2020
    </Date_enrollement>
    <Target_size>3116
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Interventional randomized controlled trial (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe;Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Aged at least 18 years&lt;br&gt;                2. Able to provide consent&lt;br&gt;                3. English speaker&lt;br&gt;                4. Owns a smartphone&lt;br&gt;                5. Current cigarette smoker&lt;br&gt;                6. Willing to be followed-up by e-mail and complete online questionnaires after 1, 4 and 30 weeks&lt;br&gt;                7. Interested in making a quit attempt within the next month&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Used the Smoke Free app in the past 6 months
    </Exclusion_Criteria>
    <Condition>Smoking cessation &lt;br&gt;Not Applicable
    </Condition>
    <Intervention>&lt;br&gt;                This will be a two-arm individually randomized controlled effectiveness trial. Participants will be adult smokers who are intending to quit in the next 4 weeks, willing to participate in a 30-week study of their smoking and able to provide consent.&lt;br&gt;&lt;br&gt;                Those who are eligible and consent to participate in the trial will be randomized at that point to intervention or comparator conditions. Randomization will be 1:1 at the individual level with no restriction (i.e. no blocking) and will be automated using a random number function.&lt;br&gt;&lt;br&gt;                After consenting, participants in the comparator condition will receive a message encouraging them to make a quit attempt within the next 4 weeks and reminding them of the importance of responding to follow-up requests which are designed to track their progress.&lt;br&gt;&lt;br&gt;                Participants in the intervention condition will receive the same advice as those in the comparator condition plus offer of the full version of the Smoke Free app free of charge, encouragement to use the app and a link to download it. The Smoke Free app is based on behaviour change techniques that would be expected from theory and evidence with face-to-face support to aid smoking cessation. It guides smokers through the first month of their quit attempt by helping them to maintain their resolve by setting a clear goal, monitoring their progress towards that goal and becoming aware of benefits of being smoke-free achieved to date. The app has several components:&lt;br&gt;                1. A calculator which tracks the total amount of money not spent on buying cigarettes and the number of cigarettes not smoked (‘Dashboard')&lt;br&gt;                2. A calendar which tracks the amount of time elapsed since cessation (‘Dashboard')&lt;br&gt;            
    </Intervention>
    <Primary_outcome>Self-reported smoking cessation for at least 26 weeks, assessed 30 weeks after enrolment
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                Assessed using self report:&lt;br&gt;                1. Having made at least one quit attempt in the 4 weeks following enrolment in the study&lt;br&gt;                2. Smoking cessation for at least 12 weeks, assessed 4 weeks after enrolment&lt;br&gt;                3. Downloading or using the Smoke Free app at least once, assessed 30 weeks after enrolment&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;CEHP/2016/556
    </Secondary_ID>
    <Source_Support>Cancer Research UK
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 06/09/2019, UCL Research Ethics Committee (University College London, 2 Taviton St, London WC1E 6BT, UK. +44 (0)207 6798717; ethics@ucl.ac.uk), ref: CEHP/2016/556
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>30/12/2021
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12513557
    </Internal_Number>
    <TrialID>NCT04567693
    </TrialID>
    <Last_Refreshed_on>5 September 2022
    </Last_Refreshed_on>
    <Public_title>Reducing Time to Spaced-out Appointments for Newly-diagnosed People Living With HIV
    </Public_title>
    <Scientific_title>Reducing Time to Spaced-out Appointments for Newly-diagnosed People Living With HIV: a Pilot Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Montefiore Medical Center
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200917
    </Date_registration3>
    <Date_registration>17/09/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04567693
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 22, 2020
    </Date_enrollement>
    <Target_size>93
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Health Services Research. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Jonathan Ross
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Montefiore Medical Center
    </Contact_Affiliation>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12630452
    </Internal_Number>
    <TrialID>NCT04556526
    </TrialID>
    <Last_Refreshed_on>31 October 2022
    </Last_Refreshed_on>
    <Public_title>A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women
    </Public_title>
    <Scientific_title>A Phase 3 Open-label Randomized Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women
    </Scientific_title>
    <Acronym>INGABO
    </Acronym>
    <Primary_sponsor>Janssen Vaccines &amp; Prevention B.V.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200916
    </Date_registration3>
    <Date_registration>16/09/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04556526
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>October 5, 2020
    </Date_enrollement>
    <Target_size>3665
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Janssen Vaccines &amp; Prevention B.V. Clinical Trial
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Janssen Vaccines &amp; Prevention B.V.
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Healthy on the basis of physical examination, medical history, obstetric history, and&#x0D;&lt;br&gt;             vital signs performed at screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Healthy on the basis of clinical laboratory tests performed at screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Confirmed singleton pregnancy by positive urine human chorionic gonadotropin (HCG) and&#x0D;&lt;br&gt;             ultrasound at time of screening and informed consent, and reconfirmed pregnancy via&#x0D;&lt;br&gt;             ultrasound at Randomization/Day 1&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Residing within catchment area of the study site&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of normal progress of gestation prior to Randomization (Day 1) based on&#x0D;&lt;br&gt;             obstetric evaluation (including obstetric history, obstetric examination and fetal&#x0D;&lt;br&gt;             ultrasound)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of Ebola Virus Disease (EVD) (self-declared or laboratory confirmed)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has received any experimental candidate Ad26- or MVA-based vaccine in the past&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines&#x0D;&lt;br&gt;             or vaccine products (including any of the constituents of the study vaccines [for&#x0D;&lt;br&gt;             example, polysorbate 80, ethylenediaminetetraacetic acid (EDTA) or L-histidine for&#x0D;&lt;br&gt;             Ad26.ZEBOV vaccine; tris (hydroxymethyl)-amino methane (THAM) for MVA-BN-Filo&#x0D;&lt;br&gt;             vaccine]), including known allergy to egg, egg products, chicken proteins and&#x0D;&lt;br&gt;             aminoglycosides&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant with acute illness (this does not include minor illnesses such as diarrhea&#x0D;&lt;br&gt;             or mild upper respiratory tract infection) or body temperature greater than or equal&#x0D;&lt;br&gt;             to (&gt;=)38.0ºC on Day 1 will be excluded from enrollment at that time but may be&#x0D;&lt;br&gt;             rescheduled for enrollment at a later date&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  During the 6 weeks prior to screening, have had any of (a) confirmed severe acute&#x0D;&lt;br&gt;             respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) infection (test positive),&#x0D;&lt;br&gt;             OR (b) suspected SARS-CoV-2 infection (clinical features without documented test&#x0D;&lt;br&gt;             results), OR (c) close contact with a person with known or suspected SARS-CoV-2&#x0D;&lt;br&gt;             infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Obstetric history including: a. &gt;= 2 consecutive spontaneous abortions, b. history of&#x0D;&lt;br&gt;             pre-eclampsia or eclampsia, c. rhesus negative multigravida, d. grand multigravida&#x0D;&lt;br&gt;             (greater than [&gt;] 5 previous pregnancies, e. previous late still birth (defined as&#x0D;&lt;br&gt;             loss of pregnancy at any time after 28 weeks gestation), f. previous low birth weight&#x0D;&lt;br&gt;             baby or premature delivery (defined as a delivery before 37 weeks gestation), g.&#x0D;&lt;br&gt;             previous neonatal death (defined as death of an infant within the first 28 days of&#x0D;&lt;br&gt;             life), h. previous delivery of an infant with a known or suspected genetic or&#x0D;&lt;br&gt;             chromosomal abnormality, i. history of other significant pregnancy-related or neonatal&#x0D;&lt;br&gt;             complications judged likely to affect the safety of the mother or infant or to&#x0D;&lt;br&gt;             significantly compromise the endpoint data collected&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Healthy
    </Condition>
    <Intervention>Biological: Ad26.ZEBOV;Biological: MVA-BN-Filo
    </Intervention>
    <Primary_outcome>Percentage of Participants with Maternal Deaths;Percentage of Participants with Spontaneous Abortion;Percentage of Participants with Stillbirth;Percentage of Participants on the Pathways to Preterm Birth;Percentage of Participants with Pre-eclampsia/ eclampsia;Percentage of Participants with Antenatal Bleeding;Percentage of Participants with Postpartum Hemorrhage;Percentage of Newborns with Major Congenital Malformations born to Participants;Percentage of Newborns Small for Gestational age (SGA) born to Participants;Percentage of Newborns with Low Birth Weight born to Participants;Percentage of Newborns with Preterm Birth born to Participants;Percentage of Neonatal Deaths in Neonates Born to Participants;Percentage of Infants (of Participants) who Fail to Thrive
    </Primary_outcome>
    <Secondary_outcome>Percentage of Participants (Pregnant Women) with Serious Adverse Events (SAEs) for Group A and B;Percentage of Participants (Pregnant Women) with SAEs for Subset of Group A and B;Percentage of Newborns (Born to Participants) with SAEs;Percentage of Participants with Solicited Local and Systemic Adverse Events (AEs);Percentage of Participants with Unsolicited AEs;Percentage of Participants with Normal Delivery;Percentage of Participants with Caesarian Section;Percentage of Participants with Anti-Ebola virus (EBOV) Glycoprotein (GP) Binding Antibodies;Percentage of Infants (Born to Participants) with Anti-Ebola virus (EBOV) Glycoprotein (GP) Binding Antibodies
    </Secondary_outcome>
    <Secondary_ID>VAC52150EBL3010;CR108739
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Center for Family Health Research (CFHR);Coalition for Epidemic Preparedness Innovations;Emory University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11654627
    </Internal_Number>
    <TrialID>CTRI/2020/09/027709
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Patterns of peritoneal cancer spread from various primary tumors
    </Public_title>
    <Scientific_title>Patterns of Peritoneal Dissemination and Response to Systemic Chemotherapy in Common and Rare Peritoneal Tumors Treated with Cytoreductive Surgery- A Prospective Multi-centric study - PRECINCT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Zydus hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200910
    </Date_registration3>
    <Date_registration>10-09-2020
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46131
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>11-09-2020
    </Date_enrollement>
    <Target_size>1600
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France;Algeria;Andorra;Angola;Antigua and Barbuda;Argentina;Armenia;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bhutan;Bolivia;Bosnia and Herzegovina;Botswana;Brazil;Brunei Darussalam;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Central African Republic;Chad;Chile;China;Colombia;Comoros;Congo;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Cyprus;Czech Republic;Democratic People's Republic of Korea;Democratic Republic of the Congo;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Fiji;Finland;Gabon;Gambia;Georgia;Germany;Ghana;Greece;Grenada;Guatemala;Guinea;Guinea-Bissau;Guyana;Haiti;Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran (Islamic Republic of);Iraq;Ireland;Israel;Italy;Jamaica;Japan;Jordan;Kazakhstan;Kenya;Kiribati;Kuwait;Kyrgyzstan;Lao People's Democratic Republic;Latvia;Lebanon;Lesotho;Liberia;Libyan Arab Jamahiriya;Lithuania;Luxembourg;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Mauritania;Mauritius;Mexico;Micronesia (Federated States of);Monaco;Mongolia;Montenegro;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norway;Oman;Other;Pakistan;Palau;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Republic of Moldova;Romania;Russian Federation;Rwanda;Saint Kitts and Nevis;Saint Lucia;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia
    </Countries>
    <Contact_Firstname>Aditi BHATT
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Zydus Hospital Road, Thaltej 
    </Contact_Address>
    <Contact_Email>aditimodi31@gmail.com
    </Contact_Email>
    <Contact_Tel>09686447863
    </Contact_Tel>
    <Contact_Affiliation>Zydus hospital, surgical oncology, room no 5
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1.	All patients undergoing cytoreductive surgery for peritoneal metastases from colorectal, ovarian, gastric and appendiceal primary tumors and peritoneal mesothelioma will be included.  &lt;br/ &gt;&lt;br&gt;2.	Only patients with biopsy proven PM will be included (pathological evaluation is not mandatory prior to CRS if imaging or exploration confirms the presence of disease).  &lt;br/ &gt;&lt;br&gt;3.	Patient undergoing debulking procedures will be included &lt;br/ &gt;&lt;br&gt;4.	For ovarian cancer, only patients with FIGO stage III-C or IV-A will be included. Patients undergoing surgery at first diagnosis, after NACT and those undergoing surgery for recurrent disease will be included. Patients without peritoneal disease will be excluded.  &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: â?¢	Patients undergoing second look procedures with no evidence of peritoneal metastases will be excluded.  &lt;br/ &gt;&lt;br&gt;â?¢	Patients undergoing palliative procedures that do not involve tumor debulking will be excluded unless the goal of surgery was to obtain a complete cytoreduction i.e. procedures performed with the intention of palliation alone like a diverting oâ??stomy will be excluded.  &lt;br/ &gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Health Condition 1: K669- Disorder of peritoneum, unspecified

    </Condition>
    <Intervention/>
    <Primary_outcome>Disease distribution in the peritoneal cavityTimepoint: At 6 months, after completion of recruitment and at 1 year, 3 years and 5 years from the end of recruitment
    </Primary_outcome>
    <Secondary_outcome>Morphology of peritoneal metastasesTimepoint: At the time of surgery;Overall survivalTimepoint: At 1 year, 3 and 5 years after recruitment;Pathological response to systemic chemotherapyTimepoint: At the time of surgery;Pattern of lymph node involvementTimepoint: At the time of surgery;Progression-free survivalTimepoint: At 1, 3 and 5 years after recruitment
    </Secondary_outcome>
    <Secondary_ID>none
    </Secondary_ID>
    <Source_Support>Zydus hospitaal
    </Source_Support>
    <Ethics_review_status>Not Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;27/07/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Lyon-sud Ethics Committee;Zydus Hospital Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11654599
    </Internal_Number>
    <TrialID>CTRI/2020/09/027681
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Determining The Best Time For Surgery After COVID-19 Infection
    </Public_title>
    <Scientific_title>Global Surg-Covid Surg Week: Determining The Optimal Timing For Surgery Following SARS-CoV-2 Infection - CovidSurg Week                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>University Of Birmingham
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200909
    </Date_registration3>
    <Date_registration>09-09-2020
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46744
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>01-10-2020
    </Date_enrollement>
    <Target_size>45000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Algeria;Argentina;Australia;Austria;Bahrain;Bangladesh;Belgium;Benin;Brazil;Bulgaria;Cameroon;Canada;Colombia;Denmark;Ecuador;Egypt;Estonia;Finland;Georgia;Germany;Ghana;Greece;Guatemala;Hungary;India;Indonesia;Iraq;Ireland;Italy;Japan;Jordan;Kenya;Kuwait;Malawi;Mali;Mexico;Montenegro;Morocco;Mozambique;Namibia;Nepal;New Zealand;Nicaragua;Nigeria;Norway;Oman;Pakistan;Panama;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Romania;Rwanda;Samoa;Saudi Arabia;Senegal;Singapore;Somalia;South Africa;Spain;Sweden;Turkey;United Arab Emirates;United Kingdom;United States of America;Uruguay;Venezuela (Bolivarian Republic of);Zambia
    </Countries>
    <Contact_Firstname>Pranay Pawar
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Department Of Surgery
Brown Road 
    </Contact_Address>
    <Contact_Email>pranay.pawar@cmcludhiana.in
    </Contact_Email>
    <Contact_Tel>9780300142
    </Contact_Tel>
    <Contact_Affiliation>Christian Medical College
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Any operation (elective or emergency) done in an operating theatre by a surgeon, excluding minor procedures previously defined by Abbott TEF, Fowler AJ, Dobbs TD, Harrison EM, Gillies MA, Pearse RM. Frequency of surgical treatment and related hospital procedures in the UK: a national ecological study using hospital episode statistics. Br J Anaesth. 2017;119(2):249-257. &lt;br/ &gt;&lt;br&gt;All surgical specialties including: acute care surgery, breast surgery, cardiac surgery, colorectal surgery, general surgery, gynaecology, hepatobiliary surgery, neurosurgery, obstetrics, oesophagogastric surgery, ophthalmology, oral and maxillofacial surgery, orthopaedics, otolaryngology, paediatric surgery, plastic surgery, thoracic surgery, trauma surgery, urology, vascular surgery. &lt;br/ &gt;&lt;br&gt;Day case surgery and inpatient surgery included. &lt;br/ &gt;&lt;br&gt;Any SARS-CoV-2 status (positive at any time, negative, not tested). &lt;br/ &gt;&lt;br&gt;All ages including children and adults. &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: All procedures not done in the operating room &lt;br/ &gt;&lt;br&gt;All Endovascular procedures &lt;br/ &gt;&lt;br&gt;All Interventional radiology procedures
    </Exclusion_Criteria>
    <Condition>Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

    </Condition>
    <Intervention>Intervention1: Pre-Operative Diagnosis of SARS-CoV-2: The intervention group includes patients with a diagnosis of SARS-CoV-2 at any time before surgery.&lt;br&gt;This includes patients diagnosed at any time before surgery (diagnosis could be days to months before surgery)&lt;br&gt;This includes patients who (1) were never symptomatic, (2) symptomatic at the time of diagnosis, but whose symptoms have now resolved (patient is not symptomatic on the day of surgery), (3) have ongoing symptoms of SARS-CoV-2 infection.&lt;br&gt;This group will be stratified by time since diagnosis (if known), severity of initial SARS-CoV-2 infection, and whether they are symptomatic at the time of surgery.&lt;br&gt;&lt;br&gt;Intervention2: Nil: Observational Study&lt;br&gt;Control Intervention1: Postoperative SARS-CoV-2: Patients who were diagnosed with SARS-CoV-2 postoperatively within 30 days after surgery (this includes both patients who do and do not have symptoms).&lt;br&gt;Control Intervention2: Non-SARS-CoV-2: Patients who have not had a diagnosis of SARS-CoV-2 before surgery or within 30 days after surgery.&lt;br&gt;Control Intervention3: Nil: Observational Study&lt;br&gt;
    </Intervention>
    <Primary_outcome>30 day post-operative mortalityTimepoint: 30 day post-operative mortality
    </Primary_outcome>
    <Secondary_outcome>30-day postoperative pulmonary complications (pneumonia [CDC definition], ARDS, unexpected ventilation) &lt;br/ &gt;&lt;br&gt;30-day venous thromboembolism (deep vein thrombosis/ pulmonary embolism) &lt;br/ &gt;&lt;br&gt;30-day Clavien-Dindo grade &lt;br/ &gt;&lt;br&gt;Timepoint: 30 days post-operatively;In-patient post-operative mortalityTimepoint: While admitted in hospital within 30 days post-operative
    </Secondary_outcome>
    <Secondary_ID>NCT04509986
    </Secondary_ID>
    <Source_Support>Birmingham Clinical Trials Unit, University Of Birmingham, Edbagston,  Birmingham United Kingdom. B15 2TT;Christian Medical College, Brown Road, Ludhiana, India 141008
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>03/10/2020;26/09/2020;07/09/2020;05/10/2020;22/08/2020;02/09/2020;02/09/2020;30/10/2020;09/09/2020;06/11/2020;12/09/2020;06/10/2020;08/09/2020;08/09/2020;10/10/2020;14/09/2020;22/10/2020;05/10/2020;28/10/2020;11/12/2020;12/09/2020;10/09/2020;10/09/2020;08/09/2020;12/09/2020;02/11/2020;28/09/2020;09/09/2020;09/09/2020;09/09/2020;10/08/2020;11/11/2020;11/09/2020;24/08/2020;28/09/2020;02/05/2020;30/09/2020;01/09/2020;14/09/2020;04/09/2020;11/09/2020;24/09/2020;27/10/2020;12/09/2020;12/09/2020;12/09/2020;29/09/2020;17/09/2020;26/09/2020;05/10/2020;03/10/2020;26/10/2020;23/10/2020;21/11/2020;11/09/2020;21/09/2020;06/10/2020;23/10/2020;01/09/2020;30/09/2020;19/09/2020;18/09/2020;03/10/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>All India Institute Of Medical Sciences Bhopal;All India Institute Of Medical Sciences Bhubaneshwar;All India Institute Of Medical Sciences Jodhpur;All India Institute Of Medical Sciences New Delhi;All India Institute Of Medical Sciences Rishikesh;Amrita Institute Of Medical Sciences Kochi;Amrita Institute Of Medical Sciences Kochi;Artemis Health Sciences Gurgaon;Aster CMI Hospital Bengaluru;Bangalore Medical College And Research institute Bengaluru;Bengal Cancer Foundation Burdwan;Cachar Cancer Hospital And Research Centre Silchar;Christian Medical College Ludhiana;Christian Medical College Vellore;Datta Meghe Institute Of Medical Sciences Sawangi;Dr Rela Institute And Medical Centre Chennai;Fortis Hospitals Mulund Mumbai;Gandhi Medical College Bhopal;Government Hospital Velayuthampalayam;Government Medical College Chandigarh;Government Medical College Patiala;H M Patel Centre For Medical Care And Education Karamsad;H M Patel Centre For Medical Care And Education Karamsad;Indian Spinal Injuries Centre New Delhi;Institute Of Neurosciences Kolkata;Jubilee Mission Medical College And Research Institute Thrissur;Jupiter Lifeline Hospitals Thane;Kasturba Medical Colleg And Kasturba Hospital Manipal;Kasturba Medical College And Kasturba Hospital Manipal;Kerudi Cancer Hospital;King George Medical University Lucknow;King Georges Medical University Lucknow;Kokilaben Dhirubhai Ambani Hospital And Medical Research Institute Mumbai;Kovai Medical Centre &amp; Hospital Limited Coimbatore;KVG Medical College And Hospital;Lady Willingdon Hospital Manali;Lilavati Hospital And Research Centre Mumbai;Lokmanya Medical Research Centre Pune;M M Institute Of Medical Sciences and Research Mullana Ambala;Mahatma Gandhi Cancer Hospital &amp; Research Centre Vishakapatnam;Maulana Azad Medical College And Associated Hospital;Medical College Thiruvananthapuram;Osmania Medical College Hyderabad;Postgraduate Institute Of Medical Education And Research Chandigarh;Postgraduate Institute Of Medical Education And Research Chandigarh;Postgraduate Institute Of Medical Education And Research Chandigarh;Rainbow Hospital;Sanjay Clinic Mumbai;Sanjay Gandhi Postgraduate Institute Of Medical Sciences;Sanjay Gandhi Postgraduate Institute Of Medical Sciences Lucknow;Santokha Durlabhji Memorial Hospital Cum Research Institute Jaipur;Sher I Kashmir Institute of Medical Sciences Srinagar;Shri Guru ram Rai Institute Of Medical &amp; Health Sciences Dehra Dun;Soni Hospital Nagpur;Sri Sathya Sai Institute Of Higher Medical Sciences Bengaluru;Sri Shankara Cancer Hospital And Research Centre Bengaluru;T N Medical College And BYL Nair Ch Hospital Mumbai;T N Medical College And BYL Nair Charitable Hospital Mumbai;Tata Medical Centre Kolkata;Tata Memorial Centre Mumbai;Vardhman Mahavir Medical College And Safdarjung Hospital New Delhi;Yenepoya Mangalore;Zydus Hospital
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
    </Ethics_review_contact_email>
    <results_date_completed>11/12/2020
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12602009
    </Internal_Number>
    <TrialID>PACTR202101512465690
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Diabetic Retinopathy Screening Using Retinal Imaging and Automated Grading with Artificial Intelligence in Rwanda- A Randomized Control Trial
    </Public_title>
    <Scientific_title>Rwanda Artificial Intelligence Diabetic Retinopathy Screening Study (RAIDERS)&#x0D;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor/>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200907
    </Date_registration3>
    <Date_registration>07/09/2020
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12353
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>44 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/02/2021
    </Date_enrollement>
    <Target_size>250
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Simple randomization using by using procedures such as coin-tossing or dice-rolling,Sealed opaque envelopes
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda;Rwanda;Rwanda;Rwanda;Rwanda;Rwanda
    </Countries>
    <Contact_Firstname>John 
    </Contact_Firstname>
    <Contact_Lastname>Nkurikiye
    </Contact_Lastname>
    <Contact_Address>RIIO MTN Centre KG 9 
    </Contact_Address>
    <Contact_Email>nkurikiye.john@gmail.com
    </Contact_Email>
    <Contact_Tel>0025788307810
    </Contact_Tel>
    <Contact_Affiliation>Rwanda International Institute of Ophthalmology 
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Recruitment: Consecutive patients with confirmed Type 1 or Type 2 diabetes diagnoses who are attending at a participating diabetes clinic at three sites in Rwanda will  receive a patient information leaflet with all the details of the trial while in the waiting room of their diabetes clinic appointment.  In addition, a researcher nurse will be available  to explained verbally the details of the trial and answer any questions. At the end of their diabetes consultation, their regular clinician will ascertain whether they wish to participate in the trial. If they express an interest, or needed further details, a trained  researcher will give further explanation and on reaching agreement to participate, written informed consent will obtained.  The individuals will then be enrolled to undergo screening for diabetic retinopathy using retinal imaging. All images will then be uploaded to Cybersight AI for interpretation. ONLY THOSE WHO GET A REFER POSITIVE AI REPORT WILL BE ENROLLED INT THE RCT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Summary of inclusion criteria:&#x0D;&lt;br&gt;1)Adults, young people and children who are aged =18years.&#x0D;&lt;br&gt;2) Are Registered with a participating diabetes clinic . &#x0D;&lt;br&gt;3) Have gradeable digital retinal images in at least one eye. &#x0D;&lt;br&gt;4) Give their informed consent for participation. &#x0D;&lt;br&gt;5) Can travel to the referral clinic at RIIO&#x0D;&lt;br&gt;6) Are not involved in any ongoing treatment or  trial investigating a treatment with ongoing appointments for care&#x0D;&lt;br&gt;7) For inclusion into the trial: Receive a refer positive Cybersight AI report
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Exclusion criteria will be: &#x0D;&lt;br&gt;&#x0D;&lt;br&gt;1) Patients who do not think that they can return for follow-up e.g. prisoners or visitors to Rwanda ; &#x0D;&lt;br&gt;2)Adults, young people and children who are aged under age 18years.&#x0D;&lt;br&gt;3)Are not registered with a participating diabetes clinic.&#x0D;&lt;br&gt;4) Are ineligible for screening for whatever reason, including inability to be imaged, having ungradable digital retinal images, or have both eyes ungradable eye with no visual potential.&#x0D;&lt;br&gt;5) Do not give consent for participation in the RCT.&#x0D;&lt;br&gt;7)Are not involved in any ongoing treatment or  trial investigating a treatment with ongoing appointments for care&#x0D;&lt;br&gt;8) Those who receive a normal Cybersight AI report (Refer negative) will not be enrolled into the trial&#x0D;&lt;br&gt;All these patients will receive appropriate clinical care but will not be included in the trial
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Eye Diseases;Eye Diseases
    </Condition>
    <Intervention>; Immediate Diabetic retinopathy grade  feedback using Cybersight Artificial intelligence platform ;Delayed feedback after human grading of diabetic retinopathy status at a reading centre
    </Intervention>
    <Primary_outcome>Primary Outcome Measurement - &lt;br&gt;The primary outcome is the attendance rate for treatment and further care  within 4 weeks of receiving appointment information in the two arms of the study. Non-attendance is defined as failure to attend any treatment appointment within 4 weeks of being invited for follow up. This outcome will be measured only among those who are disease positive as they are the ones who will have a referral within 4 weeks.&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>Patient acceptability and satisfaction measurements of delayed human grading vs immediate grading by AI including perception of impact on time in clinic of including DR screening  will bemeasured among  providers and patients using a questionnaire designed for the study &#x0D;&lt;br&gt;;Secondary Outcome Measurements - &#x0D;&lt;br&gt;Diagnostic test accuracy of Cybersight AI platform and human graders diagnoses for identifying any DR needing referral, and for identifying sight-threatening or vision-threatening DR (STDR / VTDR) ; i.e., sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and area under the receiver operating characteristic curve (AUC of ROC); and inter-rater agreement compared to gold standard (i.e., adjudicated response agreed to between the retina specialist and the UK NHS grader is the gold standard).  &#x0D;&lt;br&gt;;Inter-rater agreement of level of gradeability of the images as identified in Cybersight AI platform compared to the adjudicated human graders’ grading. &#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Source_Support>ORBIS International 
    </Source_Support>
    <Secondary_Sponsor>Rwanda International Institute of Ophthalmology 
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>02/11/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>info@rnecrwanda.org
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Rwanda National Ethics Committee  Ministry of Health 
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+250255107884
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>info@rnecrwanda.org
    </Ethics_review_contact_email>
    <results_url_link>(Pending registration at the OSF - Open Science Foundation site)
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>9662840
    </Internal_Number>
    <TrialID>ISRCTN17717312
    </TrialID>
    <Last_Refreshed_on>17 August 2020
    </Last_Refreshed_on>
    <Public_title>CORONATION: Coronavirus (COVID-19) multinational observational registry
    </Public_title>
    <Scientific_title>Coronavirus (COVID-19) Multinational observational registry (CORONATION)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Cambridge University Hospitals NHS Foundation Trust
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200723
    </Date_registration3>
    <Date_registration>23/07/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN17717312
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>30/07/2020
    </Date_enrollement>
    <Target_size>10000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational epidemiological study (Screening)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Kerrie
    </Contact_Firstname>
    <Contact_Lastname>Brusby
    </Contact_Lastname>
    <Contact_Address>
                    Cambridge Clinical Trials Centre (CCTU)
                    Cambridge University Hospitals (CUH) NHS Foundation Trust
                    Addenbrooke’s Hospital
                    Cambridge Biomedical Campus
                    Box 4
    </Contact_Address>
    <Contact_Email>add-tr.coronation@nhs.net
    </Contact_Email>
    <Contact_Tel>+44 (0)1223254472
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                All COVID-19 cases are eligible for inclusion (COVID-19 cases that pre-decease the start of the registry are eligible)&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Does not meet inclusion criteria
    </Exclusion_Criteria>
    <Condition>COVID-19 (SARS-CoV-2 infection) &lt;br&gt;Infections and Infestations &lt;br&gt;COVID-19 (SARS-CoV-2 infection)
    </Condition>
    <Intervention>&lt;br&gt;                The CORONATION registry is a patient-level disease registry capturing identifiable patient data on UK COVID-19 cases and anonymised or identifiable data on international COVID-19 cases.&lt;br&gt;&lt;br&gt;                Care teams will collect demographic and clinical data on confirmed COVID-19 cases and enter this information into a database. This will be undertaken through a simple enrollment process and linkage with other datasets.&lt;br&gt;&lt;br&gt;                Baseline data collected will include baseline demographic data, baseline clinical data (comorbidities, medication, COVID-19 status and symptoms).&lt;br&gt;
    </Intervention>
    <Primary_outcome>Demographic and clinical data on confirmed COVID-19 cases (comorbidities, medication, COVID-19 status and symptoms) collected regularly from participating centres by entering data into an online portal
    </Primary_outcome>
    <Secondary_outcome>There are no secondary outcome measures
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;CCTU0304, IRAS 282239
    </Secondary_ID>
    <Source_Support>Cambridge Biomedical Research Centre 
    </Source_Support>
    <Secondary_Sponsor>University of Cambridge
    </Secondary_Sponsor>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 20/07/2020, University of Cambridge Human Biology Research Ethics Committee (17 Mill Lane, Cambridge, CB2 1RX; +44 (0)1223 766894; cb480@admin.cam.ac.uk), ref: HBREC.2020.32
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>24/04/2025
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11653590
    </Internal_Number>
    <TrialID>CTRI/2020/07/026672
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Mental health affected by COVID-19
    </Public_title>
    <Scientific_title>Mental health among individuals dealing with COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>Tata Memorial Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200718
    </Date_registration3>
    <Date_registration>18-07-2020
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45764
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>28-07-2020
    </Date_enrollement>
    <Target_size>2000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;Andorra;Angola;Antigua and Barbuda;Argentina;Armenia;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bhutan;Bolivia;Bosnia and Herzegovina;Botswana;Brazil;Brunei Darussalam;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Central African Republic;Chad;Chile;China;Colombia;Comoros;Congo;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Cyprus;Czech Republic;Democratic People's Republic of Korea;Democratic Republic of the Congo;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Fiji;Finland;France;Gabon;Gambia;Georgia;Germany;Ghana;Greece;Grenada;Guatemala;Guinea;Guinea-Bissau;Guyana;Haiti;Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran (Islamic Republic of);Iraq;Ireland;Israel;Italy;Jamaica;Japan;Jordan;Kazakhstan;Kenya;Kiribati;Kuwait;Kyrgyzstan;Lao People's Democratic Republic;Latvia;Lebanon;Lesotho;Liberia;Libyan Arab Jamahiriya;Lithuania;Luxembourg;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Mauritania;Mauritius;Mexico;Micronesia (Federated States of);Monaco;Mongolia;Montenegro;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norway;Oman;Other;Pakistan;Palau;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Republic of Moldova;Romania;Russian Federation;Rwanda;Saint Kitts and Nevis;Saint Lucia;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia ;Seychelles;Sierra Leone;Singapore;Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;Spain;Sri Lanka;Sudan;Suriname;Swaziland;Sweden;Switzerland;Syrian Arab Republic;Taiwan;Tajikistan;Tanzania;Thailand;The former Yugoslav Republic of Macedonia;Timor-Leste;Togo;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United Republic of Tanzania;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela (Bolivarian Republic of);Viet Nam;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Arjun Singh
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Dr. E Borges Marg, Parel, Mumbai 400012, India Dr. E Borges Marg, Parel, Mumbai 400012, India
    </Contact_Address>
    <Contact_Email>arjun193@gmail.com
    </Contact_Email>
    <Contact_Tel/>
    <Contact_Affiliation>Tata Memorial Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Confirmed cases of COVID-19 diagnosed using RT-PCR (real-time reverse transcription polymerase chain reaction) &lt;br/ &gt;&lt;br&gt;2. Healthcare workers and patient relatives dealing with COVID-19 patients  &lt;br/ &gt;&lt;br&gt;3. Age between 18-65 years &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Non consenting participants
    </Exclusion_Criteria>
    <Condition>Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

    </Condition>
    <Intervention/>
    <Primary_outcome>PHQ 9 and/or WHO-BREF scoreTimepoint: Cross sectional at the time of administration of questionnaire
    </Primary_outcome>
    <Secondary_outcome>NATimepoint: NA
    </Secondary_outcome>
    <Secondary_ID>NIL
    </Secondary_ID>
    <Source_Support>Not applicable
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>15/07/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Tata Memorial Hosptial
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11653252
    </Internal_Number>
    <TrialID>CTRI/2020/07/026334
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>A study to find out the current management practices  of Sleep inducing methods, Pain reducing methods, and treatment used for management of serious disturbances in brain functions in patients admitted in intensive care units.
    </Public_title>
    <Scientific_title>Sedation, Analgesia and Delirium MANagement: an international audit of adult medical, surgical, trauma, and neuro-intensive care patients - SANDMAN Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Tata Memorial Centre
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200702
    </Date_registration3>
    <Date_registration>02-07-2020
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44719
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>31-07-2020
    </Date_enrollement>
    <Target_size>2000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;Andorra;Angola;Antigua and Barbuda;Argentina;Armenia;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bhutan;Bolivia;Bosnia and Herzegovina;Botswana;Brazil;Brunei Darussalam;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Central African Republic;Chad;Chile;China;Colombia;Comoros;Congo;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Cyprus;Czech Republic;Democratic People's Republic of Korea;Democratic Republic of the Congo;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Fiji;Finland;France;Gabon;Gambia;Georgia;Germany;Ghana;Greece;Grenada;Guatemala;Guinea;Guinea-Bissau;Guyana;Haiti;Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran (Islamic Republic of);Iraq;Ireland;Israel;Italy;Jamaica;Japan;Jordan;Kazakhstan;Kenya;Kiribati;Kuwait;Kyrgyzstan;Lao People's Democratic Republic;Latvia;Lebanon;Lesotho;Liberia;Libyan Arab Jamahiriya;Lithuania;Luxembourg;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Mauritania;Mauritius;Mexico;Micronesia (Federated States of);Monaco;Mongolia;Montenegro;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norway;Oman;Other;Pakistan;Palau;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Republic of Moldova;Romania;Russian Federation;Rwanda;Saint Kitts and Nevis;Saint Lucia;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia ;Seychelles;Sierra Leone;Singapore;Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;Spain;Sri Lanka;Sudan;Suriname;Swaziland;Sweden;Switzerland;Syrian Arab Republic;Taiwan;Tajikistan;Tanzania;Thailand;The former Yugoslav Republic of Macedonia;Timor-Leste;Togo;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United Republic of Tanzania;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela (Bolivarian Republic of);Viet Nam;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>DrSheila Nainan Myatra
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Department of Anesthesia, Critical Care and Pain, Main Building, Second Floor, Tata Memorial Hospital, Dr.E Borges Road, Parel 
    </Contact_Address>
    <Contact_Email>sheila150@hotmail.com
    </Contact_Email>
    <Contact_Tel>9820156070
    </Contact_Tel>
    <Contact_Affiliation>Tata Memorial Centre
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. All adults (â?¥18 years) admitted to a participating ICU who are invasively mechanically ventilated for more than 12 hours will be included. &lt;br/ &gt;&lt;br&gt;2. We will include medical, surgical, and neurological patients.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: There are no exclusion criteria
    </Exclusion_Criteria>
    <Condition>Health Condition 1: R098- Other specified symptoms and signsinvolving the circulatory and respiratory systems

    </Condition>
    <Intervention>Intervention1: NIL: NIL&lt;br&gt;Control Intervention1: NIL: NIL&lt;br&gt;
    </Intervention>
    <Primary_outcome>To capture an overview of sedation, analgesia and delirium management strategies used in intensive care units around the world.Timepoint: 3 months after enrollment
    </Primary_outcome>
    <Secondary_outcome>To describe and compare management between specific ICU patient groups:1 Medical patients (specifically sepsis and acute respiratory distress syndrome (ARDS)) &lt;br/ &gt;&lt;br&gt;2 Surgical patients &lt;br/ &gt;&lt;br&gt;3Trauma and Burns patients &lt;br/ &gt;&lt;br&gt;4 Neurocritical care patients &lt;br/ &gt;&lt;br&gt;5 Cardiogenic shock patients &lt;br/ &gt;&lt;br&gt;6 Patients receiving palliative careTimepoint: 3 months after enrollment;To describe international practice in ICU, and practice variation in the use of drugs, and monitoring for PAD;Timepoint: 3 months after enrollment;To quantify the adherence to the PAD clinical guidelinesTimepoint: 3 months after enrollment
    </Secondary_outcome>
    <Secondary_ID>Project No_900629 Version 3.1_20July2019
    </Secondary_ID>
    <Source_Support>Tata Memorial Hospital, Dr.E Borges Road, Parel Mumbai Maharashtra India 400012
    </Source_Support>
    <Secondary_Sponsor>Not Any
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>29/06/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Institutional Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11653114
    </Internal_Number>
    <TrialID>CTRI/2020/06/026196
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Prevention of Respiratory Complications In At Surgery in COVID-19 Pandemic
    </Public_title>
    <Scientific_title>Preventing Pulmonary Complications In Surgical Patients At Risk Of COVID-19 - PROTECT-Surg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>University Of Birmingham
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200628
    </Date_registration3>
    <Date_registration>28-06-2020
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43482
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>15-08-2020
    </Date_enrollement>
    <Target_size>6400
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized, Parallel Group, Multiple Arm Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Open Label
    </Study_design>
    <Phase>Phase 3/ Phase 4
    </Phase>
    <Countries>Benin;Ghana;India;Italy;Mexico;Nigeria;Rwanda;South Africa;United Kingdom
    </Countries>
    <Contact_Firstname>Amit Mahajan
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Christian Medical College Hospital
Brown Road
 
    </Contact_Address>
    <Contact_Email>dr_amitrock@yahoo.co.in
    </Contact_Email>
    <Contact_Tel>9988018700
    </Contact_Tel>
    <Contact_Affiliation>Christian Medical College Ludhiana
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients aged 16 years and over. &lt;br/ &gt;&lt;br&gt;2. Planned to undergo any type of elective or emergency inpatient surgery requiring general or regional anaesthesia (such as vulnerable patients undergoing surgery for a fractured neck of femur). &lt;br/ &gt;&lt;br&gt;3. Asymptomatic of COVID-19, including patients with: those not tested, negative test results, positive test but no symptoms	 &lt;br/ &gt;&lt;br&gt;4. Informed patient consent. &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Procedures under local anaesthesia. &lt;br/ &gt;&lt;br&gt;2. Symptomatic COVID-19 infection (by confirmed COVID-19 test or a clinical diagnosis) &lt;br/ &gt;&lt;br&gt;3. Existing regular preoperative treatment with trial drugs.  &lt;br/ &gt;&lt;br&gt;4. Known history of adverse reaction/contraindication to trial drugs. &lt;br/ &gt;&lt;br&gt;5.Pregnancy (including caesarean section). &lt;br/ &gt;&lt;br&gt;â?¢	Actively breastfeeding. &lt;br/ &gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Health Condition 2: O- Medical and Surgical

    </Condition>
    <Intervention>Intervention1: Lopinavir-Ritonavir: Lopinavir is a HIV-1 (Human Immunodeficiency Virus 1) protease inhibitor, normally used as part of combined drug therapy for HIV. Ritonavir is added to Lopinavir to enhance efficacy by increasing serum availability [3]. In-vitro experiments show viral susceptibility to the drug. A published series of patients treated with this Lopinavir-Ritonavir showed improved outcomes at 21 days after diagnosis, compared to historical controls. Lopinavir-Ritonavir has previously been shown to improve outcomes in animal models (marmosets) infected with MERS-CoV. A trial including 194 patients with advanced COVID-19 infection showed a small difference in time to clinical improvement, suggesting the need for further trials evaluating this drug. Though early studies have not shown any difference in post treatment viral load, some centres are using this drug combination off-label to treat COVID-19 patients. No work has yet looked at the impact of these drugs on pre-infection or pre-symptomatic treatment (or in vulnerable patients). Robust evidence is needed to prove or exclude the benefit of Lopinavir-Ritonavir use to prevent pulmonary complications in patients undergoing surgery.&lt;br&gt;Intervention2: Hydroxychloroquine: Hydroxychloroquine is usually used as an antimalarial drug and in auto-immune diseases such as Lupus and Rheumatoid Arthritis. Promising laboratory studies have shown that chloroquine decreases COVID-19 entrance and replication within cells, together with its known anti-inflammatory effect. From small early phase clinical trials in China that included more than 100 patients being treated for COVID-19 pneumonia, chloroquine was associated with a shorter course of disease and less pneumonia exacerbation. A subsequent small non-randomised study 
    </Intervention>
    <Primary_outcome>One of the following COVID-19 specific, inpatient, postoperative pulmonary complications: Pneumonia, Acute respiratory distress syndrome, Death &lt;br/ &gt;&lt;br&gt;Timepoint: All randomised participants will be followed up until death, discharge from hospital, or 30 days post-randomisation (whichever is sooner). Longer-term follow-up (e.g. 5 years) will be sought as appropriate to each participating countryâ??s settings.
    </Primary_outcome>
    <Secondary_outcome>Pneumonia, ARDS, and death will be presented and analysed separately as secondary outcomes.  &lt;br/ &gt;&lt;br&gt;Unexpected ventilation &lt;br/ &gt;&lt;br&gt;Postoperative diagnosis of proven COVID-19 pulmonary complications &lt;br/ &gt;&lt;br&gt;Overall SARS-CoV-2 infected rate  &lt;br/ &gt;&lt;br&gt;Duration of hospital stay (including time spent in intensive care, time ventilated) &lt;br/ &gt;&lt;br&gt;Pulmonary function in keeping with the WHO Solidarity Trial outcome scaleTimepoint: Secondary outcome measures will be recorded on the index hospital admission up to 30 days following surgery
    </Secondary_outcome>
    <Secondary_ID>2020-001448-24
    </Secondary_ID>
    <Source_Support>Christian Medical College Ludhiana;University Of Birmingham, UK
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>14/08/2020;29/07/2020;24/06/2020;12/06/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>All India Institute Of Medical Sciences Bhubhaneshwar;All India Institute Of Medical Sciences Jodhpur;Christian Medical College Ludhiana;Datta Meghe Institute Of Medical Sciences Wardha
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12052160
    </Internal_Number>
    <TrialID>NCT04442152
    </TrialID>
    <Last_Refreshed_on>21 March 2022
    </Last_Refreshed_on>
    <Public_title>Impact of COVID-19 on Family Dynamics on Bandebereho Study Participants
    </Public_title>
    <Scientific_title>Phone Survey for Understanding the Impact of COVID-19 on Caregiving and Family Dynamics on Bandebereho Study Participants
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Promundo, United States
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200619
    </Date_registration3>
    <Date_registration>19/06/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04442152
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>26 Years
    </Inclusion_agemin>
    <Inclusion_agemax>40 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 13, 2020
    </Date_enrollement>
    <Target_size>998
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Kate E Doyle, MA;Ruti G Levtov, PhD;Felix Sayingoza, MD, MSc;Fidele Rutayisire, MA;Shamsi Kazimbaya, MA
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>Promundo-US;Promundo-US;Ministry of Health/Rwanda Biomedical Center;Rwanda Men's Resource Center;Promundo-US
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Original inclusion criteria in the original RCT study included, for men: being between the&#x0D;&lt;br&gt;        ages of 21-35, expecting a child or having one or more children under the age of five,&#x0D;&lt;br&gt;        living in a stable partnership, and residing in the study site. For women, the criteria&#x0D;&lt;br&gt;        were simply being the partner of one of the men selected for the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion criteria for this study include previous participation in the RCT, and that the&#x0D;&lt;br&gt;        respondent indicated they or their partner owned a telephone/phone in the 21-month follow&#x0D;&lt;br&gt;        up that was conducted in November/December 2016. Based on data from the 21-month followup,&#x0D;&lt;br&gt;        approximately 80% of respondents reported a cell phone owned by them or their partner.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Gender Relations;Partner Communication;Division of Carework;Couple Conflict;Stress
    </Condition>
    <Intervention>Behavioral: MenCare+/Bandebereho fathers'/couples' group education
    </Intervention>
    <Primary_outcome>Gender division of caregiving/domestic tasks;Couple communication;Couple conflict;Men's alcohol use;Household economic situation;Stress and frustration
    </Primary_outcome>
    <Secondary_ID>265A
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Rwanda Men's Resource Center (Rwamrec);Ministry of Health/Rwanda Biomedical Center
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12601802
    </Internal_Number>
    <TrialID>PACTR202007518001972
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>INVICTUS
    </Public_title>
    <Scientific_title>INVestIgation of rheumatiC AF Treatment Using vitamin K antagonists, rivaroxaban or aspirin Studies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Population Health Research Institute
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200514
    </Date_registration3>
    <Date_registration>14/05/2020
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11057
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>44 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/01/2016
    </Date_enrollement>
    <Target_size>4500
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Simple randomization using a randomization table created by a computer software program,Central randomisation by phone/fax
    </Study_design>
    <Phase>Phase-3
    </Phase>
    <Countries>Botswana;Brazil;Cameroon;China;China;Egypt;Ethiopia;India;Kazakhstan;Kenya;Malawi;Mexico;Mozambique;Nepal;Nigeria;Pakistan;Paraguay;Philippines;Rwanda;South Africa;Sudan;United Republic of Tanzania;Uganda;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Gayle
    </Contact_Firstname>
    <Contact_Lastname>Lewis
    </Contact_Lastname>
    <Contact_Address>20 Copeland Avenue
    </Contact_Address>
    <Contact_Email>gayle.lewis@phri.ca
    </Contact_Email>
    <Contact_Tel>9055274322
    </Contact_Tel>
    <Contact_Affiliation>Associate Program Manager
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Registry: Any patient with RVHD diagnosed by echocardiography (any age)&#x0D;&lt;br&gt;Non-Inferiority Trial:&#x0D;&lt;br&gt;1.	RVHD diagnosed by echocardiography at any time prior to enrollment&#x0D;&lt;br&gt;2.	Age =18 &#x0D;&lt;br&gt;3.	Increased risk of stroke by any of the following&#x0D;&lt;br&gt;a)	CHA2DS2-VASc score = 2 OR&#x0D;&lt;br&gt;b)	Moderate/Severe mitral stenosis with valve area =2.0 cm2 OR&#x0D;&lt;br&gt;c)	Left atrial spontaneous echo contrast OR  &#x0D;&lt;br&gt;d)	Left atrial thrombus&#x0D;&lt;br&gt;4.	Heart Rhythm&#x0D;&lt;br&gt;a)	AF or Flutter should be documented on baseline 12-lead ECG, or on a previous 12-lead ECG, Holter monitor, in-hospital ECG rhythm strip or Pacemaker or ICD electrogram.&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1.	Refusal to consent&#x0D;&lt;br&gt;2.	Actively involved in any study that would compromise the protocol of INVICTUS Trial&#x0D;&lt;br&gt;3.	Severe co-morbid condition with life expectancy &lt; 1 year&#x0D;&lt;br&gt;4.	Other serious condition(s) or logistic factors likely to interfere with study participation or with the ability to complete the trial, as appropriate to country or region.&#x0D;&lt;br&gt;5.	Likely to have valve replacement surgery within 6 months&#x0D;&lt;br&gt;6.	Mechanical valve prosthesis or other condition requiring treatment with VKAs.  Patients with deep vein thrombosis or recent pulmonary embolism can be enrolled where both VKAs and rivaroxaban are approved.  &#x0D;&lt;br&gt;7.	Contraindication to the study medication of the trial&#x0D;&lt;br&gt;a.	Allergy to rivaroxaban&#x0D;&lt;br&gt;b.	Allergy to VKAs ( non-inferiority trial)&#x0D;&lt;br&gt;c.	Allergy to aspirin ( superiority trial)&#x0D;&lt;br&gt;8.	Severe renal insufficiency with an calculated creatinine clearance (Cockcroft-Gault) &lt; 15 ml/min&#x0D;&lt;br&gt;9.	Serious bleeding in the past six months or at high risk for bleeding&#x0D;&lt;br&gt;10.	Moderate to severe hepatic impairment&#x0D;&lt;br&gt;11.	Ongoing need for dual antiplatelet therapy (patients with on-going aspirin therapy =100 mg per day are not excluded). &#x0D;&lt;br&gt;12.	Ongoing need for dual strong inhibitors of CYP-3a4 or p-glycoprotein   inhibitor.&#x0D;&lt;br&gt;13.	Received an investigational drug in the past 30 days&#x0D;&lt;br&gt;14.	Patients considered unsuitable for trial inclusion because of unwillingness to attend follow up visits&#x0D;&lt;br&gt;15.	Women who are pregnant and/or breastfeeding&#x0D;&lt;br&gt;16.	Women of child bearing age who do not use an effective form of birth control&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Cardiology;Cardiology
    </Condition>
    <Intervention>;rivaroxaban
    </Intervention>
    <Primary_outcome>-	Stroke(ischemic, hemorrhagic or undetermined type)&lt;br&gt;-	Systemic embolism&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>-	Myocardial infarction&#x0D;&lt;br&gt;-	Hospitalization&#x0D;&lt;br&gt;-	Vascular death&#x0D;&lt;br&gt;-	Total Death&#x0D;&lt;br&gt;-	Composite of stroke, myocardial infarction, systemic embolism, vascular death&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Source_Support>Bayer AG
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>17/12/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>mazzedeb@hhsc.ca
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Hamilton Integrated Research Ethics Board 
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>9055212100
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>mazzedeb@hhsc.ca
    </Ethics_review_contact_email>
    <results_url_link>https://www.phri.ca/
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11652078
    </Internal_Number>
    <TrialID>CTRI/2020/05/025160
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Outcomes Of Cancer Surgery During COVID-19 Pandemic
    </Public_title>
    <Scientific_title>Outcomes of elective cancer surgery during the COVID-19 pandemic crisis: an
international, multicentre, observational cohort study - CovidSurg-Cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>University Of Birmingham United Kingdom
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200513
    </Date_registration3>
    <Date_registration>13-05-2020
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43628
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>25-05-2020
    </Date_enrollement>
    <Target_size>7000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Australia;Benin;Canada;France;Ghana;India;Italy;Mexico;Nigeria;Pakistan;Philippines;Rwanda;South Africa;Spain;United Arab Emirates;United Kingdom;United States of America;Zambia
    </Countries>
    <Contact_Firstname>Dhruva Nath Ghosh
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Department Of Pediatric Surgery
Christian Medical College Hospital
Brown Road 
    </Contact_Address>
    <Contact_Email>pdhaque@gmail.com
    </Contact_Email>
    <Contact_Tel>9872630178
    </Contact_Tel>
    <Contact_Affiliation>Christian Medical College Ludhiana
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Any centres performing elective cancer surgery are eligible for participation. &lt;br/ &gt;&lt;br&gt;2. Adults (age â?¥18 years) with a confirmed diagnosis of an included cancer type &lt;br/ &gt;&lt;br&gt;3. Multidisciplinary team (tumour board) decision for (or would have been made for) surgical management with a curative intent during the pre-COVID-19 era.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Surgery planned with non-curative intent. &lt;br/ &gt;&lt;br&gt;2. Planned neoadjuvant therapy without a firm date for surgery, or awaiting restaging.
    </Exclusion_Criteria>
    <Condition>Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Health Condition 2: O- Medical and Surgical

    </Condition>
    <Intervention>Intervention1: Nil: Nil&lt;br&gt;Control Intervention1: Nil: Nil&lt;br&gt;
    </Intervention>
    <Primary_outcome>30-day postoperative COVID-19 infection rateTimepoint: 30-day postoperative COVID-19 infection rate
    </Primary_outcome>
    <Secondary_outcome>1. 30-day postoperative mortality rate. &lt;br/ &gt;&lt;br&gt;2. Postoperative critical care utilisation rate in high-risk cancer surgery patients. &lt;br/ &gt;&lt;br&gt;3. Proportion of patients with delay of greater than 4 weeks from decision for surgery to date &lt;br/ &gt;&lt;br&gt;of surgery. &lt;br/ &gt;&lt;br&gt;4. Proportion of non-operated patients with progression to incurable disease by 3-months after decision for surgery.Timepoint: 30 days postoperatively (with Day 0 as the day of surgery). &lt;br/ &gt;&lt;br&gt;3 months (Outcomes for non-operated patients)
    </Secondary_outcome>
    <Secondary_ID>NCT04384926
    </Secondary_ID>
    <Source_Support>Christian Medical College Ludhiana
Brown Road
Ludhiana
141008
Punjab;University Of Birmingham
Research Governance Team University of Birmingham Birmingham, B152TT United Kingdom
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>11/06/2020;20/05/2020;09/05/2020;08/06/2020;09/06/2020;09/05/2020;13/05/2020;14/05/2020;28/04/2020;09/06/2020;19/06/2020;29/06/2020;29/04/2020;03/07/2020;18/05/2020;05/05/2020;09/06/2020;18/04/2020;08/06/2020;04/06/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;;;;;;;;;;;;;;;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>All India Institute Of Medical Sciences Bhubhaneshwar;All India Institute Of Medical Sciences Jodhpur;All India Institute Of Medical Sciences Rishikesh;Basavatarakam Indo American Cancer Hospital And Research Institute, Hyderabad;Cancer Institute (WIA) Regional Cancer Centre;Christian Medical College Ludhiana;Christian Medical College Vellore;Devki Devi Foundation;Goverment Medical College Srinagar;Government Medical College Patiala;Government Medical College Thiruvananthapuram;Jawaharlal Institute Of Postgraduate Medical Education And Research Puducherry;Kasturba Medical College Manipal;Kidwai Memorial Institute Of Oncology Bengaluru;King Georges Medical University UP;Narayana Health;Netaji Subhash Chandra Bose Medical College Jabalpur;Sher-i-Kashmir Institute of Medical Sciences Srinagar;Tata Medical Centre Kolkata;Tata Memorial Hospital Mumbai
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;;;;;;;;;;;;;;;;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;;;;;;;;;;;;;;;;;
    </Ethics_review_contact_email>
    <results_date_completed>01/09/2020
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12591319
    </Internal_Number>
    <TrialID>CTRI/2020/05/025163
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Surgery Outcomes in COVID patients
    </Public_title>
    <Scientific_title>Outcomes of surgery in COVID-19 infection: international cohort study - CovidSurg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>University of Birmingham
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200513
    </Date_registration3>
    <Date_registration>13-05-2020
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43610
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>20-05-2020
    </Date_enrollement>
    <Target_size>3000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Benin;France;India;Italy;Mexico;Pakistan;Philippines;Rwanda;South Africa;Spain;United Kingdom;United States of America;Zambia
    </Countries>
    <Contact_Firstname>Dhruva Nath Ghosh
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Department of Pediatric Surgery&#x0D;
Christian Medical College Hospital&#x0D;
Brown Road 
    </Contact_Address>
    <Contact_Email>dhruvghosh73@gmail.com
    </Contact_Email>
    <Contact_Tel>9915198894
    </Contact_Tel>
    <Contact_Affiliation>Christian Medical College Ludhiana
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients undergoing ANY type of surgery in an operating theatre, this includes obstetrics. &lt;br/ &gt;&#x0D;&lt;br&gt;AND &lt;br/ &gt;&#x0D;&lt;br&gt;2. The patient had COVID-19 infection diagnosed within 7 days before or 30 days after surgery, based on &lt;br/ &gt;&#x0D;&lt;br&gt;   1.positive COVID-19 lab test or computed tomography (CT) chest scan. &lt;br/ &gt;&#x0D;&lt;br&gt;OR  &lt;br/ &gt;&#x0D;&lt;br&gt;   2.clinical diagnosis (no COVID-19 lab test or CT chest performed). &lt;br/ &gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: If COVID-19 infection is diagnosed  &gt;30 days after surgery, the patient should not be included.
    </Exclusion_Criteria>
    <Condition>Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere&#x0D;
Health Condition 2: O- Medical and Surgical&#x0D;
Health Condition 3: 1- Obstetrics&#x0D;

    </Condition>
    <Intervention>Intervention1: Nil: Nil&lt;br&gt;Control Intervention1: Nil: Nil&lt;br&gt;
    </Intervention>
    <Primary_outcome>30-day mortality &lt;br/ &gt;&lt;br&gt;To determine 30-day mortality in patients with COVID-19 infection who undergo surgery. This will inform future risk stratification, decision making, and patient consent.Timepoint: 30 days (4 weeks) &lt;br/ &gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>1. 7-day mortality &lt;br/ &gt;&#x0D;&lt;br&gt;2. 30-day reoperation &lt;br/ &gt;&#x0D;&lt;br&gt;3. Postoperative ICU admission &lt;br/ &gt;&#x0D;&lt;br&gt;4. Postoperative respiratory failure &lt;br/ &gt;&#x0D;&lt;br&gt;5. Postoperative acute respiratory distress syndrome (ARDS) &lt;br/ &gt;&#x0D;&lt;br&gt;6. Postoperative sepsis &lt;br/ &gt;&#x0D;&lt;br&gt;Timepoint: 1. Within 30 days post surgery
    </Secondary_outcome>
    <Secondary_ID>NCT04323644
    </Secondary_ID>
    <Source_Support>Christian Medical College Ludhiana India&#x0D;
Brown Road&#x0D;
Ludhiana 141008&#x0D;
Punjab;University Of Birmingham United Kingdom&#x0D;
Birmingham Clinical Trials Unit (BCTU) Institute of Applied Health&#x0D;
Research College of Medical and Dental Sciences Public Health&#x0D;
Building University of Birmingham Edgbaston Birmingham B15 2TT
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>20/05/2020;11/04/2020;01/05/2020;28/04/2020;05/06/2020;29/04/2020;12/06/2020;10/06/2020;12/05/2020;18/04/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;;;;;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>All India Institute Of Medical Sciences Jodhpur;Christian Medical College Ludhiana;Christian Medical College Vellore;Government Medical College Srinagar;Indian Spinal Injuries Centre;Kasturba Medical College Manipal;Maulana Azad Medical College And Associated Hospital;Medical College And SSG Hospital Baroda;Medical College Thiruvananthapuram;Sher i Kashmir Institue Of Medical Sciences
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;;;;;;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;;;;;;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12601758
    </Internal_Number>
    <TrialID>PACTR202008822861957
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults&#x0D;
&#x0D;
Lay Title: IAVI C100
    </Public_title>
    <Scientific_title>Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>International AIDS Vaccine Initiative IAVI
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200418
    </Date_registration3>
    <Date_registration>18/04/2020
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10976
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>44 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>12/01/2019
    </Date_enrollement>
    <Target_size>176
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Simple randomization using a randomization table created by a computer software program,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Phase-2
    </Phase>
    <Countries>Kenya;Kenya;Uganda;Uganda;Rwanda;South Africa
    </Countries>
    <Contact_Firstname>Walter
    </Contact_Firstname>
    <Contact_Lastname>Jaoko
    </Contact_Lastname>
    <Contact_Address>KAVI Institute of Clinical Research, University of Nairobi
    </Contact_Address>
    <Contact_Email>wjaoko@kaviuon.org
    </Contact_Email>
    <Contact_Tel>+254727555254
    </Contact_Tel>
    <Contact_Affiliation>Principal Investigator  KAVI
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Healthy individuals, as assessed by medical history, physical exam, and laboratory tests 2. At least 18 years of age on the day of screening and have not reached their 46th birthday on the day of the first administration 3. Willing to undergo HIV testing, risk reduction counseling, and receive HIV test results; committed to maintaining low-risk behavior for the trial duration 4. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study; 5. According to the PI/designee and based on Assessment of Understanding results, has understood the information provided and potential impact and/or risks linked to IP administration and participation in the trial; written IC will be obtained from the participant before any study-related procedures are performed; 6. All participants of reproductive potential who are engaging in sexual activity that could lead to pregnancy must commit to using an effective method of contraception from enrollment until 9 months after the last administration, including Condoms, with or without spermicide, IUD &amp; implant Hormonal contraception, Successful vasectomy (male -considered successful if a woman reports that a male partner has; documentation of azoospermia by microscopy (&lt; 1 year ago), or a vasectomy more than 2 years ago with no resultant pregnancy despite sexual activity post-vasectomy)  Note: More restrictive measures may be required by study site. &#x0D;&lt;br&gt;'7. Willing to forgo donations of blood, or any other tissues during the study following confirmation of study eligibility and, for those who test HIV-positive due to antibody-induced seropositivity, until the ant-HIV antibody titers become undetectable on HIV tests used in the community. 8. Body mass index  (BMI) &gt;40 9.  &#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Confirmed HIV infection; 2. Reported risk for HIV infection within 6 months prior to investigational product administration, as defined by: Unprotected sexual intercourse with a known HIV-infected person, a partner known to be at high risk for HIV infection and/or a casual partner (i.e. no continuing established relationship)  Engaged in sex work  Frequent excessive daily alcohol use or frequent binge drinking or any other use of illicit drugs  History of newly-acquired syphilis, gonorrhea, non-gonococcal urethritis, HSV-2, chlamydia, pelvic inflammatory disease (PID), trichomonas, mucopurulent cervicitis, epididymitis, proctitis, lymphogranuloma venereum, chancroid, or hepatitis B or hepatitis C;  Three or more sexual partners; 3. Any clinically relevant abnormality on history or examination, including history of immunodeficiency or autoimmune disease; use of systemic corticosteroids (the use of topical or inhaled steroids is permitted), immunosuppressive, anticancer, antituberculosis or other medications considered significant by the investigator within the previous 6 months; The following exceptions are permitted and will not exclude study participation: use of corticosteroid nasal spray for rhinitis, topical corticosteroids for an acute uncomplicated dermatitis; or a short course (duration of 10 days or less, or a single injection) of corticosteroid for a non-chronic condition (based on investigator clinical judgment) at least 2 weeks prior to enrollment in this study; 4. Any clinically significant acute or chronic medical condition that is considered progressive or in the opinion of the investigator makes the participant unsuitable for participation in the study; 5. Asthma that is not well controlled; 6. If female, pregnant or planning a pregnancy during the period of enrollment until 9 months after the final IP administration; or lactating; 7. Bleeding disorder diagnosed by a physician (e.g., factor deficiency, coagulopathy or platelet disorder 
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;HIV/AIDS;HIV/AIDS
    </Condition>
    <Intervention>;Sodium Chloride;Antibodies 3BNC117 LS J and 10 1074 LS J
    </Intervention>
    <Primary_outcome>Safety and tolerability:&lt;br&gt;1. Proportion of participants with solicited and IP-related unsolicited adverse events that are Grade 2 and above (including confirmed laboratory abnormalities) and their duration.&lt;br&gt;2. Proportion of participants with solicited and IP-related unsolicited adverse events that are Grade 3 and above (including confirmed laboratory abnormalities) and their duration.&lt;br&gt;3. Proportion of participants with serious adverse events (SAEs) throughout the study period that are considered related to investigational product and their duration.&lt;br&gt;&lt;br&gt;Pharmacokinetics (PK):&lt;br&gt;4. The ratio of 3BNC117-LS-J to 10-1074-LS-J that, when injected SC, will maintain similar levels of each bNAb at steady state.
    </Primary_outcome>
    <Secondary_outcome>Secondary Endpoints:&#x0D;&lt;br&gt;1. Serum concentration of each bNAb in each group at multiple timepoints along with participant characteristics (e.g., sex, weight, and BMI).                                                                                                                                                                                                                 2. Serum concentration of 3BNC117-LS-J and 10-1074-LS-J in each group at multiple timepoints along with dose, dose ratio, dosing frequency and loading dose. 3. Serum concentration of anti-3BNC117-LS-J and anti-10-1074-LS-J antibodies in each group at multiple timepoints.&#x0D;&lt;br&gt;Exploratory Endpoints:&#x0D;&lt;br&gt;1. Serum concentration of the bNAb in each group at multiple timepoints along with geographical region, immunoglobulin levels and the subcutaneous site of administration (abdomen vs. arm).&#x0D;&lt;br&gt;2. Magnitude of serum neutralization of virus isolates sensitive to each antibody at 7 days and 12 weeks after each SC administration in selected participants in America and Africa.&#x0D;&lt;br&gt;3. Proportion of participants with reduction in bNAb half-life concomitant with ADA.&#x0D;&lt;br&gt;4. Proportion of participants with reduction in bNAb neutralization potency concomitant with ADA.&#x0D;&lt;br&gt;5. Proportion of participants with pIMDs throughout the study period that are considered related to investigational product and their duration.&#x0D;&lt;br&gt;6. Relationship of solicited and unsolicited adverse events, and pIMDs, to ADA.&#x0D;&lt;br&gt;7. bNAb concentrations in mucosal secretions in a subset of participants enrolled in African sites.
    </Secondary_outcome>
    <Secondary_ID>140344 FDA IND;NCT04173819
    </Secondary_ID>
    <Source_Support>Bill and Melinda Gates Foundation
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>25/03/2020;04/05/2020;04/05/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>seru@kemri.org;knhresearch@gmail.com;sdelany@wrhi.ac.za
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>KEMRI SERU;KNH UoN ERC;University of Witwatersrand Human Research Ethics Committee                               
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>0717719477;0717719477;0027112749200
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>seru@kemri.org;knhresearch@gmail.com;sdelany@wrhi.ac.za
    </Ethics_review_contact_email>
    <results_url_link>CAVD public web site: https://www.cavd.org
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12057010
    </Internal_Number>
    <TrialID>ISRCTN80453162
    </TrialID>
    <Last_Refreshed_on>21 March 2022
    </Last_Refreshed_on>
    <Public_title>The impact of the COVID-19 pandemic on the provision, practice, and outcomes of vascular surgery (COVER study)
    </Public_title>
    <Scientific_title>The impact of the COVID-19 pandemic on the provision, practice, and outcomes of vascular surgery. An international cohort study (COVER)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>University Hospitals Coventry and Warwickshire NHS Trust
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200414
    </Date_registration3>
    <Date_registration>14/04/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN80453162
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>09/04/2020
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational longitudinal study (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Ruth;Sandip
    </Contact_Firstname>
    <Contact_Lastname>Benson;Nandhra
    </Contact_Lastname>
    <Contact_Address>Vascular and Endovascular Research Network (President);Vascular and Endovascular Research Network
    </Contact_Address>
    <Contact_Email>vern.arterial.disease@gmail.com;vern.arterial.disease@gmail.com
    </Contact_Email>
    <Contact_Tel>+44 (0)121 4143344;+44 (0)191 2336161
    </Contact_Tel>
    <Contact_Affiliation>;
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Any patient with a vascular condition
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Does not meet inclusion criteria
    </Exclusion_Criteria>
    <Condition>Any vascular condition, including: aortic or other type of aneurysmal disease, peripheral arterial disease, venous disease, vascular malformations, trauma, major haemorrhage, access (for renal dialysis), carotid (and cerebrovascular) disease, any other type of pathology treated by vascular surgeons. &lt;br&gt;Circulatory System
    </Condition>
    <Intervention>&lt;br&gt;                This project is a three-tiered study designed to fully elucidate the impact of the COVID-19 pandemic on vascular surgery across the world.&lt;br&gt;&lt;br&gt;                The aim of Tier 1 is to document how the provision and availability of vascular services evolves over time per unit/region/country.&lt;br&gt;&lt;br&gt;                The aim of Tier 2  is to prospectively capture data on all vascular procedures performed during the pandemic and understand the impact on outcomes in the short and medium-term (up to 1 year).&lt;br&gt;&lt;br&gt;                The aim of Tier 3 is to document (prospectively) deviations from standards of care/practice during the pandemic in vascular patients.&lt;br&gt;&lt;br&gt;                The main objective of the COVER study is to understand and evaluate the impact of the COVID-19 pandemic on global vascular practice and the effect on outcomes for patients presenting/receiving treatment during the pandemic.&lt;br&gt;                Population (patients) – All patients with a vascular pathology.&lt;br&gt;                Outcome of interest – Tier 1: state of vascular services per centre weekly; Tier 2: procedures performed in each centre; Tier 3: assessment of longer-term outcomes.&lt;br&gt;                Time – end of study 12 months after the end of the COVID19 pandemic.&lt;br&gt;&lt;br&gt;                The study is formally supported by the Vascular Society of Great Britain and Ireland (VSGBI),  the British Society for Endovascular Therapy (BSET), the Rouleaux Club, the NIHR, SingVasc and several national vascular surgery societies in Europe, Asia, Australia, New Zealand, and the Americas.&lt;br&gt;
    </Intervention>
    <Primary_outcome>&lt;br&gt;                1. Structure and processes within the vascular service measured using a novel online questionnaire weekly until the end of data collection&lt;br&gt;                2. Document all vascular surgery and interventional procedures performed using an online purpose-built data collection tool (per centre/patient) at baseline, time/date of surgery, date of discharge from hospital, three, six, and twelve months:&lt;br&gt;                2.1. Type of procedure performed&lt;br&gt;                2.2. Time taken from presentation to the surgical team to intervention&lt;br&gt;                2.3. Mode of referral (primary vs. secondary care)&lt;br&gt;                2.4. Site of surgery – hub or spoke hospital&lt;br&gt;                2.5. Imaging modalities used and timings&lt;br&gt;                2.6. Emergency classification i.e. urgent/emergency/elective&lt;br&gt;                2.7. Operative technique(s) and device(s) used&lt;br&gt;                2.8. Mode(s) of anaesthesia (local, regional, general, locoregional, other)&lt;br&gt;                2.9. Whether suspected or confirmed COVID-19 positive (+ve) at time of surgery, COVID-19 +ve after surgery, or COVID-19 negative (-ve)&lt;br&gt;                2.10. Documentation of changes to usual practice for this specific procedure as per surgeon’s standard protocol (type of procedure, type of anaesthetic, post-procedural destination)&lt;br&gt;                3. Management of all referred urgent vascular cases using the online survey, focusing on:&lt;br&gt;                3.1.  Chronic Limb Threatening Ischaemia (CLTI):&lt;br&gt;                3.1.1. Decision to discharge/admit/refer to a "hot"/emergency clinic&lt;br&gt;                3.1.2. Decision for endovascular or open surgery first&lt;br&gt;                3.1.3. Decision for best medical therapy or palliation or primary amputation&lt;br&gt;                3.2. Carotid disease:&lt;br&gt;                3.2.1. Number of patients managed with best medical therapy (BMT)&lt;br&gt;                3.2.2. Modifications to the indication and decision for carotid endarterectomy (CEA)&lt;br&gt;                3.2.3. Delays to treatment due to lack of theatre/bed availability&lt;br&gt;                3.3. Abdominal Aortic Aneurysm (AAA)&lt;br&gt;                3.3.1. Increasing use of Endovascular repair (if applicable)&lt;br&gt;                3.3.2. Changes to criteria for intervention&lt;br&gt;                3.3.3. Decisions for palliation, i.e. ‘turn down’&lt;br&gt;                3.4. Acute Aortic syndrome (AAS)&lt;br&gt;                3.4.1. Decision to manage in non-critical care beds&lt;br&gt;                3.4.2. Changes to imaging protocol at unit level&lt;br&gt;                3.4.3. Decision to defer surgery&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Collected after surgery has been performed at three, six, and twelve months using patient records:&lt;br&gt;                1.1. Re-admission&lt;br&gt;                1.2. Re-intervention&lt;br&gt;                1.3. All-cause mortality&lt;br&gt;                1.4. Operation-specific morbidity&lt;br&gt;                1.5. Morbidity&lt;br&gt;                1.6. [If COVID-19 +ve] - respiratory outcome, admission to intensive care unit&lt;br&gt;                2. Condition-specific outcomes at 3, 6 months and 1 year:&lt;br&gt;                2.1. CLTI - limb salvage, amputation free survival, all-cause mortality&lt;br&gt;                2.2. Carotid disease - ipsilateral stroke rate, any stroke rate, all-cause mortality&lt;br&gt;                2.3. AAA - aneurysm-related mortality, all-cause mortality&lt;br&gt;                2.4. AAS - complication rate including ruptures, all-cause mortality&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;COVER_01, IRAS 282224
    </Secondary_ID>
    <Source_Support>National Institute for Health Research
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 02/04/2020, Liverpool Central NHS Research Ethics Committee (Barlow House, 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)207 104 8056; liverpoolcentral.rec@hra.nhs.uk), ref: 20/NW/0196
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/04/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>9338594
    </Internal_Number>
    <TrialID>ISRCTN63145981
    </TrialID>
    <Last_Refreshed_on>1 June 2020
    </Last_Refreshed_on>
    <Public_title>Evaluating the effectiveness of artemisinin combination therapy (ACT) in treating malaria in East Africa
    </Public_title>
    <Scientific_title>Evaluation of the Efficacy of Artemisinin Combination Therapy in East Africa: A World Bank Multi-country East Africa Public Health Laboratory Networking Project. Rwanda Protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Rwanda Biomedical Centre
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200410
    </Date_registration3>
    <Date_registration>10/04/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN63145981
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/09/2012
    </Date_enrollement>
    <Target_size>536
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>This study is part of a multicentre, two-arm, randomised controlled, phase IV trial (Treatment)
    </Study_design>
    <Phase>Phase IV
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Aged 1 to 14 years&lt;br&gt;                2. A slide-confirmed mono-infection of P. falciparum, asexual parasitemia between 1000 and 100000 p/ul&lt;br&gt;                3. Able to attend follow-up visits&lt;br&gt;                4. Written informed consent provided by parent or guardian. If the&lt;br&gt;                parent/caretaker is illiterate, a witness’ signature and the&lt;br&gt;                thumbprint of the participant’s parent/caretaker will be required.&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Severe malnutrition&lt;br&gt;                2. Co-morbidity including but not limited to: infection, severe anaemia, epilepsy, abnormal cardiac rhythm, hypoglycemia, jaundice, respiratory distress, and recent history of allergy,&lt;br&gt;                3. Presence of danger signs including: an inability to drink, vomiting in the past 24 h, an axillary temperature of &gt; 37.5°C or rectal/tympanic temp &gt; 38.0°C, a history of fever within past 24 hours, and/or a recent history of multiple convulsions, unconsciousness, inability to stand or sit&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Uncomplicated P. falciparum malaria &lt;br&gt;Infections and Infestations &lt;br&gt;Uncomplicated Plasmodium falciparum malaria
    </Condition>
    <Intervention>&lt;br&gt;                The choice of study drugs has been made deliberately in response to the needs of each country in malarial treatment particularly with the need to provide treatment beyond the formal public sector and through home treatment.&lt;br&gt;&lt;br&gt;                Duo-cotexin®-This is a combination of dihydro-artemisinine and piperaquine. The drug is referred here as Duo-cotexin® and has been tested extensively in Asia and recently in clinical trials in Uganda and Rwanda and already proposed as second line in some countries.&lt;br&gt;&lt;br&gt;                CoArtem® –This is a combination of artemether and lumefantrine. It is the the comparator because it is the only fixed dose combination with artesunate currently available and first line treatment.  The proposed studies will give an opportunity to accrue a large body of data on efficacy of CoArtem® in different countries.&lt;br&gt;&lt;br&gt;                The study drugs will be administered orally according to standard dosing schedules. Patients who vomit the first dose within 30 minutes of intake will receive a repeat dose. Since this project will compare different treatment regimens, it is important that children or their guardians and clinician or nurse are unaware of the administered treatment in order to prevent biased results.&lt;br&gt;&lt;br&gt;                Treatment with artemether-lumefantrine (CoArtem®) will be based on the Rwanda National Malaria Treatment Guidelines 2012 revised,  based on patient body weight. Over 3 days, CoArtem® will be given at 0, 8, 24, 36, 48, and 60 h.&lt;br&gt;&lt;br&gt;                Treatment with Duo-cotexin® will follow the Kenya National Malaria Treatment Guidelines 2010, based on patient age. Over 3 days, Duo-cotexin® will be given at 0, 24 and 48 h.&lt;br&gt;&lt;br&gt;                Any use of concomitant medications (including paracetamol) will be documented i
    </Intervention>
    <Primary_outcome>PCR-unadjusted and PCR-adjusted adequate clinical and parasitological response (ACPR) at 28 and 42 days follow-up. ACPR, Early treatment failure (ETF), late parasitological failure (LPF), and late clinical failure (LCF) will be classified in accordance with the WHO protocol. A participant will be considered as experiencing ACPR if they are not classified as experiencing ETF, LPR or LCF. Parasite clearance will be determined from Giemsa-stained blood films on day 2 and day 3.  Blood smears will be taken at baseline, 1, 2, 3, 7, 14, 21, 28, 42 and 68 days. Trained microscopy technicians will quantify asexual parasites on thick smears (per 8000 white blood cells) and thin smears will be used for species identification. A minimum of 100 fields will be read before slides were deemed parasite negative. Each slide will be assessed independently by two microscopy technicians at each health centre and a geometric mean parasite density will be calculated.
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Adverse events on CoArtem® and Duo-cotexin® assessed through serious adverse event forms completed by the investigators by 68 days follow-up&lt;br&gt;                2. Proportion of parasites associated with molecular markers related to reduced susceptibility to Duo-cotexin® and CoArtem® assessed through dried filter paper blood spots from patients at baseline and from patients with parasite recurrence on day 7 and onwards if necessary (at 14, 21, 28, 42, and 68 days). These will be placed in a 96-well plate, lysed overnight in a saponin solution and DNA will be extracted with the InstaGene Matrix resin (Bio-Rad, Hercules, CA, USA) as described previously by Canier et al. DNA samples from day 0 and from the day of parasite recurrence will be analysed for genotyping of msp1, msp2 (merozoite surface proteins 1 and 2) and glurp. Mutations in the propeller domain of PfKelch13 (PF3D7_1343700, codons 440–680, 720 bp), associated with resistance to artemisinin, will be  identified by capillary sequencing of PCR products, as described by Menard et al, NEJM 2016.&lt;br&gt;                3. Post-treatment gametocytaemia &amp; malaria transmission will be assessed by quantitative nucleic acid sequence-based amplification (QT-NASBA) and real-time molecular beacon detection. The multiplex assay will consist of both 18s rRNA QT-NASBA to quantify P. falciparum and pfs25 mRNA QT-NASBA to specifically quantify mature gametocytes at baseline, 1, 2, 3, 7, 14, 21, 28, 42 and 68 days&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;Rwanda Protocol
    </Secondary_ID>
    <Source_Support>World Bank Group
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>
                    Approved 16/05/2012, the Rwanda National Ethics Committee (MInistry of Health, P.O. Box. 84, Kilgali, Rwanda; +250 2 55 10 78 84; rnec@moh.gov.rw), ref: RNEC129/RNEC/2012

                
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>31/05/2016
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12630014
    </Internal_Number>
    <TrialID>NCT04324463
    </TrialID>
    <Last_Refreshed_on>31 October 2022
    </Last_Refreshed_on>
    <Public_title>Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial
    </Public_title>
    <Scientific_title>Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial
    </Scientific_title>
    <Acronym>ACTCOVID19
    </Acronym>
    <Primary_sponsor>Population Health Research Institute
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200325
    </Date_registration3>
    <Date_registration>25/03/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04324463
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 21, 2020
    </Date_enrollement>
    <Target_size>6667
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Brazil;Canada;Colombia;Ecuador;Egypt;India;Nepal;Pakistan;Philippines;Russian Federation;South Africa;United Arab Emirates;Brazil;Canada;Colombia;Ecuador;Egypt;India;Nepal;Pakistan;Philippines;Russian Federation;South Africa;United Arab Emirates;Chile;Rwanda;Saudi Arabia
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Richard Whitlock, MD PhD;Emilie Belley-Cote, MD PhD;John Eikelboom, MBBS MSc
    </Contact_Lastname>
    <Contact_Email>;;
    </Contact_Email>
    <Contact_Tel>;;
    </Contact_Tel>
    <Contact_Affiliation>Population Health Research Institute;Population Health Research Institute;Population Health Research Institute
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Outpatient trial:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Symptomatic and laboratory-confirmed diagnosis of COVID-19.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Age = 30 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. High risk: either age =70 or one of the following: male; obesity (BMI =30); chronic&#x0D;&lt;br&gt;             cardiovascular, respiratory or renal disease; active cancer; diabetes.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Within 7 days (ideally 72 hours) of diagnosis, or worsening clinically.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. General: advanced kidney disease; advanced liver disease; pregnancy (known or&#x0D;&lt;br&gt;             potential) or lactation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Colchicine: allergy or planned use; current or planned use of cyclosporine, verapamil,&#x0D;&lt;br&gt;             HIV protease inhibitor, azole antifungal, or macrolide antibiotic (except&#x0D;&lt;br&gt;             azithromycin).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. ASA: allergy; high risk of bleeding, current or planned use of other anti-thrombotic&#x0D;&lt;br&gt;             drugs (e.g., P2Y12 inhibitors, direct oral anticoagulants, vitamin K antagonists,&#x0D;&lt;br&gt;             heparins)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inpatient trial:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Symptomatic and laboratory-confirmed diagnosis of COVID-19.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Age =18 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Within 72 hours (ideally 24 hours) of admission, or worsening clinically.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. General: advanced kidney disease; advanced liver disease, pregnancy (known or&#x0D;&lt;br&gt;             potential) or lactation, already ventilated for &gt;72 hours.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Colchicine: allergy or planned use; current or planned use of cyclosporine, verapamil,&#x0D;&lt;br&gt;             HIV protease inhibitors, azole antifungals, or macrolide antibiotics (except&#x0D;&lt;br&gt;             azithromycin).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. ASA and rivaroxaban: allergy; high risk of bleeding; estimated GFR &lt;15 ml/min; current&#x0D;&lt;br&gt;             or planned use of P2Y12 inhibitors or therapeutic doses of anticoagulants* (e.g.,&#x0D;&lt;br&gt;             direct oral anticoagulants, vitamin K antagonists, heparin, LMWH), current or planned&#x0D;&lt;br&gt;             use of strong inhibitors of both CYP 3A4 and P-gp (e.g., lopinavir/ritonavir,&#x0D;&lt;br&gt;             carbamazepine, ketoconazole). *Note that prophylactic doses of anticoagulants can be&#x0D;&lt;br&gt;             used in patients who are randomized to control.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Coronavirus;Severe Acute Respiratory Syndrome
    </Condition>
    <Intervention>Drug: Colchicine;Drug: Interferon-Beta;Drug: Aspirin;Drug: Rivaroxaban
    </Intervention>
    <Primary_outcome>Outpatient trial - Colchicine vs. control: Time from randomization to first occurrence of the composite of hospitalization or death;Outpatient trial - Aspirin vs. control: Time from randomization to first occurrence of the composite of hospitalization, death or major thrombosis (MI, stroke, ALI, or PE);Inpatient trial - Colchicine vs. control: Time from randomization to first occurrence of the composite of high flow oxygen, mechanical ventilation, or death;Inpatient trial - Aspirin and Rivaroxaban vs. control: Time from randomization to first occurrence of the composite of high flow oxygen, mechanical ventilation, death or major thrombosis (MI, stroke, ALI, or PE)
    </Primary_outcome>
    <Secondary_outcome>Outpatient trial - Aspirin vs. control: Time from randomization to first occurrence of any thrombosis (MI, stroke, ALI, PE, or DVT);Inpatient trial - Colchicine vs. control: Time from randomization to first occurrence of the composite of high flow oxygen, mechanical ventilation, or respiratory death;Inpatient trial - Aspirin vs. control: Time from randomization to first occurrence of the composite of high flow oxygen, mechanical ventilation, or respiratory death;Inpatient trial - Aspirin vs. control: Time from randomization to first occurrence of any thrombosis (MI, stroke, ALI, PE, or DVT)
    </Secondary_outcome>
    <Secondary_ID>PHRI.ACT.COVID19
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Bayer
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12591147
    </Internal_Number>
    <TrialID>CTRI/2020/02/023606
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>CHEETAH Trial Testing Measures To Reduce Surgical Site Infections
    </Public_title>
    <Scientific_title>Cluster randomised trial of sterile glove and instrument change at the time of wound closure to reduce surgical site infection - ChEETAh                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>University Of Birmingham
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200226
    </Date_registration3>
    <Date_registration>26-02-2020
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=36685
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>01-03-2020
    </Date_enrollement>
    <Target_size>12800
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Cluster Randomized Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Not Applicable  Blinding and masking:Participant Blinded
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>India;Benin;Egypt;Ghana;Mexico;Nigeria;Rwanda;South Africa
    </Countries>
    <Contact_Firstname>Dhruva Nath Ghosh
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Department Of Pediatric Surgery, Christian Medical College Hospital Ludhiana&#x0D;
&#x0D;
 
    </Contact_Address>
    <Contact_Email>dhruvghosh73@gmail.com
    </Contact_Email>
    <Contact_Tel>9915198894
    </Contact_Tel>
    <Contact_Affiliation>Christian Medical College  Hospital, Ludhiana Punjab
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Hospital Inclusion Criteria: &lt;br/ &gt;&#x0D;&lt;br&gt; 1. Hospitals where glove and instrument change is not currently routine practice &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;Patient Inclusion Criteria: &lt;br/ &gt;&#x0D;&lt;br&gt; Patients undergoing abdominal surgery who satisfy the following criteria are eligible: &lt;br/ &gt;&#x0D;&lt;br&gt; 1a. Emergency (surgery on an unplanned admission) or elective (surgery on a planned admission) &lt;br/ &gt;&#x0D;&lt;br&gt; 1b. Intraoperative finding of clean-contaminated, contaminated or dirty surgery.  &lt;br/ &gt;&#x0D;&lt;br&gt; 1c. With at least one abdominal incision that is equal to or greater than 5 cms &lt;br/ &gt;&#x0D;&lt;br&gt; 2. Patients aged 5 years and above &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;Country Inclusion Criteria: &lt;br/ &gt;&#x0D;&lt;br&gt; 1. Low and Middle Income Country as defined by DAC ODA list &lt;br/ &gt;&#x0D;&lt;br&gt; 2. At least 4 eligible hospitals per country &lt;br/ &gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients undergoing caeserian section
    </Exclusion_Criteria>
    <Condition>Health Condition 1: O- Medical and Surgical&#x0D;

    </Condition>
    <Intervention>Intervention1: Change Of Surgical Gloves: Change of sterile gloves (or outer gloves if double gloved) for operating surgeon, assistant surgeon(s), scrub staff.&lt;br&gt;Change of gloves should be undertaken for all clean-contaminated, contaminated, and dirty surgeries. After completion of the abdominal component of the operation and at the time of the count of surgical swabs and instruments (preparing for the Ã¢â?¬Ë?sign outÃ¢â?¬â?¢ component of the WHO Surgical&lt;br&gt;Safety Checklist (28)), the surgical team should confirm eligibility of the participant. If the patient is eligible, the surgical team should change gloves before handling the wound edges to facilitate closure&lt;br&gt;&lt;br&gt;Start of all operations in general and emergency surgery operating theatres: This refers to all patients undergoing an abdominal incision. Since the final level of contamination may not be known until during the operation, all cases need to be prepared for glove change&lt;br&gt;Intervention2: Separate Sterile Instruments before closing abdominal wall.: Change of instruments should be undertaken for all clean-contaminated, contaminated, and dirty surgeries. After completion of the abdominal component of the operation and at the time of the count of surgical swabs and instruments (preparing for the Ã¢â?¬Ë?sign outÃ¢â?¬â?¢ component of the WHO Surgical Safety Checklist (28)), the surgical team should confirm eligibility of the participant. If the patient is eligible, the surgical team should change use the clean instruments before handling the wound edges to facilitate closure.&lt;br&gt;&lt;br&gt;Instruments: A sterile set of instruments for abdominal wall closure including a&lt;br&gt;needle holder, forceps, and scissors. This should be implemented in each hospital&lt;br&gt;according to local practice and availability. For example, th
    </Intervention>
    <Primary_outcome>Surgical Site Infections within 30 days of surgeryTimepoint: 30 days after surgery
    </Primary_outcome>
    <Secondary_outcome>1. Unexpected re-admission into hospital for a wound-related problem within 30- &lt;br/ &gt;&#x0D;&lt;br&gt;days post surgery. &lt;br/ &gt;&#x0D;&lt;br&gt;2. Unexpected re-operation for a wound-related problem within 30-days post &lt;br/ &gt;&#x0D;&lt;br&gt;surgery. &lt;br/ &gt;&#x0D;&lt;br&gt;3. Length of hospital stay. &lt;br/ &gt;&#x0D;&lt;br&gt;4. Return to normal activities (e.g. work, school, or family duties) within 30-days &lt;br/ &gt;&#x0D;&lt;br&gt;post surgery. &lt;br/ &gt;&#x0D;&lt;br&gt;5. Death within 30 days of surgery.Timepoint: Clinical outcomes thirty days post surgery
    </Secondary_outcome>
    <Secondary_ID>Cheetah Protocol Version 2.0 (09/07/2019);NCT03980652
    </Secondary_ID>
    <Source_Support>UK National Institute Of Health Research,&#x0D;
Core funding (ref. 16/136/79) &#x0D;
United Kingdom;University Of Birmingham, &#x0D;
Research Governance Team&#x0D;
University of Birmingham&#x0D;
Birmingham, B15 2TT&#x0D;
United Kingdom
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>29/07/2020;08/08/2020;01/01/2020;26/12/2019;04/12/2019;04/12/2019;10/06/2020;14/07/2020;04/12/2019;26/08/2020;13/05/2020;10/10/2020;23/06/2020;10/12/2020;13/12/2019;14/05/2020;11/03/2020;23/10/2020;06/07/2020;17/06/2020;14/07/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;;;;;;;;;;;;;;;;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>All India Institute Of Medical Sciences Jodhpur;All India Institute Of Medical Sciences Rishikesh;Christian Medical College Hospital;Christian Medical College Hospital Vellore;Emmanuel Hospital Association;Emmanuel Hospital Association;Emmanuel Hospital Association;Emmanuel Hospital Association;Emmanuel Hospitals Association;Government Medical College Chandigarh;Government Medical College Patiala;Kalpana Chawla Government Medical College Karnal;Kasturba Medical College &amp; Kasturba Hospital;King Georges Medical University Lucknow;Lady Willingdon Hospital Manali;Maulana Azad Medical College And Associated Hospitals;Padhar Hospital;Postgraduate Institute Of Medical Education And Research Chandigarh;Sheri Kashmir Institute Of Medical Sciences Srinagar;St Stephens Hospital Delhi;Tata Medical Centre Kolkata
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;;;;;;;;;;;;;;;;;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;;;;;;;;;;;;;;;;;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11650500
    </Internal_Number>
    <TrialID>CTRI/2020/02/023582
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>An international,observational study to collect information about the practices of blood transfusion followed by doctors working in intensive care units.
    </Public_title>
    <Scientific_title>International Point Prevalence Study of Intensive Care Unit Transfusion Practices (InPUT)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Academic Medical Center
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200225
    </Date_registration3>
    <Date_registration>25-02-2020
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=40701
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>28-02-2020
    </Date_enrollement>
    <Target_size>10000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;Andorra;Angola;Antigua and Barbuda;Argentina;Armenia;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bhutan;Bolivia;Bosnia and Herzegovina;Botswana;Brazil;Brunei Darussalam;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Central African Republic;Chad;Chile;China;Colombia;Comoros;Congo;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Cyprus;Czech Republic;Democratic People's Republic of Korea;Democratic Republic of the Congo;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Fiji;Finland;France;Gabon;Gambia;Georgia;Germany;Ghana;Greece;Grenada;Guatemala;Guinea;Guinea-Bissau;Guyana;Haiti;Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran (Islamic Republic of);Iraq;Ireland;Israel;Italy;Jamaica;Japan;Jordan;Kazakhstan;Kenya;Kiribati;Kuwait;Kyrgyzstan;Lao People's Democratic Republic;Latvia;Lebanon;Lesotho;Liberia;Libyan Arab Jamahiriya;Lithuania;Luxembourg;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Mauritania;Mauritius;Mexico;Micronesia (Federated States of);Monaco;Mongolia;Montenegro;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norway;Oman;Other;Pakistan;Palau;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Republic of Moldova;Romania;Russian Federation;Rwanda;Saint Kitts and Nevis;Saint Lucia;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia ;Seychelles;Sierra Leone;Singapore;Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;Spain;Sri Lanka;Sudan;Suriname;Swaziland;Sweden;Switzerland;Syrian Arab Republic;Taiwan;Tajikistan;Tanzania;Thailand;The former Yugoslav Republic of Macedonia;Timor-Leste;Togo;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United Republic of Tanzania;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela (Bolivarian Republic of);Viet Nam;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Dr Sheila Nainan Myatra
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Room No 5, Department of Anesthesia, Critical care and Pain, Main building, Dr E Borges Road, parel 
    </Contact_Address>
    <Contact_Email>sheila150@hotmail.com
    </Contact_Email>
    <Contact_Tel>9820156070
    </Contact_Tel>
    <Contact_Affiliation>Tata Memorial Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. All adult (age more than 18yrs)patients admitted to the ICU in a pre-specified week
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients younger than 18 years old.
    </Exclusion_Criteria>
    <Condition>Health Condition 1: R69- Illness, unspecified

    </Condition>
    <Intervention>Intervention1: Nil: Nil&lt;br&gt;Control Intervention1: Nil: Nil&lt;br&gt;
    </Intervention>
    <Primary_outcome>1.To describe current transfusion practiceTimepoint: once a day after intensive care unit admission till discharge or maximum upto 28 days
    </Primary_outcome>
    <Secondary_outcome>Differences of transfusion practices between different patient subgroupsTimepoint: Once at the time of data analysis;Differences of transfusion regimes between world regionsTimepoint: Once at the time of data analysis;Mortality and length of stay in the intensive care unitTimepoint: Once a day after intensive care unit admission till discharge or maximum upto 28 days
    </Secondary_outcome>
    <Secondary_ID>Project No 3397 Version 5.0 dated 17 Oct 2019
    </Secondary_ID>
    <Source_Support>Tata Memorial Hospital, Dr.E Borges Road, Parel Mumbai 400012
    </Source_Support>
    <Secondary_Sponsor>Not Any
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>23/01/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Institutional Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10356759
    </Internal_Number>
    <TrialID>NCT04283929
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Evaluation of Clinical Impacts and Costs of eHealth in Rwanda
    </Public_title>
    <Scientific_title>Evaluation of the Clinical Impacts and Costs of eHealth in Rwanda Using Innovative Frameworks and Local Capacity Building
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>National University, Rwanda
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200221
    </Date_registration3>
    <Date_registration>21/02/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04283929
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 15, 2018
    </Date_enrollement>
    <Target_size>112
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Fraser HAMISH, MBChB;Jeanine CONDO, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Brown University: hamish_fraser@brown.edu;University of Rwanda
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Is a health center with an average (3 month) monthly volume of 50-700 patients&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Is owned and operated by the public sector or faith-based institutions&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has a power source&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has network connectivity&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has at least 3 computers and 1 printer&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  District hospitals (typically with high patient volume)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Privately owned facilities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Facilities operated by Partners in Health (who already run a version of the&#x0D;&lt;br&gt;             intervention)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Facilities that only offer PMTCT services&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Facilities that run OpenMRS version 1.9 (rather than 1.6)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV/AIDS and Infections;Electronic Medical Records;Clinical Decision Support System
    </Condition>
    <Intervention>Other: Experimental: Intervention 1 (Int1);Other: Experimental: Intervention 2 (Int2);Other: Experimental: Intervention 3 (Int3)
    </Intervention>
    <Primary_outcome>Rate of linkage to care among HIV-positive patients;Percentage of ART patients have viral load results in EMR (initial);Percentage of ART patients with treatment failure experience clinical action;Percentage of patients who experience treatment failure who are fully suppressed 4 months after the point of failure
    </Primary_outcome>
    <Secondary_outcome>Time from HIV+ test result to linkage to care;Percentage of ART patients have viral load results in EMR (annual);Time from detection of treatment failure to clinical action
    </Secondary_outcome>
    <Secondary_ID>GH000782
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Centers for Disease Control and Prevention;Ministry of Health, Rwanda;Rwanda Biomedical Centre;Partners in Health;Innovative Support to Emergencies Diseases and Disasters;University of Pittsburgh;Jembi Health Systems;Brown University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12182133
    </Internal_Number>
    <TrialID>NCT04258085
    </TrialID>
    <Last_Refreshed_on>19 April 2022
    </Last_Refreshed_on>
    <Public_title>Promoting Earlier Detection of Breast Cancer in Rwanda: Scaleup in the National Health Care System
    </Public_title>
    <Scientific_title>Promoting Earlier Detection of Breast Cancer in Rwanda: Scaleup in the National Health Care System
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Brigham and Women's Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200204
    </Date_registration3>
    <Date_registration>04/02/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04258085
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 1, 2020
    </Date_enrollement>
    <Target_size>17379
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Lydia Pace
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Brigham and Women's Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All women and men who are evaluated for a breast concern or receive breast cancer&#x0D;&lt;br&gt;             screening through implementation of the nationally-led early detection programs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  None&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Breast Cancer;Benign Breast Disease
    </Condition>
    <Intervention>Other: Early diagnosis program combined with electronic medical record
    </Intervention>
    <Primary_outcome>Cancer detection rate;Loss to follow-up;Patient volume and services received
    </Primary_outcome>
    <Secondary_outcome>Breast cancer stage;Patients' costs
    </Secondary_outcome>
    <Secondary_ID>2014P002688a
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Rwanda Biomedical Centre;Partners in Health;Breast Cancer Research Foundation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12279901
    </Internal_Number>
    <TrialID>NCT04257383
    </TrialID>
    <Last_Refreshed_on>23 May 2022
    </Last_Refreshed_on>
    <Public_title>The Sugira Muryango PLAY Collaborative
    </Public_title>
    <Scientific_title>The PLAY Collaborative: Testing an Implementation Strategy for Scaling Out Evidence-Based ECD Home-Visiting in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Boston College
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200130
    </Date_registration3>
    <Date_registration>30/01/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04257383
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 5, 2021
    </Date_enrollement>
    <Target_size>1333
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Theresa Betancourt, Sc.D
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Boston College School of Social Work
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Household inclusion criteria: Participants must be the primary caregiver to a child between&#x0D;&lt;br&gt;        birth and 36 months. Caregivers must live in the same household as the child and must be&#x0D;&lt;br&gt;        the child's legal guardian. Legal guardians may be parents, aunts, uncles, grandparents, or&#x0D;&lt;br&gt;        foster parents. Participants must be categorized as Ubudehe 1 under the socio-economic&#x0D;&lt;br&gt;        categorization of households from LODA.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Government Official inclusion criteria: Government officials must be located at the&#x0D;&lt;br&gt;        Village, Cell, Sector and/or District level and must participate in the 1-day ECD training.&#x0D;&lt;br&gt;        Government officials must also agree to participate in the PLAY Collaborative activities&#x0D;&lt;br&gt;        throughout the course of program delivery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        IZU interventionist inclusion criteria: IZUs must be a part of the Inshuti&#x0D;&lt;br&gt;        z'Umuryango/Friends of the Family program, must be over the age of 18, and must be literate&#x0D;&lt;br&gt;        in Kinyarwanda.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Cell Level IZU Mentor inclusion criteria: Cell Level IZU Coordinators must be situated at&#x0D;&lt;br&gt;        the Cell Level and able to supervise at least 12 IZU interventionists, they must be over 18&#x0D;&lt;br&gt;        years of age, and must be literate in Kinyarwanda.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Household exclusion criteria: Potential participants will be excluded if they do not meet&#x0D;&lt;br&gt;        the inclusion criteria above, are experiencing an active crisis (e.g., psychosis), or have&#x0D;&lt;br&gt;        severe cognitive impairments which preclude their ability to speak to the research&#x0D;&lt;br&gt;        questions/assessments under scrutiny.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Government Official exclusion criteria: Government officials will be excluded from&#x0D;&lt;br&gt;        participation in the PLAY Collaborative if they are not located at the Cell, Sector or&#x0D;&lt;br&gt;        District level and if they are unable to meet the demands of participation in the PLAY&#x0D;&lt;br&gt;        Collaborative.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        IZU interventionist exclusion criteria: IZUs will be excluded from participation if they do&#x0D;&lt;br&gt;        not meet the inclusion criteria above and if they are unable to meet the demands of&#x0D;&lt;br&gt;        delivering the Sugira Muryango program.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Cell Level IZU Mentor exclusion criteria: Cell Level IZU Coordinators will be excluded if&#x0D;&lt;br&gt;        they do not meet the inclusion criteria above or are unable to meet the demands of&#x0D;&lt;br&gt;        supporting the delivery of the Sugira Muryango program.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Child Development;Parenting;Parent-Child Relations;Child Malnutrition
    </Condition>
    <Intervention>Other: Sugira Muryango
    </Intervention>
    <Primary_outcome>Home Observation for Measurement of the Environment (HOME) Inventory;Observation of Mother-Child Interaction (OMCI);UNICEF MICS Family Care Indicators (FCI);Dissemination and Implementation Measure (D&amp;I);Program Sustainability Assessment Tool (PSAT);Malawi Development Assessment Tool (MDAT);Ages and Stages Questionnaire-3 (ASQ-3);UNICEF MICS: Child Discipline Module;Rwanda Demographic Health Survey- Intimate Partner Violence
    </Primary_outcome>
    <Secondary_outcome>Rwanda Demographic and Health Survey (DHS);WHO infant and young child feeding practices;Child Anthropometrics
    </Secondary_outcome>
    <Secondary_ID>001210997
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>FXB;Laterite;LEGO;Grand Challenges Canada;Echidna Giving;The ELMA Foundation;InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11942986
    </Internal_Number>
    <TrialID>NCT04230161
    </TrialID>
    <Last_Refreshed_on>21 February 2022
    </Last_Refreshed_on>
    <Public_title>Estimating the Malaria Prevention Impact of New Nets: Observational Analyses to Evaluate the Evidence Generated During Piloted New Net Distributions in Rwanda
    </Public_title>
    <Scientific_title>Estimating the Malaria Prevention Impact of New Nets: Observational Analyses to Evaluate the Evidence Generated During Piloted New Net Distributions in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>PATH
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200114
    </Date_registration3>
    <Date_registration>14/01/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04230161
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 24, 2020
    </Date_enrollement>
    <Target_size>3669
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Joseph Wagman, PhD;Aimable Mbituyumuremyi, MD;Joseph Wagman, PhD;Aimable Mbituyumuremyi, MD
    </Contact_Lastname>
    <Contact_Email>;;jwagman@path.org;aimable.mbituyumuremyi@rbc.gov.rw
    </Contact_Email>
    <Contact_Tel>;;2025404359;
    </Contact_Tel>
    <Contact_Affiliation>PATH;Rwanda Biomedical Centre;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Passive data collection: all suspected malaria cases (fevers) that self-present to the&#x0D;&lt;br&gt;             national health system and are counted in the district health surveillance systems.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cross sectional survey: Households in the district.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Residents of the household visited.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Questionnaire: any adult member of the household .&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Malaria screening: all members aged 6 months or older from the above consenting&#x0D;&lt;br&gt;                  household.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals of box sexes, not belonging to vulnerable categories (those with cognitive&#x0D;&lt;br&gt;             impairment or other person for whom full and open consent cannot be guaranteed) (Key&#x0D;&lt;br&gt;             informant interviews, focus group discussions, and participant observations).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals 18 years old and above (Key informant interviews, focus group discussions,&#x0D;&lt;br&gt;             and observations).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals of both sexes regardless of age (observations).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  District non-residents.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Malaria screening: history of recent (within one month) malaria infection or treatment&#x0D;&lt;br&gt;             with anti-malarial medication (cross-sectional).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parents or guardians who have not yet reached age of consent (18 years) and their&#x0D;&lt;br&gt;             children will not be included in study activities requiring consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals belonging to vulnerable categories (key informant interviews, focus group&#x0D;&lt;br&gt;             discussions, observations).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals unwilling and/or unable of giving consent (key informant interviews, focus&#x0D;&lt;br&gt;             group discussions, observations).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals below age of consent (20 years) (key informant interviews, focus group&#x0D;&lt;br&gt;             discussions, observations).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Heads of households unwilling and/or unable of giving consent (observations).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who do not wish to be included in observations will be excluded&#x0D;&lt;br&gt;             (observations).&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria
    </Condition>
    <Intervention>Other: Standard long-lasting insecticidal net;Other: Chlorfenapyr insecticide treated net;Other: Indoor residual spraying
    </Intervention>
    <Primary_outcome>Cumulative malaria incidence
    </Primary_outcome>
    <Secondary_outcome>Vector species composition;Species-specific population densities;Biting behaviors;Estimated entomological inoculation rates;Insecticide resistance profile;Parasite prevalence in children 6 months or older
    </Secondary_outcome>
    <Secondary_ID>1409734-2
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Rwanda Biomedical Centre;University of Rwanda;Liverpool School of Tropical Medicine
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11649335
    </Internal_Number>
    <TrialID>CTRI/2019/12/022417
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Alternative Approach for General Health Issues
    </Public_title>
    <Scientific_title>Frequency Embedded Crystal Ball Water Technology - FECB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Portoworld
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191218
    </Date_registration3>
    <Date_registration>18-12-2019
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=38957
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>20-12-2019
    </Date_enrollement>
    <Target_size>1000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized Factorial Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Case Record Numbers  Blinding and masking:Open Label
    </Study_design>
    <Phase>Phase 1
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;Angola;Argentina;Australia;Bahamas;Bangladesh;Belarus;Belgium;Benin;Bhutan;Botswana;Brazil;Bulgaria;Burundi;Cambodia;Canada;Central African Republic;Chad;China;Colombia;Congo;Croatia;Cuba;Democratic People's Republic of Korea;Ecuador;Egypt;El Salvador;Equatorial Guinea;Ethiopia;France;Gambia;Germany;Greece;Guinea;Guyana;Haiti;Hong Kong;India;Indonesia;Iran (Islamic Republic of);Ireland;Israel;Japan;Kazakhstan;Kuwait;Liberia;Libyan Arab Jamahiriya;Malaysia;Marshall Islands;Mauritius;Mexico;Morocco;Myanmar;Namibia;Nauru;Netherlands;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norway;Oman;Other;Palau;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Republic of Moldova;Romania;Russian Federation;Rwanda;Saint Kitts and Nevis;Saint Lucia;Saint Vincent and the Grenadines;Samoa;San Marino;Saudi Arabia;Serbia ;Singapore;Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;Spain;Sri Lanka;Sudan;Suriname;Sweden;Syrian Arab Republic;Taiwan;Tajikistan;Tanzania;Thailand;The former Yugoslav Republic of Macedonia;Timor-Leste;Togo;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United Republic of Tanzania;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela (Bolivarian Republic of);Viet Nam;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>O Mohammed Shadab
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Room No - H 6A , Department of public information and Records  , Portoworld, krupa colony,
First Avenue , Ashok Nagar,Chennai 
    </Contact_Address>
    <Contact_Email>portoworld1@gmail.com
    </Contact_Email>
    <Contact_Tel/>
    <Contact_Affiliation>Portoworld
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Healthy Induvidual Above the age of 18yrs and Below 70yrs are involved
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Any Induvidual below the age of Five Years and pregnant ladies are exempted from this trial
    </Exclusion_Criteria>
    <Condition/>
    <Intervention>Intervention1: FREQUENCY EMBEEDED WATER: DIFFERENT FREQUENCIES ARE EMBEEDED IN A CRYSTAL BALL AND THEN THE BALL WITH FREQUENCY IS DIPPED IN A DRINKING WATER FOR 10 MINUTES AND THE WATER IS PRESENTED TO PATIENTS&lt;br&gt;Control Intervention1: NOT APPLICABLE: NOT APPLICABLE&lt;br&gt;
    </Intervention>
    <Primary_outcome>General Health AND IMMUNITYTimepoint: 30 days
    </Primary_outcome>
    <Secondary_outcome>Blood sugar becomes NormalTimepoint: 30 days;Metabolism impovedTimepoint: 20 days;Noctonal Pain in joints were reducedTimepoint: 3 months;Testosterone Level increasedTimepoint: 30 days
    </Secondary_outcome>
    <Secondary_ID>IYRF/IND/TN/8947
    </Secondary_ID>
    <Source_Support>Portoworld
H-6A , krupa colony,
First Avenue , Ashok Nagar,Chennai
    </Source_Support>
    <Secondary_Sponsor>Dr Krishnamurthy Kannan
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>20/07/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>International Youth Research Foundation
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12289526
    </Internal_Number>
    <TrialID>NCT04198272
    </TrialID>
    <Last_Refreshed_on>30 May 2022
    </Last_Refreshed_on>
    <Public_title>Impact Evaluation of CyberRwanda: A Digital Health Intervention for Adolescents
    </Public_title>
    <Scientific_title>Impact Evaluation of CyberRwanda: A Digital Health Intervention for Adolescents
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of California, Berkeley
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191211
    </Date_registration3>
    <Date_registration>11/12/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04198272
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>12 Years
    </Inclusion_agemin>
    <Inclusion_agemax>19 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 20, 2021
    </Date_enrollement>
    <Target_size>6000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Sandra McCoy, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>UC Berkeley
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Attending a study school at baseline;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Between 12 and 19 years of age;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Assent to participate;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parents have provided consent for their child to participate in the study; and&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willingness to provide valid contact information for study follow-up purposes.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Pregnancy in Adolescence;Adolescent Health;Health Services Accessibility
    </Condition>
    <Intervention>Behavioral: CyberRwanda
    </Intervention>
    <Primary_outcome>Uptake of a modern contraceptive method (age 15-19);Initiation of childbearing (age 15-19);HIV testing (age 12-19)
    </Primary_outcome>
    <Secondary_outcome>FPRH Knowledge: % of youth (12-19) that understand the phases of a girl's menstrual cycle;Behavioral Intentions: % of youth (15-19) who intend to use a modern contraceptive method in the next 12 months;Self-efficacy Contraceptive Use: % of adolescents (15-19) who are confident that they could get their partner(s) to use contraceptives/condoms if they desired
    </Secondary_outcome>
    <Secondary_ID>2019-04-12145
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Youth Development Labs, Inc dba YLabs;Society for Family Health, Rwanda
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11732916
    </Internal_Number>
    <TrialID>NCT04202107
    </TrialID>
    <Last_Refreshed_on>13 December 2021
    </Last_Refreshed_on>
    <Public_title>Dietary Assessment in Rwanda - Food Frequency Questionnaire
    </Public_title>
    <Scientific_title>Development and Evaluation of a Semi-quantitative Food Frequency Questionnaire for Use in Urban and Rural Communities of Rwanda
    </Scientific_title>
    <Acronym>FFQ Rwanda
    </Acronym>
    <Primary_sponsor>University Ghent
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191127
    </Date_registration3>
    <Date_registration>27/11/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04202107
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>49 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 30, 2020
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Stefaan De Henauw, Md. PhD;Souheila Abbeddou, MSc. PhD;Jerome Some, Md. PhD;Hilda Vasanthakaalam, PhD;Souheila Abbeddou, MSc. PhD;Phenias Nsabimana, MSc.
    </Contact_Lastname>
    <Contact_Email>;;;;Souheila.Abbeddou@UGent.be;nsaphe@gmail.com
    </Contact_Email>
    <Contact_Tel>;;;;+32467630892;00250783054143
    </Contact_Tel>
    <Contact_Affiliation>University of Ghent;UGent;Institut de Recherche en Sciences de la Sante, Ouagadougou, Burkina Faso;University of Rwanda;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Permanent residence of the selected urban or rural villages&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Holding a valid health insurance card&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Aged between 18 and 49 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signing informed consent form&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Familiar with the diet and cooking practices&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Registration in city demographic system, since study participants will be selected&#x0D;&lt;br&gt;             from population registration cards at village level,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Accept enumerators for home visit and data collection for one year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mental disorders such as clinically diagnosed depression, anxiety disorders, eating&#x0D;&lt;br&gt;             disorders and addictive behaviors&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dietary Assessment
    </Condition>
    <Intervention>Other: Food Frequency Questionnaire;Other: 24 Hour food recall
    </Intervention>
    <Primary_outcome>Median proportion of energy intake from carbohydrates assessed by the 24 hour recalls;Median proportion of energy intake from carbohydrates assessed by the Food Frequency Questionnaire;Median proportion of energy intake from fat assessed by the 24 hour recalls;Median proportion of energy intake from fat assessed by the Food Frequency Questionnaire;Median proportion of energy intake from proteins assessed by the 24 hour recalls;Median proportion of energy intake from proteins assessed by the Food Frequency Questionnaire;Median daily intake of fibers assessed by the 24 hour recalls;Median daily intake of fibers assessed by the Food Frequency Questionnaire
    </Primary_outcome>
    <Secondary_ID>EC/2019/1578
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut de Recherche en Sciences de la Sante, Burkina Faso;University of Rwanda
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11732921
    </Internal_Number>
    <TrialID>NCT04204538
    </TrialID>
    <Last_Refreshed_on>13 December 2021
    </Last_Refreshed_on>
    <Public_title>Dietary Practices and Metabolic Syndrome in the Young Adult Population of Rwanda
    </Public_title>
    <Scientific_title>Evaluation of Dietary Practices and Assessment of Nutritional Status and Associated Risk Factors for Metabolic Syndrome in the Young Adult Population of Rwanda
    </Scientific_title>
    <Acronym>NutriTransit
    </Acronym>
    <Primary_sponsor>University Ghent
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191127
    </Date_registration3>
    <Date_registration>27/11/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04204538
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>35 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 1, 2021
    </Date_enrollement>
    <Target_size>1092
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Stefaan De Henauw, Md. PhD;Souheila Abbeddou, MSc. PhD;Hilda Vasanthakaalam, PhD;Jerome Some, Md. PhD;Souheila Abbeddou, MSc. PhD;Hilda Vasanthakaalam, PhD
    </Contact_Lastname>
    <Contact_Email>;;;;Souheila.Abbeddou@UGent.be;hildajeya@hotmail.com
    </Contact_Email>
    <Contact_Tel>;;;;+32467630892;+250788530367
    </Contact_Tel>
    <Contact_Affiliation>University of Ghent;University of Ghent;University of Rwanda;Institut de Recherche en Sciences de la Sante, Ouagadougou, Burkina Faso;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Permanent residence of the selected urban or rural villages&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Holding a valid health insurance card&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Aged between 18 and 35 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signing informed consent form&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Registration in city demographic system, since study participants will be selected&#x0D;&lt;br&gt;             from population registration cards at village level,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Accept enumerators for home visit and data collection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Accept to visit the laboratory for blood sample collection,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Not suffering from any chronic disease such as VIH/ AIDS, diabetes, asthma, etc.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lactating, pregnant, and recently delivering (less than six month-postpartum) women&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Physical disabilities that can prevent participants from working&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mental disability such as clinically diagnosed depression, anxiety disorders, eating&#x0D;&lt;br&gt;             disorders and addictive behaviors.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Metabolic Syndrome;Nutritional Status;Diet Habit
    </Condition>
    <Intervention>Other: Dietary habits;Other: Risk factors associated with metabolic syndrome
    </Intervention>
    <Primary_outcome>Prevalence of the different dietary patterns;Prevalence of large waist circumference;Prevalence of high triglyceride concentrations;Prevalence of high-density lipoprotein (HDL) cholesterol;Prevalence of high blood pressure;Prevalence of high levels of fasting blood sugar;Prevalence of participants with nutrition knowledge
    </Primary_outcome>
    <Secondary_outcome>Prevalence of Food Insecure Households
    </Secondary_outcome>
    <Secondary_ID>EC/2019/1577
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Rwanda;Institut de Recherche en Sciences de la Sante, Burkina Faso
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10348594
    </Internal_Number>
    <TrialID>NCT04177654
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Monitoring Drug Efficacy and Anthelmintic Resistance in Soil-transmitted Helminth Programs
    </Public_title>
    <Scientific_title>Establishing a Surveillance System to Monitor the Global Patterns of Drug Efficacy and Emergence of Anthelmintic Resistance in Soil-transmitted Helminth Programs
    </Scientific_title>
    <Acronym>StarwormsWP2
    </Acronym>
    <Primary_sponsor>University Ghent
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191118
    </Date_registration3>
    <Date_registration>18/11/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04177654
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 Years
    </Inclusion_agemin>
    <Inclusion_agemax>14 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 15, 2019
    </Date_enrollement>
    <Target_size>8000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Bangladesh;Cambodia;Ghana;Haiti;Lao People's Democratic Republic;Rwanda;Senegal;Vietnam;Bangladesh;Cambodia;Ghana;Haiti;Lao People's Democratic Republic;Rwanda;Senegal;Vietnam
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Bruno Levecke, PhD;Bruno Levecke, PhD
    </Contact_Lastname>
    <Contact_Email>;bruno.levecke@ugent.be
    </Contact_Email>
    <Contact_Tel>;+3292 64 74 04
    </Contact_Tel>
    <Contact_Affiliation>University Ghent;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject, male or female, is 5-14 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is otherwise in healthy condition (based on medical history and physical&#x0D;&lt;br&gt;             examination)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parent(s)/guardians of subject signed an informed consent document indicating that&#x0D;&lt;br&gt;             they understand the purpose of and procedures required for the study and that they are&#x0D;&lt;br&gt;             willing to have their child participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject of =6 years has assented to participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject of =12 years has signed an informed consent document indicating that they&#x0D;&lt;br&gt;             understand the purpose of the study and procedures required for the study and are&#x0D;&lt;br&gt;             willing to participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject has provided a stool sample of at least 5 grams.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject has active diarrhoea (defined as the passage of 3 or more loose or liquid&#x0D;&lt;br&gt;             stools per day) at baseline or follow-up.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject has an acute medical condition or is experiencing a severe concurrent medical&#x0D;&lt;br&gt;             condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject has a known hypersensitivity to ALB or MEB&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject has received anthelmintic treatment within 90 days prior to the start of the&#x0D;&lt;br&gt;             treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject vomited within 4 hours following drug ingestion.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is not able to provide a stool sample of minimum 5 grams at baseline or&#x0D;&lt;br&gt;             follow-up.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject has not swallowed the entire tablet.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Soil-transmitted Helminth Infections
    </Condition>
    <Intervention>Drug: Benzimidazoles
    </Intervention>
    <Primary_outcome>Measure the prevalence of moderate/heavy intensity infections of the different STH;Assessment of the drug efficacy of a single dose of BZ drugs against STH infections in these countries;Measure the frequency of the ß-tubulin SNPs linked to BZ resistance
    </Primary_outcome>
    <Secondary_outcome>Measurement of costs related to monitoring drug efficacy and AR in national PC programs for STH.;Expand the Starworms repository of STH field samples
    </Secondary_outcome>
    <Secondary_ID>OPP1120972_WP2
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12360008
    </Internal_Number>
    <TrialID>NCT04173819
    </TrialID>
    <Last_Refreshed_on>20 June 2022
    </Last_Refreshed_on>
    <Public_title>Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults
    </Public_title>
    <Scientific_title>Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>International AIDS Vaccine Initiative
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191113
    </Date_registration3>
    <Date_registration>13/11/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04173819
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>45 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 25, 2019
    </Date_enrollement>
    <Target_size>225
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Countries>United States;Kenya;Rwanda;South Africa;Uganda;Kenya;Rwanda;South Africa;Uganda;United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Marina Caskey, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Rockefeller University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Healthy male and female individuals, as assessed by a medical history, physical exam,&#x0D;&lt;br&gt;             and laboratory tests&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  At least 18 years of age on the day of screening and have not reached their 46th&#x0D;&lt;br&gt;             birthday on the day of the first administration&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to undergo HIV testing, risk reduction counseling and receive HIV test&#x0D;&lt;br&gt;             results; committed to maintaining low-risk behavior for the trial duration&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to comply with the requirements of the protocol and available for follow-up&#x0D;&lt;br&gt;             for the planned duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All male and female participants of reproductive potential who are engaging in sexual&#x0D;&lt;br&gt;             activity that could lead to pregnancy must commit to use an effective method of&#x0D;&lt;br&gt;             contraception from enrollment until 9 months after the last administration&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to forgo donations of blood, or any other tissues during the study following&#x0D;&lt;br&gt;             confirmation of study eligibility and, for those who test HIV-positive due to&#x0D;&lt;br&gt;             antibody-induced seropositivity, until the anti-HIV antibody titers become&#x0D;&lt;br&gt;             undetectable on HIV tests used in the community&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Confirmed HIV infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Reported risk for HIV infection within 6 months prior to investigational product&#x0D;&lt;br&gt;             administration, as defined by: Unprotected sexual intercourse with a known&#x0D;&lt;br&gt;             HIV-infected person, a partner known to be at high risk for HIV infection and/or a&#x0D;&lt;br&gt;             casual partner (i.e. no continuing established relationship), engaged in sex work,&#x0D;&lt;br&gt;             frequent excessive daily alcohol use or frequent binge drinking or any other use of&#x0D;&lt;br&gt;             illicit drugs, history of newly-acquired syphilis, gonorrhea, non-gonococcal&#x0D;&lt;br&gt;             urethritis, HSV-2, chlamydia, pelvic inflammatory disease (PID), trichomonas,&#x0D;&lt;br&gt;             mucopurulent cervicitis, epididymitis, proctitis, lymphogranuloma venereum, chancroid,&#x0D;&lt;br&gt;             or hepatitis B or hepatitis C, three or more sexual partners&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any clinically significant acute or chronic medical condition that is considered&#x0D;&lt;br&gt;             progressive or in the opinion of the investigator makes the participant unsuitable for&#x0D;&lt;br&gt;             participation in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Infectious disease diagnosis: Hepatitis B infection as measured by HbsAg and/or PCR,&#x0D;&lt;br&gt;             Hepatitis C infection (US: HCV RNA positive, or interferon-alpha treatment for&#x0D;&lt;br&gt;             hepatitis C infection in the past year, or interferon-alpha-free treatment for&#x0D;&lt;br&gt;             hepatitis C infection completed in the past 6 months; Africa: HCV Ab positive and/or&#x0D;&lt;br&gt;             PCR positive), active syphilis (positive RPR confirmed by TPHA)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Receipt of blood transfusion or blood-derived products within the previous 3 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in another clinical trial of an investigational product currently,&#x0D;&lt;br&gt;             within the previous 3 months or expected participation during this study (Concurrent&#x0D;&lt;br&gt;             participation in an observational trial not requiring blood or tissue sample&#x0D;&lt;br&gt;             collection is not an exclusion)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychiatric condition that compromises safety of the participant and precludes&#x0D;&lt;br&gt;             compliance with the protocol. Specifically excluded are persons with psychoses within&#x0D;&lt;br&gt;             the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture&#x0D;&lt;br&gt;             within the past 3 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Body mass index (BMI) &gt;40&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active tuberculosis&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV-1-infection
    </Condition>
    <Intervention>Biological: 3BNC117-LS-J;Biological: 10-1074-LS-J;Biological: Combination 3BNC117-LS-J and 10-1074-LS-J;Biological: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1;Biological: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2;Biological: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3;Biological: Placebo;Biological: Placebo
    </Intervention>
    <Primary_outcome>1. Proportion of participants with solicited and treatment-related unsolicited adverse events and their duration.;Proportion of participants with serious adverse events (SAEs) throughout the study period that are considered related to investigational product and their duration.;Serum concentration of each antibody in each group at multiple timepoints along with participant characteristics (e.g. sex, weight, and BMI);The ratio of 3BNC117-LS-J to 10-1074-LS-J that, when injected SC, will maintain similar levels of each bNAb at steady state.
    </Primary_outcome>
    <Secondary_outcome>Serum concentration of anti-3BNC117-LS-J antibodies in each group at multiple timepoints.;Serum concentration of anti-10-1074-LS-J antibodies in each group at multiple timepoints.
    </Secondary_outcome>
    <Secondary_ID>IAVI C100
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Fred Hutchinson Cancer Center;Rockefeller University;Brigham and Women's Hospital
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12618552
    </Internal_Number>
    <TrialID>NCT04088591
    </TrialID>
    <Last_Refreshed_on>24 October 2022
    </Last_Refreshed_on>
    <Public_title>High-dose Intravenous Vitamin C as an Adjunctive Treatment for Sepsis in Rwanda
    </Public_title>
    <Scientific_title>High-dose Intravenous Vitamin C as an Adjunctive Treatment for Sepsis in Rwanda: a Feasibility Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Virginia Commonwealth University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190911
    </Date_registration3>
    <Date_registration>11/09/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04088591
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2022
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Dennis A Hopkinson, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Virginia Commonwealth University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adult patients between the ages of 18 and 80 who provide informed consent (or consent&#x0D;&lt;br&gt;             obtained by family member if patient is incapacitated) AND&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with a strong suspicion or confirmation of infection AND&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of organ dysfunction brought on by sepsis. This defined by an increase of two&#x0D;&lt;br&gt;             or more points in the qSOFA score&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known allergic reaction to ascorbic acid&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant patients or those who may be pregnant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of renal stones&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of end-stage renal disease (ESRD) requiring dialysis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of glucose-6-phosphatase dehydrogenase (G6PD) deficiency&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of hemochromatosis&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Sepsis
    </Condition>
    <Intervention>Drug: Ascorbic Acid 500Mg/Ml Inj;Drug: Dextrose in Water
    </Intervention>
    <Primary_outcome>Feasibility - number of participants recruited;Feasibility - number of participants adherence to study protocol
    </Primary_outcome>
    <Secondary_outcome>Change in SOFA score;Change in Universal Vital Assessment (UVA) score;Rate of acute kidney injury;Rate of thrombocytopenia;Rate of mechanical ventilation;Duration of mechanical ventilation;Rate of vasopressor usage;Duration of vasopressor usage;Rate of acute respiratory distress syndrome;Length of intensive care unit stay;Length of hospital stay;Rate of in-hospital mortality
    </Secondary_outcome>
    <Secondary_ID>HM20018390
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Rwanda
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12601400
    </Internal_Number>
    <TrialID>PACTR201909733644315
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Evaluation of the First Steps "Intera za Mbere" Program
    </Public_title>
    <Scientific_title>Evaluation of the First Steps "Intera za Mbere" Program                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Save the Children Rwanda
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190826
    </Date_registration3>
    <Date_registration>26/08/2019
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=9352
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>44 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/09/2019
    </Date_enrollement>
    <Target_size>1188
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Stratified allocation where factors such as age, gender, center, or previous treatment are used in the stratification,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Phase-3
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>Magdalena 
    </Contact_Firstname>
    <Contact_Lastname>Vinyard
    </Contact_Lastname>
    <Contact_Address>Plot 1563, KG 12 Avenue, Gaculiro, Kinyinya Kigali
    </Contact_Address>
    <Contact_Email>mvinyard@laterite.com
    </Contact_Email>
    <Contact_Tel>+250782994553
    </Contact_Tel>
    <Contact_Affiliation>Research Manager
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Households that have children 6-23 months at baseline.&#x0D;&lt;br&gt;Households are situated in the geographic area of the study.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: -
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Early Childhood Development;Early Childhood Development
    </Condition>
    <Intervention>;Control Group;Light Touch Intervention.;Full touch intervention.
    </Intervention>
    <Primary_outcome>Child development assessment scores in the following domains - gross motor, fine motor, social-emotional, expressive language. Scored using the Malawi Developmental Assessment Test, MDAT
    </Primary_outcome>
    <Secondary_outcome>ECD-related parenting practices, assessed using questions from the MICS ;Infant and young child feeding practices - breastfeeding and introduction of complementary foods;Child care of illness, assessed using questions from the MICS
    </Secondary_outcome>
    <Source_Support>Grand Challenges Canada
    </Source_Support>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>16/08/2019;08/07/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>info@rnecrwanda.org;info@statistics.gov.rw
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Rwanda National Ethics Committee;National Institute of Statistics of Rwanda
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+250255107884;+250788383103
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>info@rnecrwanda.org;info@statistics.gov.rw
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10374970
    </Internal_Number>
    <TrialID>NCT04521101
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Can we Make a VAST Improvement? Promoting Anaesthetists' Non-technical Skills Through the Vital Anaesthesia Simulation Training Course in a Low-resource Setting
    </Public_title>
    <Scientific_title>Can we Make a VAST Improvement? Promoting Anaesthetists' Non-technical Skills Through the Vital Anaesthesia Simulation Training Course in a Low-resource Setting
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Dalhousie University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190819
    </Date_registration3>
    <Date_registration>19/08/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04521101
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 24, 2018
    </Date_enrollement>
    <Target_size>32
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Health Services Research. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All anesthesia (anesthesiologists, anesthesia residents and non-physician&#x0D;&lt;br&gt;             anesthetists) VAST Course participants during the study period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  VAST Course participants who do not practice anesthesia (surgeons, nurses, midwives&#x0D;&lt;br&gt;             etc.)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>To Determine the Change in Demonstrated Anesthesia Non-technical Skills After Delivery of the VAST Course
    </Condition>
    <Intervention>Other: VAST Course
    </Intervention>
    <Primary_outcome>Total Anesthesia NonTechnical Skills (ANTS) Score;Total Anesthesia NonTechnical Skills (ANTS) Score;Total Anesthesia NonTechnical Skills (ANTS) Score
    </Primary_outcome>
    <Secondary_outcome>Category Anesthesia NonTechnical Skills (ANTS) Score;Category Anesthesia NonTechnical Skills (ANTS) Score;Category Anesthesia NonTechnical Skills (ANTS) Score
    </Secondary_outcome>
    <Secondary_ID>2018-4474
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12601384
    </Internal_Number>
    <TrialID>PACTR201908758321490
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Adaptation of health education program for improving the uptake of HIV self-testing by men in Rwanda
    </Public_title>
    <Scientific_title>Effectiveness of a locally adapted health education program on uptake of HIV self-testing among men in Kigali, Rwanda                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>College of Health Sciences PhD Scholarship
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190808
    </Date_registration3>
    <Date_registration>08/08/2019
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=8310
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>13 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>18 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>01/10/2019
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Simple randomization using a randomization table created by a computer software program,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>Tafadzwa 
    </Contact_Firstname>
    <Contact_Lastname>Dzinamarira
    </Contact_Lastname>
    <Contact_Address>Plot 793-794, KG7 Avenue
    </Contact_Address>
    <Contact_Email>219095@stu.ukzn.ac.za
    </Contact_Email>
    <Contact_Tel>+250786999838
    </Contact_Tel>
    <Contact_Affiliation>PhD Candidate School of Nursing and Public Health University of KwaZulu Natal
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Adult men 18 and older, do not know HIV status and visit the selected health facility during the enrollment period, willing to be followed up three months’ post enrollment
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Women&#x0D;&lt;br&gt;Men younger than 18 years&#x0D;&lt;br&gt;Adult men 18 years and older  who self-report to know their HIV status or to not know their HIV status but unwilling to be followed up three months’ post enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;HIV/AIDS;HIV/AIDS
    </Condition>
    <Intervention>;Routine health education;Adapted health education 
    </Intervention>
    <Primary_outcome>Recruitment, uptake
    </Primary_outcome>
    <Secondary_outcome>HIV diagnosis among participants, linkage to care men who tested HIV positive, repeat test from men who tested HIV negative, HIV status disclosure to sexual partner(s) post HIV self-testing
    </Secondary_outcome>
    <Source_Support>College of Health Sciences PhD Scholarship
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>29/05/2019;17/06/2019;08/08/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>info@rnecrwanda.org;chuk.hospital@chukigali.com;brec@ukzn.ac.za
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Rwanda National Ethics Committee;University Teaching Hospital of Kigali Ethics Committee;UKZN Biomedical Ethhics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+250255107884;+250576638;+27312602486
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>info@rnecrwanda.org;chuk.hospital@chukigali.com;brec@ukzn.ac.za
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12485386
    </Internal_Number>
    <TrialID>NCT04081441
    </TrialID>
    <Last_Refreshed_on>22 August 2022
    </Last_Refreshed_on>
    <Public_title>Impacts of Clean Cookstoves and Empowerment Training on Women's Health in Refugee Settings
    </Public_title>
    <Scientific_title>Impacts of Clean Cookstoves/Efficient Fuels Uptake and Empowerment Trainings on Women's Health and Well Being in Humanitarian Settings in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Johns Hopkins Bloomberg School of Public Health
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190805
    </Date_registration3>
    <Date_registration>05/08/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04081441
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>45 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>August 1, 2018
    </Date_enrollement>
    <Target_size>1555
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Anita V Shankar, Ph.D.;Naira Kalra, Ph.D.
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Johns Hopkins Bloomberg School of Public Health;Johns Hopkins Bloomberg School of Public Health
    </Contact_Affiliation>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12601251
    </Internal_Number>
    <TrialID>PACTR201906487904130
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Ecosocial Intervention for Strengthening Mental Health
    </Public_title>
    <Scientific_title>Data Analysis of an Internal Evaluation of HOPEthiopia Program for Community Resiliency Training in Rwanda                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>Yeshiva University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190422
    </Date_registration3>
    <Date_registration>22/04/2019
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=7091
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>44 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>07/01/2014
    </Date_enrollement>
    <Target_size>32
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously,Randomised,Simple randomization using by using procedures such as coin-tossing or dice-rolling,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>Jonathan
    </Contact_Firstname>
    <Contact_Lastname>Nattel
    </Contact_Lastname>
    <Contact_Address>Inindi House
    </Contact_Address>
    <Contact_Email>jon.nattel@gmail.com
    </Contact_Email>
    <Contact_Tel>+18458684136
    </Contact_Tel>
    <Contact_Affiliation>Psychosocial Development Coordinator  HOPEthiopia
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Attendance at preliminary evaluation session&#x0D;&lt;br&gt;Membership in AERG (Student association of genocide survivors)
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Concurrent psychiatric or mental health intervention&#x0D;&lt;br&gt;History of severe mental illness (bipolar or psychotic)&#x0D;&lt;br&gt;Concurrent substance abuse or addiction&#x0D;&lt;br&gt;Significant suicidal ideation&#x0D;&lt;br&gt;Active involvement in the local organising committee of AERG&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Mental and Behavioural Disorders;Mental and Behavioural Disorders
    </Condition>
    <Intervention>;Collaborative Resiliency Training;Waitlisted Control Group
    </Intervention>
    <Primary_outcome>Multivariate analysis of PTSD, depression and anxiety symptoms
    </Primary_outcome>
    <Secondary_outcome>PTSD symptoms - Symptom Checklist of Harvard Trauma Questionnaire;Depression symptoms - Hopkins Symptom Checklist;Anxiety Symptoms - Hopkins Symptom Checklist;High-Frequency Heart Rate Variability
    </Secondary_outcome>
    <Source_Support>Self Funded
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>15/11/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>irb@einstein.yu.edu
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Albert Einstein College of Medicine
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+17187985657
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>irb@einstein.yu.edu
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10331536
    </Internal_Number>
    <TrialID>NCT03955562
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Impact of Pedestrian Footbridges on Economic, Health and Educational Outcomes in Rural Communities
    </Public_title>
    <Scientific_title>Impact of Pedestrian Footbridges on Economic, Health and Educational Outcomes in Rural Communities
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Colorado, Boulder
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190415
    </Date_registration3>
    <Date_registration>15/04/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03955562
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 15, 2019
    </Date_enrollement>
    <Target_size>2400
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Evan Thomas, PhD;Evan Thomas, PhD;Laura A MacDonald, PhD
    </Contact_Lastname>
    <Contact_Email>;ethomas@colorado.edu;laura.a.macdonald@colorado.edu
    </Contact_Email>
    <Contact_Tel>;3035504671;7206212501
    </Contact_Tel>
    <Contact_Affiliation>University of Colorado, Boulder;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Random selection of first 100 households in a village from administrative data&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Head of household in intervention and comparison villages&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  None&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Head of Household
    </Condition>
    <Intervention>Other: Footbridge;Other: Comparison villages
    </Intervention>
    <Primary_outcome>Household food expenditure;Household income;Household use of fertilizer;Monetary value of livestock;Work outside of community;Access to health care;Mid-upper arm circumference (MUAC)
    </Primary_outcome>
    <Secondary_outcome>Child enrollment in school;Days of school missed;Access to prenatal care;Type of prenatal services received;Prenatal tetanus vaccination;Child vaccination
    </Secondary_outcome>
    <Secondary_ID>18-0739
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Yale University;University of Notre Dame;University of Colorado, Denver
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12601241
    </Internal_Number>
    <TrialID>PACTR201905538846394
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Implementation of home glucose meter use for insulin dependent Type 1 and 2 Diabetes patients in rural districts in Rwanda
    </Public_title>
    <Scientific_title>Implementation of home glucose meter use for insulin dependent Type 1 and 2 Diabetes patients in rural districts in Rwanda                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>Brigham and Womens Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190415
    </Date_registration3>
    <Date_registration>15/04/2019
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=6072
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>13 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>18 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>10/06/2019
    </Date_enrollement>
    <Target_size>90
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously,Randomised,Simple randomization using a randomization table created by a computer software program,Sealed opaque envelopes
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda;Rwanda;Rwanda
    </Countries>
    <Contact_Firstname>Paul
    </Contact_Firstname>
    <Contact_Lastname>Park
    </Contact_Lastname>
    <Contact_Address>75 Francis St.
    </Contact_Address>
    <Contact_Email>ppark@bwh.harvard.edu
    </Contact_Email>
    <Contact_Tel>6175213381
    </Contact_Tel>
    <Contact_Affiliation>Brigham and Womens Hospital and Partners In Health and Harvard Medical School
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: a diagnosis of Type 1 or T2DM&#x0D;&lt;br&gt;must be on insulin regimen&#x0D;&lt;br&gt;possess the ability to read and write well enough to record blood glucose levels/ have reliable access to a guardian who can read and write ( ability to read and write will be assessed during the enrollment period by asking participants to read and record blood sugar levels during the training session)&#x0D;&lt;br&gt;at least 18 years of age &#x0D;&lt;br&gt;HbA1C &gt; 7.0%&#x0D;&lt;br&gt;must be active in clinic ( attending clinic follow ups at-least six months prior to enrollment)
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: a diagnosis of gestational diabetes&#x0D;&lt;br&gt;inability to read and write&#x0D;&lt;br&gt;lack of access to a person at home who can read and write &#x0D;&lt;br&gt;diagnosis of chronic kidney disease
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Nutritional, Metabolic, Endocrine &lt;br&gt;Paediatrics;Nutritional, Metabolic, Endocrine;Paediatrics
    </Condition>
    <Intervention>;Self monitoring blood glucose ;Usual care
    </Intervention>
    <Primary_outcome>Feasibility - use of log manual, glucose meter, perceived usefulness and/or concerns of glucose meter use at home
    </Primary_outcome>
    <Secondary_outcome>Clinical improvement - HbA1c, retention to care including SMBG program, quality of life, hospitalization rates
    </Secondary_outcome>
    <Source_Support>Helmsley Charitable Trust
    </Source_Support>
    <Secondary_Sponsor>Partners In Health
    </Secondary_Sponsor>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>18/02/2019;09/04/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>info@rnecrwanda.org;irb@partners.org
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Rwanda National Ethics Comittee;Partners IRB
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+250255107874;+16172781000
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>info@rnecrwanda.org;irb@partners.org
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12288873
    </Internal_Number>
    <TrialID>NCT03923725
    </TrialID>
    <Last_Refreshed_on>30 May 2022
    </Last_Refreshed_on>
    <Public_title>A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.
    </Public_title>
    <Scientific_title>A Multi-centre Randomised Controlled Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies Versus First-line ACTs + Placebo for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Africa
    </Scientific_title>
    <Acronym>DeTACT-Africa
    </Acronym>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190409
    </Date_registration3>
    <Date_registration>09/04/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03923725
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>12 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 1, 2020
    </Date_enrollement>
    <Target_size>3240
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Burkina Faso;Congo, The Democratic Republic of the;Gambia;Guinea;Nigeria;Niger;Rwanda;Tanzania;Burkina Faso;Congo, The Democratic Republic of the;Gambia;Guinea;Niger;Nigeria;Rwanda;Tanzania
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Mehul Dhorda, Ph.D
    </Contact_Lastname>
    <Contact_Email>Mehul@tropmedres.ac
    </Contact_Email>
    <Contact_Tel>+66 2 203-6333
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female, aged =6 months to &lt;12 years (For Gambia, Rwanda sites only: =6 months)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to take oral medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acute uncomplicated P. falciparum monoinfection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Asexual P. falciparum parasitaemia: 1,000/µL to =10% parasitaemia, determined on a&#x0D;&lt;br&gt;             peripheral blood film (At Gambia, Rwanda sites only: For subjects =12 years - 1000/µL&#x0D;&lt;br&gt;             to 200,000/µL)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fever defined as = 37.5°C tympanic temperature or a history of fever within the last&#x0D;&lt;br&gt;             24 hours&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent by the subject or by parent/guardian in case of children&#x0D;&lt;br&gt;             lower than the age of consent and assent if required (per local regulations)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willingness and ability of the subjects or parents/guardians to comply with the study&#x0D;&lt;br&gt;             protocol for the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signs of severe malaria (adapted from WHO criteria)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients not fulfilling criteria for severe malaria but with another indication for&#x0D;&lt;br&gt;             parenteral antimalarial treatment at the discretion of the treating physician&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Haematocrit &lt;15% at screening (For Gambia, Rwanda sites only: For subjects =12 years -&#x0D;&lt;br&gt;             Haematocrit &lt;20% at screening)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects who have received artemisinin or a derivative within the previous 7 days OR&#x0D;&lt;br&gt;             lumefantrine or amodiaquine within the previous 14 days OR mefloquine or piperaquine&#x0D;&lt;br&gt;             within the previous 30 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In applicable countries: use of seasonal malaria chemoprophylaxis (SMC) within the&#x0D;&lt;br&gt;             last 14 days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acute illness other than malaria requiring systemic treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe acute malnutrition (in Niger only - only those patients with Severe Acute&#x0D;&lt;br&gt;             Malnutrition and complications requiring inpatient nutritional treatment will be&#x0D;&lt;br&gt;             excluded)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known HIV infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known tuberculosis infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For females: post-menarche (For Gambia, Rwanda sites only: females who are pregnant,&#x0D;&lt;br&gt;             trying to get pregnant or are lactating)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of allergy or known contraindication to any of the study drugs, including&#x0D;&lt;br&gt;             neuropsychiatric disorders and epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous splenectomy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Enrolment in DeTACT in the previous 3 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in another interventional study in the previous 3 months&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Plasmodium Falciparum Malaria (Uncomplicated)
    </Condition>
    <Intervention>Drug: Artemether-lumefantrine+ Amodiaquine (AL+AQ);Drug: Artemether-lumefantrine + placebo (AL+PBO);Drug: Artesunate-mefloquine+piperaquine (AS-MQ+PPQ);Drug: Artesunate-mefloquine+placebo (AS-MQ+PBO)
    </Intervention>
    <Primary_outcome>42 days Efficacy defined as PCR corrected adequate clinical and parasitological response (ACPR).
    </Primary_outcome>
    <Secondary_outcome>63-day PCR corrected and uncorrected efficacy;42-day PCR uncorrected efficacy;Parasite clearance half-life;Proportion of subjects with microscopically detectable P. falciparum parasitaemia;Fever clearance time;Proportion of subjects with gametocytaemia;Incidence of adverse events;Incidence of serious adverse events;Number of cardiotoxicity events;Change in haemoglobin stratified for G6PD status/genotype;Proportion of subjects requiring retreatment due to vomiting;Proportion of subjects that reports completing a full course of observed TACT;Proportion of subjects that reports completing a full course of observed ACT;proportion of subjects that reports completing a full course of observed TACT or ACT without withdrawal of consent or exclusion from study because of drug related serious adverse event.;Pharmacokinetic profiles;Pharmacokinetic interactions;Plasma levels of partner drugs
    </Secondary_outcome>
    <Secondary_ID>MAL18004
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Mahidol Oxford Tropical Medicine Research Unit
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12590738
    </Internal_Number>
    <TrialID>CTRI/2019/04/018388
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>FALCON Trial Testing Measures To Reduce Surgical Site Infections
    </Public_title>
    <Scientific_title>Pragmatic multicentre factorial randomised controlled trial testing measures to reduce surgical site infection in low and middle income countries                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>University OF Birmingham
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190402
    </Date_registration3>
    <Date_registration>02-04-2019
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30043
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>15-04-2019
    </Date_enrollement>
    <Target_size>5480
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized Factorial Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Participant and Outcome Assessor Blinded
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Benin;Egypt;Ghana;Guatemala;India;Mexico;Nigeria;Pakistan;Peru;Philippines;Rwanda;South Africa;Zambia
    </Countries>
    <Contact_Firstname>Dhruva Nath Ghosh
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Dept Of Paediatric Surgery&#x0D;
Christian Medical College Hospital&#x0D;
Ludhiana 
    </Contact_Address>
    <Contact_Email>dhruvghosh73@gmail.com
    </Contact_Email>
    <Contact_Tel>9915198894
    </Contact_Tel>
    <Contact_Affiliation>Christian Medical College &amp; Hospital Ludhiana, Punjab
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients with at least one abdominal incision that is equal to or greater than five cms with an anticipated clean contaminated, contaminated or dirty surgical wound &lt;br/ &gt;&#x0D;&lt;br&gt;Patients undergoing emergency or elective operations &lt;br/ &gt;&#x0D;&lt;br&gt;Any operative indication including trauma surgery &lt;br/ &gt;&#x0D;&lt;br&gt;Patient willing and able to provide written informed consent
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients with documented or suspected allergy to iodine, shellfish or chlorhexidine skin preparation solution &lt;br/ &gt;&#x0D;&lt;br&gt;Patient unable to complete post operative follow up
    </Exclusion_Criteria>
    <Condition>Health Condition 1: O- Medical and Surgical&#x0D;

    </Condition>
    <Intervention>Intervention1: 2% Alcoholic Chlorhexidine,: Surgical Pre-Operative Skin Preparation. 2% Alcoholic Chlorhexidine will be used in the usual standardised technique. The preparation will be applied on the skin of the operative area. The preparation will be applied as available pre-prepared solution prior to surgical incision. The surgeon will wait for this surgical prep to dry before giving the incision. The usual time for drying is approximately 3 mins. This pre-operative skin preparation will be used only once pre-operatively at the surgical site as is standard practice and is done before draping surgical site. After surgery is over the remnant skin prep will be cleaned using saline before applying surgical site dressing&lt;br&gt;Intervention2: Triclosan Coated Suture, Non Coated Suture: For Fascial Closure Of Wound&lt;br&gt;Intervention3: Triclosan Coated Suture: For fascial closure of abdominal wound. Triclosan (bactericidal &amp; fungicidal) coated  PDS or Vicryl sutures as is commercially available will be used to close the fascial layer of the anterior abdominal wall as is standard practice after surgery. The technique of closure is as per the preference of the operating surgeon. The suture will be used on the fascia of the muscles of the anterior abdominal wall. The fascial closure will be done only once by this suture during the time the patient is on the trial. The closure of the abdominal wall fascia is standard practice.&lt;br&gt;Control Intervention1: 10% Povidone Iodine: Surgical Pre-Operative Skin Preparation. 10% Povidone Iodine will be used in the usual standardised technique. The preparation will be applied on the skin of the operative area. The preparation will be applied as available pre-prepared solution prior to surgical incision. The surgeon will wait for this surgical pre
    </Intervention>
    <Primary_outcome>Surgical site infection at thirty days post surgeryTimepoint: Surgical site infection at thirty days post surgery
    </Primary_outcome>
    <Secondary_outcome>Length of hospital stay for index admissionTimepoint: Discharge date;Mortality within 30 days post surgeryTimepoint: 30 days;Re operation for surgical site infectionsTimepoint: 30 days;ReadmissionTimepoint: 30 Days;Resistance of organisms detected from wound swabs to prophylactic antibiotics administered within one hour of incisionTimepoint: 1 hour;Return to normal activitiesTimepoint: 30 Days;Surgical site infection at discharge from hospitalTimepoint: Discharge;Unplanned wound opening within 30 days of surgeryTimepoint: 30 days
    </Secondary_outcome>
    <Secondary_ID>1.0;14/08/2018;NCT03700749
    </Secondary_ID>
    <Source_Support>Monetary: National Institute For Health Research, United Kingdom&#x0D;
Material: 1. BARD Medical 2. Ethicon
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>14/03/2019;03/03/2020;17/06/2019;05/08/2019;05/08/2019;22/01/2020;13/05/2020;05/04/2019;11/03/2020;02/07/2020;17/05/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;;;;;;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Christian Medical College Hospital Ludhiana;Christian Medical College Ludhiana;Christian Medical College Vellore;Emmanuel Hospital Association Chinchpada Christian Hospital;Emmanuel Hospital Association Madhipura Christian Hospital;Government Medical College Bharatpur;Government Medical College Patiala;Lady Willingdon Hospital Manali;Padhar Hospital;Postgraduate Institute Of Medical Education And Research Chandigarh;St Stephens Hospital Delhi
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;;;;;;;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;;;;;;;;
    </Ethics_review_contact_email>
    <results_date_completed>07/09/2020
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12275547
    </Internal_Number>
    <TrialID>ISRCTN20474555
    </TrialID>
    <Last_Refreshed_on>16 May 2022
    </Last_Refreshed_on>
    <Public_title>Community-based Socio-therapy Adapted for Refugees: the COSTAR study.
    </Public_title>
    <Scientific_title>Treating depressive symptomatology in Congolese refugees in Uganda and Rwanda: Adapting and evaluating community-based socio-therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>University of Liverpool
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190327
    </Date_registration3>
    <Date_registration>27/03/2019
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN20474555
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/06/2019
    </Date_enrollement>
    <Target_size>640
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Two-arm cluster randomised controlled trial (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda;Uganda
    </Countries>
    <Contact_Firstname>Ross
    </Contact_Firstname>
    <Contact_Lastname>White
    </Contact_Lastname>
    <Contact_Address>
                    School of Psychology
                    Queen's University Belfast
                    Room 03.528, David Keir Building
                    8-30 Malone Road
                
    </Contact_Address>
    <Contact_Email>r.white@qub.ac.uk
    </Contact_Email>
    <Contact_Tel>+44 (0)28 9097 6566
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Adult  &lt;18 years&lt;br&gt;                2. Living in Kyangwali (updated 22/07/2019, previously: Nakivale) settlement, Uganda and Gihembe refugee camp, Rwanda&lt;br&gt;                3. Identify as Congolese refugees&lt;br&gt;                4. Have a self-reported good level of fluency in the languages that aCBS will be delivered in (Kinyarwanda in Rwanda / Kiswahili in Uganda).&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Current diagnosis of a complex mental disorder (e.g. psychotic disorders, PTSD, substance dependence)&lt;br&gt;                2. Severe cognitive impairment (e.g. severe intellectual disability, dementia)&lt;br&gt;                3. Actively express suicidal intent&lt;br&gt;&lt;br&gt;                Individuals that are excluded because of a diagnosis of a mental disorder or imminent risk of suicide will be referred for urgent local mental health support.&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Depressive symptomatology of Congolese refugees &lt;br&gt;Mental and Behavioural Disorders
    </Condition>
    <Intervention>&lt;br&gt;                The Adapted Community Based Sociotherapy (aCBS) intervention is delivered in groups of 10 to 15 people living in the same geographic area (e.g. villages in camps). The aCBS intervention does not target specific diagnoses or symptoms. Rather attention is placed on being inclusive of all people in the community. Thus, aCBS minimises the potential stigma associated with disorder-focused interventions. Training and supervision for 24 facilitators across Rwanda and Uganda will be provided by CBS Rwanda (an organisation with 15 years’ experience of delivering CBS in Rwanda). The fidelity of aCBS delivery will be monitored in a subset (10%) of randomly selected sessions using an existing checklist that is completed by field staff.&lt;br&gt;&lt;br&gt;                Clusters of participants (e.g. villages) in the Gihembe camps and the Kyangwali (updated 22/07/2019, previously: Nakivale) settlement will be randomised to aCBS or ECU with a ratio of 1:1. Randomisation will be conducted independently by the Clinical Trials Research Centre (CTRC), University of Liverpool. The outcome of the randomisation will be communicated directly to the Trial Coordinator based at University of Rwanda. In the selected clusters, participants will be recruited through door-to-door approach. This approach has been used successfully in refugee camps in Uganda.  Participants will be recruited prior to randomization of clusters. Informed consent will be obtained from participants. Outcome assessors will be blind to group allocation.&lt;br&gt;&lt;br&gt;                There is a theoretical possibility of contamination by recruiting refugees who might interact each other and therefore divulge intervention components from people in the experimental arm to those in the control condition. In order to minimize the possibility
    </Intervention>
    <Primary_outcome>1. Depressive symptomatology score as measured on the PHQ-937 at 16-weeks (primary endpoint) and 32-weeks (secondary endpoint) compared between the aCBS programme and ECU.
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Self-Reporting Questionnaire for detecting CMDs in primary health care settings.&lt;br&gt;                2. Checklist for Daily Life Stressors (CDES), WHO-5 for wellbeing.&lt;br&gt;                3. WHO Quality of Life BREF, Shortened and Adapted Social Capital Assessment Tool, PTSD Check List – Screener (PCL-6) and Multi-dimensional Scale of Perceived Social Support to measure social connectivity.&lt;br&gt;&lt;br&gt;                Outcomes will be assessed at baseline, and at 16- (primary outcome)- and 32-weeks (secondary outcome) post-baseline. The Major Depressive Episode module of the MINI will be used at baseline only.&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;ES/S000976/1
    </Secondary_ID>
    <Source_Support>Economic &amp; Social Research Council  (ES/S000976/1)
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>
                    1. Approved 22/11/2018, Makerere University (School of Social Sciences Research and Ethics Committee, Makerere University College of Humanities and Social Sciences, P. O Box 7062, Kampala- Uganda; 256 41(+256) 0414 -545040; research@chs.mak.ac.ug/rresearch9@gmail.com), ref: makss rec 11.18.237
                    2. Approved 07/02/2019 University of Rwanda (Ministry of Health, P.O.Box 84, Kigali, Rwanda; (250) 55 10 78 84; rnec@moh.gov.rw), ref: No 065/CMHS IRB/2019
        
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>30/09/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10641574
    </Internal_Number>
    <TrialID>NCT03890211
    </TrialID>
    <Last_Refreshed_on>22 February 2021
    </Last_Refreshed_on>
    <Public_title>Trial of a Non Electric Infant Warmer for Prevention and Treatment of Hypothermia in Rwanda
    </Public_title>
    <Scientific_title>Stepped Wedge Randomized Control Trial of a Non Electric Infant Warmer for Prevention and Treatment of Hypothermia in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Boston Children's Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190321
    </Date_registration3>
    <Date_registration>21/03/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03890211
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>3 Months
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 11, 2019
    </Date_enrollement>
    <Target_size>3179
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Anne Hansen, MD, MPH
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Boston Children's Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Any infant with the following criteria for whom caregiver not available for KMC, or KMC is&#x0D;&lt;br&gt;        not adequate (less than 0.5°C/hour rise in temperature):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Axillary temperature &lt; 36.5 °C&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             a) If an electric warmer is available and the infant's temperature is &lt; 35°C, then the&#x0D;&lt;br&gt;             infant will start by being warmed on the electric warmer until the infant's&#x0D;&lt;br&gt;             temperature reaches 36°C, then can start non-electric Infant Warmer use.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Infants at-risk for hypothermia (criteria: estimated post-menstrual age of &lt; 35 weeks&#x0D;&lt;br&gt;             or current body weight of &lt; 2.5 kg).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Any infant whose family is unwilling to consent to the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Mothers who are critically ill at the time of infant eligibility or deemed not&#x0D;&lt;br&gt;             medically stable by nursing staff to be approached for consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Any infant with a contraindication to KMC (medical instability) and electrical heating&#x0D;&lt;br&gt;             source available.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Any infant with initial temperature &lt; 35°C and electrical heating source available.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Infants requiring phototherapy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Infants with significant skin condition.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Stop Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        If an electric heating source is available, the infant will be taken off of the study and&#x0D;&lt;br&gt;        warmed with an appropriate source of electric heat if the infant:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. If an electric heating source is available, the infant will be taken off of the study&#x0D;&lt;br&gt;             and warmed with an appropriate source of electric heat if the infant:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             i. Has temp &lt; 36 °C while receiving maximum non-electric heat exposure and temperature&#x0D;&lt;br&gt;             decreases on any measurement ii. Has temp &lt; 36 °C while receiving maximum non-electric&#x0D;&lt;br&gt;             heat exposure and temperature does not begin to rise within 30 minutes iii.Has temp &lt;&#x0D;&lt;br&gt;             36 °C while receiving maximum non-electric heat exposure and not heating at a rate of&#x0D;&lt;br&gt;             &gt; ½ °C per hour until temperature &gt;36.5°C iv.Has a temperature that falls below 36°C&#x0D;&lt;br&gt;             despite maximum non-electric heat exposure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Definition of maximum non-electric heat exposure:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. IW, KMC, hat; if KMC available&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. IW, blanket, hat; if KMC not available&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. Blanket, hat; while seeking caregiver for KMC and/or preparing IW if KMC and IW&#x0D;&lt;br&gt;                  not available&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Has temperature &gt; 37.5 °C&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Is ever considered to be too severely ill by the medical team to be safely cared for&#x0D;&lt;br&gt;             in the non-electric Infant Warmer.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. The warmer will be removed once its temperature drops below phase change temperature&#x0D;&lt;br&gt;             as assessed by noting that the material begins to harden and turn white and is no&#x0D;&lt;br&gt;             longer warm in area under where baby is lying.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hypothermia Neonatal
    </Condition>
    <Intervention>Device: Non-Electric Infant Warmer
    </Intervention>
    <Primary_outcome>Ability to regulate infant body temperature;Incidence of adverse events as assessed by staff observation
    </Primary_outcome>
    <Secondary_outcome>Studying the practicality of applying the device in a clinical setting;Functionality
    </Secondary_outcome>
    <Secondary_ID>IRB-P00030705
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Ministry of Health, Rwanda;Rwandan Biomedical Counsel (RBC);Harvard Medical School;Partners in Health;Rwanda National Ethics Committee (RNEC);Lawrence Berkeley National Laboratory
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10326971
    </Internal_Number>
    <TrialID>NCT03896087
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Evaluation of Dried Blood Spot for HCV RNA Testing
    </Public_title>
    <Scientific_title>Multicentre Clinical Trial to Assess the Performance of Centralized Assays for Hepatitis C Virus RNA Detection From Dried Blood Spot (DBS) Samples
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Foundation for Innovative New Diagnostics, Switzerland
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190314
    </Date_registration3>
    <Date_registration>14/03/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03896087
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 1, 2019
    </Date_enrollement>
    <Target_size>815
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Australia;Cameroon;Georgia;Greece;Rwanda;Australia;Cameroon;Georgia;Greece;Rwanda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Elena Ivanova, Ph.D.;Elena Ivanova, Ph.D.
    </Contact_Lastname>
    <Contact_Email>;elena.ivanova@finddx.org
    </Contact_Email>
    <Contact_Tel>;+41 22 749 29 48
    </Contact_Tel>
    <Contact_Affiliation>Foundation for Innovative New Diagnostics;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Three different population groups will be considered:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Individuals at risk of having HCV infection based on positive HCV serology test&#x0D;&lt;br&gt;             results&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Inclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Aged 18 years or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Able to understand the scope of the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Provided written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Documented positive result of HCV serology test&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Individuals at risk of having HCV infection based on past and/or current exposure to&#x0D;&lt;br&gt;             risk factors&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Inclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Aged 18 years or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Able to understand the scope of the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Provided written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Past and/or current exposure to one of the high risk factors as defined by WHO&#x0D;&lt;br&gt;                  and CDC guidelines (Appendix I)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Individuals diagnosed with chronic HCV infection who initiated or completed the&#x0D;&lt;br&gt;             anti-HCV treatment with direct acting antivirals (DAA) presenting at the clinical site&#x0D;&lt;br&gt;             for treatment monitoring or test of cure (i.e. sustained virological response)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Aged 18 years or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to understand the scope of the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Provided written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Initiated on DAA treatment (regardless of type of DAA regimen) within 12 months prior&#x0D;&lt;br&gt;             to the enrolment to the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria (for all trial populations):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previously enrolled in the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unwilling to provide required volume of fingerstick blood&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unwilling to provide required volume of venous whole blood&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hepatitis C, Chronic
    </Condition>
    <Intervention>Diagnostic Test: Abbott RealTime HCV assay from DBS;Diagnostic Test: HCV for use on the cobas® 6800/8800 Systems from PSC and DBS;Diagnostic Test: Aptima® HCV Quant Dx Assay from DBS;Diagnostic Test: HCV for use on the cobas® 4800Systems from PSC and DBS
    </Intervention>
    <Primary_outcome>Point estimates (with 95% confidence intervals) of sensitivity and specificity for each assay for HCV RNA detection from DBS and/or PSC specimens measured against Abbott RealTime HCV VL assay performed at the clinical site;Evaluation of the correlation of HCV viral load level determined by each assay performed from DBS and/or PSC specimens with the HCV viral load level in plasma determined by Abbott RealTime HCV VL assay performed at the clinical site
    </Primary_outcome>
    <Secondary_outcome>Point estimates (with 95% confidence intervals) of sensitivity and specificity for each assay for HCV RNA detection from DBS and/or PSC specimens measured against the performance of the same assay in plasma;Evaluation of the correlation of HCV viral load level determined by each assay performed from DBS and/or PSC specimens with the HCV RNA level in plasma determined by the same assay;WHO technician's appraisal sheet completed by all operators performing investigational test;point estimates (with 95% confidence intervals) of sensitivity and specificity for each assay for HCV RNA detection in plasma measured against the performance of Roche cobas® 6800 HCV VL assay;evaluation of the correlation of HCV RNA levels in plasma determined by each assay with HCV RNA levels in plasma determined by Roche cobas® 6800 HCV VL assay
    </Secondary_outcome>
    <Secondary_ID>8160-2/1
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>UNITAID
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10326407
    </Internal_Number>
    <TrialID>NCT03888729
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)
    </Public_title>
    <Scientific_title>Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)
    </Scientific_title>
    <Acronym>SHARED3
    </Acronym>
    <Primary_sponsor>Partners in Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190215
    </Date_registration3>
    <Date_registration>15/02/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03888729
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 26, 2019
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Neil Gupta, MD, MPH;Fredrick Kateera, MD, PhD;Fabienne Shumbusho, MD;Fabienne Shumbusho
    </Contact_Lastname>
    <Contact_Email>;;Fshumbusho@pih.org;Fshumbusho@pih.org
    </Contact_Email>
    <Contact_Tel>;;+250788559065;+250788559065
    </Contact_Tel>
    <Contact_Affiliation>Partners In Health; Brigham and Women's Hospital; Harvard Medical School;Partners In Health/Inshuti Mu Buzima - Rwanda;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing and able to provide written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age = 18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HCV RNA &gt;1000 IU/mL at Screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For SOF/VEL arm, HCV treatment-naïve or interferon/ribavirin-experienced&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For SOF/VEL/VOX arm, history of virologic failure to SOF/LDV or other DAA-containing&#x0D;&lt;br&gt;             regimen as defined by a quantifiable HCV viral load any time at or after the end of&#x0D;&lt;br&gt;             HCV therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Screening ultrasound excluding hepatocellular carcinoma (HCC)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acceptable laboratory values including:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Hemoglobin =8.0 g/dL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Platelet count =40,000/mm3&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  AST, ALT, and alkaline phosphatase =10 × ULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Calculated creatinine clearance (CrCl) =30 mL/min&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  General good health&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to comply with the dosing instructions for study drug administration and to&#x0D;&lt;br&gt;             complete the study schedule of assessments&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If HIV-infected:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  The participant must have completed at least 6 months of any approved HIV&#x0D;&lt;br&gt;                  antiretroviral therapy (ART) before starting enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  The participant at time of screening and for at least 2 weeks prior to screening&#x0D;&lt;br&gt;                  must be on ART compatible with SOF/VEL and SOF/VEL/VOX&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Screening HIV RNA &lt; 200 copies/mL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Screening CD4 T-cell count of =100 cells/µL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women of reproductive potential must have a negative urine pregnancy test at Screening&#x0D;&lt;br&gt;             and a negative urine pregnancy test at Entry prior to enrollment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current or history of clinical hepatic decompensation (i.e., ascites, encephalopathy&#x0D;&lt;br&gt;             or variceal hemorrhage)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active tuberculosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other clinically-significant illness (except HCV and/or HIV) or any other major&#x0D;&lt;br&gt;             medical disorder that, in the opinion of the site investigator, may interfere with&#x0D;&lt;br&gt;             participant treatment, assessment or compliance with the protocol; participants&#x0D;&lt;br&gt;             currently under evaluation for a potentially clinically-significant illness (other&#x0D;&lt;br&gt;             than HCV/HIV) are also excluded.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active Hepatitis B infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Difficulty with blood collection and/or poor venous access for the purposes of&#x0D;&lt;br&gt;             phlebotomy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or nursing female&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active drug or alcohol use or dependence that, in the opinion of the site&#x0D;&lt;br&gt;             investigator, would interfere with adherence to study procedures and treatment&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hepatitis C, Chronic
    </Condition>
    <Intervention>Drug: sofosbubir/velpatasvir;Drug: sofosbubir/velpatasvir/voxilaprevir
    </Intervention>
    <Primary_outcome>Proportion of participants with sustained viral response 12 weeks after discontinuation of study treatment (SVR12);Proportion of patients treated with SOF/VEL FDC and SOF/VEL/VOX FDC with a new grade 3 or 4 adverse event as defined by the DAIDS Scales or with premature study drug discontinuation due to an adverse event
    </Primary_outcome>
    <Secondary_outcome>Proportion of participants by HCV genotype subtypes with SVR12 after completing treatment with SOF/VEL FDC and SOF/VEL/VOX FDC;Adherence to SOF/VEL FDC and SOF/VEL/VOX FDC;Odds ratio for achievement of SVR12 by treatment type for the following variables: age (per 10 year increase), female sex, HIV co-infection, genotype subtype 4r, baseline HCV viral load (per 1 log increase), APRI &gt; 1.0;Proportion of HIV co-infected subjects that maintain HIV-1 RNA&lt; 200 copies/mL while on HCV treatment;Effect of SOF/VEL FDC and SOF/VEL/VOX FDC and SVR12 on quality of life
    </Secondary_outcome>
    <Secondary_ID>PartnersIH
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>8116835
    </Internal_Number>
    <TrialID>ISRCTN14071325
    </TrialID>
    <Last_Refreshed_on>17 June 2019
    </Last_Refreshed_on>
    <Public_title>An international study to investigate rates of death and illness following liver surgery
    </Public_title>
    <Scientific_title>International Snapshot Study on the Outcomes of Liver surgery - LiverGroup.org                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Royal Free London NHS Foundation Trust, UCL Partners
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190213
    </Date_registration3>
    <Date_registration>13/02/2019
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN14071325
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/01/2019
    </Date_enrollement>
    <Target_size>2000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational snapshot study  (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. All liver surgery indications (including benign and living donor resections, open, laparoscopic or robotic surgery, single wedge resections to extended liver resections, single- or two-stage hepatectomies, procedures with liver volume enhancement such as PVE, PVL, ALPPS, resections involving cold perfusion (ex-situ and ante-situ)&lt;br&gt;                2. Any co-morbidity&lt;br&gt;&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Liver transplantation&lt;br&gt;                2. Imaging-guided RFA, MWA, or other ablation techniques&lt;br&gt;                3. Liver biopsies&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Any indication for liver surgery &lt;br&gt;Surgery
    </Condition>
    <Intervention>The intervention includes any type of liver surgery. The patients's progress will be observed from the day of the operation until hospital discharge as well as up to 90 days postoperatively.
    </Intervention>
    <Primary_outcome>Death recorded up to 90 days postoperatively using the patients' medical records
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Postoperative complications as measured by the Clavien-Dindo Classification, FABIB Liver-Specific Classification and the Comprehensive Complication Index® (CCI®)&lt;br&gt;                2. Liver failure as measured by the FABIB Liver-Specific Classification, the ISGLS criteria and the 50-50 criteria up to 90 days postoperatively&lt;br&gt;                3. Length of hospital stay (defined as the duration of hospitalization from the day of the operation until the day of discharge from the hospital) recorded up to 90 days postoperatively using the patients' medical records&lt;br&gt;                4. Rehospitalization (defined as any readmission to any hospital within 90 days from the operation) assessed using the patients' medical records up to 90 days postoperatively using the patients' medical records&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>NCT03768141;v.1.3
    </Secondary_ID>
    <Source_Support>Royal Free Hospital, Universidad de Zaragoza
    </Source_Support>
    <Secondary_Sponsor>Department of Surgery, University Hospital Miguel Servet, University of Zaragoza, Spain
    </Secondary_Sponsor>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1990
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>This project is considered as an audit and does not require ethics committee approval in the UK. 
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>10/03/2020
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10312958
    </Internal_Number>
    <TrialID>NCT03713658
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities
    </Public_title>
    <Scientific_title>A Pilot-Study in Rwandan Health Care Settings to Examine the Feasibility of a Large Pragmatic Clinical Study to Assess the Value of Paliperidone Palmitate in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Janssen Research &amp; Development, LLC
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20181018
    </Date_registration3>
    <Date_registration>18/10/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03713658
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 18, 2018
    </Date_enrollement>
    <Target_size>34
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Health Services Research. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Janssen Research &amp; Development, LLC Clinical Trial
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Janssen Research &amp; Development, LLC
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants with diagnosis of schizophrenia by mini international neuropsychiatric&#x0D;&lt;br&gt;             interview (MINI)- Screen/ MINI (Module K) that requires treatment initiation or a&#x0D;&lt;br&gt;             change in treatment to better address safety or efficacy limitations of current&#x0D;&lt;br&gt;             treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants at least moderately ill as measured by the clinical global impressions -&#x0D;&lt;br&gt;             severity of schizophrenia (CGI-SS) scale for schizophrenia, or experiencing poorly&#x0D;&lt;br&gt;             tolerated side effects from their current medications, or having difficulty with&#x0D;&lt;br&gt;             adequate adherence to treatment, per the investigator's judgement&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants have a primary caregiver who is willing to participate in this study&#x0D;&lt;br&gt;             (caregiver should be knowledgeable about the participant's condition and is expected&#x0D;&lt;br&gt;             to be with the participant for greater than (&gt;) 24 hours each week for the duration of&#x0D;&lt;br&gt;             the study)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants able to give consent to participate in a clinical study that includes&#x0D;&lt;br&gt;             treatment with risperidone and long-acting injectable formulations of paliperidone&#x0D;&lt;br&gt;             palmitate. Participants must be willing to receive injections. The participant and the&#x0D;&lt;br&gt;             caregiver participant must sign an informed consent form (ICF) indicating that he or&#x0D;&lt;br&gt;             she understands the purpose of, and procedures required for, the study and is willing&#x0D;&lt;br&gt;             to participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants must be willing and able to provide responses for all self-administered&#x0D;&lt;br&gt;             questionnaires&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants have a physical, mental, or legal incapacity that prevents a valid&#x0D;&lt;br&gt;             consent or capacity to complete about 12 months of treatment with antipsychotic&#x0D;&lt;br&gt;             medication and compliance with this study protocol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants with history of organic brain syndromes, comorbid psychiatric and/or&#x0D;&lt;br&gt;             physical illnesses, or significant comorbid substance abuse that is likely to&#x0D;&lt;br&gt;             interfere with understanding of or compliance with study requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants with known allergies, hypersensitivity, or intolerance to risperidone or&#x0D;&lt;br&gt;             paliperidone palmitate or their excipients&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants with poor prior response to risperidone&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants who received an investigational medication (including investigational&#x0D;&lt;br&gt;             vaccines) or used an invasive investigational medical device within 30 days before the&#x0D;&lt;br&gt;             planned first dose of study medication, or is currently enrolled in an investigational&#x0D;&lt;br&gt;             study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Schizophrenia
    </Condition>
    <Intervention>Drug: Risperidone 3 mg;Drug: Paliperidone Palmitate 50 mg eq.;Drug: Paliperidone Palmitate 75 mg eq.;Drug: Paliperidone Palmitate 100 mg eq.;Drug: Paliperidone Palmitate 150 mg eq.;Drug: Paliperidone Palmitate 175 mg eq.;Drug: Paliperidone Palmitate 263 mg eq.;Drug: Paliperidone Palmitate 350 mg eq.;Drug: Paliperidone Palmitate 525 mg eq.
    </Intervention>
    <Primary_outcome>Percentage of Participants With Successful Completion of Study Procedures;Percentage of Participants With Successful Delivery of Risperidone/PP1M/PP3M for the Duration of the Study;Percentage of Participants With Successful Administration of Risperidone/PP1M/PP3M Throughout the Study;Quality of Life as Assessed by World Health Organization Quality of Life Scale Brief Version (WHO QoL-BREF) Total Score;Clinician Satisfaction as Assessed by Clinician Satisfaction Rating Scale Score
    </Primary_outcome>
    <Secondary_outcome>Number of Participants Who Met Mini-International Neuropsychiatric Interview (MINI)-MINI Screen and Module K Criteria;Number of Participants Intended to Complete/Attend Next Visit as Assessed by Intent-to-Attend (ITA) Plus Assessment Scale;Direct Cost Assessment of Schizophrenia Care as Assessed by Client Service Receipt Inventory (CSRI) Scale Score;Indirect Cost Assessment of Schizophrenia Care as Assessed by Cost Assessment Questionnaire (CAQ);Change From Baseline in Sheehan Disability Scale (SDS) Total Score;Number of Participants With Adverse Events (AEs) as a Measure of Safety;Psychosis as Assessed by Mental Illness With Lay Evidence (SMILE) Scale Score;Clinical Global Impression - Severity of Schizophrenia (CGI-SS) Scale Total Score
    </Secondary_outcome>
    <Secondary_ID>R092670PSY4001;CR108551
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11642751
    </Internal_Number>
    <TrialID>CTRI/2018/09/015833
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>International, multi-centre study on comparing management and outcomes of children born with congenital diseases between Low-Â­, Middle-Â­ and Highâ??Income Countries.
    </Public_title>
    <Scientific_title>Management and Outcomes of Congenital Anomalies in Low-Â­, Middle-Â­ and Highâ??Income Countries:
A Multi-centre, International, Prospective Cohort Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Naomi Wright
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180926
    </Date_registration3>
    <Date_registration>26-09-2018
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=28425
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>01-10-2018
    </Date_enrollement>
    <Target_size>27201
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Afghanistan;Algeria;Angola;Argentina;Australia;Bangladesh;Belgium;Bolivia;Bosnia and Herzegovina;Brazil;Brunei Darussalam;Burundi;Cambodia;Cameroon;Canada;Chile;China;Colombia;Democratic Republic of the Congo;Ecuador;Egypt;Ethiopia;France;Germany;Ghana;Guatemala;India;Indonesia;Iraq;Jordan;Kenya;Lao People's Democratic Republic;Libyan Arab Jamahiriya;Lithuania;Madagascar;Malawi;Malaysia;Mauritania;Mexico;Morocco;Myanmar;Nepal;New Zealand;Nigeria;Other;Pakistan;Peru;Philippines;Poland;Republic of Korea;Rwanda;Saudi Arabia;Singapore;South Africa;Spain;Sudan;Sweden;Switzerland;Tanzania;Thailand;Tunisia;Turkey;Uganda;United Kingdom;United States of America;Uzbekistan;Venezuela (Bolivarian Republic of);Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Dr Sundeep PT
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Associate Professor, Department of Pediatric Surgery, Kasturba Medical College, Manipal Academy of Higher Education, Manipal 
    </Contact_Address>
    <Contact_Email>vijay.kumar@manipal.edu
    </Contact_Email>
    <Contact_Tel>9845857787
    </Contact_Tel>
    <Contact_Affiliation>Kasturba Medical College, Manipal
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Any neonate, infant or child under the age of 16â??years, presenting for the first time, with one of the study conditions listed below can be included in the study. &lt;br/ &gt;&lt;br&gt;1. Oesophageal atresia with or without tracheoâ??oesophageal atresia &lt;br/ &gt;&lt;br&gt;2. Congenital diaphragmatic hernia &lt;br/ &gt;&lt;br&gt;3. Intestinal atresia &lt;br/ &gt;&lt;br&gt;4. Gastroschisis &lt;br/ &gt;&lt;br&gt;5. Exomphalos (also known as omphalocele) &lt;br/ &gt;&lt;br&gt;6. Anorectal Malformation &lt;br/ &gt;&lt;br&gt;7. Hirschsprungâ??s Disease
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Any child above the age of 16-years. &lt;br/ &gt;&lt;br&gt;2. Any neonate, infant or child with one of the study conditions who has previously received surgery for their condition.  &lt;br/ &gt;&lt;br&gt;3. If they have recently received surgery for their condition, were discharged and then represented with a complication of the surgery during the study period
    </Exclusion_Criteria>
    <Condition>Health Condition 1: Q391- Atresia of esophagus with tracheo-esophageal fistula
Health Condition 2: Q390- Atresia of esophagus without fistula
Health Condition 3: Q422- Congenital absence, atresia and stenosis of anus with fistula
Health Condition 4: Q423- Congenital absence, atresia and stenosis of anus without fistula
Health Condition 5: Q410- Congenital absence, atresia and stenosis of duodenum
Health Condition 6: Q412- Congenital absence, atresia and stenosis of ileum
Health Condition 7: Q411- Congenital absence, atresia and stenosis of jejunum
Health Condition 8: Q428- Congenital absence, atresia and stenosis of other parts of large intestine
Health Condition 9: Q420- Congenital absence, atresia and stenosis of rectum with fistula
Health Condition 10: Q421- Congenital absence, atresia and stenosis of rectum without fistula
Health Condition 11: Q790- Congenital diaphragmatic hernia
Health Condition 12: Q439- Congenital malformation of intestine, unspecified
Health Condition 13: Q792- Exomphalos
Health Condition 14: Q793- Gastroschisis

    </Condition>
    <Intervention>Intervention1: Not Applicable: Not Applicable&lt;br&gt;Control Intervention1: Not Applicable: Not Applicable&lt;br&gt;
    </Intervention>
    <Primary_outcome>All-cause, in-hospital mortality.Timepoint: 30 days following primary intervention or primary admission
    </Primary_outcome>
    <Secondary_outcome>Complications occurring within 30-Â­days of primary intervention including: &lt;br/ &gt;&lt;br&gt;1. Surgical site-Â­infection &lt;br/ &gt;&lt;br&gt;2. Wound dehiscence &lt;br/ &gt;&lt;br&gt;3. Need for re-Â­intervention &lt;br/ &gt;&lt;br&gt;4. Condition specific complications &lt;br/ &gt;&lt;br&gt;5. Condition specific outcome variables &lt;br/ &gt;&lt;br&gt;6. Length of hospital stay (time from admission to death in patients who do not survive) &lt;br/ &gt;&lt;br&gt;7. 30-Â­day post primary intervention mortalityTimepoint: 30 days
    </Secondary_outcome>
    <Secondary_ID>NCT03666767
    </Secondary_ID>
    <Source_Support>Kingâ??s Centre for Global Health and Health Partnerships, Kingâ??s College London, UK;Wellcome Trust
    </Source_Support>
    <Secondary_Sponsor>Ankit Raj Dr Vijay Kumar Dr Sundeep PT
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>15/08/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Institutional Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12600968
    </Internal_Number>
    <TrialID>PACTR201812547047839
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>CBEHPP Filter Intervention Trial
    </Public_title>
    <Scientific_title>Impact Evaluation on the Integration of Advanced Water Filters into the Community Based Environmental Health Promotion Programme (CBEHPP)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Emory University Rollins School of Public Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180906
    </Date_registration3>
    <Date_registration>06/09/2018
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=3579
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>44 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>10/12/2018
    </Date_enrollement>
    <Target_size>1500
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Stratified allocation where factors such as age, gender, center, or previous treatment are used in the stratification,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>Sabrina
    </Contact_Firstname>
    <Contact_Lastname>Haque
    </Contact_Lastname>
    <Contact_Address>1518 Clifton Road, NE 
    </Contact_Address>
    <Contact_Email>sshaque@emory.edu
    </Contact_Email>
    <Contact_Tel>+17576357184
    </Contact_Tel>
    <Contact_Affiliation>Doctoral Student
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: i) All villages receiving CBEHPP programming via community health clubs (CHC) through SNV/CRS are eligible to be randomly selected for the study. &#x0D;&lt;br&gt;ii) The study will randomly select 60 villages across the Rwamagana district of Eastern Province, Rwanda, using a probability proportional to size selection approach based on CHC size.  &#x0D;&lt;br&gt;iii) Only households enrolled in CBEHPP CHCs at baseline are eligible to participate in the study. &#x0D;&lt;br&gt;iv) In addition to CHC membership, households must have a respondent who is 18 years of age and older, and at least one child under five years of age or have a pregnant woman living in the household at the time of baseline.  &#x0D;&lt;br&gt;v) Only 25 households per village will be selected for baseline/follow-up (randomly selected from eligibility list), though all eligible households in the intervention arm will receive the intervention.  
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: i) Households living outside Rwamagana district or outside selected study villages.&#x0D;&lt;br&gt;ii) Any households that are not participating in CBEHPP and do not have a child under five years of age or a pregnant woman. &#x0D;&lt;br&gt;iii) Households where there are no respondents 18 years of age or older or over age 80.&#x0D;&lt;br&gt;iv) Households will also be excluded from the study if the respondent does not consent to participate, or if they already own an intervention filter that is reported to be in good working order (i.e. usable). &#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Diarrheal disease;Diarrheal disease
    </Condition>
    <Intervention>;CBEHPP and Advanced Water Filter;CBEHPP
    </Intervention>
    <Primary_outcome>Escherichia coli (E. coli) in point-of-use drinking water at household-level
    </Primary_outcome>
    <Secondary_outcome>Caregiver-reported diarrhea prevalence in the previous 7 days among children under five, defined as 3 or more loose or watery stools within a 24-hour period.;Incidence of visits to community health workers for diarrhea among children under 5 years of age, determined through review of village-based registers.;Water Filter Coverage and Uptake, determined by confirmed receipt of the filter, self-report, and observed use such as presence of water in the filter at time of visit. ;Incidence of health facility-confirmed diarrhea among children under 5 years of age, determined by self-report from caregiver/respondent 
    </Secondary_outcome>
    <Secondary_ID>00001497;IRB00106424
    </Secondary_ID>
    <Source_Support>Bill and Melinda Gates Foundation
    </Source_Support>
    <Secondary_Sponsor>SweetSense Inc. 
    </Secondary_Sponsor>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>02/10/2018;06/11/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>info@rnecrwanda.org;IRB@emory.edu
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Rwanda National Ethics Committee;Emory University Institutional Review Board
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+250255107884;+14047120720
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>info@rnecrwanda.org;IRB@emory.edu
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>7971567
    </Internal_Number>
    <TrialID>ISRCTN66313469
    </TrialID>
    <Last_Refreshed_on>29 April 2019
    </Last_Refreshed_on>
    <Public_title>Learning clinical breast exam skills with high fidelity versus low fidelity simulators in Rwanda
    </Public_title>
    <Scientific_title>
                Clinical breast exam skill acquisition using high fidelity versus low fidelity simulation models in Rwanda: a randomised crossover trial

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>Center for Surgery and Public Health, Brigham and Women's Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180905
    </Date_registration3>
    <Date_registration>05/09/2018
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN66313469
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/07/2014
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Interventional single-centre randomised crossover trial (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Consenting medical students or residents rotating at CHUK hospital in Kigali, Rwanda&lt;br&gt;                2. Aged 18 years or older&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: N/A
    </Exclusion_Criteria>
    <Condition>Breast cancer &lt;br&gt;Cancer &lt;br&gt;Neoplasm of breast
    </Condition>
    <Intervention>&lt;br&gt;                Participants were randomised using a computerised random number generator in blocks of two. For every two participants, one was randomised to the high fidelity simulation (HF) group and one to the low fidelity simulation (LF) group. Participants received their fidelity group in a sealed envelope. Participants were not blinded to the models, as both types of models were present in the classroom. The video recordings were coded with unique identifiers so that the video rater was blinded to the level of trainee (medical student versus resident), and the exam attempt (exam 1, 2, 3, versus 4).&lt;br&gt;                A one day four-hour simulation-based session designed to teach clinical breast examination (CBE) was implemented for both groups. This educational course was developed using standardized materials and lesson plans adapted for Rwanda based off primary literature, medical textbooks, the American College of Surgeons (ACS) student simulation-based surgical skills curriculum, surgical council on resident education (SCORE), and breast objective structured clinical exam (OSCE). Participants performed a baseline CBE on the model they were randomised to prior to any teaching sessions. Following this pre-test (Exam 1), participants engaged in a two-hour didactic lecture series on breast anatomy, breast pathology, and CBE. Didactic teaching sessions between HF and LF groups were identical. All lectures were taught by investigator Murthy, SS, with the exception of breast anatomy lecture, which was taught by investigator Ingabire, A when his clinical duties permitted. Following the lectures, students performed a clinical breast examination on the model they were randomised to (Exam 2). After this second exam, students had 90 minutes of hands-on training and practice with the simulator model by investigator (Murthy, SS). Trainees had the opportunity to undergo repeated practice of CBE with immediate feedback from study investigator (Murthy, SS). After lectures, h
    </Intervention>
    <Primary_outcome>&lt;br&gt;                Our primary outcome was to determine mean difference in CBE exam scores between HF and LF groups.  The evaluation tool used to score clinical breast exams was published in a study by Schubart et. al and we obtained permission from the authors to use their tool. We expanded and adapted the tool to fit it to the Rwandan cultural context with a similar scoring system as the original research paper.&lt;br&gt;                This was assessed at exams 1-4 and 1 month after the intervention.&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                The following are assessed at exams 1-4 and 1 month after the intervention:&lt;br&gt;                1. Overall improvement in CBE exam scores after the education intervention was implemented&lt;br&gt;                2. Whether addition of simulation to lectures improved the mean difference in CBE exam scores&lt;br&gt;                3. Provider level traits that may affect the mean difference in exam scores&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>N/A
    </Secondary_ID>
    <Source_Support>Center for Surgery and Public Health, Brigham and Women's Hospital
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1990
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>
                    Rwanda National Health Research Committee, 10/09/2014, NHRC/2014/PROT/0182
                    CHUK Ethics Committee, 08/08/2014, EC/CHUK/2014/14
                
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/05/2017
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11641781
    </Internal_Number>
    <TrialID>CTRI/2018/07/014863
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Umbiflow Device to identify high risk fetus
    </Public_title>
    <Scientific_title>Prevalence and outcomes of abnormal continuous wave Doppler flow indices in unselected obstetric populations in low- and middle income countries:
The Umbiflowâ?¢ International Study (A65924)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>World Health Organization
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180713
    </Date_registration3>
    <Date_registration>13-07-2018
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=26694
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>01-08-2018
    </Date_enrollement>
    <Target_size>7035
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Ghana;India;Kenya;Rwanda;South Africa
    </Countries>
    <Contact_Firstname>Dr Yeshita V Pujar
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Department of OBGYN
J N Medical College
Nehru Nagar
Belagavi 
    </Contact_Address>
    <Contact_Email>yvpujar@hotmail.com
    </Contact_Email>
    <Contact_Tel>9448142989
    </Contact_Tel>
    <Contact_Affiliation>J N Medical College
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Singleton pregnancy  &lt;br/ &gt;&lt;br&gt;2. Accurate gestational age between more than or equal to 28 weeks 0 days and less than or equal to 34 weeks 0 daysâ?? gestation. &lt;br/ &gt;&lt;br&gt;3. Women expected to give birth in study hospital or its catchment area &lt;br/ &gt;&lt;br&gt;4. Women currently considered as â??low riskâ?? according to local antenatal care guidelines &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Multiple pregnancy &lt;br/ &gt;&lt;br&gt;2. Women not expected to give birth in study hospital or likely to migrate from its catchment area &lt;br/ &gt;&lt;br&gt;3. Pregnant women who are incapable of giving informed consent or assent for any reason. &lt;br/ &gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Health Condition 1: O099- Supervision of high risk pregnancy, unspecified

    </Condition>
    <Intervention>Intervention1: Umbiflow continuous-wave Doppler device: Umbiflow is a handheld, mobile continuous-wave Doppler ultrasound device, which consists of a handheld proprietary Doppler probe (transducer) with a universal serial bus (USB) cable that connects to any Windows-based platform (e.g. computer, laptop, tablet or smartphone) on which the necessary software is installed. Umbiflow has been established as a practical, simple-to-use device that has been developed and tested in real-world clinical settings in South Africa, and can be used by a range of health worker cadres. In this study, Umbiflow assessments will be performed by nurses, midwives or non-specialist doctors at participating ANC clinics, who have received the mandatory training in how to correctly perform and interpret the Umbiflow assessment. This mandatory training has been developed as part of previous Umbiflow research studies. As part of training, participants undergo practical training on real patients, and will be signed off by a trainer before conducting Umbiflow assessments for the study.&lt;br&gt;
    </Intervention>
    <Primary_outcome>Prevalence of Abnormal flow indices as assessed by Umbiflow-resistance Index, pulsatility index, systolic or diastolic ratio &lt;br/ &gt;&lt;br&gt;Prevalence of Absent End Diastolic FlowTimepoint: 28 weeks of gestation to 7 days postpartum
    </Primary_outcome>
    <Secondary_outcome>Birth outcomes &lt;br/ &gt;&lt;br&gt;1 Onset of labour (spontaneous or induced) &lt;br/ &gt;&lt;br&gt;2 Mode of birth-vaginal, assisted vaginal or caesarean &lt;br/ &gt;&lt;br&gt;3 Gestational age at birth &lt;br/ &gt;&lt;br&gt;4 Birthweight &lt;br/ &gt;&lt;br&gt;Timepoint: until 7 days postpartum;Fetal and neonatal outcomes &lt;br/ &gt;&lt;br&gt;1 Stillbirth- macerated and fresh stillbirth more than or equal to 28 weeks gestation &lt;br/ &gt;&lt;br&gt;2 Early neonatal death  &lt;br/ &gt;&lt;br&gt;3 Perinatal mortality-stillbirths and early neonatal deaths &lt;br/ &gt;&lt;br&gt;4 Small for Gestational Age -Birthweight less than 10th centile according to local growth charts &lt;br/ &gt;&lt;br&gt;5 Ponderal indexTimepoint: up to day 7 postnatal or discharge;Maternal pregnancy outcomes &lt;br/ &gt;&lt;br&gt;1 Maternal morbidity outcomes  &lt;br/ &gt;&lt;br&gt;2 Maternal mortalityTimepoint: 28 weeks of gestation to 7 days postpartum;Use of investigations, interventions and health systems outcomes &lt;br/ &gt;&lt;br&gt;1 Referral of women to higher level of care &lt;br/ &gt;&lt;br&gt;2 Completed referral &lt;br/ &gt;&lt;br&gt;3 Number, timing and care provider of antenatal care visits  &lt;br/ &gt;&lt;br&gt;4 Hospital admission &lt;br/ &gt;&lt;br&gt;5 Number, timing and findings of ultrasound assessments-like biophysical profile, UA Doppler &lt;br/ &gt;&lt;br&gt;6 Antenatal corticosteroids &lt;br/ &gt;&lt;br&gt;7 Planned provider-initiated deliveryTimepoint: 28 weeks of gestation to 7 days postpartum
    </Secondary_outcome>
    <Secondary_ID>NIL
    </Secondary_ID>
    <Source_Support>World Health Organization
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>29/05/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>KLE University Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>7440860
    </Internal_Number>
    <TrialID>ISRCTN17048881
    </TrialID>
    <Last_Refreshed_on>22 October 2018
    </Last_Refreshed_on>
    <Public_title>A randomized cross-over trial focused on breast core needle biopsy skill acquisition and confidence using high fidelity versus low fidelity simulation models in Rwanda
    </Public_title>
    <Scientific_title>A randomized cross-over trial focused on breast core needle biopsy skill acquisition and confidence using high fidelity versus low fidelity simulation models in Rwanda                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Center for Surgery and Public Health
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180608
    </Date_registration3>
    <Date_registration>08/06/2018
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN17048881
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/10/2014
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single-center randomized education cross-over trial (Other)
    </Study_design>
    <Phase/>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: Residents training in either surgery or obstetrics and gynecology (OB/GYN) in any postgraduate year (PGY) at the University of Rwanda, rotating at CHUK hospital in Kigali, Rwanda
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Medical students and anyone who was not a postgraduate Rwandan resident in surgery or OB-GYN rotating at University Teaching Hospital, in Kigali, Rwanda
    </Exclusion_Criteria>
    <Condition>Benign or malignant breast disease &lt;br&gt;Cancer
    </Condition>
    <Intervention>A one-day, five-hour BCNB educational training course for surgical residents was implemented after baseline assessment. Similar sessions were conducted for OB/GYN residents on different days. During the first course for surgical residents, instructors included two fellowship trained Rwandan and United States (USA) breast surgeons, one radiologist, and one emergency department physician with fellowship training in ultrasound. The OB/GYN training sessions were identical in lecture and evaluation content except only one USA fellowship trained breast surgeon and one USA trained radiologist were available as instructors and evaluators. &lt;br&gt;&lt;br&gt;Residents performed a baseline BCNB exam prior to any educational intervention on the model to which they were randomized (Exam 1). After the baseline exam, participants listened to a four-hour lecture session. Subsequently they had 60 minutes of hands-on training by an attending physician with the simulator model to which they were originally randomized. After the lectures and hands-on simulation practice, participants took a second BCNB exam (Exam 2) and then participated in a third BCNB exam where they crossed over to the other model (Exam 3). At the end of the course, participants took a confidence survey.&lt;br&gt;&lt;br&gt;Prior to the course, the instructors were trained on how to evaluate participants in a similar manner using the US guided BCNB evaluation tool.
    </Intervention>
    <Primary_outcome>The mean difference in BCNB exam scores between HF and LF groups, measured on the day the education intervention was implemented (exam 1, 2 and 3)
    </Primary_outcome>
    <Secondary_outcome>1. Provider level traits that may affect mean difference in exam scores&lt;br&gt;2. Participant confidence assessed using survey at the end of the course
    </Secondary_outcome>
    <Secondary_ID>N/A
    </Secondary_ID>
    <Source_Support>Investigator initiated and funded
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1990
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Ethics Committee at University Teaching Hospital, Kigali (CHUK), 18/07/2014, ref: NHRC/2014/PROT/0182, and the Ministry of Health of Rwanda (MOH). It was granted exempt study status by the institutional review board at Partners Healthcare in Boston at Brigham and Women's Hospital. 
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>20/05/2017
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12600787
    </Internal_Number>
    <TrialID>PACTR201804003257400
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Helicobacter pylori Treatment Success Rate amongst Rwandan Endoscopy Patients
    </Public_title>
    <Scientific_title>Helicobacter pylori Treatment Success Rate amongst Rwandan Endoscopy Patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>Butare University Teaching Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180328
    </Date_registration3>
    <Date_registration>28/03/2018
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=3257
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>120 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>02/11/2015
    </Date_enrollement>
    <Target_size>244
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Random pick up of a piece of paper from a basket,Pieces of paper with 4 different regimens were mixed in a basket. A patient would choose a piece of paper randomly
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>Jean Damascene;Celestin
    </Contact_Firstname>
    <Contact_Lastname>Kabakambira;Hategeka
    </Contact_Lastname>
    <Contact_Address>5407 W Cedar Ln;&#x0D;
        
    </Contact_Address>
    <Contact_Email>damaskabakambira@gmail.com;celestin.hategeka@gmail.com
    </Contact_Email>
    <Contact_Tel>+12023447389;+17789907941
    </Contact_Tel>
    <Contact_Affiliation>Research Fellow/ NIH;Epidemiologist
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Adults aged 21 years and above&#x0D;&lt;br&gt;Referred for upper gastro-intestinal endoscopy at Butare University Teaching Hospital &#x0D;&lt;br&gt;Positive modified rapid urease test on endoscopic biopsies&#x0D;&lt;br&gt;study medications
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Pregnant women&#x0D;&lt;br&gt;Patients with suspected malignancies on endoscopy&#x0D;&lt;br&gt;Patients with known allergy to one of the 
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Digestive System &lt;br&gt;H. Pylori &lt;br&gt;H. pylori;Digestive System;H. Pylori;H. pylori
    </Condition>
    <Intervention>;omeprazole+ amoxicillin+ clarithromycin (CLARITHRO);omeprazole+ amoxicillin+ ciprofloxacin (CIPRO);omeprazole+ amoxicillin+ metronidazole (METRO);omeprazole+ amoxicillin+ ciprofloxacin+Doxycyclin) (CIPRO-Plus)
    </Intervention>
    <Primary_outcome>Evidence of H. Pylori eradication ;Health related quality of life score change by SF-NDI 
    </Primary_outcome>
    <Source_Support>Butare University Teaching Hospital
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>09/03/2015
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>CMHS Institutional Review Board
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10744379
    </Internal_Number>
    <TrialID>NCT03455647
    </TrialID>
    <Last_Refreshed_on>22 March 2021
    </Last_Refreshed_on>
    <Public_title>Enhancing Milk Consumption for Improved Nutrition in Rwanda
    </Public_title>
    <Scientific_title>Enhancing Milk Quality and Consumption for Improved Income and Nutrition in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>RTI International
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180228
    </Date_registration3>
    <Date_registration>28/02/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03455647
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>49 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>April 23, 2018
    </Date_enrollement>
    <Target_size>746
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Valerie Flax, PhD, MPH
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>RTI International
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Arm 1:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Household is located in an intervention cell&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Household received a cow under the government of Rwanda Girinka program before 2017&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Household contains a mother 18-49 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Household contains a child between the ages of 12 and 29 months at baseline&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Arm 2:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Household is located in a comparison cell&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Household received a cow under the government of Rwanda Girinka program before 2017&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Household contains a mother 18-49 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Household contains a child between the ages of 12 and 29 months at baseline&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Arm 3:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -- Household is located in a comparison cell&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Household is eligible to receive a cow under the government of Rwanda Girinka program&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Household contains a mother 18-49 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Household contains a child between the ages of 12 and 29 months at baseline&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Failure to meet inclusion criteria&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Inadequate Child Growth
    </Condition>
    <Intervention>Behavioral: ASF promotion plus Girinka
    </Intervention>
    <Primary_outcome>Child height-for-age z-score (HAZ);Child height-for-age z-score (HAZ);Child dairy milk consumption;Child milk consumption;Child dietary diversity;Child dietary diversity
    </Primary_outcome>
    <Secondary_outcome>Child weight-for-height z-score (WHZ);Child weight-for-height z-score (WHZ);Child weight for age z-score (WAZ);Child weight for age z-score (WAZ);Maternal body-mass index;Maternal body-mass index
    </Secondary_outcome>
    <Secondary_ID>0215801
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>The International Livestock Research Institute (ILRI);University of Rwanda;TechnoServe
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12600743
    </Internal_Number>
    <TrialID>PACTR201803003147805
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Effects of exercise on HIV - Associated Peripheral neuropathy
    </Public_title>
    <Scientific_title>The effect of physiotherapeutic exercises on peripheral neuropathy among PLHIV on ART in Kigali - Rwanda                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor/>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180226
    </Date_registration3>
    <Date_registration>26/02/2018
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=3147
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>59 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>05/03/2012
    </Date_enrollement>
    <Target_size>120
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously,Randomised,120 participants were randomised into 60 in the experimental and 60 in the control group, using computer generated random numbers.,Concealed allocation to groups was assured by an independent research assistant placing the   numbers into opaque sealed envelopes which were then given to eligible participants by a second research assistant
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>David 
    </Contact_Firstname>
    <Contact_Lastname>Tumusiime
    </Contact_Lastname>
    <Contact_Address> University of Rwanda; Remera Campus
    </Contact_Address>
    <Contact_Email>dktumusiime@gmail.com
    </Contact_Email>
    <Contact_Tel>+250 788749398
    </Contact_Tel>
    <Contact_Affiliation>Senior Lecturer; University of Rwanda
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Included all people living with HIV on ART from the selected public outpatient ART clinics in Rwanda, aged 18 and above; both females and males, with no active opportunistic infection such as TB or others. 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: People living with HIV on ART with known disorders of the central nervous system, PLHIV with a known history of diabetes, Vitamin B12 deficiency, TB, renal failure, hypothyroidism and other pathologies that may be associated with neuropathy, any clinical history that would be an exercise contraindication, unwilling to participate in the PTExs and the rest of the follow up programme, very weak patients who could not walk without support, other neuromusculoskeletal impairments such as, musculoskeletal deformity, amputation, scoliosis, and inability to actively and functionally move ankle and knee joints, lower extremity arthritis, and central neuropathies like hemiparesis and central paralyses.
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;HIV/AIDS &lt;br&gt;Peripheral Neuropathy;HIV/AIDS;Peripheral Neuropathy
    </Condition>
    <Intervention>;Exercise intervention;Routine health Care at ART clinic 
    </Intervention>
    <Primary_outcome>Change in Peripheral neuropathy symptoms and signs
    </Primary_outcome>
    <Secondary_outcome>Functional ability of lower extremity 
    </Secondary_outcome>
    <Source_Support>University of Rwanda, College of Medicine  and Health Sciences (former Kigali Health Institute
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>16/09/2008
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Human Research Ethics Committee , University of the Witwatersrand
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10297192
    </Internal_Number>
    <TrialID>NCT03508349
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Routine Antenatal Care Versus Screening and Treatment of Malaria in Pregnancy in Rwanda
    </Public_title>
    <Scientific_title>Effectiveness of Intermittent Screening and Treatment of Malaria in Pregnancy (ISTp) on Maternal and Birth Outcomes in Selected Districts in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Jhpiego
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180123
    </Date_registration3>
    <Date_registration>23/01/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03508349
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>49 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>September 5, 2016
    </Date_enrollement>
    <Target_size>1786
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Reena Sethi, DrPH
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Jhpiego
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant women age 18 or older who have their first ANC visit during the study&#x0D;&lt;br&gt;             recruitment period&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to participate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  • Pregnant women below the age of 18&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Not willing to participate&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria in Pregnancy
    </Condition>
    <Intervention>Diagnostic Test: IST
    </Intervention>
    <Primary_outcome>Prevalence of placental malaria at delivery (tested by PCR)
    </Primary_outcome>
    <Secondary_outcome>Prevalence of maternal anemia at delivery;Prevalence of low birth weight babies (&lt;37 weeks gestation);Prevalence of preterm births;Episodes of clinical malaria during the course of the pregnancy
    </Secondary_outcome>
    <Secondary_ID>6829
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Rwanda Malaria and Other Parasitic Diseases Division (MOPDD);Centers for Disease Control and Prevention
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10683153
    </Internal_Number>
    <TrialID>NCT03376607
    </TrialID>
    <Last_Refreshed_on>1 March 2021
    </Last_Refreshed_on>
    <Public_title>Community- and mHealth-Based Integrated Management of Diabetes in Primary Healthcare in Rwanda
    </Public_title>
    <Scientific_title>Community- and mHealth-Based Integrated Management of Diabetes in Primary Healthcare in Rwanda: The D²Rwanda Study
    </Scientific_title>
    <Acronym>D²Rwanda
    </Acronym>
    <Primary_sponsor>University of Aarhus
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20171206
    </Date_registration3>
    <Date_registration>06/12/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03376607
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 11, 2019
    </Date_enrollement>
    <Target_size>209
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Per Kallestrup, MD, PhD;Claus Vögele, DPsych, PhD;Jeanine Condo Umutesi, MD, MSc, PhD;Conchitta D'Ambrosio, MSc, PhD
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>University of Aarhus;University of Luxembourg;Rwanda Biomedical Center;University of Luxembourg
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria for patients:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Adult patients (male and female) aged between 21 and 80 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Diagnosed and confirmed as diabetic patient at least 6 months prior to study start&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Living in the administrative areas (called "cells") of the district hospitals&#x0D;&lt;br&gt;             participating in the first phase of the HBCP programme&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Residing, and planning to reside within a 2-hour travel distance on foot from the&#x0D;&lt;br&gt;             study site for the duration of follow-up&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Willing and able to adhere to the study protocol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Willing and able to give informed consent for enrolment in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria for patients:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Severe mental health conditions, including cognitive impairments, as registered in&#x0D;&lt;br&gt;             their clinical records&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Severe hearing and visual impairments as registered in their clinical records&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Terminal illness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Illiteracy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Pregnancy or post-partum period&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion criteria for HBCPs:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Permanent residence in one of the cells of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Willing and able to give informed consent for enrolment in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria for HBCPs:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        1. Not capable of accomplishing questionnaires due to reading or communication problems&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Diabetes Mellitus;Telemedicine;Community Health Workers
    </Condition>
    <Intervention>Other: HBCP programme;Behavioral: mobile health application
    </Intervention>
    <Primary_outcome>Change in HbA1c
    </Primary_outcome>
    <Secondary_outcome>Change in medication adherence;Number of dropouts of the NCD clinics of the district hospitals;Number of lost appointments to the NCD clinics of the district hospitals;Mortality;Number of complications;Number of referrals;Change in health literacy;Change in health-related quality of life;Change in mental well-being;Percentage of patients with at least one measurement of HbA1c;Percentage of patients with at least one measurement of fasting blood glucose (FBG) levels;Percentage of patients with at least one measurement of creatinine;Percentage of patients with at least one measurement of urine proteins (dipstick);Percentage of patients with at least one measurement of blood pressure;Percentage of patients with at least one recording of body mass index (BMI);Fasting blood glucose (FBG);Creatinine;Urine proteins (dipstick);Blood pressure;Body mass index (BMI);Recorded number of smokers;Number of patients with recorded pack years;Number of patients with recorded alcohol intake per week;Number of smokers;Number of cigarettes per day;Alcohol intake per week
    </Secondary_outcome>
    <Secondary_ID>D²Rwanda
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Luxembourg;Karen Elise Jensens Fond;University of Rwanda;Rwanda Biomedical Center (RBC);Luxembourg Institute of Socio-Economic Research (LISER)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10286788
    </Internal_Number>
    <TrialID>NCT03367637
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>A Novel mHealth Approach to Assess and Manage Palliative Care Needs for Cancer Patients in Kigali
    </Public_title>
    <Scientific_title>A Novel mHealth Approach to Assess and Manage Palliative Care Needs for Cancer Patients in Kigali
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Massachusetts General Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20171205
    </Date_registration3>
    <Date_registration>05/12/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03367637
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2018
    </Date_enrollement>
    <Target_size>80
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Aparna Parikh, MD;Aparna Parikh, MD;Christian Ntizimira, MD
    </Contact_Lastname>
    <Contact_Email>;aparna.parikh@mgh.harvard.edu;ntiheritier@gmail.com
    </Contact_Email>
    <Contact_Tel>;+1-6177267942;
    </Contact_Tel>
    <Contact_Affiliation>Massachusetts General Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  At least 18 years old;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosed with advanced cancer and in moderate or severe pain, as defined by use of&#x0D;&lt;br&gt;             World Health Organization (WHO) as requiring step 2 drugs (Tramadol or Codeine) or WHO&#x0D;&lt;br&gt;             step 3 drugs (narcotics other than Codeine) to manage their pain.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Eligible patients or their primary care giver must have a smartphone and/or have a&#x0D;&lt;br&gt;             family member that lives at home with a smartphone; and&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Projected life expectancy of &lt;3 months at the time of enrollment, to be estimated by&#x0D;&lt;br&gt;             their healthcare provider&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients enrolled in the smartphone application development phases (earlier than RCT)&#x0D;&lt;br&gt;             of the study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cancer Pain
    </Condition>
    <Intervention>Other: Standard palliative care;Other: Smart Phone based symptom evaluation application
    </Intervention>
    <Primary_outcome>Difference in pain score as measured by the expanded African Palliative Care Outcomes Scale (APCA POS)
    </Primary_outcome>
    <Secondary_outcome>Difference in other symptoms and quality of life (QOL) scores from the remaining portion of the expanded APCA POS individually and as composite score.
    </Secondary_outcome>
    <Secondary_ID>2017P002380
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Rwanda Palliative Care and Hospice Organization;University of California, San Francisco;Cornell Tech;King's College London
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10293110
    </Internal_Number>
    <TrialID>NCT03455127
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Alliance for Family Strengthening: Improved Early Childhood Development in Rwanda
    </Public_title>
    <Scientific_title>Community Based Lay Worker Pilot of FSI-ECD
    </Scientific_title>
    <Acronym>FSI-ECD
    </Acronym>
    <Primary_sponsor>Boston College
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20171109
    </Date_registration3>
    <Date_registration>09/11/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03455127
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>36 Months
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 10, 2017
    </Date_enrollement>
    <Target_size>90
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Theresa Betancourt, Sc.D., M.A.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Boston College School of Social Work
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Beneficiary Inclusion Criteria: All participants must live in chosen District(s) of&#x0D;&lt;br&gt;             Rwanda. Inclusion criteria for families are: (a) being VUP-eligible, (b) having at&#x0D;&lt;br&gt;             least one children aged 6-36 months living in the home and (c) having caregiver&#x0D;&lt;br&gt;             willing to discuss and enhance their parenting practices by interacting with a&#x0D;&lt;br&gt;             home-visiting coach. Caregiver eligibility: (a) is aged 18 or older and cares for&#x0D;&lt;br&gt;             child(ren) and (b) lives in the same household as child(ren). We will enroll both&#x0D;&lt;br&gt;             single and dual caregiver families to reflect population dynamics. Legal guardians may&#x0D;&lt;br&gt;             be aunts, uncles, grandparents, or foster parents.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Community Based Lay Worker Exclusion Criteria: Community based workers selected to deliver&#x0D;&lt;br&gt;        the FSI-ECD intervention must: (a) live in the sector of beneficiary households they will&#x0D;&lt;br&gt;        deliver the intervention to, (b) be Rwanda, (c) be aged 18 or older; (d) be able to write,&#x0D;&lt;br&gt;        read, and count in local language; (e) be committed to young children and family values;&#x0D;&lt;br&gt;        (f) have the required amount of time to carry out the FSI-ECD intervention with a select&#x0D;&lt;br&gt;        number of households, (e) be recommended and approved by local community and authorities.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Beneficiary Exclusion Criteria: Potential participants will be excluded if they do not&#x0D;&lt;br&gt;             live in chosen District of Rwanda, do not have children between the ages of 6 and 36&#x0D;&lt;br&gt;             months living in their household for whom they are the primary caregiver, they are not&#x0D;&lt;br&gt;             eligible/enrolled in Rwanda's public works social protection program, VUP, or have&#x0D;&lt;br&gt;             severe cognitive impairments which preclude their ability to speak to the research&#x0D;&lt;br&gt;             questions under study. We will exclude families in the midst of crisis (e.g., a&#x0D;&lt;br&gt;             caregiver with active suicidal attempts or psychosis) and refer them to appropriate&#x0D;&lt;br&gt;             services.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Community Based Lay Worker Exclusion Criteria: Community based workers will not be selected&#x0D;&lt;br&gt;        to deliver the FSI-ECD intervention if they do/are not: (a) live in the sector of&#x0D;&lt;br&gt;        beneficiary households they will deliver the intervention to, (b) Rwanda, (c) aged 18 or&#x0D;&lt;br&gt;        older; (d) able to write, read, and count in local language; (e) committed to young&#x0D;&lt;br&gt;        children and family values; (f) have required amount of time to carry out the FSI-ECD&#x0D;&lt;br&gt;        intervention with a select number of households, (e) recommended and approved by local&#x0D;&lt;br&gt;        community and authorities.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Child Development
    </Condition>
    <Intervention>Other: FSI ECD
    </Intervention>
    <Primary_outcome>Ages Stages Questionnaire-3
    </Primary_outcome>
    <Secondary_outcome>Hopkins Symptoms Check List;Multiple Indicator Cluster Survey 5;Rwanda Comprehensive Food Security and Vulnerability Analysis and Nutrition Survey;Local Derived Scale;System for Observing Family Therapy Alliances;Difficulties in Emotional Regulation (DERS);Malawi Development Assessment Tool (MDAT);Home Observation for the Measurement of the Environment (HOME Inventory);Observation of Mother Child Interaction (OMCI);Ages Stages Questionnaire Socio-Emotional
    </Secondary_outcome>
    <Secondary_ID>IRB-16 1570_Activity B
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>World Bank;United States Agency for International Development (USAID);Network of European Foundations;ELMA Philanthropies
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11486078
    </Internal_Number>
    <TrialID>NCT03334747
    </TrialID>
    <Last_Refreshed_on>18 October 2021
    </Last_Refreshed_on>
    <Public_title>Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.
    </Public_title>
    <Scientific_title>A Phase 2, Multi-center, Randomized, Open-label, Dose-escalation Study to Determine Safety of Single (QD) and Multiple (3 QD) Doses of KAE609, Given to Adults With Uncomplicated Plasmodium Falciparum Malaria.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Novartis Pharmaceuticals
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20171027
    </Date_registration3>
    <Date_registration>27/10/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03334747
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 16, 2017
    </Date_enrollement>
    <Target_size>188
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Gabon;Ghana;Mali;Rwanda;Uganda;Gabon;Ghana;Mali;Rwanda;Uganda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Novartis Pharmaceuticals
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Novartis Pharmaceuticals
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        KEY Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male and female patients = 18 years with a body weight = 45 kg.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Microscopic confirmation of acute uncomplicated P. falciparum using by Giemsa-stained&#x0D;&lt;br&gt;             thick film.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. P. falciparum parasitaemia of 500 to 50 000 parasites/µL.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Axillary temperature = 37.5ºC or oral/tympanic/rectal temperature = 38.0ºC; or history&#x0D;&lt;br&gt;             of fever during the previous 24 hours.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Written informed consent must be obtained before any study assessment is performed. If&#x0D;&lt;br&gt;             the patient is unable to write, then a witnessed consent according to local ethical&#x0D;&lt;br&gt;             standards is permitted.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        KEY Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Mixed Plasmodium infections.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Signs and symptoms of severe malaria according to World Health Organization (WHO) 2016&#x0D;&lt;br&gt;             criteria (WHO 2016).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Known liver abnormalities, liver cirrhosis (compensated or decompensated), known&#x0D;&lt;br&gt;             active or history of hepatitis B or C (testing not required), known gallbladder or&#x0D;&lt;br&gt;             bile duct disease, acute or chronic pancreatitis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Clinical or laboratory evidence of any of the following:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. AST/ALT &gt; 1.5 x the upper limit of normal range (ULN), regardless of the level of&#x0D;&lt;br&gt;             total bilirubin&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. AST/ALT &gt; 1.0 and = 1.5 x ULN and total bilirubin is &gt; ULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Total bilirubin &gt; 2 x ULN, regardless of the level of AST/ALT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. History of photodermatitis/increased sensitivity to sun.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Pregnant or nursing (lactating) women.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Known disturbances of electrolyte balance, e.g. hypokalemia, hypocalcemia or&#x0D;&lt;br&gt;             hypomagnesemia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Moderate to severe anemia (Hemoglobin level &lt;8 g/dL).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Other protocol-defined inclusion/exclusion criteria may apply&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria
    </Condition>
    <Intervention>Drug: KAE609;Drug: Coartem
    </Intervention>
    <Primary_outcome>Number of Participants With at Least 2 CTCAE Grades Increase From Baseline in Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST)
    </Primary_outcome>
    <Secondary_outcome>Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected and Uncorrected Adequate Clinical and Parasitological Response (ACPR) at Day 15 and Day 29;Parasite Clearance Time (PCT);Fever Clearance Time (FCT);Time to Recrudescence and Reinfection at Study Day 29;Maximum Peak Observed Concentration (Cmax);Tmax;AUC0-24;Half-life (T^1/2)
    </Secondary_outcome>
    <Secondary_ID>207813/Z/17/Z;CKAE609A2202
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Supported by Wellcome Trust via Grant # Grant Number 207813/Z/17/Z
    </Secondary_Sponsor>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>25/09/2020
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT03334747
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10283555
    </Internal_Number>
    <TrialID>NCT03311399
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Using mHealth Technology to Identify and Refer Surgical Site Infections in Rwanda
    </Public_title>
    <Scientific_title>Using mHealth Technology to Identify and Refer Surgical Site Infections in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Brigham and Women's Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20171011
    </Date_registration3>
    <Date_registration>11/10/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03311399
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>March 15, 2017
    </Date_enrollement>
    <Target_size>653
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Screening. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Bethany Hedt-Gauthier, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Harvard Medical School
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adult patients that have undergone cesarean-section surgery at Kirehe District&#x0D;&lt;br&gt;             Hospital&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients from Mahama Refugee Camp will not be asked to participate in follow-up&#x0D;&lt;br&gt;             activities due to travel autonomy issues&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients that are not residents of Kirehe District&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients that have surgery other than cesarean delivery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients that have not been discharged by 7 post-operative days (POD)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Surgical Site Infection
    </Condition>
    <Intervention>Other: SSI Screening Tool used in home visits by CHWs;Other: SSI Screening Tool used via phone call follow-up
    </Intervention>
    <Primary_outcome>Number of patients with SSI returning to care
    </Primary_outcome>
    <Secondary_ID>2016P001943
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Harvard Medical School;Partners in Health
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10309220
    </Internal_Number>
    <TrialID>NCT03665012
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>The Pediatric Development Clinic Study
    </Public_title>
    <Scientific_title>The Pediatric Development Clinic Study: the Development, Medical and Nutritional Outcomes of Children Discharged From the Neonatal Unit in Rural Rwanda
    </Scientific_title>
    <Acronym>PDC
    </Acronym>
    <Primary_sponsor>Partners in Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20171011
    </Date_registration3>
    <Date_registration>11/10/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03665012
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>5 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 1, 2017
    </Date_enrollement>
    <Target_size>376
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Rwanda
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All under-five children meeting PDC referral criteria as described in the study&#x0D;&lt;br&gt;             population description will be enrolled in PDC.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who do not meet referral criterial for PDC or who are over age 5 years.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Pregnancy, Puerperium and Perinatal Conditions
    </Condition>
    <Intervention>Other: Pediatric Development Clinic (PDC)
    </Intervention>
    <Primary_outcome>To compare developmental outcomes of children who were enrolled in the PDC to children who did not receive PDC services and to the general population.
    </Primary_outcome>
    <Secondary_outcome>To compare nutritional outcomes of children who were enrolled in the PDC to children who did not receive PDC services and to the general population.
    </Secondary_outcome>
    <Secondary_ID>222
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Grand Challenges Canada
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>8261149
    </Internal_Number>
    <TrialID>ISRCTN82438662
    </TrialID>
    <Last_Refreshed_on>29 July 2019
    </Last_Refreshed_on>
    <Public_title>Long run effects of early life growth faltering: a retrospective analysis of 847 birth cohorts in low- and middle-income countries
    </Public_title>
    <Scientific_title>Long run effects of early life growth faltering: a retrospective analysis of 847 birth cohorts in low- and middle-income countries                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
    </Scientific_title>
    <Primary_sponsor>Boston University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20171005
    </Date_registration3>
    <Date_registration>05/10/2017
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN82438662
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/01/1985
    </Date_enrollement>
    <Target_size>211318
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational cross-sectional cohort study (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Burkina Faso;Cameroon;Colombia;Cote d'Ivoire;Dominican Republic;Egypt;Ghana;Haiti;Jordan;Kenya;Madagascar;Malawi;Mali;Nepal;Niger;Nigeria;Pakistan;Peru;Rwanda;Senegal;Tanzania;Uganda;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: 211,318 adults who born between 1985 and 1995 across 34 DHS surveys that were conducted between 2006 and 2014 in 24 low- and middle-income countries
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Missing income data
    </Exclusion_Criteria>
    <Condition>Early life growth faltering (height and stunting at childhood) &lt;br&gt;Not Applicable
    </Condition>
    <Intervention>&lt;br&gt;                All available anthropometric data collected through the Demographic and Health Surveys (DHS) is combined to construct country-region measures of early childhood exposure to growth faltering, and this dataset is used to quantify the long-term outcomes of cohort-level changes in early life environments. The final analytic sample consists of 211,318 adult records across 34 DHS surveys that were conducted between 2006 and 2014 in 24 low- and middle-income countries.&lt;br&gt;&lt;br&gt;                Data from the Demographic and Health Surveys were used to compute average height-for-age z-scores for children under age 5 at the country-region and birth cohort level. The cohort measures of early life growth were then linked to adult height and educational attainment. The primary exposure of interest was population-level early life growth faltering, with adult height and adult educational attainment as primary outcomes. Multivariable linear regression models were used to estimate the associations between adult outcomes and population-level measures of early life linear growth.&lt;br&gt;
    </Intervention>
    <Primary_outcome>&lt;br&gt;                1. Adult height, measured by reported height in adulthood, taken from DHS surveys conducted between 2006 and 2014&lt;br&gt;                2. Educational attainment, measured by the highest educational grade completed, taken from DHS surveys conducted between 2006 and 2014&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>No secondary outcome measures
    </Secondary_outcome>
    <Secondary_ID>IRB16-0515
    </Secondary_ID>
    <Source_Support>Boston University
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1990
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>This study obtained a human subjects exemption from the institutional review board at Harvard University,  05/04/2016, protocol number IRB16-0515. Only de-identified data were obtained from the Demographic and Health (DHS) survey program at https://dhsprogram.com/
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_completed>28/09/2017
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12447719
    </Internal_Number>
    <TrialID>NCT03303963
    </TrialID>
    <Last_Refreshed_on>15 August 2022
    </Last_Refreshed_on>
    <Public_title>DIAgnostics for Multidrug Resistant Tuberculosis in Africa
    </Public_title>
    <Scientific_title>Culture Free Diagnosis and Follow-up of Multidrug Resistant Tuberculosis Patients
    </Scientific_title>
    <Acronym>DIAMA
    </Acronym>
    <Primary_sponsor>Dissou AFFOLABI
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170924
    </Date_registration3>
    <Date_registration>24/09/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03303963
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 4, 2017
    </Date_enrollement>
    <Target_size>2840
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Belgium;Benin;Cameroon;Congo, The Democratic Republic of the;Ethiopia;Guinea;Mali;Nigeria;Rwanda;Senegal;Belgium;Benin;Cameroon;Congo, The Democratic Republic of the;Ethiopia;Guinea;Mali;Nigeria;Rwanda;Senegal
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Dissou AFFOLABI, MD, MSc, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Laboratoire de Référence des Mycobactéries
    </Contact_Affiliation>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11636812
    </Internal_Number>
    <TrialID>CTRI/2017/09/009894
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Heat therapy(agnikarma) in Tennis Elbow
    </Public_title>
    <Scientific_title>An Open Label Comparative Clinical Study to assess the Efficacy of Agnikarma in Snayugatavata Treatment Protocol with Agnikarma Alone in Tennis Elbow                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>AMRITA SCHOOL OF AYURVEDA
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170922
    </Date_registration3>
    <Date_registration>22-09-2017
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=16586
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>11-11-2016
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized, Parallel Group, Active Controlled Trial&lt;br&gt;  Method of generating randomization sequence:Coin toss, Lottery, toss of dice, shuffling cards etc  Method of allocation concealment:Case Record Numbers  Blinding and masking:Open Label
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;Andorra;Angola;Antigua and Barbuda;Argentina;Armenia;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bhutan;Bolivia;Bosnia and Herzegovina;Botswana;Brazil;Brunei Darussalam;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Central African Republic;Chad;Chile;China;Colombia;Comoros;Congo;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Cyprus;Czech Republic;Democratic People's Republic of Korea;Democratic Republic of the Congo;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Fiji;Finland;France;Gabon;Gambia;Georgia;Germany;Ghana;Greece;Grenada;Guatemala;Guinea;Guinea-Bissau;Guyana;Haiti;Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran (Islamic Republic of);Iraq;Ireland;Israel;Italy;Jamaica;Japan;Jordan;Kazakhstan;Kenya;Kiribati;Kuwait;Kyrgyzstan;Lao People's Democratic Republic;Latvia;Lebanon;Lesotho;Liberia;Libyan Arab Jamahiriya;Lithuania;Luxembourg;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Mauritania;Mauritius;Mexico;Micronesia (Federated States of);Monaco;Mongolia;Montenegro;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norway;Oman;Other;Pakistan;Palau;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Republic of Moldova;Romania;Russian Federation;Rwanda;Saint Kitts and Nevis;Saint Lucia;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia ;Seychelles;Sierra Leone;Singapore;Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;Spain;Sri Lanka;Sudan;Suriname;Swaziland;Sweden;Switzerland;Syrian Arab Republic;Taiwan;Tajikistan;Thailand;The former Yugoslav Republic of Macedonia;Timor-Leste;Togo;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United Republic of Tanzania;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela (Bolivarian Republic of);Viet Nam;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Dr Lakshmy C Senan
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Amrita School of Ayurveda,Amrita Viswavidyapeetham
Vallikavu, Clappana PO, Kollam, Kerala, India, PIN- 690525 
    </Contact_Address>
    <Contact_Email>drrabi73@gmail.com
    </Contact_Email>
    <Contact_Tel>9567554883
    </Contact_Tel>
    <Contact_Affiliation>AMRITA SCHOOL OF AYURVEDA
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1.Patients  selected irrespective of sex, religion, Occupation, socioeconomic status etc &lt;br/ &gt;&lt;br&gt;2.Diagnosis on the basis of signs and symptoms found in Tennis elbow like  &lt;br/ &gt;&lt;br&gt;3.Pain on the outer side of the elbow jt.  &lt;br/ &gt;&lt;br&gt;4.Radiation of pain from elbow to forearm or hand.  &lt;br/ &gt;&lt;br&gt;5.Tenderness over the lateral epicondyle  &lt;br/ &gt;&lt;br&gt;6.Weak grip so that there is Inability to do daily routine work  &lt;br/ &gt;&lt;br&gt;7.Pricking sensation  &lt;br/ &gt;&lt;br&gt;8.Cozenâ??s test positive[13] &lt;br/ &gt;&lt;br&gt;9.Millâ??s maneuver positive[14] &lt;br/ &gt;&lt;br&gt;10.Patient who are willing to undergo trial, are only registered.  &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria:  &lt;br/ &gt;&lt;br&gt;1.Patients not willing to undergo trial.  &lt;br/ &gt;&lt;br&gt;2.Patients below 20 years and above 60 years of age. &lt;br/ &gt;&lt;br&gt;3.Pregnant women. &lt;br/ &gt;&lt;br&gt;4.Patients having joint disorders (viz. RA, OA, GA of elbow joint), Tuberculosis, Diabetes or having associated some other constitutional disorders etc &lt;br/ &gt;&lt;br&gt;5.Malignant tumors, senile osteoporosis etc in and around the elbow region. &lt;br/ &gt;&lt;br&gt;6.Patients associated with Golferâ??s elbow, Olecranon bursitis, Radial tunnel syndrome etc. &lt;br/ &gt;&lt;br&gt;7.Patients with history of compound fracture, Pathological fracture, non united fracture and mal-united fracture of complaining limb  &lt;br/ &gt;&lt;br&gt;8.Agnikarma anarhas &lt;br/ &gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Health Condition 1: null- tennis elbow patients

    </Condition>
    <Intervention>Intervention1: thermal cauterization&lt;br&gt;: 1.AGNIKARMA(thermal cauterization/ application of heat energy over the specific site)&lt;br&gt;&lt;br&gt;&lt;br&gt;Control Intervention1: upanaha,pichu,agnikarma: 1. upanaha-12 hourly bandage with hot medicated paste of kottamchukkadichoorna, kottamchukkadi taila, saindhava and dhanyamla&lt;br&gt;&lt;br&gt;2.pichu- oil applied over cotton in a localized area&lt;br&gt;&lt;br&gt;3. agnikarma-(thermal cauterization/ application of heat energy over the specific site)&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>1.Pain on the outer side of the elbow joint assessed by Visual Analogue Scale.  &lt;br/ &gt;&lt;br&gt;2. Radiation of pain towards forearm or hand.  &lt;br/ &gt;&lt;br&gt;3. Restricted range of movements. &lt;br/ &gt;&lt;br&gt;4. Pricking sensation  &lt;br/ &gt;&lt;br&gt; &lt;br/ &gt;&lt;br&gt; OBJECTIVE CRITERIA: &lt;br/ &gt;&lt;br&gt;1. Tenderness over the lateral epicondyle &lt;br/ &gt;&lt;br&gt;2. Cozenâ??s test positive &lt;br/ &gt;&lt;br&gt;3. Millâ??s maneuver positive &lt;br/ &gt;&lt;br&gt;Timepoint: Periodic observation will be done on 0th day, 8th day, 15 th, 30 th, and 90 th day.
    </Primary_outcome>
    <Secondary_outcome>recurrenceTimepoint: within 90 days
    </Secondary_outcome>
    <Secondary_ID>NIL
    </Secondary_ID>
    <Source_Support>Amrita School OF Ayurveda,
Amrita Vishwa Vidyapeetam,
Vallikavu,
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>20/06/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Amrita Institute of Medical Science-Institutional Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11636484
    </Internal_Number>
    <TrialID>CTRI/2017/08/009566
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Investigation of effect of clot preventing drugs such as Rivaroxaban, Vitamin K Antagonists and Aspirin on prevention of stroke in patients having Rheumatic Heart Disease along with irregularity of heart rhythm (Atrial Fibrillation).
    </Public_title>
    <Scientific_title>INVestIgation of rheumatiC AF Treatment Using vitamin K antagonists, rivaroxaban or aspirin Studies - INVICTUS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Population Health Research Institute
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170831
    </Date_registration3>
    <Date_registration>31-08-2017
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13588
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>01-07-2016
    </Date_enrollement>
    <Target_size>6500
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized, Parallel Group, Active Controlled Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Open Label
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Angola;Botswana;Brazil;Cameroon;China;Egypt;Ethiopia;Guatemala;India;Kazakhstan;Kenya;Kyrgyzstan;Mauritius;Mozambique;Namibia;Nigeria;Pakistan;Paraguay;Philippines;Rwanda;South Africa;Sudan;Uganda;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Dr G Krthikeyan
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Room. No. 24, 7th Floor, Cardio-Thoracic Sciences Center, AIIMS, New Dlehi 
    </Contact_Address>
    <Contact_Email>karthik2010@gmail.com
    </Contact_Email>
    <Contact_Tel>011-26594464
    </Contact_Tel>
    <Contact_Affiliation>All India Institute of Medical Scinces
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Non-Inferiority Trial: &lt;br/ &gt;&lt;br&gt;1. RVHD diagnosed by echocardiography at any time prior to enrollment &lt;br/ &gt;&lt;br&gt;2. Age â?¥18 &lt;br/ &gt;&lt;br&gt;3. Increased risk of stroke by any of the following &lt;br/ &gt;&lt;br&gt;a) CHA2DS2-VASc score â?¥ 2 OR &lt;br/ &gt;&lt;br&gt;b) Moderate/Severe mitral stenosis with valve area â?¤2.0 cm2 OR &lt;br/ &gt;&lt;br&gt;c) Left atrial spontaneous echo contrast OR &lt;br/ &gt;&lt;br&gt;d) Left atrial thrombus &lt;br/ &gt;&lt;br&gt;4. Heart Rhythm &lt;br/ &gt;&lt;br&gt;a) AF or Flutter should be documented on baseline 12-lead ECG, or on a &lt;br/ &gt;&lt;br&gt;previous 12-lead ECG, Holter monitor, in-hospital ECG rhythm strip or &lt;br/ &gt;&lt;br&gt;Pacemaker or ICD electrogram. &lt;br/ &gt;&lt;br&gt; &lt;br/ &gt;&lt;br&gt;Superiority Trial &lt;br/ &gt;&lt;br&gt;1. RVHD diagnosed by echocardiography at any time prior to enrollment &lt;br/ &gt;&lt;br&gt;2. Age â?¥18 &lt;br/ &gt;&lt;br&gt;3. Increased risk of stroke by any of the following &lt;br/ &gt;&lt;br&gt;a) CHA2DS2-VASc score â?¥ 2 OR &lt;br/ &gt;&lt;br&gt;b) Moderate/Severe mitral stenosis with valve area â?¤2.0 cm2 OR &lt;br/ &gt;&lt;br&gt;c) Left atrial spontaneous echo contrast OR &lt;br/ &gt;&lt;br&gt;d) Left atrial thrombus &lt;br/ &gt;&lt;br&gt;4. Heart Rhythm &lt;br/ &gt;&lt;br&gt;a) AF or Flutter and unsuitable for VKA therapy. (AF or Flutter should be &lt;br/ &gt;&lt;br&gt;documented on baseline 12-lead ECG, or on a previous 12-lead ECG, &lt;br/ &gt;&lt;br&gt;Holter monitor, in-hospital ECG rhythm strip or Pacemaker or ICD &lt;br/ &gt;&lt;br&gt;electrogram) OR &lt;br/ &gt;&lt;br&gt;b) In the absence of AF or Flutter, patients would be eligible in the presence &lt;br/ &gt;&lt;br&gt;of any one of the following: &lt;br/ &gt;&lt;br&gt;a. Left atrial enlargement â?¥5.5 cm OR &lt;br/ &gt;&lt;br&gt;b. Left atrial spontaneous echo contrast OR &lt;br/ &gt;&lt;br&gt;c. Left atrial thrombus OR &lt;br/ &gt;&lt;br&gt;d. Frequent ectopic atrial activity ( &gt;1000/24 hours) on Holter monitoring
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: For both Non-inferiority and Superiority trials: &lt;br/ &gt;&lt;br&gt;1. Refusal to consent &lt;br/ &gt;&lt;br&gt;2. Actively involved in any study that would compromise the protocol of &lt;br/ &gt;&lt;br&gt;INVICTUS Trial &lt;br/ &gt;&lt;br&gt;3. Severe co-morbid condition with life expectancy  &lt; 1 year &lt;br/ &gt;&lt;br&gt;4. Other serious condition(s) or logistic factors likely to interfere with study &lt;br/ &gt;&lt;br&gt;participation or with the ability to complete the trial, as appropriate to country &lt;br/ &gt;&lt;br&gt;or region. &lt;br/ &gt;&lt;br&gt;5. Likely to have valve replacement surgery within 6 months &lt;br/ &gt;&lt;br&gt;6. Mechanical valve prosthesis or other condition requiring treatment with VKAs. &lt;br/ &gt;&lt;br&gt;Patients with deep vein thrombosis or recent pulmonary embolism can be &lt;br/ &gt;&lt;br&gt;enrolled where both VKAs and rivaroxaban are approved. &lt;br/ &gt;&lt;br&gt;7. Contraindication to the study medication of the trial &lt;br/ &gt;&lt;br&gt;a. Allergy to rivaroxaban &lt;br/ &gt;&lt;br&gt;b. Allergy to VKAs ( non-inferiority trial) &lt;br/ &gt;&lt;br&gt;c. Allergy to aspirin ( superiority trial) &lt;br/ &gt;&lt;br&gt;8. Severe renal insufficiency with an calculated creatinine clearance (Cockcroft- &lt;br/ &gt;&lt;br&gt;Gault)  &lt; 15 ml/min &lt;br/ &gt;&lt;br&gt;9. Serious bleeding in the past six months or at high risk for bleeding &lt;br/ &gt;&lt;br&gt;10. Moderate to severe hepatic impairment &lt;br/ &gt;&lt;br&gt;11. Ongoing need for dual antiplatelet therapy (patients with on-going aspirin &lt;br/ &gt;&lt;br&gt;therapy â?¤100 mg per day are not excluded). &lt;br/ &gt;&lt;br&gt;12. Ongoing need for dual strong inhibitors of CYP-3a4 or p-glycoprotein &lt;br/ &gt;&lt;br&gt;inhibitor. &lt;br/ &gt;&lt;br&gt;13. Received an investigational drug in the past 30 days &lt;br/ &gt;&lt;br&gt;14. Patients considered unsuitable for trial inclusion because of unwillingness to &lt;br/ &gt;&lt;br&gt;attend follow up visits &lt;br/ &gt;&lt;br&gt;15. Women who are pregnant and/or breastfeeding &lt;br/ &gt;&lt;br&gt;16. Women of child bearing age who do not use an effective form of birth control.
    </Exclusion_Criteria>
    <Condition>Health Condition 1: null- Rheumatic Valvular Heart Disease with either atrial fibrillation or high risk of stroke.

    </Condition>
    <Intervention>Intervention1: Rivaroxaban: Oral Rivaroxaban 20 mg daily (in Non-inferiority Trial) for the duration of the study (four years),&lt;br&gt;Oral Rivaroxaban 15 mg daily (in Superiority Trial) for the duration of the study (four years)&lt;br&gt;Control Intervention1: Vitamin K Antagonists (such as Warfarin and Acenocoumarol): Once daily Oral Vitamin K Antagonists for the duration of the study (four years). The dose varies from patient to patient and time to time for the same patient to achieve PT INR range 2 to 3&lt;br&gt;Control Intervention2: Aspirin: Oral Aspirin 75 to 100 mg once daily (in Superiority trial) for the duration of the study (four years)&lt;br&gt;
    </Intervention>
    <Primary_outcome>1) Stroke(ischemic, hemorrhagic or undetermined type) &lt;br/ &gt;&lt;br&gt;2) Systemic embolismTimepoint: At first one month follow-up, and then every at six month follow-up there after , till four years from randomization.
    </Primary_outcome>
    <Secondary_outcome>Myocardial infarction &lt;br/ &gt;&lt;br&gt;- Hospitalization &lt;br/ &gt;&lt;br&gt;- Vascular death &lt;br/ &gt;&lt;br&gt;- Total Death &lt;br/ &gt;&lt;br&gt;- Composite of stroke, myocardial infarction, systemic embolism, vascular deathTimepoint: At first one month follow-up, and then every at six month follow-up there after , till four years from randomization.;Safety Outcomes:  &lt;br/ &gt;&lt;br&gt;Major Bleeding (ISTH definition) &lt;br/ &gt;&lt;br&gt;Minor bleedingTimepoint: At first one month follow-up, and then every at six month follow-up there after , till four years from randomization.
    </Secondary_outcome>
    <Secondary_ID>NIL
    </Secondary_ID>
    <Source_Support>Population Health Research Institute (PHRI)
Hamilton General Hospital Campus, DBCVSRI
237 Barton Street East
Hamilton, Ontario, Canada L8L 2X2
    </Source_Support>
    <Ethics_review_status>Not Approved;Not Approved;Not Approved;Not Approved;Not Approved;Approved;Approved;Approved;Not Approved;Approved;Not Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;01/01/1900;01/01/1900;01/01/1900;01/01/1900;18/01/2016;16/08/2017;01/06/2017;01/01/1900;25/04/2017;01/01/1900;25/04/2017;10/02/2017;28/04/2017
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;;;;;;;;;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethics Committee , Indira Gandhi Medical College, Shimla;Ethics Committee , SMS Medical College &amp; Attached Hospital;Ethics Committee Command Hospital (Air Force);Ethics Committee Silver, CMC Vellore;Institute Ethics Committee (Human Studies) IGMC &amp; RI;Institute Ethics Committee All India Institute of Medical Sciences;Institute Ethics Committee, Dr. RML Hospital;Institutional Ethics Committee;Institutional Ethics Committee I &amp; II, Seth GS Medical College and KEM Hospital;Institutional Ethics Committee PGI, Chandigarh;Institutional Ethics committee, JIPMER;Institutional Ethics Committee, MAMC;King Georges Medical University, Institutional Ethics Committee;SriJayadeva Institute Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;;;;;;;;;;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;;;;;;;;;;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>8681476
    </Internal_Number>
    <TrialID>ISRCTN89017827
    </TrialID>
    <Last_Refreshed_on>6 January 2020
    </Last_Refreshed_on>
    <Public_title>Wasting and stunting in young children in developing countries
    </Public_title>
    <Scientific_title>Children who are both wasted and stunted are also underweight and have a high risk of death – policy implications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Emergency Nutrition Network
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170821
    </Date_registration3>
    <Date_registration>21/08/2017
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN89017827
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/01/1992
    </Date_enrollement>
    <Target_size>1796991
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational cross-sectional study (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;American Samoa;Angola;Bahrain;Bangladesh;Benin;Burkina Faso;Burundi;Cambodia;Cameroon;Cape Verde;Central African Republic;Chad;Congo;Congo, Democratic Republic;Cote d'Ivoire;Djibouti;Ecuador;Equatorial Guinea;Eritrea;Ethiopia;Gabon;Gambia;Ghana;Guinea-Bissau;Haiti;India;Indonesia;Kenya;Laos;Lesotho;Liberia;Madagascar;Malawi;Mali;Mauritania;Mozambique;Myanmar;Namibia;Nepal;Niger;Nigeria;Pakistan;Rwanda;Senegal;Sierra Leone;Somalia;South Sudan;Sudan;Tajikistan;Tanzania;Timor-Leste;Uganda;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. 6-59 month old children&lt;br&gt;                2. Males and females&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Children over 59 months of age
    </Exclusion_Criteria>
    <Condition>Nutrition &lt;br&gt;Nutritional, Metabolic, Endocrine
    </Condition>
    <Intervention>A database of cross-sectional survey datasets containing data for almost 1.8 million children was compiled. This was analysed to determine the intersection between sets of wasted, stunted, and underweight children; the association between being wasted and being stunted; the severity of wasting and stunting in WaSt children; and the prevalence of WaSt by age and sex. An additional analysis of the WHO Growth Standards sought the maximum possible weight-for-age z-score for WaSt children.
    </Intervention>
    <Primary_outcome>Overlap between wasted, stunted and underweight children as measured by &lt;-2SD WHZ, HAZ, WAZ
    </Primary_outcome>
    <Secondary_outcome>Degree of concurrence i.e. &lt;-2SDWHZ AND ,-2SDHAZ in children and by age (6-59 months) and by sex (male/female) 
    </Secondary_outcome>
    <Secondary_ID>N/A
    </Secondary_ID>
    <Source_Support>United States Agency for International Development, 295 Grant Number: ENN AID-OFDA-G-15-00190 , Irish Aid
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1990
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>This is an observational study so does not need ethical approval. All data was anonymous and was secondary and readily available for further analysis. There were no human or animal subjects.
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/12/2015
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10303910
    </Internal_Number>
    <TrialID>NCT03595852
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Antibiotic Prophylaxis in Clean Surgery. Impact on Surgical Site Infection
    </Public_title>
    <Scientific_title>Preoperative Antibiotic Prophylaxis Versus Placebo in Clean, Non-prosthetic Surgery at CHUK. Impact on Surgical Site Infections and Patient Cost.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Rwanda
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170803
    </Date_registration3>
    <Date_registration>03/08/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03595852
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 1, 2018
    </Date_enrollement>
    <Target_size>138
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Health Services Research. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>FAUSTIN NTIRENGANYA, MMed, FCS
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>fostino21@yahoo.fr
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  - All elective non-prosthetic surgical procedures such as hernia, thyroid, hydrocele,&#x0D;&lt;br&gt;             undescended testes surgery, removal of orthopedic implants, low risk breast surgical&#x0D;&lt;br&gt;             procedures and other all procedures deemed to be clean.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  - Emergency cases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any patient with American Society of Anesthesiologists Score (ASA)&gt;2&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Procedures lasting more than 2 hours&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who were taking antibiotics 2 days prior to operation&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Surgical Site Infection
    </Condition>
    <Intervention>Drug: Cefazolin;Drug: Placebos
    </Intervention>
    <Primary_outcome>Surgical site infection
    </Primary_outcome>
    <Secondary_outcome>mortality;morbidity
    </Secondary_outcome>
    <Secondary_ID>1234
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>7971756
    </Internal_Number>
    <TrialID>ISRCTN13633207
    </TrialID>
    <Last_Refreshed_on>29 April 2019
    </Last_Refreshed_on>
    <Public_title>Effect of immunitum supplementation on prevention of recurrent infectious episodes in children with moderate malnutrition: a randomised, double-blind, placebo-controlled trial
    </Public_title>
    <Scientific_title>Effect of immunitum supplementation on prevention of recurrent infectious episodes in children (aged 12 - 59 months) with moderate malnutrition: a randomised, double-blind, placebo-controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>Foundation Actigenomics
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170704
    </Date_registration3>
    <Date_registration>04/07/2017
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN13633207
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>24/09/2012
    </Date_enrollement>
    <Target_size>220
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomised double-blind placebo-controlled trial (Prevention)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Children aged 12 to 59 months&lt;br&gt;                2. Moderate malnutrition as per WHO criteria&lt;br&gt;                3. History of recurrent infectious episodes of upper and lower respiratory tract and gastrointestinal tract&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Children aged less than 12 months and 60 months and over&lt;br&gt;                2. Suffering from severe malnutrition (MUAC&lt;115 mm et W/A = - 3 Z Score et H/A = - 3 Z Score)&lt;br&gt;                3. Suffering from a progressive disease (Tuberculosis, HIV)&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>
                Recurrent infectious diseases in children with malnutrition:
                1. ENT sphere infections
                2. Broncho-pulmonary infections
                3. Gastrointestinal tract infections
                4. Malaria
 &lt;br&gt;Infections and Infestations &lt;br&gt;
                1. ENT sphere infections
                2. Broncho-pulmonary infections
                3. Gastrointestinal tract infections
                4. Malaria
            
    </Condition>
    <Intervention>&lt;br&gt;                Participants are randomly allocated to one of two groups using a 1:1 randomisation at the time of enrolment to allocate five participants in each arm for every round of ten enrollments. The study is double-bling, with the study and control products being indistinugishable in shape, size, colour and taste. They are pre-labeled for the entire study by a third-party person who does not play a role in the study implementation.&lt;br&gt;&lt;br&gt;                Group 1: Participants in this group receive an oral capsule of immunitum twice daily.&lt;br&gt;&lt;br&gt;                Group 2: Participants receive the placebo oral capsule which is taken twice daily.&lt;br&gt;&lt;br&gt;                Participants in both groups receive the treatment for 12 months. Clinical follow up and study visits are the same for both groups, with the study product given at the time of enrollment and randomisation and then participants are seen monthly for a clinical follow-up, nutritional status and treatment compliance until month 12.&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>&lt;br&gt;                1. Incidence of infectious diseases (e.g., ENT sphere infections, broncho-pulmonary infections, gastrointestinal tract infections, and malaria) common in children (12-59 months) with moderate malnutrition as defined by WHOis assessed by a trained general medical doctor with experience in pediatric case management in district hospitals (supervised daily and closely by an experienced pediatrician) Each enrolled participant was discussed together at her arrival at health center, on regular appointments, and every time a family called saying that the child has a health problem. In addition, when recruited children arrived to health centers, they were seen by a trained nurse working regularly in PCIME or IMCI (Integrated Management of Childhood Illness), who records the case in a dedicated register and reported the case immediately on phone when urgent or complicated situations. Otherwise the case was reported to the study team during the following monthly visit.&lt;br&gt;                2. Severity and length (in days) of each infectious episode is measured by the medical doctor who is assigned to see participants from the beginning of the disease and follow participant till the end of episode of the disease. Symptoms notified at the beginning are verified every day by a community health worker who see the participant twice a day for giving the immunitum/placebo and asks questions about the signs and symptoms of the disease at each visit then records in the trial notebook which is presented to the medical doctor at the regular visit at the health center or for severe cases at the district hospital, when the child is hospitalized.&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Weight and height are measured using standard anthropomorphic techniques at health center during each monthly visit for 12 months&lt;br&gt;                2. General vitality is assessed using the general vitality questionnaire that measures apathy, sleep, feeding and fatigue; at health center during each monthly visit for 12 months&lt;br&gt;                3. Tolerance and compliance is assessed by the assigned community health worker at home, and then by the study team at health center during each monthly visit for 12 months&lt;br&gt;                4. Proteinemia is measured using spectrophotometry, transferrin is measured by turbidimetry, CRP is measured by ELISA, blood sugar is measured by spectrometry, hemoglobin is measured by spectrometry, erythrocyte sedimentation rate, RBC, WBC, thick blood smear, HIV, stool (for parasites and culture when child has diarrhea, one of the stool sample taken at 12 months will be analysed for microbiome composition) are measured using sample analysis by specific lab techniques for each lab exam and following well defined lab protocols at baseline, six and 12 months&lt;br&gt;                5. Levels of vitamins A, B1, B2, B9, B12, C, D, E, PP are measured using high-performance liquid chromatography at baseline, six and 12 months&lt;br&gt;                6. Levels of iodine will be determined by mass spectrometry, sodium, potassium and chlorine by ion-selective electrode (ISE), selenium by atomic absorption spectroscopy, zinc by atomic absorption spectrophotometry, and iron by spectrophotometric assay at baseline, six and 12 months&lt;br&gt;                7. Genomic analyses will be done by single nucleotide polymorphism and proteomics by electrophoresis at baseline, six and 12 months&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>RPA0001
    </Secondary_ID>
    <Source_Support>Actigenomics SA, Africa Alive, Sucafina, Nutrigenomics, Renta 4
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1990
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Rwanda National Ethic Committee (RNEC), ref: 158/RNEC/2011
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>18/10/2013
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10276436
    </Internal_Number>
    <TrialID>NCT03184948
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Understanding Neonatal Jaundice in Rwanda
    </Public_title>
    <Scientific_title>Understanding Neonatal Jaundice in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of California, Merced
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170605
    </Date_registration3>
    <Date_registration>05/06/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03184948
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 29, 2017
    </Date_enrollement>
    <Target_size>46
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Health Services Research. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Ketki Sheth, PhD;Lisine Tuysenge, MD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>University of California, Merced;Rwanda Pediatric Association
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For patient level record (de-identified), diagnosed by the facility for having infant&#x0D;&lt;br&gt;             jaundice&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The facilities are included based on selection by the Ministry of Health for receiving&#x0D;&lt;br&gt;             additional phototherapy machines.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Jaundice, Neonatal
    </Condition>
    <Intervention>Device: Brilliance
    </Intervention>
    <Primary_outcome>Length of treatment for infant jaundice;Length of hospital duration for infant jaundice
    </Primary_outcome>
    <Secondary_outcome>Increased rate of reduction in bilirubin;Improved Treatment of Jaundice;Improved Treatment of Jaundice By Not Being Referred Elsewhere;Improved Treatment of Jaundice by Receiving Phototherapy;Improved Treatment of Jaundice by Not Sharing Phototherapy;Improved Treatment of Jaundice by Using Single Phototherapy Device;Improved Treatment of Jaundice by Reducing Exchange Transfusions;Improved Treatment of Jaundice by Not Meeting Threshold for Exchange Transfusion
    </Secondary_outcome>
    <Secondary_ID>FWA Assurance No: 00001973
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Rwanda Pediatric Association;Ministry of Health, Rwanda;Rwanda Bio-Medical Center;Child Relief International;D-Rev
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10274794
    </Internal_Number>
    <TrialID>NCT03154177
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Group Antenatal/Postnatal Care in Rwanda
    </Public_title>
    <Scientific_title>Group Antenatal/Postnatal Care in Rwanda: a Cluster Randomized Control Trial (RCT) to Measure Its Effectiveness on Increasing Gestational Age, Mortality Among Preterm and Low Birth Weight Infants
    </Scientific_title>
    <Acronym>PTBi Rwanda
    </Acronym>
    <Primary_sponsor>University of California, San Francisco
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170414
    </Date_registration3>
    <Date_registration>14/04/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03154177
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>13 Years
    </Inclusion_agemin>
    <Inclusion_agemax>64 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>May 15, 2017
    </Date_enrollement>
    <Target_size>26381
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Dilys Walker, MD;Sabine F Musange, MD, MSc
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>University of California, San Francisco;University of Rwanda
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Individual inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Women receiving ANC and PNC care&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  all women who enroll in ANC -including pregnant adolescents&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  primary data analysis will be restricted to those women in the intervention and&#x0D;&lt;br&gt;             control facilities who present for ANC 1 before 24 weeks gestation and have attended&#x0D;&lt;br&gt;             more than 1 ANC visit at the health facility.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Providers • Currently provide antenatal or postnatal care&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Individual exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Women receiving ANC and PNC care&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  women who present for ANC 1 after 24 weeks gestation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  women who do not attend more than 1 ANC at the health facility will be excluded from&#x0D;&lt;br&gt;             the primary analysis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Providers&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        • Providers that do not provide antenatal or postnatal care&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Site-level exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        • sites that have less than 2 ANC providers.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Site-level inclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        • Study sites that have at least 2 ANC providers were included in the final selection of 36&#x0D;&lt;br&gt;        sites. The following are study sites by district:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Nyamasheke District Nyamasheke Kibingo Mugera Mwezi Karengera Kibogora Gisakura Yove&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Nyarugenge District Cor-unum Biryogo Rugarama Kabusunzu&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Rubavu District Murara Nyakiriba Busasamana Karambo Gisenyi Kigufi Mudende&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Bugesera District Ruhuha Gakurazo Gashora Ngeruka Kamabuye Nyamata Ntarama Juru Mayange&#x0D;&lt;br&gt;        Nzangwa Nyarugenge&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Burera District Cyanika Kirambo Ndongozi Gitare Gahunga Mucaca&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Pregnancy Complications;Preterm Birth;Preterm Labor;Stillbirth;Low Birth Weight;Neonatal Mortality
    </Condition>
    <Intervention>Behavioral: Group ANC/PNC;Procedure: Ultrasound+Pregnancy Testing
    </Intervention>
    <Primary_outcome>Gestational Age
    </Primary_outcome>
    <Secondary_outcome>Preterm birth rate;Preterm 28-day and 42-day mortality rate;Women who adhered to four ANC visits;Adherence to 6 week postnatal visit;1st ANC visit during the first trimester;High-risk Women;C-section deliveries;Newborns with neonatal morbidities, specifically, jaundice, rapid breathing, fever, pneumonia, hypothermia, and/or cord infection
    </Secondary_outcome>
    <Secondary_ID>A123218-Rw (UCSF RAS #)
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Rwanda;Rwanda Biomedical Center;Ministry of Health, Rwanda
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>6674685
    </Internal_Number>
    <TrialID>NCT03067519
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Fast Track Surgery for Abdominal Surgery in Rwanda
    </Public_title>
    <Scientific_title>Fast Track Surgery for Abdominal Surgery in Rwanda: a Randomized Controlled Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Rwanda
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170221
    </Date_registration3>
    <Date_registration>21/02/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03067519
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2015
    </Date_enrollement>
    <Target_size>62
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda;Rwanda;Rwanda;Rwanda;Rwanda
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>AHMED KISWEZI, MMed;AHMED KISWEZI, MMed;AHMED KISWEZI, MMed;AHMED KISWEZI, MMed;AHMED KISWEZI, MMed
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>University of Rwanda;University of Rwanda;University of Rwanda;University of Rwanda;University of Rwanda
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients admitted for elective abdominal surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients with comorbidity, American Society of Anesthesiologists score greater than 2&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients admitted for elective abdominal surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients with comorbidity, American Society of Anesthesiologists score greater than 2&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients admitted for elective abdominal surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients with comorbidity, American Society of Anesthesiologists score greater than 2&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients admitted for elective abdominal surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients with comorbidity, American Society of Anesthesiologists score greater than 2&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Elective Surgical Procedures;Elective Surgical Procedures;Elective Surgical Procedures;Elective Surgical Procedures
    </Condition>
    <Intervention>Other: Fast track surgery;Other: Conventional management;Other: Fast track surgery;Other: Conventional management;Other: Fast track surgery;Other: Conventional management;Other: Fast track surgery;Other: Conventional management
    </Intervention>
    <Primary_outcome>hospital stay;hospital stay;hospital stay
    </Primary_outcome>
    <Secondary_outcome>Major complications
    </Secondary_outcome>
    <Secondary_ID>URwanda
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11634712
    </Internal_Number>
    <TrialID>CTRI/2017/02/007794
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>A household intervention trial to study the effects of LPG stoves on women and childrenâ??s health
    </Public_title>
    <Scientific_title>Household Air Pollution and Health: A Multi-country LPG Intervention Trial - HAPIN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
    </Scientific_title>
    <Primary_sponsor>Sri Ramachandra University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170207
    </Date_registration3>
    <Date_registration>07-02-2017
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=16165
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>01-09-2017
    </Date_enrollement>
    <Target_size>7200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized, Parallel Group, Active Controlled Trial&lt;br&gt;  Method of generating randomization sequence:Permuted block randomization, variable  Method of allocation concealment:Centralized  Blinding and masking:Open Label
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Guatemala;India;Peru;Rwanda
    </Countries>
    <Contact_Firstname>G Thangavel
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Department of Environmental Health Engineering
Sri Ramachandra University Porur 
    </Contact_Address>
    <Contact_Email>kalpanasrmc@ehe.org.in
    </Contact_Email>
    <Contact_Tel/>
    <Contact_Affiliation>Sri Ramachandra University
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria:  &lt;20 weeks gestation confirmed by ultrasound &lt;br/ &gt;&lt;br&gt;Singleton pregnancy &lt;br/ &gt;&lt;br&gt;No fetal anomalies identified during first ultrasound &lt;br/ &gt;&lt;br&gt;Use biomass stove &lt;br/ &gt;&lt;br&gt;Not currently a smoker &lt;br/ &gt;&lt;br&gt;No plans to move out of her current household in next 30 months &lt;br/ &gt;&lt;br&gt;Agrees to participate with informed consent &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Lives in household that has LPG stove
    </Exclusion_Criteria>
    <Condition/>
    <Intervention>Intervention1: LPG: Liquefied petroleum gas (LPG) cookstove and gas supply 30 months.&lt;br&gt;&lt;br&gt;Delayed LPG cookstove and gas supply (end of study)&lt;br&gt;Intervention2: LPG: Liquefied petroleum gas (LPG) cookstove and gas supply 30 months&lt;br&gt;Intervention3: LPG: Liquefied petroleum gas (LPG) cook stove and gas supply&lt;br&gt;30 months&lt;br&gt;Control Intervention1: Traditional cook stove: Delayed LPG cookstove and gas supply (end of study)&lt;br&gt;
    </Intervention>
    <Primary_outcome>Low birth weight, Stunting, Pneumonia, HypertensionTimepoint: Outcome Name: low birth weight, Time-point: Up to 5 months (within 24 hours of birth) &lt;br/ &gt;&lt;br&gt;Outcome Name: stunting, Time point: 24months &lt;br/ &gt;&lt;br&gt;Outcome Name: pneumonia, Time points: weekly over 24 months &lt;br/ &gt;&lt;br&gt;Outcome Name: hypertension, Time point: 30 months &lt;br/ &gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>Maternal hypertension, Premature birth, Fetal growth, Gross motor development, Endothelial function (brachial artery reactivity test, â??BARTâ??; carotid intima-media thickness, â??CIMTâ??) and St. Georgeâ??s Respiratory Questionnaire score.Timepoint: Outcome Name: Maternal hypertension, Time-point: 5 months  &lt;br/ &gt;&lt;br&gt;Outcome Name: Premature birth, Time-point: 5 months &lt;br/ &gt;&lt;br&gt;Outcome Name: Fetal growth, Time-point: 5 months &lt;br/ &gt;&lt;br&gt;Outcome Name: Gross motor development, Time-point: 24 months &lt;br/ &gt;&lt;br&gt;Outcome Name: Endothelial function (brachial artery reactivity test, â??BARTâ??; carotid intima-media thickness, â??CIMTâ??), Time-point: 24 months &lt;br/ &gt;&lt;br&gt;Outcome Name: St. Georgeâ??s Respiratory Questionnaire score, Time-point: 24 months
    </Secondary_outcome>
    <Secondary_ID>NIL
    </Secondary_ID>
    <Source_Support>National Institutes of Health
9000 Rockville Pike
Bethesda, Maryland 20892
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>16/07/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Sri Ramachandra University IEC
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>30/09/2021
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10268962
    </Internal_Number>
    <TrialID>NCT03045809
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Women's Improvement of Sexual Health (WISH) Demonstration Project
    </Public_title>
    <Scientific_title>Improving HIV Prevention and Sexual and Reproductive Health Care in High Risk Women in Rwanda Using Lessons Learnt From Previous Rinda Ubuzima Projects
    </Scientific_title>
    <Acronym>WISH
    </Acronym>
    <Primary_sponsor>Janneke van de Wijgert
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170202
    </Date_registration3>
    <Date_registration>02/02/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03045809
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>July 5, 2016
    </Date_enrollement>
    <Target_size>705
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Janneke van de Wijgert, MD PhD MPH
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Liverpool
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Female, at least 18 years old (no upper age limit)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  At high risk of HIV/STIs, defined as having had more than one sexual partner in the&#x0D;&lt;br&gt;             last 12 months OR having been treated for an STI in the last 12 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing and able to provide written informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Already participated in this study before (each woman can only participate once)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participating in another health intervention study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For any other reason as judged by the Principal Investigator (these reasons will be&#x0D;&lt;br&gt;             recorded)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Sexually Transmitted Disease;Bacterial Vaginosis;Vaginal Candidiasis;Urinary Tract Infections
    </Condition>
    <Intervention>Diagnostic Test: Urogenital infection point-of-care tests
    </Intervention>
    <Primary_outcome>Feasibility of Integrating Point-of-care Testing (Monitoring &amp; Evaluation Indicators);Feasibility of Integrating Point-of-care Testing (Client Satisfaction Surveys);Performance of Syndromic Management With or Without Integration of Point-of-care Tests
    </Primary_outcome>
    <Secondary_ID>UoL001208
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Rinda Ubuzima, Rwanda;Institute of Tropical Medicine, Belgium
    </Secondary_Sponsor>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>11/09/2019
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT03045809
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10268215
    </Internal_Number>
    <TrialID>NCT03031431
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Electricity-free Infant Warmer for Newborn Thermoregulation in Rwanda
    </Public_title>
    <Scientific_title>Electricity-free Infant Warmer for Newborn Thermoregulation in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Boston Children's Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161213
    </Date_registration3>
    <Date_registration>13/12/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03031431
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>3 Months
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 2016
    </Date_enrollement>
    <Target_size>130
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Supportive Care. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Anne Hansen, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Boston Children's Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any infant with the following criteria for whom caregiver is not available for&#x0D;&lt;br&gt;             Kangaroo Mother Care, or Kangaroo Mother Care is not adequate (less than ½ degree&#x0D;&lt;br&gt;             Celsius per hour rise in temperature).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. axillary temperature &lt; 36 degrees C and =35 degrees C 1a) If an electric warmer&#x0D;&lt;br&gt;                  is available and the infant's temperature is &lt; 35 degrees C, then the infant&#x0D;&lt;br&gt;                  would start by being warmed on the electric warmer until the infant's temperature&#x0D;&lt;br&gt;                  reaches 36 degrees C, then can start non-electric infant warmer use&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Infants at-risk for hypothermia (criteria: estimated post-menstrual age of &lt; 35&#x0D;&lt;br&gt;                  weeks or current body weight of &lt; 2.5 kg)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Any infant whose family is unwilling to consent to study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Mothers who are critically ill at the time of infant eligibility or deemed not&#x0D;&lt;br&gt;             medically stable by nursing staff to be approached for consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Any infant with a contraindication to Kangaroo Mother Care (medical instability) and&#x0D;&lt;br&gt;             electrical heating source available.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Any infant with initial temperature &lt; 35 degrees C and electrical heating source&#x0D;&lt;br&gt;             available.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Infants within the first hour of admission to neonatal unit or first hour of life in&#x0D;&lt;br&gt;             maternity.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Infants requiring phototherapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Infants with significant skin condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Infants with Hypoxic Ischemic Encephalopathy (HIE)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Stopping Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        If an electric heating source is available, the infant will be taken off the study and&#x0D;&lt;br&gt;        warmed with an appropriate source of electric heat if the infant:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Is hypothermic and temperature decreases on any measurement&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Is hypothermic and temperature does not begin to rise within 30 minutes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Is hypothermic and not heating at a rate of &gt; ½ degree C per hour until temperature is&#x0D;&lt;br&gt;             &gt;36.5 degrees C&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Has a temperature that falls below 36 degrees C despite maximum exposure to the heat&#x0D;&lt;br&gt;             source&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Is ever considered to be too severely ill by the medical team to be safely cared for&#x0D;&lt;br&gt;             in the non-electric infant warmer.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. The warmer will be removed once its temperature drops below 36 degrees, and/or the&#x0D;&lt;br&gt;             phase change material begins to harden.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hypothermia Neonatal
    </Condition>
    <Intervention>Device: Non-Electric Infant Warmer
    </Intervention>
    <Primary_outcome>Temperature/Effectiveness
    </Primary_outcome>
    <Secondary_outcome>Usability;Functionality;Qualitative Survey
    </Secondary_outcome>
    <Secondary_ID>IRB-P00016205
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Ministry of Health, Rwanda;Rwandan Biomedical Counsel (RBC);Harvard Medical School;Institute for Transformative Technologies (ITT);Brigham and Women's Hospital;Partners in Health
    </Secondary_Sponsor>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>13/01/2020
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT03031431
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11398186
    </Internal_Number>
    <TrialID>NCT02964091
    </TrialID>
    <Last_Refreshed_on>27 September 2021
    </Last_Refreshed_on>
    <Public_title>Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World
    </Public_title>
    <Scientific_title>Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World
    </Scientific_title>
    <Acronym>SHARED
    </Acronym>
    <Primary_sponsor>Partners in Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161103
    </Date_registration3>
    <Date_registration>03/11/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02964091
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2016
    </Date_enrollement>
    <Target_size>300
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Neil Gupta, MD;Jules Kabahizi, MD;Aimable Mbituyumuremyi, MD;Philip Grant, MD;Claude M Muvunyi, MD
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>Partners in Health;Rwanda Military Hospital;Rwanda Biomedical Center;Stanford University;University of Rwanda
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients that are willing and able to provide written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age = 18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HCV RNA = 103 IU/mL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HCV genotype 1 or 4&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  screening ultrasound excluding hepatocellular carcinoma (HCC)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  acceptable laboratory values (hemoglobin =8.0 g/dL, platelet count =40,000/mm3; AST,&#x0D;&lt;br&gt;             ALT, and alkaline phosphatase =10 × ULN; creatinine clearance =30 mL/min)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  general good health&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ability to comply with study procedures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV-infected patients must have completed at least 6 months of any approved HIV&#x0D;&lt;br&gt;             antiretroviral therapy (ART) per Rwanda National Guidelines 2013, have been taking for&#x0D;&lt;br&gt;             at least 2 weeks prior to screening ART compatible with SOF/LDV (efavirenz,&#x0D;&lt;br&gt;             rilpivirine, raltegravir, dolutegravir, emtricitabine, lamivudine, zidovudine,&#x0D;&lt;br&gt;             tenofovir), have screening HIV RNA &lt; 200 copies/mL, and have screening CD4 T-cell&#x0D;&lt;br&gt;             count of =100 cells/µL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  current or history of clinical hepatic decompensation (i.e., ascites, encephalopathy&#x0D;&lt;br&gt;             or variceal hemorrhage)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  active tuberculosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  other clinically-significant illness (except HCV and/or HIV) or any other major&#x0D;&lt;br&gt;             medical disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  active Hepatitis B infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  difficulty with blood collection and/or poor venous access for the purposes of&#x0D;&lt;br&gt;             phlebotomy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  any IFN-containing regimen within 8 weeks prior to screening or any prior exposure to&#x0D;&lt;br&gt;             HCV-specific direct-acting antiviral agent (other than a NS3/4A protease inhibitor and&#x0D;&lt;br&gt;             SOF), current pregnancy or breastfeeding, and active drug or alcohol use or dependence&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Chronic Hepatitis C
    </Condition>
    <Intervention>Drug: sofosbuvir/ledipasvir
    </Intervention>
    <Primary_outcome>Proportion of participants with a new grade 3 or 4 adverse event or premature study drug discontinuation due to an adverse event.;Proportion of participants with sustained viral response as defined by an HCV RNA below the limit of quantification 12 weeks after discontinuation of study treatment;Proportion of participants with sustained viral response as defined by an HCV RNA below the limit of quantification 12 weeks after discontinuation of study treatment, with limited lab monitoring
    </Primary_outcome>
    <Secondary_outcome>A set of minimum required monitoring tests;Distribution of HCV genotypes subtypes among participants;SVR12, stratified by genotypic subtype;Basic demographic and clinical characteristics of patients referred for HCV treatment;Adherence to SOF/LDV measured by pill count;Proportion of participants with virologic failure;Proportion of participants with HCV RNA below the level of quantitation (BLQ) while on treatment;Proportion of HIV co-infected participants that maintain HIV-1 RNA&lt; 200 copies/mL while on HCV treatment;Proportion of participants reporting increased quality of life after SVR12 using the Medical Outcomes Study HIV Health Survey
    </Secondary_outcome>
    <Secondary_ID>SHARED 092415
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12572495
    </Internal_Number>
    <TrialID>NCT02944682
    </TrialID>
    <Last_Refreshed_on>10 October 2022
    </Last_Refreshed_on>
    <Public_title>Household Air Pollution and Health: A Multi-country LPG Intervention Trial
    </Public_title>
    <Scientific_title>Household Air Pollution and Health: A Multi-country LPG Intervention Trial
    </Scientific_title>
    <Acronym>HAPIN
    </Acronym>
    <Primary_sponsor>Emory University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161017
    </Date_registration3>
    <Date_registration>17/10/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02944682
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>79 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 16, 2018
    </Date_enrollement>
    <Target_size>3640
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Guatemala;India;Peru;Rwanda;Guatemala;India;Peru;Rwanda;United Kingdom;United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Thomas Clasen, PhD;Jennifer Peel, PhD;William Checkley, MD PhD
    </Contact_Lastname>
    <Contact_Email>;;
    </Contact_Email>
    <Contact_Tel>;;
    </Contact_Tel>
    <Contact_Affiliation>Emory University;Colorado State University;Johns Hopkins School of Medicine
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria for Pregnant Women:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Confirmed pregnancy (hCG positive blood or urine test)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Aged 18 to &lt;35 years (via self-report)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uses biomass stove predominantly&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lives in study area&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  9 - &lt;20 weeks gestation confirmed by ultrasound&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Singleton pregnancy (one fetus)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Viable fetus with normal fetal heart rate (120-180 beats per minute) at time of&#x0D;&lt;br&gt;             ultrasound&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Continued pregnancy at the time of randomization confirmed by self-report&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to participate with informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria for Pregnant Women:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently smokes cigarettes or other tobacco products&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Plans to move permanently outside study area in the next 12 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uses LPG stove predominantly, or is likely to use LPG predominantly in the near future&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria for Older Adult Woman in the Same Household:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Aged 40 to &lt;80 years (via self-report)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria for Older Adult Woman in the Same Household:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently smokes cigarettes or other tobacco products&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant (by self-report)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Plans to move out of her current household in the next 12 months&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Infant, Low Birth Weight
    </Condition>
    <Intervention>Other: Liquefied petroleum gas (LPG) cookstove
    </Intervention>
    <Primary_outcome>Birth weight;Incidence of HAPIN Severe Pneumonia;Length-for-age z-score 2 standard deviations below the standard;Systolic blood pressure
    </Primary_outcome>
    <Secondary_outcome>Maternal blood pressure;Differences in fetal growth outcomes between intervention and control;Preterm birth;Gestational age at birth;Change in child development;Brachial artery reactivity testing (BART);Carotid intima-media thickness (CIMT);Adult respiratory health and well-being;Adult Quality of Life: Short Form 36 survey and EuroQOL-5D survey;WHO severe pneumonia;WHO non-severe pneumonia;Hospitalization for respiratory illness;Diastolic blood pressure;Mean arterial pressure;Pulse pressure;Change in neuro-development
    </Secondary_outcome>
    <Secondary_ID>1UM1HL134590-01;IRB00089799
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institutes of Health (NIH);National Heart, Lung, and Blood Institute (NHLBI);Bill and Melinda Gates Foundation;Berkeley Air Monitoring Group;Colorado State University;Global LPG Partnership;Harvard University;Johns Hopkins University;London School of Hygiene and Tropical Medicine;Asociacion Benefica Prisma;Sri Ramachandra University;Universidad del Valle, Guatemala;Universidad Peruana Cayetano Heredia;University of Georgia;Washington University School of Medicine;University of Rwanda;Eagle Research Center;University of Oxford
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12628445
    </Internal_Number>
    <TrialID>NCT02935686
    </TrialID>
    <Last_Refreshed_on>31 October 2022
    </Last_Refreshed_on>
    <Public_title>A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults
    </Public_title>
    <Scientific_title>A Randomized, Parallel-group, Placebo-controlled, Double-blind Phase 1/2a Study in Healthy HIV Uninfected Adults to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost Regimens: Priming With Tetravalent Ad26.Mos4.HIV and Boosting With Tetravalent Ad26.Mos4.HIV and Either Clade C gp140 Plus Adjuvant OR a Combination of Mosaic and Clade C gp140 Plus Adjuvant
    </Scientific_title>
    <Acronym>IPCAVD-012
    </Acronym>
    <Primary_sponsor>Janssen Vaccines &amp; Prevention B.V.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161014
    </Date_registration3>
    <Date_registration>14/10/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02935686
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 31, 2017
    </Date_enrollement>
    <Target_size>155
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Countries>United States;Kenya;Rwanda;Kenya;Rwanda;United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Janssen Vaccines &amp; Prevention B.V. Clinical Trial
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Janssen Vaccines &amp; Prevention B.V.
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be healthy on the basis of medical history, physical examination, and&#x0D;&lt;br&gt;             vital signs measurement performed at screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants are negative for human immunodeficiency virus (HIV) infection at&#x0D;&lt;br&gt;             screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants are amenable to HIV-risk reduction counseling and committed to&#x0D;&lt;br&gt;             maintaining behavior consistent with low risk of HIV exposure through the last&#x0D;&lt;br&gt;             required protocol clinic visit&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All female participants of childbearing potential must have a negative serum&#x0D;&lt;br&gt;             (beta-human chorionic gonadotropin [beta-hCG]) at the screening visit, and a negative&#x0D;&lt;br&gt;             urine pregnancy test pre-dose on Day 1&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants are willing/able to adhere to the prohibitions and restrictions specified&#x0D;&lt;br&gt;             in the protocol and study procedures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be enrolled in the LTE phase to receive the late boost vaccination&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has chronic hepatitis B (measured by hepatitis B surface antigen test) or active&#x0D;&lt;br&gt;             hepatitis C (measured by hepatitis C virus [HCV] Ab test; if positive, HCV ribonucleic&#x0D;&lt;br&gt;             acid [RNA] polymerase chain reaction (PCR) test will be used to confirm active versus&#x0D;&lt;br&gt;             past HCV infection), active syphilis infection, chlamydia, gonorrhea, or trichomonas&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In the 12 months prior to randomization, participant has a history of newly acquired&#x0D;&lt;br&gt;             herpes simplex virus type 2 (HSV-2), syphilis, gonorrhea, non-gonococcal urethritis,&#x0D;&lt;br&gt;             chlamydia, pelvic inflammatory disease, trichomonas, mucopurulent cervicitis,&#x0D;&lt;br&gt;             epididymitis, proctitis, lymphogranulomavenereum, chancroid, or hepatitis B&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has had major surgery (eg, requiring general anesthesia) within the 4&#x0D;&lt;br&gt;             weeks before screening, or will not have fully recovered from surgery, or has surgery&#x0D;&lt;br&gt;             planned through the course of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has had a thyroidectomy or active thyroid disease requiring medication&#x0D;&lt;br&gt;             during the last 12 months (not excluded: a stable thyroid supplementation)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current or past drug/alcohol use that investigator assesses poses any more than a&#x0D;&lt;br&gt;             remotely increased risk of the ability of the participant to comply with the protocol&#x0D;&lt;br&gt;             requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has been in receipt of any licensed vaccine within 14 days prior to the first dose of&#x0D;&lt;br&gt;             study vaccine or placebo, plans to receive within 14 days after the first study&#x0D;&lt;br&gt;             vaccination, or plans to receive within 14 days before or after the second, third or&#x0D;&lt;br&gt;             fourth vaccination&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Is a recipient of a prophylactic or therapeutic HIV vaccine candidate at any time, or&#x0D;&lt;br&gt;             a recipient of other experimental vaccine(s) within the last 12 months prior to the&#x0D;&lt;br&gt;             Day 1 visit (Vaccination 1). For participants who received an experimental vaccine&#x0D;&lt;br&gt;             (except HIV vaccine) more than 12 months prior to the Day 1 visit (Vaccination 1),&#x0D;&lt;br&gt;             documentation of the identity of the experimental vaccine must be provided to the&#x0D;&lt;br&gt;             sponsor, who will determine eligibility on a case-by-case basis&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Healthy
    </Condition>
    <Intervention>Biological: Ad26.Mos4.HIV;Biological: Clade C gp140 plus adjuvant;Biological: Clade C gp140/Mosaic gp140 plus adjuvant;Other: Placebo;Biological: gp140 HIV Bivalent Vaccine
    </Intervention>
    <Primary_outcome>Number of Participants With Solicited Local and Systemic Adverse Events (AEs);Number of Participants With Adverse events (AEs);Discontinuations From Vaccination/From Study due to AEs;Number of Participants With Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs) of Confirmed Human Immunodeficiency Virus (HIV) Infection;Envelope (Env)-specific Binding Antibody (Abs) (Titers and Breadth);Number of Participants with AESIs of Thrombosis With Thrombocytopenia Syndrome (TTS)
    </Primary_outcome>
    <Secondary_outcome>Env-specific Neutralizing Antibody (nAbs) (Titers and Breadth) (for Tier 1 and Tier 2 Viruses);Env-specific Functional Abs (Phagocytosis Score and Breadth);Env-specific Binding Ab Isotypes (Immunoglobulin A [IgA], IgG1-4) (Titers and Breadth);Interferon (IFN)-gamma Peripheral Blood Mononuclear Cell (PBMC) Responders to Mosaic and Potential T-cell Epitope (PTE) peptide pools of Env/Group-specific Antigen (Gag)/ Polymerase (Pol);Cluster of Differentiation (Cd)4+ and Cd8+ T-Cell Functionality (Percentage [%] Cells Producing I-alpha, IFN-gamma, Interleukin [IL-2], IL-4, Tumor Necrosis Factor [TNF]-alpha);T-Cell Development With Emphasis on Follicular Helper T-Cells and Memory Differentiation
    </Secondary_outcome>
    <Secondary_ID>VAC89220HPX2003;CR108207
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12423364
    </Internal_Number>
    <TrialID>NCT02788045
    </TrialID>
    <Last_Refreshed_on>29 July 2022
    </Last_Refreshed_on>
    <Public_title>Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults
    </Public_title>
    <Scientific_title>A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Phase 1/2a Study in Healthy HIV Uninfected Adults to Assess the Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost Regimens; Priming With Trivalent Ad26.Mos.HIV and Boosting With Trivalent Ad26.Mos.HIV And Clade C Gp140 Plus Adjuvant or Priming With Tetravalent Ad26.Mos4.HIV and Boosting With Tetravalent Ad26.Mos4.HIV and Clade C Gp140 Plus Adjuvant
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Janssen Vaccines &amp; Prevention B.V.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160527
    </Date_registration3>
    <Date_registration>27/05/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02788045
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>50 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 8, 2016
    </Date_enrollement>
    <Target_size>201
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Countries>United States;Rwanda;United States;United States;Rwanda;United States;United States;Rwanda;United States;United States;Rwanda;United States
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Janssen Vaccines &amp; Prevention B.V. Clinical Trial;Janssen Vaccines &amp; Prevention B.V. Clinical Trial;Janssen Vaccines &amp; Prevention B.V. Clinical Trial;Janssen Vaccines &amp; Prevention B.V. Clinical Trial
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>Janssen Vaccines &amp; Prevention B.V.;Janssen Vaccines &amp; Prevention B.V.;Janssen Vaccines &amp; Prevention B.V.;Janssen Vaccines &amp; Prevention B.V.
    </Contact_Affiliation>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>5401448
    </Internal_Number>
    <TrialID>EUCTR2016-000728-24-Outside-EU/EEA
    </TrialID>
    <Last_Refreshed_on>14 March 2016
    </Last_Refreshed_on>
    <Public_title>A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants
    </Public_title>
    <Scientific_title>A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment of Soil-Transmitted Helminth Infections (Ascaris lumbricoides and Trichuris trichiura) in Pediatric Subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Janssen Research &amp; Development, LLC
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160301
    </Date_registration3>
    <Date_registration>01/03/2016
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-000728-24
    </web_address>
    <Recruitment_Status>Not Available
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement/>
    <Target_size>240
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2

    </Study_design>
    <Countries>Ethiopia;Rwanda
    </Countries>
    <Contact_Firstname>Clinical Registry Group-JB BV
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Archimedesweg 29
    </Contact_Address>
    <Contact_Email>ClinicalTrialsEU@its.jnj.com
    </Contact_Email>
    <Contact_Tel/>
    <Contact_Affiliation>Janssen Research and Development
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;-Female participants who are &gt;=9 years old must have a negative urine pregnancy test at screening or at the time of randomization &lt;br&gt;-Participants must be an otherwise healthy child, based on medical history, physical examination, vital signs, hemoglobin, and concomitant medications &lt;br&gt;-Participants &gt;=3 years of age must have teeth and be able to chew &lt;br&gt;-Participant must be available to return to the study site for all visits, including the follow-up visit &lt;br&gt;-Parent(s)/guardians of participants (or their legally-accepted representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to have their child participate in the study &lt;br&gt;-Children 6 years of age and older will be asked to assent (agree) to their participation using appropriate language to their level of understanding; assent will be documented.&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: 240&lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-Participant has active diarrhea (defined as the passage of 3 or more loose or liquid stools per day) at screening or at the time of randomization &lt;br&gt;-Participant has a significant medical disorder, participant has difficulty in chewing or swallowing &lt;br&gt;-Participant has significant anemia (&lt;8 g/dL) -Participant has significant wasting (greater than 2 standard deviations below the mean World Health Organization [WHO] Child Growth Standards for weight-for-height or body&lt;br&gt;mass index) &lt;br&gt;-Participant has a known hypersensitivity to mebendazole, any inert ingredients in the chewable formulation &lt;br&gt;-Participant has preplanned surgery/procedures that would interfere with the conduct of the study during the course of study &lt;br&gt;-Participants has received an investigational drug (including vaccines) or used an investigational medical device within 30 days before the planned start of treatment, or is currently enrolled in an investigational study &lt;br&gt;-Employees of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator &lt;br&gt;-Participant has taken any form of medication containing mebendazole or any other treatment for soil transmitted helminth infection within 30 days of entry into the study&lt;br&gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Helminth infections;Therapeutic area: Diseases [C] - Parasitic Diseases [C03]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: Mebendazole&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Mebendazole&lt;br&gt;CAS Number: 31431-39-7&lt;br&gt;Other descriptive name: MEBENDAZOLE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;Pharmaceutical form of the placebo: Chewable tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: The purpose of this study is to evaluate the efficacy and safety of mebendazole compared with placebo in pediatric participants with Helminth infections.;Secondary Objective: Not applicable;Primary end point(s): - Cure rate for A. lumbricoides for those participants with a positive egg count for that soil-transmitted helminth at baseline &lt;br&gt;&lt;br&gt;-Cure rate for T. trichiura for those participants with a positive egg count for that soil-transmitted helminth at baseline&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;;Timepoint(s) of evaluation of this end point: -Baseline (Day 1) to Day 20 Cure is defined as a post treatment egg count of zero in participants who had a positive egg count at baseline.&lt;br&gt;&lt;br&gt;-Baseline (Day 1) to Day 20 Cure is defined as a post treatment egg count of zero in participants who had a positive egg count at baseline.&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): -The percentage egg reduction for A. lumbricoides for those participants with a positive egg count for that soil-transmitted helminth at baseline&lt;br&gt;&lt;br&gt;-The percentage egg reduction for T. trichiura for those participants with a positive egg count for that soil-transmitted helminth at baseline;Timepoint(s) of evaluation of this end point: -Baseline (Day 1) to Day 20 Egg count at end of treatment period minus egg count at baseline divided by egg count at baseline multiplied by 100%.&lt;br&gt;&lt;br&gt;-Baseline (Day 1) to Day 20 Egg count at end of treatment period minus egg count at baseline divided by egg count at baseline multiplied by 100%.
    </Secondary_outcome>
    <Secondary_ID>MEBENDAZOLGAI3003
    </Secondary_ID>
    <Source_Support>Janssen Research and Development
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11963589
    </Internal_Number>
    <TrialID>NCT02661464
    </TrialID>
    <Last_Refreshed_on>28 February 2022
    </Last_Refreshed_on>
    <Public_title>Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
    </Public_title>
    <Scientific_title>A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Janssen Vaccines &amp; Prevention B.V.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160108
    </Date_registration3>
    <Date_registration>08/01/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02661464
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>71 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 31, 2016
    </Date_enrollement>
    <Target_size>677
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>United States;Burkina Faso;France;Kenya;Tanzania;Uganda;United Kingdom;Burkina Faso;France;Kenya;Tanzania;Uganda;United Kingdom;United States;Côte D'Ivoire;Mozambique;Nigeria;Rwanda;Sierra Leone
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Janssen Vaccines &amp; Prevention B.V. Clinical Trial
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Janssen Vaccines &amp; Prevention B.V.
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female who participated in a Phase 1, 2 or 3 clinical study with Human&#x0D;&lt;br&gt;             adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein&#x0D;&lt;br&gt;             (Ad26.ZEBOV) and/or Modified Vaccinia Virus Ankara - Bavarian Nordic Filo-vector&#x0D;&lt;br&gt;             (MVA-BN-Filo) and has been exposed to Ad26.ZEBOV and/or MVA-BN-Filo (Cohort 1)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Female who participated in a Phase 1, 2 or 3 clinical study with Ad26.ZEBOV and/or&#x0D;&lt;br&gt;             MVA-BN-Filo and became pregnant with estimated conception within 28 days after&#x0D;&lt;br&gt;             vaccination with MVA-BN-Filo or within 3 months after vaccination with Ad26.ZEBOV&#x0D;&lt;br&gt;             (Cohort 2)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Child born to female participants exposed to Ad26.ZEBOV and/or MVA-BN-Filo in a Phase&#x0D;&lt;br&gt;             1, 2, or 3 clinical study who became pregnant with estimated conception within 28 days&#x0D;&lt;br&gt;             after vaccination with MVA-BN-Filo or within 3 months after vaccination with&#x0D;&lt;br&gt;             Ad26.ZEBOV (Cohort 3)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must sign an informed consent form for the current study (or their legally acceptable&#x0D;&lt;br&gt;             representative must sign) indicating that he or she understands the purpose of, and&#x0D;&lt;br&gt;             procedures required for, the study and is willing to participate in the study (or let&#x0D;&lt;br&gt;             their child participate); Assent is also required of children capable of understanding&#x0D;&lt;br&gt;             the nature of the study (typically 7 years of age and older)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No exclusions beyond those that are not meeting the inclusion criteria&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hemorrhagic Fever, Ebola
    </Condition>
    <Intervention>Biological: Ad26.ZEBOV;Biological: MVA-BN-Filo
    </Intervention>
    <Primary_outcome>Percentage of Serious Adverse Events (SAEs);Percentage of pregnancies with estimated conception within 28 days after vaccination with MVA-BN-Filo or within 3 months after vaccination with Ad26.ZEBOV;Percentage of pregnancies (with estimated conception within 28 days after vaccination with MVA-BN-Filo or within 3 months after vaccination with Ad26.ZEBOV) by pregnancy outcome;Percentage of live-born children from a pregnancy with estimated conception within 28 days after vaccination with MVA-BN-Filo or within 3 months after vaccination with Ad26.ZEBOV;Percentage of serious adverse events in children born from a pregnancy with estimated conception within 28 days after vaccination with MVA-BN-Filo or within 3 months after vaccination with Ad26.ZEBOV
    </Primary_outcome>
    <Secondary_ID>2015-004139-11;VAC52150EBL4001;CR108112
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Bavarian Nordic GmbH
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12581546
    </Internal_Number>
    <TrialID>NCT02832544
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority
    </Public_title>
    <Scientific_title>INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies
    </Scientific_title>
    <Acronym>INVICTUS-VKA
    </Acronym>
    <Primary_sponsor>Population Health Research Institute
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20151210
    </Date_registration3>
    <Date_registration>10/12/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02832544
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 22, 2016
    </Date_enrollement>
    <Target_size>4565
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Botswana;Brazil;Cameroon;China;Egypt;Ethiopia;India;Kazakhstan;Kenya;Kyrgyzstan;Malawi;Mexico;Mozambique;Nepal;Nigeria;Pakistan;Paraguay;Philippines;Rwanda;South Africa;Sudan;Tanzania;Uganda;Zambia;Zimbabwe;Botswana;Brazil;Cameroon;China;Egypt;Ethiopia;India;Kazakhstan;Kenya;Kyrgyzstan;Malawi;Mexico;Mozambique;Nepal;Nigeria;Pakistan;Paraguay;Philippines;Rwanda;South Africa;Sudan;Tanzania;Uganda;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Stuart Connolly, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Population Health Research Institute
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. RVHD diagnosed by echocardiography at any time prior to enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Age =18&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Increased risk of stroke by any of the following&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  CHA2DS2-VASc score = 2 OR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Moderate/Severe mitral stenosis with valve area =2.0 cm2 OR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Left atrial spontaneous echo contrast OR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Left atrial thrombus&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Heart Rhythm *AF or Flutter should be documented on baseline 12-lead ECG, or on a&#x0D;&lt;br&gt;             previous 12-lead ECG, Holter monitor, in-hospital ECG rhythm strip or Pacemaker or ICD&#x0D;&lt;br&gt;             electrogram.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Refusal to give informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Actively involved in any study that would compromise the protocol of INVICTUS Trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Severe co-morbid condition with life expectancy &lt; 1 year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Other serious condition(s) or logistic factors likely to interfere with study&#x0D;&lt;br&gt;             participation or with the ability to complete the trial, as appropriate to country or&#x0D;&lt;br&gt;             region.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Likely to have valve replacement surgery within 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Mechanical valve prosthesis or other condition requiring treatment with VKAs. Patients&#x0D;&lt;br&gt;             with deep vein thrombosis or recent pulmonary embolism can be enrolled where both VKAs&#x0D;&lt;br&gt;             and rivaroxaban are approved.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Contraindication to the study medication of the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Allergy to rivaroxaban&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Allergy to VKAs ( non-inferiority trial)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Allergy to aspirin ( superiority trial)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Severe renal insufficiency with an calculated creatinine clearance (Cockcroft-Gault)&#x0D;&lt;br&gt;             &lt;15 ml/min&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Serious bleeding in the past six months or at high risk for bleeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Moderate to severe hepatic impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Ongoing need for dual antiplatelet therapy (patients with on-going aspirin therapy&#x0D;&lt;br&gt;             =100 mg per day are not excluded)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Ongoing need for dual strong inhibitors of CYP-3a4 or p-glycoprotein inhibitor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Received an investigational drug in the past 30 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Patients considered unsuitable for trial inclusion because of unwillingness to attend&#x0D;&lt;br&gt;             follow up visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. Women who are pregnant and/or breastfeeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. Women of child bearing age who do not use an effective form of birth control.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Rheumatic Heart Disease
    </Condition>
    <Intervention>Drug: Rivaroxaban (20 mg);Drug: Vitamin K antagonists (VKA)
    </Intervention>
    <Primary_outcome>Time from randomization to the first occurrence of vascular death or death of unknown cause, stroke, myocardial infarction or systemic embolism
    </Primary_outcome>
    <Secondary_outcome>Time from randomization to the first occurrence of composite of stroke or systemic embolism
    </Secondary_outcome>
    <Secondary_ID>INVICTUS - VKA
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Cape Town;Bayer
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12599941
    </Internal_Number>
    <TrialID>PACTR201511001346115
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Use of a Mixture of Lignocaine and Bupivacaine Versus Lignocaine Alone for Male Circumcision Under Local Anesthesia at a referral hospital in Rwanda (
    </Public_title>
    <Scientific_title>Use of a Mixture of Lignocaine and Bupivacaine Versus Lignocaine Alone for Male Circumcision Under Local Anesthesia at a referral hospital in Rwanda (University Teaching Hospital of Butare ). A Randomized Controlled Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>UNIVERSITY OF RWANDA
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20151113
    </Date_registration3>
    <Date_registration>13/11/2015
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=1346
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>17 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>39 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>02/03/2015
    </Date_enrollement>
    <Target_size>52
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,computer generated random sequences,Sealed opaque envelopes
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria:  Males (15-49years) who requested circumcision&#x0D;&lt;br&gt;Completion for informed consent (those 21 years and older consented to be enrolled in the study while participants below 21 years assented and guardians consented for them
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 	Those with known bleeding disorders (difficult hemostasis previously)&#x0D;&lt;br&gt;	Allergy to local anesthesia&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Surgery &lt;br&gt;pain management &lt;br&gt;Anaesthesia;Surgery;pain management;Anaesthesia
    </Condition>
    <Intervention>;use of a mixture of lignocaine and bupivacaine;Lignocaine alone group
    </Intervention>
    <Primary_outcome>pain during and after surgery
    </Primary_outcome>
    <Secondary_outcome>additional anesthesia and additional analgesia
    </Secondary_outcome>
    <Source_Support>UNIVERSITY OF RWANDA
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>25/02/2015
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>College of Medicine and Health Sciences Institutional Review Board 
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>5327976
    </Internal_Number>
    <TrialID>NCT02603250
    </TrialID>
    <Last_Refreshed_on>18 January 2016
    </Last_Refreshed_on>
    <Public_title>Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
    </Public_title>
    <Scientific_title>Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>PATH
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20151109
    </Date_registration3>
    <Date_registration>09/11/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02603250
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>59 Months
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>September 2015
    </Date_enrollement>
    <Target_size>132
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational Model: Case-Only, Time Perspective: Cross-Sectional
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Megan E Parker, MSc, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>PATH
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children, 6 to 59 months of age, receiving outpatient health care from CHUK who will&#x0D;&lt;br&gt;             already be providing a venous blood sample for their care. Outpatients typically&#x0D;&lt;br&gt;             receive care for upper respiratory infections, pneumonia, malaria, HIV infection,&#x0D;&lt;br&gt;             allergies, simple diarrhea, ear infection, malnutrition, and chronic fever. Children&#x0D;&lt;br&gt;             experiencing these health issues can be included in the sample. Children experiencing&#x0D;&lt;br&gt;             more mild health issues will also be included in the sample.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability and willingness of study participant's parent/legal guardian to provide&#x0D;&lt;br&gt;             informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Giving a venous blood sample for Hb measurement as part of their standard of care.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Younger than 6 months of age.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Older than 59 months of age.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Weight less than 3 kg.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Weight greater than 30 kg.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any medical condition that would interfere with participant's ability to participate&#x0D;&lt;br&gt;             in the study. Such medical conditions include trauma, dehydration, shock, and all&#x0D;&lt;br&gt;             acute illnesses requiring urgent care.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Skin abnormalities (e.g., burns, scar tissue, infections) at the planned application&#x0D;&lt;br&gt;             sites that would interfere with or preclude sensor placement and ability to&#x0D;&lt;br&gt;             transluminate the finger.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Anemia
    </Condition>
    <Primary_outcome>Pronto® Hb measurement
    </Primary_outcome>
    <Secondary_outcome>HemoCue® Hb measurement
    </Secondary_outcome>
    <Secondary_ID>703581-3
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Rwanda
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>5197299
    </Internal_Number>
    <TrialID>NCT02581722
    </TrialID>
    <Last_Refreshed_on>2 November 2015
    </Last_Refreshed_on>
    <Public_title>Safety and Efficacy Study of Non-Surgical MC Device for Adolescent Male Population Including Contraindicated Subjects
    </Public_title>
    <Scientific_title>A Safety and Efficacy Study of Non-surgical MC Device on PrePex Adolescent Male Population, Including Contraindicated Subjects Scheduled to Undergo Circumcision in an Effort to Prevent the Spread of HIV in Resource Limited Settings
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Ministry of Health, Rwanda
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20151019
    </Date_registration3>
    <Date_registration>19/10/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02581722
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>10 Years
    </Inclusion_agemin>
    <Inclusion_agemax>17 Years
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>August 2015
    </Date_enrollement>
    <Target_size>300
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Vincent Mutabazi, M.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Ministry of Health, Rwanda
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adolescent Males in ages - 10 to 17 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncircumcised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject wants to be circumcised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject assent to the procedure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Legal guardian consent to the procedure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject with or without the following conditions: Preputial adhesions and /or narrow&#x0D;&lt;br&gt;             foreskin/Phimosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to understand the study procedures and requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to abstain from sexual intercourse for 8 weeks after circumcision&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to abstain from masturbation for at least 2 weeks after Removal&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to return to the health care facility for follow-up visits (or as instructed)&#x0D;&lt;br&gt;             after his circumcision for a period of 7 weeks post removal (8 weeks total)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject able to comprehend and freely give informed consent for participation in this&#x0D;&lt;br&gt;             study and is considered by the investigator to have good compliance for the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject agrees to anonymous video and photographs of the procedure and follow up&#x0D;&lt;br&gt;             visits.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Legal guardian withholds consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active genital infection, anatomic abnormality or other condition, which in the&#x0D;&lt;br&gt;             opinion of the investigator prevents the subject from undergoing a circumcision&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject with the following diseases/conditions: paraphimosis, warts under the&#x0D;&lt;br&gt;             prepuce, torn or tight frenulum, hypospadias, epispadias&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known bleeding / coagulation abnormality, uncontrolled diabetes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject that to the opinion of the investigator is not a good candidate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject does not agree to anonymous video and photographs of the procedure and follow&#x0D;&lt;br&gt;             up visits.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Circumcision, Adolescents
    </Condition>
    <Intervention>Device: PrePex Device
    </Intervention>
    <Primary_outcome>Incidence of Serious Adverse Events on adolescent male population including contraindicated subjects in ages 10 to 17
    </Primary_outcome>
    <Secondary_outcome>Glans fully exposed;The pain at key time points;Time to complete healing;Time to numb the foreskin using topical Lidocaine 5% cream - for contraindicated subjects only;Rate of side effects
    </Secondary_outcome>
    <Secondary_ID>RMC-04A
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10246814
    </Internal_Number>
    <TrialID>NCT02564523
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
    </Public_title>
    <Scientific_title>A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults, Including Elderly Subjects, HIV-infected Subjects, and Healthy Children in Two Age Strata in Africa
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Janssen Vaccines &amp; Prevention B.V.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150929
    </Date_registration3>
    <Date_registration>29/09/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02564523
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>4 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 6, 2015
    </Date_enrollement>
    <Target_size>1075
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Burkina Faso;Côte D'Ivoire;Kenya;Uganda;Burkina Faso;Côte D'Ivoire;Kenya;Uganda;Ghana;Rwanda;Tanzania
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Janssen Vaccines &amp; Prevention B.V. Clinical Trial
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Janssen Vaccines &amp; Prevention B.V.
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Criteria for healthy adults and elderly participants:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be healthy in the investigator's clinical judgment on the basis of&#x0D;&lt;br&gt;             clinical laboratory tests, medical history, ECG, physical examination and vital signs&#x0D;&lt;br&gt;             performed at screening. Participants with hemoglobin values outside the local&#x0D;&lt;br&gt;             laboratory reference ranges may be included if the hemoglobin is above the age/gender&#x0D;&lt;br&gt;             specific limits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Female participants of childbearing potential must use adequate birth control&#x0D;&lt;br&gt;             measures, must have a negative pregnancy test at screening and immediately prior to&#x0D;&lt;br&gt;             each study vaccination&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A man who is sexually active with a woman of childbearing potential must be willing to&#x0D;&lt;br&gt;             use condoms for sexual intercourse beginning prior to enrollment, unless a vasectomy&#x0D;&lt;br&gt;             was performed more than 1 year prior to screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must pass the test of understanding (TOU)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be available and willing to participate for the duration of the study&#x0D;&lt;br&gt;             visits and follow-up, provide verifiable identification, and have a means to be&#x0D;&lt;br&gt;             contacted Additional Inclusion Criteria HIV-infected Participants&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be between 18 to 50 years of age and must have a documented&#x0D;&lt;br&gt;             HIV-infection for at least 6 months prior to screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be on a stable 3 drug regimen of Highly Active Antiretroviral Therapy&#x0D;&lt;br&gt;             for at least 4 weeks prior to screening and having a CD4 positive cell count of &gt;350&#x0D;&lt;br&gt;             cells/microliter. Also participant must be in an otherwise reasonable good medical&#x0D;&lt;br&gt;             condition Additional Inclusion Criteria Children Participants&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parent/legal guardian must pass the TOU before signing the inform consent form.&#x0D;&lt;br&gt;             Informed assent must be obtained from adolescents and older children, depending on&#x0D;&lt;br&gt;             local regulations and practice&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pediatric participant's age on the day of randomization must be within one of the 2&#x0D;&lt;br&gt;             age strata: 12-17 years or 4-11 years (all ages inclusive)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pediatric participants must have received all routine immunizations appropriate for&#x0D;&lt;br&gt;             his or her age as reported by the parent(s)/legal guardian, according to local routine&#x0D;&lt;br&gt;             vaccination schedules&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosed with Ebola virus disease or previously exposed to Ebola virus including&#x0D;&lt;br&gt;             travel to epidemic Ebola areas less than 1 month prior to screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having received any candidate Ebola vaccine or any experimental candidate Ad26- or&#x0D;&lt;br&gt;             MVA-based vaccine in the past&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having HIV type 1 or type 2 infection (for healthy adults/elderly/children)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pediatric participants with weight-per-height below 10th percentile according to the&#x0D;&lt;br&gt;             Centers for Disease Control and Prevention (CDC) growth charts (4- to 11-year-olds)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A woman who is pregnant, breast-feeding or planning to become pregnant while enrolled&#x0D;&lt;br&gt;             in the study or within at least 3 months after the prime vaccination or up to 1 month&#x0D;&lt;br&gt;             after the boost vaccination (whichever takes longer) or within at least 3 months after&#x0D;&lt;br&gt;             the third vaccination&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For HIV+ adults, no AIDS-defining illnesses&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hemorrhagic Fever, Ebola
    </Condition>
    <Intervention>Biological: Ad26.ZEBOV;Biological: MVA-BN-Filo;Biological: Placebo
    </Intervention>
    <Primary_outcome>Number of Participants With Adverse Events;Number of Participants With Serious Adverse Events;Number of Participants with Solicited Local and Systemic Adverse Events
    </Primary_outcome>
    <Secondary_outcome>Antibody levels against the EBOV GP measured by an enzyme-linked immunosorbent assay (ELISA);Number of Participants With Adverse Events as a Measure of Safety and Tolerability of a Third Vaccination With Ad26.ZEBOV
    </Secondary_outcome>
    <Secondary_ID>VAC52150EBL2002;2019-000690-22;CR107249
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>EBOVAC2 Consortium;Institut National de la Santé Et de la Recherche Médicale, France;Centre Muraz
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10244803
    </Internal_Number>
    <TrialID>NCT02514122
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Subcutaneous Ketamine for Postoperative Pain Relief in Rwanda
    </Public_title>
    <Scientific_title>Subcutaneous Ketamine for Postoperative Pain Relief in Rwanda: a Randomized Control Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Saskatchewan
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150731
    </Date_registration3>
    <Date_registration>31/07/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02514122
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>60 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 2015
    </Date_enrollement>
    <Target_size>61
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>William Mckay, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Saskatchewan
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        - All patients undergoing upper abdominal, thoracic, gynecologic or orthopaedic surgeries&#x0D;&lt;br&gt;        during a one month period with expected post operative hospital admission&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Allergy to Ketamine&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of narcotic abuse or dependence&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Those patients for which decreased cognitive function is a barrier to accurate data&#x0D;&lt;br&gt;             collection&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Post Operative Pain;Pain
    </Condition>
    <Intervention>Drug: Ketamine;Drug: Saline
    </Intervention>
    <Primary_outcome>Postoperative Pain as Measured on a 11-point Numerical Rating Scale
    </Primary_outcome>
    <Secondary_outcome>Hallucination
    </Secondary_outcome>
    <Secondary_ID>Bio# 14-193
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National University, Rwanda
    </Secondary_Sponsor>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>09/11/2018
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT02514122
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10244656
    </Internal_Number>
    <TrialID>NCT02510313
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Strong Families, Thriving Children "Sugira Muryango"_Activity C
    </Public_title>
    <Scientific_title>Effectiveness Trial of a Family Home Visiting Intervention to Promote Early Child Development Among Families Served by the Social Protection System in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Boston College
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150726
    </Date_registration3>
    <Date_registration>26/07/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02510313
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>36 Months
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 10, 2018
    </Date_enrollement>
    <Target_size>2911
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Theresa Betancourt, Sc.D
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Boston College School of Social Work
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Beneficiary Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        - All participants must live in chosen District(s) of Rwanda.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion criteria for families are:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. being VUP-eligible&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. having at least one children aged 0-6 years living in the home&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. having caregiver willing to discuss and enhance their parenting practices by&#x0D;&lt;br&gt;             interacting with a home-visiting coach.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Caregiver eligibility:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. is aged 18 or older and cares for child(ren)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. lives in the same household as child(ren). We will enroll both single and dual&#x0D;&lt;br&gt;             caregiver families to reflect population dynamics. Legal guardians may be aunts,&#x0D;&lt;br&gt;             uncles, grandparents, or foster parents.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  do not live in chosen District of Rwanda&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  do not have children between the ages of 0 and 6 years living in their household for&#x0D;&lt;br&gt;             whom they are the primary caregiver&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  they are not enrolled in Rwanda's public works social protection program VUP, or have&#x0D;&lt;br&gt;             severe cognitive impairments which preclude their ability to speak to the research&#x0D;&lt;br&gt;             questions under study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  families in the midst of crisis (e.g., a caregiver with active suicidal attempts or&#x0D;&lt;br&gt;             psychosis) and refer them to appropriate services.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Child Development, Social Protection
    </Condition>
    <Intervention>Other: Sugira Muryango
    </Intervention>
    <Primary_outcome>Change from baseline in parent-child relationship;Change from baseline in responsive caregiving practices;Change from baseline in child development;Change from baseline in violence in the home;Change from baseline in child health and nutrition
    </Primary_outcome>
    <Secondary_ID>IRB16-1570
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12599860
    </Internal_Number>
    <TrialID>PACTR201604001185358
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Integration ICF  to facilitate interprofessional collaboration among Health Professionals in Rwanda district hospitals
    </Public_title>
    <Scientific_title>Use of International Classification of Functioning, Disability and Health (ICF) as a Theoretical Framework to inform Inter-professional Assessment and Management by Health Care Professionals in Rwanda: A Cluster Randomised Control Trial.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>Rwanda Education Board (REB)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150630
    </Date_registration3>
    <Date_registration>30/06/2015
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=1185
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>50 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>23/07/2015
    </Date_enrollement>
    <Target_size>160
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design/>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda;Rwanda;Rwanda
    </Countries>
    <Contact_Firstname>Jeanne Kagwiza 
    </Contact_Firstname>
    <Contact_Lastname>Kagwiza 
    </Contact_Lastname>
    <Contact_Address> Kigali
    </Contact_Address>
    <Contact_Email>jkagwiza@yahoo.fr
    </Contact_Email>
    <Contact_Tel>+250788755364
    </Contact_Tel>
    <Contact_Affiliation>Acting Principal of College of Medicine and Health Sciences/Univerity of Rwanda
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &#x0D;&lt;br&gt;¿Health care professional working either in Orthopaedic/Surgical, Medical and Paediatric wards.&#x0D;&lt;br&gt;¿Full time health care professionals during the period of intervention and data collection.                                  &#x0D;&lt;br&gt;¿Qualified health care professional.                              Health care professional with at least 6 moths of working experience in the above mentioned wards.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Patients Folders:&#x0D;&lt;br&gt;¿Medical records of patients who have been admitted to the orthopedic/surgical, medical and paediatric wards for at least five days.                                                                                         &#x0D;&lt;br&gt;¿Medical records of patients who have been discharged.  &#x0D;&lt;br&gt;¿Medical records of discharged patients in six months prior to the study. &#x0D;&lt;br&gt;¿Medical records of discharged patients during the six months after training.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;                                                                         &#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: None 
    </Exclusion_Criteria>
    <Condition/>
    <Intervention>;Inter-professional training ;Inter-professional training
    </Intervention>
    <Primary_outcome>The primary outcome of this study was the improved interprofessional practice within the district hospitals and comprehensiveness of the patients¿ records demonstrated by the score
    </Primary_outcome>
    <Source_Support>Rwanda Education Board
    </Source_Support>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>12/02/2016;12/02/2015
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Rwanda National Ethics Committee;University of Cape Town, Faculty of Health Sciences, Human Research Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>(250)255107884;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10242858
    </Internal_Number>
    <TrialID>NCT02464423
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Improving Adherence Among HIV+ Rwandan Youth: A TI-CBTe Indigenous Leader Model
    </Public_title>
    <Scientific_title>Improving Adherence Among HIV+ Rwandan Youth: A TI-CBTe Indigenous Leader Model
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Hektoen Institute for Medical Research
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20150410
    </Date_registration3>
    <Date_registration>10/04/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02464423
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>14 Years
    </Inclusion_agemin>
    <Inclusion_agemax>21 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2013
    </Date_enrollement>
    <Target_size>731
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Mardge Cohen, MD;Sabin Nsanzimana, MD;Geri Donenberg, PhD
    </Contact_Lastname>
    <Contact_Email>;;
    </Contact_Email>
    <Contact_Tel>;;
    </Contact_Tel>
    <Contact_Affiliation>We-ACTx;Rwanda Biomedical Center;University of Illinois-Chicago
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  male or female&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  14-21 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  seeking HIV care and treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  enrolled in support groups at CHUK or We-ACTx For Hope&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  able to understand the informed consent process.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  are unable to understand the consent/assent process&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  do not speak Kinyarwanda (all instruments will be translated and back-translated)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  are not HIV+&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  received an HIV diagnosis in the past week&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Human Immunodeficiency Virus
    </Condition>
    <Intervention>Behavioral: Trauma-Informed Cognitive Behavioral Therapy enhanced (TI-CBTe)
    </Intervention>
    <Primary_outcome>ART Adherence Behavior Composite Self Report
    </Primary_outcome>
    <Secondary_outcome>Health Care Utilization (Number of Clinic Visits)
    </Secondary_outcome>
    <Secondary_ID>R01HD074977
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12599787
    </Internal_Number>
    <TrialID>PACTR201505001045388
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>SOCCER INJURY SURVEILLANCE AND IMPLEMENTATION OF AN INJURY PREVENTION PROGRAMME IN RWANDA
    </Public_title>
    <Scientific_title>EFFECT OF THE FIFA 11+ WARM UP PROGRAMME ON THE INCIDENCE OF INJURIES IN SOCCER CLUBS IN RWANDA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Government of Rwanda through the Embassy
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150221
    </Date_registration3>
    <Date_registration>21/02/2015
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=1045
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>35 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>01/04/2015
    </Date_enrollement>
    <Target_size>434
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously,Randomised,This is a cluster randomisation where the soccer clubs will be the unit of randomisation. ,Soccer clubs will be represented by numbers. They will be allocated to the intervention or control group using simple random technique. A blinded person will pick the numbers to allocate them in two groups. After group allocation the coin tossing will be the decider for the allocation of the group to either the intervention or the control group
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>Nuhu
    </Contact_Firstname>
    <Contact_Lastname>Assuman
    </Contact_Lastname>
    <Contact_Address> Anzio Road
    </Contact_Address>
    <Contact_Email>Nuhu.Assuman@gmail.com
    </Contact_Email>
    <Contact_Tel>+27810729728
    </Contact_Tel>
    <Contact_Affiliation>Student
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Head, assistants and goalkeeper coaches of the teams in the second division clubs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Players who have contracts and licenses of teams enrolled to play in the second division
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Players and coaches who will not agree to participate in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Players with preexisting injuries will be excluded
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Injury, Occupational Diseases, Poisoning &lt;br&gt;soccer injuries;Injury, Occupational Diseases, Poisoning;soccer injuries
    </Condition>
    <Intervention>;A comprehensive warm up programme/ FIFA 11+ warm up programme;usual warm up programme
    </Intervention>
    <Primary_outcome>Reduction of the incidence in soccer injuries
    </Primary_outcome>
    <Source_Support>Government of Rwanda through the Embassy
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>18/09/2014
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Human Research Ethics Committee 
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4826252
    </Internal_Number>
    <TrialID>NCT02391077
    </TrialID>
    <Last_Refreshed_on>23 March 2015
    </Last_Refreshed_on>
    <Public_title>A Trial Assessing Efficacy of Various Antimicrobial Techniques for Reducing Bacterial Load
    </Public_title>
    <Scientific_title>A Randomized, Open Label, Two Phase Trial, to Assess Various Antimicrobial Techniques for Reducing Bacterial Load Prior PrePex Removal
    </Scientific_title>
    <Acronym>RMC-11
    </Acronym>
    <Primary_sponsor>Ministry of Health, Rwanda
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150215
    </Date_registration3>
    <Date_registration>15/02/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT02391077
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>49 Years
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>April 2015
    </Date_enrollement>
    <Target_size>33
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
    </Study_design>
    <Phase>Phase 1
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Vincent Mutabazi, M.D.;Vincent Mutabazi, M.D.;Leon Muyenzi Ngeruka, M.D.
    </Contact_Lastname>
    <Contact_Email>;mutabazivincent@yahoo.com;dr_ngemleon@yahoo.com
    </Contact_Email>
    <Contact_Tel>;250788410827;+250 788501063
    </Contact_Tel>
    <Contact_Affiliation>Ministry of Health, Rwanda;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ages - 21 to 49 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject wants to be circumcised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncircumcised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to understand the study procedures and requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to participate in either arm and to follow the hygiene and wound care&#x0D;&lt;br&gt;             instructions&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to have swab samples&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to abstain sexual intercourse for 6 weeks post device removal&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to abstain from masturbation for 2 weeks post device removal&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to return to the health care facility for follow-up visits (or as instructed)&#x0D;&lt;br&gt;             after his circumcision&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject able to comprehend and freely give informed consent for participation in this&#x0D;&lt;br&gt;             study and is considered by the investigator to have good compliance for the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject agrees to anonymous video and photographs of the procedure and follow up&#x0D;&lt;br&gt;             visits.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active genital infection, anatomic abnormality or other condition, which in the&#x0D;&lt;br&gt;             opinion of the investigator prevents the subject from undergoing a circumcision&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject with the following diseases/conditions: phimosis, paraphimosis, warts under&#x0D;&lt;br&gt;             the prepuce, torn or tight frenulum, narrow prepuce, hypospadias, epispadias&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known bleeding / coagulation abnormality, uncontrolled diabetes, by questionnaire&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known allergy to Betadin-Iodine&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known allergy to antibiotics containing Bacitracin, Neomycin and Polymixin&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject who have an abnormal penile anatomy or any penile diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject that to the opinion of the investigator is not a good candidate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject does not agree to anonymous video and photographs of the procedure and follow&#x0D;&lt;br&gt;             up visits.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Disease Due to Gram-positive Bacteria
    </Condition>
    <Intervention>Other: Povidone-Iodine;Other: Antibiotic topical cream;Other: Chlorhexidine 1%
    </Intervention>
    <Primary_outcome>The semi quantitative count of bacteria on days 0 and 7
    </Primary_outcome>
    <Secondary_outcome>Placement preparation technique as a measure of reduction of preputial space bacterial load
    </Secondary_outcome>
    <Secondary_ID>RMC-11
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12422630
    </Internal_Number>
    <TrialID>NCT02315703
    </TrialID>
    <Last_Refreshed_on>29 July 2022
    </Last_Refreshed_on>
    <Public_title>Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention
    </Public_title>
    <Scientific_title>A Phase 1/2a Trial to Evaluate the Safety/Tolerability and Immunogenicity of Homologous Ad26 Mosaic Vector Regimens or Ad26 Mosaic and MVA Mosaic Heterologous Vector Regimens, With High-Dose, Low-Dose or no Clade C gp140 Protein Plus Adjuvant for HIV Prevention
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Janssen Vaccines &amp; Prevention B.V.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20141209
    </Date_registration3>
    <Date_registration>09/12/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02315703
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>50 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 2014
    </Date_enrollement>
    <Target_size>393
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Countries>United States;Rwanda;South Africa;Thailand;Uganda;Rwanda;South Africa;Thailand;Uganda;United States;United States;Rwanda;South Africa;Thailand;Uganda;Rwanda;South Africa;Thailand;Uganda;United States;United States;Rwanda;South Africa;Thailand;Uganda;Rwanda;South Africa;Thailand;Uganda;United States;United States;Rwanda;South Africa;Thailand;Uganda;Rwanda;South Africa;Thailand;Uganda;United States
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Janssen Vaccines &amp; Prevention B.V. Clinical Trials;Janssen Vaccines &amp; Prevention B.V. Clinical Trials;Janssen Vaccines &amp; Prevention B.V. Clinical Trials;Janssen Vaccines &amp; Prevention B.V. Clinical Trials
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>Janssen Vaccines &amp; Prevention B.V.;Janssen Vaccines &amp; Prevention B.V.;Janssen Vaccines &amp; Prevention B.V.;Janssen Vaccines &amp; Prevention B.V.
    </Contact_Affiliation>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>04/11/2020
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT02315703
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10236722
    </Internal_Number>
    <TrialID>NCT02295800
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>The Kabeho Study: Kigali Antiretroviral and Breastfeeding Assessment for the Elimination of HIV
    </Public_title>
    <Scientific_title>The Kabeho Study: Kigali Antiretroviral and Breastfeeding Assessment for the Elimination of HIV
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Elizabeth Glaser Pediatric AIDS Foundation
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20141015
    </Date_registration3>
    <Date_registration>15/10/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02295800
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>April 2013
    </Date_enrollement>
    <Target_size>1216
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Emily A. Bobrow, PhD, MPH
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Elizabeth Glaser Pediatric AIDS Foundation
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Documented HIV infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant, in the last trimester of pregnancy or within two weeks post-delivery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in the PMTCT program during antenatal care at one of the study sites&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Planning on remaining in the Kigali area after delivery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able and willing to give informed consent for study participation for herself and her&#x0D;&lt;br&gt;             infant(s).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        If a pregnant woman is less than 18 years of age and still living with her parents,&#x0D;&lt;br&gt;        informed consent will also be required from one of her parents&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women not willing to provide informed consent to participate&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Mother-to-child HIV Transmission
    </Condition>
    <Intervention>Other: Standard of care;Other: Semi-structured interviews
    </Intervention>
    <Primary_outcome>18 - 24 month HIV-free survival of children born to HIV-positive pregnant women
    </Primary_outcome>
    <Secondary_outcome>HIV-exposed infants with stunting, underweight, or wasting Infants and young children breastfed (exclusive or any breastfeeding) at various ages;Infants and young children breastfed (exclusive or any breastfeeding) at various ages;Adherence to the universal antiretroviral therapy (ARV) regimen among pregnant and postpartum women (Option B+) and their HIV-exposed children, including the proportion of study women with HIV RNA &lt; 1000 copies/ml or &gt; 2 log10 copies/mL decrease in viral
    </Secondary_outcome>
    <Secondary_ID>EGPAF0098
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Ministry of Health, Rwanda;University of Rwanda
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4763795
    </Internal_Number>
    <TrialID>NCT02281461
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Feasibility Study of PrePex Device When Performed on Early Infants &amp; Children Male Population by Physicians
    </Public_title>
    <Scientific_title>A Feasibility Study of PrePex Device for Infants and for Children, When Performed on Early Infants and Children Male Population by Physicians
    </Scientific_title>
    <Acronym>RMC-06
    </Acronym>
    <Primary_sponsor>Ministry of Health, Rwanda
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20141005
    </Date_registration3>
    <Date_registration>05/10/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT02281461
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>10 Years
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>March 2014
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Jean Paul Bitega, M.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Military Insurance, Medical Head of Clinical Affairs
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Early infants and children males in ages - 5 to 33 days or 4-10 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Weighs more than 2500gr (for early infants)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The infant or child should be healthy and in full-term&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parent/legal guardian consent to the circumcision procedure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncircumcised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parent/legal guardian able to understand the study procedures and requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parent/legal guardian agree to keep the infant for 48 hours or child for 24 hours&#x0D;&lt;br&gt;             hospitalization&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parent/legal guardian agree to return to the health care facility for follow-up&#x0D;&lt;br&gt;             visits (or as instructed) after his circumcision until complete healing is achieved&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parent/legal guardian able to comprehend and freely give informed consent for&#x0D;&lt;br&gt;             participation in this study and is considered by the investigator to have a good&#x0D;&lt;br&gt;             compliance for the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parent/legal guardian agrees to anonymous video and photographs of the procedure and&#x0D;&lt;br&gt;             follow up visits.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parent/legal guardian withhold consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active genital infection, anatomic abnormality or other condition, which in the&#x0D;&lt;br&gt;             opinion of the investigator prevents the participant from undergoing a circumcision&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant with the following diseases/conditions: Bilateral hydroceles, Curvature&#x0D;&lt;br&gt;             with penile torsion, Absence of ventral foreskin, Concealed penis (trapping urine&#x0D;&lt;br&gt;             beneath the foreskin), Megalourethra with deficiency of corpus spongiosum,&#x0D;&lt;br&gt;             Penoscrotal webbing, Epispadias, dorsal curvature, Hypospadias, Phimosis,&#x0D;&lt;br&gt;             paraphimosis, warts under the prepuce, torn or tight frenulum, narrow prepuce,&#x0D;&lt;br&gt;             hypospadias, epispadias, known haematological disorders and jaundice, yellow sclera&#x0D;&lt;br&gt;             or purpuric skin lesions, congenital abnormality&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known bleeding / coagulation abnormality, uncontrolled diabetes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant that to the opinion of the investigator is not a good candidate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parent/legal guardian does not agree to anonymous video and photographs of the&#x0D;&lt;br&gt;             procedure and follow up visits.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Medical Device Complication
    </Condition>
    <Intervention>Device: Male circumcision using a non-surgical device
    </Intervention>
    <Primary_outcome>Safety and efficacy of the PrePex device among early infants and children male population when performed by experienced surgeons
    </Primary_outcome>
    <Secondary_outcome>Effectiveness of the PrePex device on early infants and children;Effectiveness of the PrePex device on early infants and children;Effectiveness of the PrePex device on early infants and children;Effectiveness of the PrePex device on early infants and children;Effectiveness of the PrePex device on early infants and children;Effectiveness of the PrePex device on early infants and children;Effectiveness of the PrePex device on early infants and children
    </Secondary_outcome>
    <Secondary_ID>RMC-06
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>5757617
    </Internal_Number>
    <TrialID>NCT02239250
    </TrialID>
    <Last_Refreshed_on>19 September 2016
    </Last_Refreshed_on>
    <Public_title>Water Filters and Improved Cookstoves in Western Rwanda
    </Public_title>
    <Scientific_title>Assessing the Health Impact of Advance Water Filters and Improved Cookstoves in Western Province, Rwanda: A Cluster-randomised Controlled Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>London School of Hygiene and Tropical Medicine
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140909
    </Date_registration3>
    <Date_registration>09/09/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02239250
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>5 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>August 2014
    </Date_enrollement>
    <Target_size>1582
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Thomas Clasen, JD MSc PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>LSHTM &amp; Emory University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For Sector-level study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All households shown on updated 2012 government registers to be members of ubudehe 1&#x0D;&lt;br&gt;             and 2 in Western Province, Rwanda will be eligible to participate in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For nested village-level study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All villages from all sectors in Western province, according to official Government&#x0D;&lt;br&gt;             lists will be eligible for participation with the exception of those villages that&#x0D;&lt;br&gt;             were selected for participation in Phase 1.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  At the village-level, all households that are classified as ubudehe 1 &amp; 2 according&#x0D;&lt;br&gt;             to updated 2012 government registers, are part of the village, are able to provide&#x0D;&lt;br&gt;             informed consent, and that have at least one child under 4 years of age at the time&#x0D;&lt;br&gt;             of enrollment will be eligible for participation. Presence of a child under 4 years&#x0D;&lt;br&gt;             of age will be assessed by checking dates of birth or recorded age in months in the&#x0D;&lt;br&gt;             CHW register of children &lt;5 years (Igitabo Cy'Ibikorwa Byo Gukurikirana), which are&#x0D;&lt;br&gt;             maintained at the village by CHW (though occasionally these are transferred to health&#x0D;&lt;br&gt;             centers). If this data is missing will be assesses based on CHW's report. In those&#x0D;&lt;br&gt;             cases where a village has more than the required number of participating households&#x0D;&lt;br&gt;             (10 household), a random selection of 10 households will be drawn.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For the assessment of personal exposure to HAP a stricter set of eligibility criteria&#x0D;&lt;br&gt;             will be applied. Households that comply with the following eligibility criteria will&#x0D;&lt;br&gt;             be eligible for the exposure to HAP sub-study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Have a child 1.5-4 year old,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Have a child healthy enough to wear the monitoring equipment (as perceived by&#x0D;&lt;br&gt;                  the mother),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Have a non-smoking primary cook,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Have a primary cook that is currently not pregnant (as far as she is aware of),&#x0D;&lt;br&gt;                  and&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Have a primary cook that is in a healthy state to wear the monitoring equipment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The first two households identified from a randomised list will be invited to&#x0D;&lt;br&gt;             participate.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For the biomarker sub-studies, both the primary cook and the child under 4 years of&#x0D;&lt;br&gt;             age from households undergoing HAP exposure assessment will be eligible for the&#x0D;&lt;br&gt;             inflammatory cytokine biomarker study. For the enteric seroconversion study, all&#x0D;&lt;br&gt;             children aged 6 to 12 months will be eligible for participation.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Diarrhoeal Disease;Respiratory Infection;Pneumonia
    </Condition>
    <Intervention>Device: Water filter and cookstove
    </Intervention>
    <Primary_outcome>Incidence of IMCI defined pneumonia in children under 5 years of age in ubudehe 1 &amp; 2 categories;Incidence of IMCI defined diarrhoea in children under 5 years of age in ubudehe 1 &amp; 2 categories
    </Primary_outcome>
    <Secondary_outcome>All-cause mortality in children under 5 years of age in ubudehe 1 &amp; categories;Incidence of maternal health outcomes among women un ubudehe 1 &amp; 2 categories;Prevalence of self-reported diarrhoea in children under 5 years of age in ubudehe 1 &amp; 2 categories;Prevalence of pneumonia in children under 5 years of age in ubudehe 1 &amp; 2 categories
    </Secondary_outcome>
    <Secondary_ID>NCT01882777_2
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>DelAgua;Emory University;Portland State University;University of Colorado, Boulder;Oregon Health and Science University;Ministry of Health, Rwanda;National University, Rwanda
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11631683
    </Internal_Number>
    <TrialID>CTRI/2014/07/004764
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Phase 3 trial with dispersible arterolane maleate and PQP tablets in pediatric malaria patients
    </Public_title>
    <Scientific_title>A Phase 3 open label randomized multicenter trial to assess the efficacy and safety of the dispersible arterolane maleate 37.5 mg and piperaquine phosphate (PQP) 187.5 mg tablets in comparison with Coartem dispersible in pediatric patients with acute uncomplicated Plasmodium falciparum malaria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Sun Pharmaceutical Industries Ltd
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140725
    </Date_registration3>
    <Date_registration>25-07-2014
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=7539
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>08-08-2015
    </Date_enrollement>
    <Target_size>840
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized, Parallel Group, Active Controlled Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:An Open list of random numbers  Blinding and masking:Open Label
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Mozambique;Cote d'Ivoire;Democratic Republic of the Congo;India;Malawi;Mali;Rwanda;Senegal
    </Countries>
    <Contact_Firstname>Dr Rajinder K Jalali
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Medical Affairs and Clinical Research
Sector 18, Sarhaul, Udyog Vihar Industrial Area, Gurgaon 
Haryana â?? 122 015, India 
    </Contact_Address>
    <Contact_Email>SanjayK.Sharma2@sunpharma.com
    </Contact_Email>
    <Contact_Tel>91-124-4016858
    </Contact_Tel>
    <Contact_Affiliation>Sun Pharmaceutical Industries Ltd
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients must fulfil the following inclusion criteria to be eligible for enrolment into the study: &lt;br/ &gt;&lt;br&gt;1.Children of either gender (male or female) aged between 6 months to 12 years, both inclusive. &lt;br/ &gt;&lt;br&gt;2.Minimum body weight of 5 kg. &lt;br/ &gt;&lt;br&gt;3.Able to take drugs under study by the oral route &lt;br/ &gt;&lt;br&gt;4.Absence of severe malnutrition (defined as a child who has symmetrical oedema involving at least the feet and whose weight-for-height is below -3 standard deviation or less than 70% of the median of the NCHS/ WHO normalized reference values or mid-upper arm circumference  &lt; 110 mm) &lt;br/ &gt;&lt;br&gt;5.Minimum Hemoglobin (Hb) level of  &gt; 8 gm/dL. &lt;br/ &gt;&lt;br&gt;6.Presence of acute symptomatic uncomplicated malaria with a diagnosis confirmed by a positive blood smear with asexual forms of P. falciparum parasites only. &lt;br/ &gt;&lt;br&gt;7.Initial parasite densities appropriate for inclusion will be between 1,000 and 100,000 asexual parasites/Î¼L blood (both inclusive). &lt;br/ &gt;&lt;br&gt;8.Presence of fever (axillary temperature â?¥ 37.5 Â°C) or a history of fever in the past 24 hours. &lt;br/ &gt;&lt;br&gt;9.Written informed consent, provided by parent/guardian. If parent/guardian is unable to provide informed consent in writing, a thumbprint to indicate consent in the presence of at least one witness is acceptable. &lt;br/ &gt;&lt;br&gt;10.Willingness and ability to comply with the study protocol for the duration of the study. &lt;br/ &gt;&lt;br&gt;11.Patient resides within a reasonable distance of the investigational site, so that attendance of all study visits and follow-up by medical staff are logistically feasible. &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: If any of the following conditions apply, the patient should not be enrolled in the study. &lt;br/ &gt;&lt;br&gt;1.Known allergy to artesunate, artemether, artemisinin derived products, piperaquine or any other related drug. &lt;br/ &gt;&lt;br&gt;2.Infants with a history of hyperbilirubinemia during the neonatal period. &lt;br/ &gt;&lt;br&gt;3.Use of concomitant medications that may induce haemolysis or haemolytic anaemia from the World Health Organization (WHO) list of essential drugs. &lt;br/ &gt;&lt;br&gt;4.Evidence of any concomitant infection at the time of presentation (including P. vivax, P. ovale and P. malariae). &lt;br/ &gt;&lt;br&gt;5.Any other underlying disease that may compromise the diagnosis and the evaluation of the response to the study medication (including clinical symptoms of immunosuppression, tuberculosis, bacterial infection; cardiac or pulmonary disease). &lt;br/ &gt;&lt;br&gt;6.Patients with severe malaria as per WHO criteria. &lt;br/ &gt;&lt;br&gt;7.Presence of general danger signs of severe malaria among children 5 years old (as per WHO). &lt;br/ &gt;&lt;br&gt;8.Female patients between the age group of 8 to 12 years (both inclusive) who are pregnant at screening. The selection of the candidate for pregnancy screening test would be as per the judgment of the Investigator. &lt;br/ &gt;&lt;br&gt;9.Female patients between the age group of 8 to 12 years who are lactating at the time of screening. &lt;br/ &gt;&lt;br&gt;10.Any antimalarial treatment during 1 month prior to screening, as assessed by medical history. &lt;br/ &gt;&lt;br&gt;11.Participation in any investigational drug study during the 30 days prior to screening. &lt;br/ &gt;&lt;br&gt;12.Electrocardiogram (ECG) abnormalities with clinical significance or relevance that require urgent management. These abnormalities include QTc interval  450 msec at screening and cardiac conduction disorders, with the exception of right bundle branch block. &lt;br/ &gt;&lt;br&gt;13.Gastrointestinal dysfunction that could alter absorption or motility (e.g., diarrhoea defined as  3 episodes of watery stools in the previous 24 hours or patients who have had 3 episodes of vomiting within 24 hours prior to screening). &lt;br/ &gt;&lt;br&gt;14.Patients with known significant renal or hepatic impairment indicated by the following laboratory evaluations at screening: &lt;br/ &gt;&lt;br&gt;Serum creatinine  1.5Ã?upper limit of normal (ULN). &lt;br/ &gt;&lt;br&gt;Aspartate transaminase  2.5 Ã? ULN. &lt;br/ &gt;&lt;br&gt;Alanine transaminase  2.5 Ã? ULN. &lt;br/ &gt;&lt;br&gt;Serum bilirubin  3 mg/dL. &lt;br/ &gt;&lt;br&gt;15.Patients who have had a splenectomy as confirmed by history or clinical examination. &lt;br/ &gt;&lt;br&gt;16.Patients with known history of human immunodeficiency virus (HIV) infection or other immunosuppressive disorders. &lt;br/ &gt;&lt;br&gt;17.Evidence of clinically significant cardiovascular, pulmonary, metabolic, gastrointestinal, neurological, or endocrine diseases, malignancy, or other abnormalities (other than the indication being studied). &lt;br/ &gt;&lt;br&gt;18.Patients taking any drug which is metabolised by the cytochrome enzyme CYP2D6 (flecainide, metoprolol, imipramine, amitriptyline, clomipramine, etc) &lt;br/ &gt;&lt;br&gt;19.With known disturbances of electrolyte balance at screening:  &lt;br/ &gt;&lt;br&gt;Serum potassium LLN  &lt;br/ &gt;&lt;br&gt;Serum Sodium LLN  &lt;br/ &gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Health Condition 1: null- acute uncomplicated P.falciparum malaria in pediatric patients

    </Condition>
    <Intervention>Intervention1: FDC of arterolane maleate and piperaquine phosphate dispersible formulation: Arterolane maleate 37.5 mg and piperaquine phosphate 187.5 mg&lt;br&gt;&lt;br&gt;Investigational drug product will be administered orally as a single daily dose for 3 consecutive days. Number (No.) of tablets in a single dose will be provided according to the following age category of the patients.&lt;br&gt;6 months to 2yrs :1 tablet; &lt;br&gt;2 yrs to 6yrs :2 tablets; &lt;br&gt;6 yrs to â?¤12yrs:3 tablets&lt;br&gt;&lt;br&gt;Control Intervention1: Coartem Dispersible tablets: CoartemÂ® dispersible (artemether 20mg and lumefantrine 120mg)&lt;br&gt;A 3-day treatment schedule with a total of 6 oral doses will be given to patients  randomized to CoartemÂ® dispersible (artemether 20mg and lumefantrine 120mg) regimen according to the following bodyweight category of the patients:&lt;br&gt;5 to 15kg  : 1 tablet; &lt;br&gt;15 to 25kg : 2 tablets; &lt;br&gt;25 to 35kg : 3 tablets &lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Day 28 PCR corrected ACPRTimepoint: Day 28 PCR corrected ACPR
    </Primary_outcome>
    <Secondary_outcome>â?¢Median parasite clearance time (time to reach 100% clearance) (PCT). &lt;br/ &gt;&lt;br&gt;â?¢Fever clearance time (FCT). &lt;br/ &gt;&lt;br&gt;â?¢Proportion of patients with PCR-uncorrected ACPR on Day 28 and Day 42. &lt;br/ &gt;&lt;br&gt;â?¢Safety endpoints: Incidence of adverse events or clinically significant changes in laboratory parameters, physical examination, ECG, or vital signs. &lt;br/ &gt;&lt;br&gt;Timepoint: parasitology and body temperature at 6 hour intervals, discharge/ Day 3, on follow-up Days 7 (Â±1), 14(Â±1), 28(Â±1) and 42(Â±1)   &lt;br/ &gt;&lt;br&gt;Laboratory assessment Day 2, Day 28(Â±1) and Day 42(Â±1) &lt;br/ &gt;&lt;br&gt;ECG screening, and Day 2 between 2 and 4 hrs   &lt;br/ &gt;&lt;br&gt;Vital signs Days 1, 2, 3, 7(Â±1), 14(Â±1), 28(Â±1) and 42(Â±1)
    </Secondary_outcome>
    <Secondary_ID>R2012005, version 2, dated April 02, 2013
    </Secondary_ID>
    <Source_Support>Sun Pharmaceutical Industries Ltd. Plot No 20 Sector 18 Udyog Vihar Industrial Area Gurgaon 122015 Haryana
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>12/06/2014;08/08/2014;14/07/2014;20/09/2013;28/10/2014;30/10/2014;08/05/2015;06/06/2014;16/08/2014;08/09/2015;02/02/2015;24/08/2015;29/08/2013;22/09/2015;15/11/2013;09/12/2013;12/03/2014;12/11/2013;02/04/2014;11/11/2014;23/08/2013;13/12/2013;21/01/2014;24/09/2013
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;;;;;;;;;;;;;;;;;;;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Comite D Ethique de la FMPOS, Mali;Comite D Ethique KUTH for Gakurazo Health center Rwanda;Comite National Dethique Et De La Recherche Ivory Coast;Ecole de Sante Publique Comite D Ethique DRC;Ecole de Sante Publique Comite D Ethique DRC for kinshasa site;Ethics Cimmittee for Human Research LHMC and associated Hospitals new delhi;Ethics Committee AIIMS, Bhubaneswar;Ethics Committee Centre Hospitlier Universtaire University Teaching Hospital Kigali Rwanda;Ethics Committee St Theresas Hospital, Hyderabad;Institutional Ethics Comittee;Institutional Ethics Comittee, IGH, Rourkela;Institutional Ethics Committee;Institutional Ethics Committee for Human Research of Medical College, Kolkata;Institutional Ethics Committee ICH;Institutional Ethics Committee of Kalinga Institute of Medical Sciences (KIMS) Bhubaneswar;Institutional Ethics Committee Seth GS medical College &amp; KEM hospital Mumbai;Institutional Ethics Committee, AJMC, Mangalore;Institutional Ethics Committee, Calcutta School of Tropical Medicines, Kolkata;Institutional Ethics Committee, KGH, Visakhapatnam;Institutional Ethisc Committee BJMC Pune;Ministere de lenseignement Superieur Et De La Recherche Scientifique Mali;National Health Sciences Research Committee Malawi;Pentamed Ethics Committee, Medipoint Hospital Pune;Republique Du Senegal Ministere De La Sante Et De La Prevention Direction De la  Sante Dakar senegal
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;;;;;;;;;;;;;;;;;;;;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;;;;;;;;;;;;;;;;;;;;;
    </Ethics_review_contact_email>
    <results_date_completed>27/01/2016
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>5049257
    </Internal_Number>
    <TrialID>NCT02348580
    </TrialID>
    <Last_Refreshed_on>10 August 2015
    </Last_Refreshed_on>
    <Public_title>Effectiveness Study of Teacher Training and Social and Financial Education in Rwanda's Primary and Secondary Schools
    </Public_title>
    <Scientific_title>Active Learning Methods for Social and Financial Education in Rwanda's Primary and Secondary Schools: A Cluster Randomized Controlled Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Stichting Child Savings International
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20140709
    </Date_registration3>
    <Date_registration>09/07/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02348580
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>September 2013
    </Date_enrollement>
    <Target_size>1750
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Schools willing to participate in the intervention.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Classes of students in grade P6 or S3 during academic year 2014&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Teachers of entrepreneurship, social studies, or mathematics&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-consenting individuals&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Active Learning Methods and Life-skills Education
    </Condition>
    <Intervention>Behavioral: Child centered teaching of life-skills
    </Intervention>
    <Primary_outcome>Change in Teacher Use of Active Learning Methods (Observed);Change in Teacher Use of Active Learning Methods (Self-reported);Change in Teacher Use of Active Learning Methods (Student report);Change in Classroom Level of Student Engagement (Observed);Change in Student engagement (Student report)
    </Primary_outcome>
    <Secondary_outcome>Change in Students' Generalized Self-efficacy Scale (GSES-10);Change in Students' Pro-Social (PS) (6-item) and Conduct Disorder (CD) (6-item) subscales of the Strengths and Difficulties Questionnaire (SDQ);Change in Students' Financial Literacy;Change in Students' Planning Attitudes;Change in Students' Savings Behavior;Change in Students' Savings Attitudes;Change in Students' Entrepreneurship Attitudes &amp; Behavior
    </Secondary_outcome>
    <Secondary_ID>TOUN-2013-Rwanda-AMIR01
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Association of Microfinance Institutions in Rwanda
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10234159
    </Internal_Number>
    <TrialID>NCT02215278
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>A Multiple Meal Stable Iron Isotope Study in Iron Deficient Rwandese Women to Investigate the Performance of Low Phytic Acid Bean Seeds
    </Public_title>
    <Scientific_title/>
    <Acronym/>
    <Primary_sponsor>GroundWork
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140612
    </Date_registration3>
    <Date_registration>12/06/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02215278
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>30 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>February 2014
    </Date_enrollement>
    <Target_size>25
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Nicolai Petry, PhD;Diego Moretti, PhD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>GroundWork;ETH Zurich
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  non pregnant women, non lactating women&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  18-30 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  &lt;65 kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  metabolic, chronic or gastrointestinal disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  long term medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  blood donation within the last 6 month&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Enrichment of Blood With Stable Iron Isotopes
    </Condition>
    <Intervention>Dietary Supplement: 10 x 55 g/ bean per arm
    </Intervention>
    <Primary_outcome>Iron bioavailability from lpa bean variety compared to an iron biofortified variety
    </Primary_outcome>
    <Secondary_ID>lpa_002
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>HarvestPlus
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12511286
    </Internal_Number>
    <TrialID>NCT02150980
    </TrialID>
    <Last_Refreshed_on>5 September 2022
    </Last_Refreshed_on>
    <Public_title>INternational ORthopaedic MUlticenter Study in Fracture Care (INORMUS)
    </Public_title>
    <Scientific_title>INORMUS 40,000: Large Observational Cohort Study of Orthopedic Trauma Patients
    </Scientific_title>
    <Acronym>INORMUS
    </Acronym>
    <Primary_sponsor>McMaster University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140528
    </Date_registration3>
    <Date_registration>28/05/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02150980
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 2014
    </Date_enrollement>
    <Target_size>40000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Botswana;Brazil;China;Ethiopia;Ghana;India;Kenya;Malawi;Mexico;Nepal;Nigeria;Pakistan;Rwanda;South Africa;Tanzania;Uganda;Vietnam;Botswana;Brazil;China;Ethiopia;Ghana;India;Kenya;Malawi;Mexico;Nepal;Nigeria;Pakistan;Rwanda;South Africa;Tanzania;Uganda;Vietnam;Bhutan;Zimbabwe
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Mohit Bhandari, MD, PhD;Philip Devereaux, MD, PhD;Rebecca Ivers, MPH, PhD;Silvia Li
    </Contact_Lastname>
    <Contact_Email>;;;silviali@mcmaster.ca
    </Contact_Email>
    <Contact_Tel>;;;905.527.4322
    </Contact_Tel>
    <Contact_Affiliation>McMaster University;McMaster University;The George Institute;
    </Contact_Affiliation>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4753985
    </Internal_Number>
    <TrialID>NCT02153658
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>An Open Label, Blinded Assessor, Trial Comparing Odor Levels Due to Different Hygiene Methods With PrePexTM
    </Public_title>
    <Scientific_title>A Prospective, Randomized, Open Label, Blinded Assessor, Trial Comparing Odor Levels Due to Different Hygiene Techniques When Using the PrePexTM Device
    </Scientific_title>
    <Acronym>RMC-10
    </Acronym>
    <Primary_sponsor>Ministry of Health, Rwanda
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20140522
    </Date_registration3>
    <Date_registration>22/05/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT02153658
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>49 Years
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>November 2013
    </Date_enrollement>
    <Target_size>101
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Vincent Mutabazi, M.D.;Jean Paul Bitega, M.D.
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>RBC-Medical Research Centre (MRC);Military Insurance Medical
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Ages - 21 to 49 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Subject wants to be circumcised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Uncircumcised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Able to understand the study procedures and requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Agrees to participate in one of the arms and to follow hygiene instructions&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Agrees to have Independent blinded smell reviewers in the same room on Removal&#x0D;&lt;br&gt;                  visit&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Agrees that his partner will be interviewed via telephone&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Agrees to abstain sexual intercourse for 6 weeks post device removal&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Agrees to abstain from masturbation for 2 weeks post device removal&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Agrees to return to the health care facility for follow-up visits (or as&#x0D;&lt;br&gt;                  instructed) after his circumcision for a period of 1 week&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Subject able to comprehend and freely give informed consent for participation in&#x0D;&lt;br&gt;                  this study and is considered by the investigator to have good compliance for the&#x0D;&lt;br&gt;                  study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Subject agrees to anonymous video and photographs of the procedure and follow up&#x0D;&lt;br&gt;                  visits.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active genital infection, anatomic abnormality or other condition, which in the&#x0D;&lt;br&gt;             opinion of the investigator prevents the subject from undergoing a circumcision&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject with the following diseases/conditions: phimosis, paraphimosis, warts under&#x0D;&lt;br&gt;             the prepuce, torn or tight frenulum, narrow prepuce, hypospadias, epispadias&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known bleeding / coagulation abnormality, uncontrolled diabetes, by questionnaire&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject who have an abnormal penile anatomy or any penile diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject that to the opinion of the investigator is not a good candidate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject does not agree to anonymous video and photographs of the procedure and follow&#x0D;&lt;br&gt;             up visits.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Odor Levels of Study Arms
    </Condition>
    <Intervention>Procedure: Subjects cleaned the foreskin with soapy water using a syringe once a day.;Procedure: Subjects cleaned the foreskin with diluted chlorhexidine (1%) using a syringe once a day.
    </Intervention>
    <Primary_outcome>Change in Dilution-to-Threshold" (D/T) values
    </Primary_outcome>
    <Secondary_ID>Odor Study (RMC-10)
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4763793
    </Internal_Number>
    <TrialID>NCT02281435
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Follow Up Study to Evaluate a Non-Surgical Device for Adult Male Circumcision for Screen Failure Subjects
    </Public_title>
    <Scientific_title>One-arm, Open Label, Phase I (Out of 3 Phases), Pilot Study to Verify the Safety of PrePex™ Device for Screen Failure Subjects (Men With Narrow Foreskin and Phimosis) for Adult Male Circumcision, Performed by Physicians, in a Male Population That is Scheduled to Undergo Circumcision in an Effort to Prevent the Spread of HIV.
    </Scientific_title>
    <Acronym>RMC-05
    </Acronym>
    <Primary_sponsor>Ministry of Health, Rwanda
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20140522
    </Date_registration3>
    <Date_registration>22/05/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT02281435
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>49 Years
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>November 2012
    </Date_enrollement>
    <Target_size>36
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Vincent Mutabazi, M.D.;Jean Paul Bitega, M.D.
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Rwanda Ministry of Health;Rwanda Military Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ages - 21 to 49 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject wants to be circumcised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncircumcised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV sero-negative&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to understand the study procedures and requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to abstain sexual intercourse for 9 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to abstain from masturbation for 2 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to remain in the health care facility for up to 48 hours post procedure as&#x0D;&lt;br&gt;             required&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to return to the health care facility for follow-up visits (or as instructed)&#x0D;&lt;br&gt;             after his circumcision for a period of 8 weeks post removal (9 weeks total)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject able to comprehend and freely give informed consent for participation in this&#x0D;&lt;br&gt;             study and is considered by the investigator to have good compliance for the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject agrees to anonymous video and photographs of the procedure and follow up&#x0D;&lt;br&gt;             visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject that was a medical screen failure in RMC-03 study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active genital infection, anatomic abnormality or other condition, which in the&#x0D;&lt;br&gt;             opinion of the investigator prevents the subject from undergoing circumcision&#x0D;&lt;br&gt;             according to the study procedure and can only undergo surgical MC&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV sero-positive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known bleeding / coagulation abnormality, uncontrolled diabetes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject does not agree to anonymous video and photographs of the procedure and follow&#x0D;&lt;br&gt;             up visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Refusal to take HIV test&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Refuse to be hospitalized in the medical center for up to 48 hours post Placement as&#x0D;&lt;br&gt;             required&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects that should be excluded from standard surgical MC, such as warts under the&#x0D;&lt;br&gt;             prepuce, hypospadias, epispadias, un treated UTI.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Male Circumcision;HIV Prevention;Screen Failure Subjects;Narrow Foreskin
    </Condition>
    <Intervention>Device: PrePex™ device
    </Intervention>
    <Primary_outcome>Rate of clinical  Adverse Events (AEs)
    </Primary_outcome>
    <Secondary_outcome>Rate of complete circumcision;Time to complete healing;Device related incidents;Optimal methodology to perform PrePex procedure on subjects with very narrow opening of the foreskin.;Safety and effectiveness of performing PrePex MC for subjects with tight frenulum or torn frenulum
    </Secondary_outcome>
    <Secondary_ID>RMC-05 (Phase I)
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10938968
    </Internal_Number>
    <TrialID>NCT02118818
    </TrialID>
    <Last_Refreshed_on>17 May 2021
    </Last_Refreshed_on>
    <Public_title>RhEumatiC Heart diseAse Genetics
    </Public_title>
    <Scientific_title>Next Generation Sequencing Approach to the Study of Rheumatic Heart Disease
    </Scientific_title>
    <Acronym>RECHARGE
    </Acronym>
    <Primary_sponsor>Brigham and Women's Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140415
    </Date_registration3>
    <Date_registration>15/04/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02118818
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 2014
    </Date_enrollement>
    <Target_size>1000
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Jochen D Muehlschlegel, MD MMSc;Jochen D Muehlschlegel, MD, MMSc;Leon Mutesa, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;jmuehlschlegel@partners.org;lmutesa@nur.ac.rw
    </Contact_Email>
    <Contact_Tel>;+1 617 732 7330;+250 78 845 10 13
    </Contact_Tel>
    <Contact_Affiliation>Brigham and Women's Hospital, Harvard Medical School;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical and echocardiographic signs of RHD using WHF criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Congenital heart disease&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Rheumatic Heart Disease
    </Condition>
    <Intervention>Genetic: Next generation sequencing
    </Intervention>
    <Primary_outcome>Echocardiographic signs of rheumatic heart disease
    </Primary_outcome>
    <Secondary_ID>2013P002682/BWH
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National University, Rwanda
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10787464
    </Internal_Number>
    <TrialID>NCT02104700
    </TrialID>
    <Last_Refreshed_on>29 March 2021
    </Last_Refreshed_on>
    <Public_title>Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir
    </Public_title>
    <Scientific_title>Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir in Virologically-suppressed HIV-infected Rwandans (Near-Rwanda)"
    </Scientific_title>
    <Acronym>Near-Rwanda
    </Acronym>
    <Primary_sponsor>Philip Grant
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140401
    </Date_registration3>
    <Date_registration>01/04/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02104700
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 2014
    </Date_enrollement>
    <Target_size>150
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Andrew Zolopa, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Stanford University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western&#x0D;&lt;br&gt;             blot at any time prior to study entry. A second antibody test by a method other than&#x0D;&lt;br&gt;             ELISA is acceptable as an alternative confirmatory test or a previous detectable HIV&#x0D;&lt;br&gt;             RNA level&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV RNA level below the limit of quantification of the viral load assay in use&#x0D;&lt;br&gt;             in-country within the last 12 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Screening HIV RNA level below the limit of quantification as defined by the local&#x0D;&lt;br&gt;             assay&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  At least twelve months of stable first-line antiretroviral therapy consisting of&#x0D;&lt;br&gt;             nevirapine and 2 nRTIs approved by the Rwandan HIV Treatment guidelines. (No prior&#x0D;&lt;br&gt;             changes in ART are allowed)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Enrolled in the Rwanda National ART Program with no in-country transfer within the&#x0D;&lt;br&gt;             program.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Negative TB symptom screen or eligible based on algorithm outlined in&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Laboratory values obtained within 30 days prior to study entry:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Hemoglobin greater than 8.0 g/dL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Platelet count greater than 40,000/mm3&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  AST (SGOT), ALT (SGPT), and alkaline phosphatase less than 5 X ULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Total bilirubin less than 2.5 x ULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Calculated creatinine clearance greater than 60 mL/min as estimated by the&#x0D;&lt;br&gt;                  Cockcroft-Gault equation:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;                    -  Ability to meet the nutritional requirements for rilpivirine; largest meal&#x0D;&lt;br&gt;                       should consist of at least 400 total kcals and 117 kcals of fat (13 grams)&#x0D;&lt;br&gt;                       to be assessed at screening.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;                    -  For women of reproductive potential, negative serum or urine pregnancy test&#x0D;&lt;br&gt;                       within 4 weeks of initiating study medications and a negative urine&#x0D;&lt;br&gt;                       pregnancy test at the entry visit prior to randomization.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  "Women of reproductive potential" is defined as women who have not been&#x0D;&lt;br&gt;             post-menopausal for at least 24 consecutive months (i.e., who have had menses within&#x0D;&lt;br&gt;             the preceding 24 months) and have not undergone surgical sterilization (e.g.,&#x0D;&lt;br&gt;             hysterectomy, bilateral oophorectomy, or tubal ligation).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age greater than18 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability and willingness of subject to give informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of on-treatment virologic failure (defined as HIV RNA level greater than 200&#x0D;&lt;br&gt;             copies/mL at or after 6 months of antiretroviral therapy)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any change in prior ART.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently breastfeeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active tuberculosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Serious illness requiring systemic treatment and/or hospitalization until candidate&#x0D;&lt;br&gt;             either completes therapy or is clinically stable on therapy, in the opinion of the&#x0D;&lt;br&gt;             site investigator, for at least 14 days prior to study entry.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  NOTE: Isolated cutaneous Kaposi's Sarcoma, oral candidiasis, vaginal candidiasis,&#x0D;&lt;br&gt;             mucocutaneous herpes simplex, and other non-serious illnesses (as judged by the site&#x0D;&lt;br&gt;             investigator) have no restriction.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known allergy/sensitivity to study drugs or their formulations.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active drug or alcohol use or dependence that, in the opinion of the site&#x0D;&lt;br&gt;             investigator, would interfere with adherence to study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Requirement for any current medications that are prohibited with any study treatment.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV
    </Condition>
    <Intervention>Drug: Rilpivirine/Emtricitabine/Tenofovir
    </Intervention>
    <Primary_outcome>Explore Efficacy
    </Primary_outcome>
    <Secondary_outcome>HIV RNA levels
    </Secondary_outcome>
    <Secondary_ID>ISR-In-US-264-0123;Near Rwanda
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Gilead Sciences
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>6507107
    </Internal_Number>
    <TrialID>NCT02034162
    </TrialID>
    <Last_Refreshed_on>19 October 2017
    </Last_Refreshed_on>
    <Public_title>A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants
    </Public_title>
    <Scientific_title>A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment of Soil-Transmitted Helminth Infections (Ascaris Lumbricoides and Trichuris Trichiura) in Pediatric Subjects
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Janssen Research &amp; Development, LLC
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140109
    </Date_registration3>
    <Date_registration>09/01/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02034162
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>1 Year
    </Inclusion_agemin>
    <Inclusion_agemax>16 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 2014
    </Date_enrollement>
    <Target_size>295
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design/>
    <Phase>Phase 3
    </Phase>
    <Countries>Ethiopia;Rwanda;Ethiopia;Rwanda;Ethiopia;Rwanda;Ethiopia;Rwanda;Ethiopia;Rwanda;Ethiopia;Rwanda;Ethiopia;Rwanda;Ethiopia;Rwanda
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Janssen Research &amp; Development, LLC Clinical Trial;Janssen Research &amp; Development, LLC Clinical Trial;Janssen Research &amp; Development, LLC Clinical Trial;Janssen Research &amp; Development, LLC Clinical Trial
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>Janssen Research &amp; Development, LLC;Janssen Research &amp; Development, LLC;Janssen Research &amp; Development, LLC;Janssen Research &amp; Development, LLC
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Female participants who are &gt;=9 years old must have a negative urine pregnancy test at&#x0D;&lt;br&gt;             screening or at the time of randomization&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants must be an otherwise healthy child, based on medical history, physical&#x0D;&lt;br&gt;             examination, vital signs, hemoglobin, and concomitant medications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants &gt;=3 years of age must have teeth and be able to chew&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be available to return to the study site for all visits, including&#x0D;&lt;br&gt;             the follow-up visit&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parent(s)/guardians of participants (or their legally-accepted representatives) must&#x0D;&lt;br&gt;             have signed an informed consent document indicating that they understand the purpose&#x0D;&lt;br&gt;             of and procedures required for the study and are willing to have their child&#x0D;&lt;br&gt;             participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children 6 years of age and older will be asked to assent (agree) to their&#x0D;&lt;br&gt;             participation using appropriate language to their level of understanding; assent will&#x0D;&lt;br&gt;             be documented&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has active diarrhea (defined as the passage of 3 or more loose or liquid&#x0D;&lt;br&gt;             stools per day) at screening or at the time of randomization&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has a significant medical disorder, participant has difficulty in chewing&#x0D;&lt;br&gt;             or swallowing&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has significant anemia (&lt;8 g/dL)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has significant wasting (greater than 2 standard deviations below the mean&#x0D;&lt;br&gt;             World Health Organization [WHO] Child Growth Standards for weight-for-height or body&#x0D;&lt;br&gt;             mass index)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has a known hypersensitivity to mebendazole, any inert ingredients in the&#x0D;&lt;br&gt;             chewable formulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has preplanned surgery/procedures that would interfere with the conduct of&#x0D;&lt;br&gt;             the study during the course of study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants has received an investigational drug (including vaccines) or used an&#x0D;&lt;br&gt;             investigational medical device within 30 days before the planned start of treatment,&#x0D;&lt;br&gt;             or is currently enrolled in an investigational study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Employees of the investigator or study site, with direct involvement in the proposed&#x0D;&lt;br&gt;             study or other studies under the direction of that investigator or study site, as well&#x0D;&lt;br&gt;             as family members of the employees or the investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has taken any form of medication containing mebendazole or any other&#x0D;&lt;br&gt;             treatment for soil transmitted helminth infection within 30 days of entry into the&#x0D;&lt;br&gt;             study&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Female participants who are &gt;=9 years old must have a negative urine pregnancy test at&#x0D;&lt;br&gt;             screening or at the time of randomization&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants must be an otherwise healthy child, based on medical history, physical&#x0D;&lt;br&gt;             examination, vital signs, hemoglobin, and concomitant medications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants &gt;=3 years of age must have teeth and be able to chew&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be available to return to the study site for all visits, including&#x0D;&lt;br&gt;             the follow-up visit&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parent(s)/guardians of participants (or their legally-accepted representatives) must&#x0D;&lt;br&gt;             have signed an informed consent document indicating that they understand the purpose&#x0D;&lt;br&gt;             of and procedures required for the study and are willing to have their child&#x0D;&lt;br&gt;             participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children 6 years of age and older will be asked to assent (agree) to their&#x0D;&lt;br&gt;             participation using appropriate language to their level of understanding; assent will&#x0D;&lt;br&gt;             be documented&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has active diarrhea (defined as the passage of 3 or more loose or liquid&#x0D;&lt;br&gt;             stools per day) at screening or at the time of randomization&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has a significant medical disorder, participant has difficulty in chewing&#x0D;&lt;br&gt;             or swallowing&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has significant anemia (&lt;8 g/dL)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has significant wasting (greater than 2 standard deviations below the mean&#x0D;&lt;br&gt;             World Health Organization [WHO] Child Growth Standards for weight-for-height or body&#x0D;&lt;br&gt;             mass index)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has a known hypersensitivity to mebendazole, any inert ingredients in the&#x0D;&lt;br&gt;             chewable formulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has preplanned surgery/procedures that would interfere with the conduct of&#x0D;&lt;br&gt;             the study during the course of study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants has received an investigational drug (including vaccines) or used an&#x0D;&lt;br&gt;             investigational medical device within 30 days before the planned start of treatment,&#x0D;&lt;br&gt;             or is currently enrolled in an investigational study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Employees of the investigator or study site, with direct involvement in the proposed&#x0D;&lt;br&gt;             study or other studies under the direction of that investigator or study site, as well&#x0D;&lt;br&gt;             as family members of the employees or the investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has taken any form of medication containing mebendazole or any other&#x0D;&lt;br&gt;             treatment for soil transmitted helminth infection within 30 days of entry into the&#x0D;&lt;br&gt;             study&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Female participants who are &gt;=9 years old must have a negative urine pregnancy test at&#x0D;&lt;br&gt;             screening or at the time of randomization&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants must be an otherwise healthy child, based on medical history, physical&#x0D;&lt;br&gt;             examination, vital signs, hemoglobin, and concomitant medications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants &gt;=3 years of age must have teeth and be able to chew&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be available to return to the study site for all visits, including&#x0D;&lt;br&gt;             the follow-up visit&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parent(s)/guardians of participants (or their legally-accepted representatives) must&#x0D;&lt;br&gt;             have signed an informed consent document indicating that they understand the purpose&#x0D;&lt;br&gt;             of and procedures required for the study and are willing to have their child&#x0D;&lt;br&gt;             participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children 6 years of age and older will be asked to assent (agree) to their&#x0D;&lt;br&gt;             participation using appropriate language to their level of understanding; assent will&#x0D;&lt;br&gt;             be documented&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has active diarrhea (defined as the passage of 3 or more loose or liquid&#x0D;&lt;br&gt;             stools per day) at screening or at the time of randomization&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has a significant medical disorder, participant has difficulty in chewing&#x0D;&lt;br&gt;             or swallowing&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has significant anemia (&lt;8 g/dL)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has significant wasting (greater than 2 standard deviations below the mean&#x0D;&lt;br&gt;             World Health Organization [WHO] Child Growth Standards for weight-for-height or body&#x0D;&lt;br&gt;             mass index)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has a known hypersensitivity to mebendazole, any inert ingredients in the&#x0D;&lt;br&gt;             chewable formulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has preplanned surgery/procedures that would interfere with the conduct of&#x0D;&lt;br&gt;             the study during the course of study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants has received an investigational drug (including vaccines) or used an&#x0D;&lt;br&gt;             investigational medical device within 30 days before the planned start of treatment,&#x0D;&lt;br&gt;             or is currently enrolled in an investigational study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Employees of the investigator or study site, with direct involvement in the proposed&#x0D;&lt;br&gt;             study or other studies under the direction of that investigator or study site, as well&#x0D;&lt;br&gt;             as family members of the employees or the investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has taken any form of medication containing mebendazole or any other&#x0D;&lt;br&gt;             treatment for soil transmitted helminth infection within 30 days of entry into the&#x0D;&lt;br&gt;             study&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Female participants who are &gt;=9 years old must have a negative urine pregnancy test at&#x0D;&lt;br&gt;             screening or at the time of randomization&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants must be an otherwise healthy child, based on medical history, physical&#x0D;&lt;br&gt;             examination, vital signs, hemoglobin, and concomitant medications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants &gt;=3 years of age must have teeth and be able to chew&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be available to return to the study site for all visits, including&#x0D;&lt;br&gt;             the follow-up visit&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parent(s)/guardians of participants (or their legally-accepted representatives) must&#x0D;&lt;br&gt;             have signed an informed consent document indicating that they understand the purpose&#x0D;&lt;br&gt;             of and procedures required for the study and are willing to have their child&#x0D;&lt;br&gt;             participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children 6 years of age and older will be asked to assent (agree) to their&#x0D;&lt;br&gt;             participation using appropriate language to their level of understanding; assent will&#x0D;&lt;br&gt;             be documented&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has active diarrhea (defined as the passage of 3 or more loose or liquid&#x0D;&lt;br&gt;             stools per day) at screening or at the time of randomization&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has a significant medical disorder, participant has difficulty in chewing&#x0D;&lt;br&gt;             or swallowing&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has significant anemia (&lt;8 g/dL)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has significant wasting (greater than 2 standard deviations below the mean&#x0D;&lt;br&gt;             World Health Organization [WHO] Child Growth Standards for weight-for-height or body&#x0D;&lt;br&gt;             mass index)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has a known hypersensitivity to mebendazole, any inert ingredients in the&#x0D;&lt;br&gt;             chewable formulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has preplanned surgery/procedures that would interfere with the conduct of&#x0D;&lt;br&gt;             the study during the course of study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants has received an investigational drug (including vaccines) or used an&#x0D;&lt;br&gt;             investigational medical device within 30 days before the planned start of treatment,&#x0D;&lt;br&gt;             or is currently enrolled in an investigational study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Employees of the investigator or study site, with direct involvement in the proposed&#x0D;&lt;br&gt;             study or other studies under the direction of that investigator or study site, as well&#x0D;&lt;br&gt;             as family members of the employees or the investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant has taken any form of medication containing mebendazole or any other&#x0D;&lt;br&gt;             treatment for soil transmitted helminth infection within 30 days of entry into the&#x0D;&lt;br&gt;             study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Helminth Infections;Helminth Infections;Helminth Infections;Helminth Infections
    </Condition>
    <Intervention>Drug: Mebendazole;Drug: Placebo;Drug: Mebendazole;Drug: Placebo;Drug: Mebendazole;Drug: Placebo;Drug: Mebendazole;Drug: Placebo
    </Intervention>
    <Primary_outcome>Cure Rate for Ascaris Lumbricoides at the End of Double-blind Treatment Period;Cure Rate for Trichuris Trichiura at the End of Double-blind Treatment Period;Number of Participants Reporting Treatment Emergent Adverse Event (TEAE) in Double-Blind Treatment Period;Number of Participants Reporting Treatment Emergent Adverse Event (TEAE) in Open-Label Treatment Period;Cure Rate for Ascaris Lumbricoides at the End of Double-blind Treatment Period;Cure Rate for Trichuris Trichiura at the End of Double-blind Treatment Period;Number of Participants Reporting Treatment Emergent Adverse Event (TEAE) in Double-Blind Treatment Period;Number of Participants Reporting Treatment Emergent Adverse Event (TEAE) in Open-Label Treatment Period
    </Primary_outcome>
    <Secondary_outcome>Egg Count Reduction Rate (Percent) for Ascaris Lumbricoides Infestation at the End of Double-blind Treatment Period;Egg Count Reduction Rate (Percent) for Trichuris Trichiura Infestation at the End of Double-blind Treatment Period;Maximum Plasma Concentration (Cmax) of Mebendazole;Time to Reach Maximum Plasma Concentration (Tmax) of Mebendazole;Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours (AUC8h) of Mebendazole;Area Under the Plasma Concentration-Time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-last) of Mebendazole
    </Secondary_outcome>
    <Secondary_ID>MEBENDAZOLGAI3003;CR100933
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>04/11/2016
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT02034162
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4744657
    </Internal_Number>
    <TrialID>NCT02032108
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Effects of Lifestyle Education Programs on Diabetes Control in Rwanda
    </Public_title>
    <Scientific_title>Effects of Lifestyle Education Programs on Diabetes Control Among Diabetic Patients at Kigali University Teaching Hospital Rwanda
    </Scientific_title>
    <Acronym>LIDI
    </Acronym>
    <Primary_sponsor>Kigali University Teaching Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20140108
    </Date_registration3>
    <Date_registration>08/01/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT02032108
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>March 2013
    </Date_enrollement>
    <Target_size>250
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Charlotte M. Bavuma, Dr;Etienne Amendezo, Dr
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Kigali University Teaching Hospital;Kigali University Teaching Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of diabetes known since three months at least,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  being currently on treatment (insulin or oral hypoglycemiants),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  able to follow up at CHUK&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients with advanced diabetic complications (advanced nephropathy &amp; CKD,&#x0D;&lt;br&gt;             proliferative retinopathy, recent history of myocardial infarction &amp; severe Heart&#x0D;&lt;br&gt;             Failure (LVEF&lt;35%), peripheral artery disease, stroke, severe diabetic foot disease,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  any other severe illness that may impede the patient's functional capacity,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe psychiatric disorders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pregnancy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Diabetes Mellitus
    </Condition>
    <Intervention>Behavioral: lifestyle counselling
    </Intervention>
    <Primary_outcome>between groups difference in glycated haemoglobin (HbA1c)
    </Primary_outcome>
    <Secondary_outcome>endpoint versus baseline differences in glycated hemoglobin
    </Secondary_outcome>
    <Secondary_ID>LID
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Sanofi
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>6633175
    </Internal_Number>
    <TrialID>NCT01998282
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Evaluation of a Project to Distribute Water Filters and Cook Stoves in Western Rwanda--Phase 1B
    </Public_title>
    <Scientific_title>Assessing the Impact of Water Filters and Improved Cook Stoves on Drinking Water and Quality and Indoor Air Pollution: A Matched Cohort Study in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>London School of Hygiene and Tropical Medicine
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20131108
    </Date_registration3>
    <Date_registration>08/11/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01998282
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2013
    </Date_enrollement>
    <Target_size>1035
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda;Rwanda;Rwanda;Rwanda;Rwanda
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Thomas F Clasen, PhD;Thomas F Clasen, PhD;Thomas F Clasen, PhD;Thomas F Clasen, PhD;Thomas F Clasen, PhD
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>London School of Hygiene and Tropical Medicine;London School of Hygiene and Tropical Medicine;London School of Hygiene and Tropical Medicine;London School of Hygiene and Tropical Medicine;London School of Hygiene and Tropical Medicine
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Households will be eligible to participate in the study if they reside in selected villages&#x0D;&lt;br&gt;        and are willing to participate after receiving complete details regarding the study.&#x0D;&lt;br&gt;        Intervention households must have a functioning stove and water filter in order to&#x0D;&lt;br&gt;        participate, though they do not need to be in regular use. We will enroll all households&#x0D;&lt;br&gt;        with a child under 5 years of age if they are in Ubudehe groups 1 or 2.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Households will be eligible to participate in the study if they reside in selected villages&#x0D;&lt;br&gt;        and are willing to participate after receiving complete details regarding the study.&#x0D;&lt;br&gt;        Intervention households must have a functioning stove and water filter in order to&#x0D;&lt;br&gt;        participate, though they do not need to be in regular use. We will enroll all households&#x0D;&lt;br&gt;        with a child under 5 years of age if they are in Ubudehe groups 1 or 2.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Households will be eligible to participate in the study if they reside in selected villages&#x0D;&lt;br&gt;        and are willing to participate after receiving complete details regarding the study.&#x0D;&lt;br&gt;        Intervention households must have a functioning stove and water filter in order to&#x0D;&lt;br&gt;        participate, though they do not need to be in regular use. We will enroll all households&#x0D;&lt;br&gt;        with a child under 5 years of age if they are in Ubudehe groups 1 or 2.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Households will be eligible to participate in the study if they reside in selected villages&#x0D;&lt;br&gt;        and are willing to participate after receiving complete details regarding the study.&#x0D;&lt;br&gt;        Intervention households must have a functioning stove and water filter in order to&#x0D;&lt;br&gt;        participate, though they do not need to be in regular use. We will enroll all households&#x0D;&lt;br&gt;        with a child under 5 years of age if they are in Ubudehe groups 1 or 2.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Focus of Study is to Assess Filter and Stove Use and Efficacy in Reducing Exposure to Waterborne and Airborne Pathogens;Focus of Study is to Assess Filter and Stove Use and Efficacy in Reducing Exposure to Waterborne and Airborne Pathogens;Focus of Study is to Assess Filter and Stove Use and Efficacy in Reducing Exposure to Waterborne and Airborne Pathogens;Focus of Study is to Assess Filter and Stove Use and Efficacy in Reducing Exposure to Waterborne and Airborne Pathogens
    </Condition>
    <Primary_outcome>Personal exposure to PM2.5 and CO (mg/m3);Personal exposure to PM2.5 and CO (mg/m3);Personal exposure to PM2.5 and CO (mg/m3)
    </Primary_outcome>
    <Secondary_outcome>Thermotolerant coliforms (TTC) in colony forming units (CFU) per 100ml of sample water
    </Secondary_outcome>
    <Secondary_ID>6457
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Rwanda Ministry of Health;DelAgua;Portland State University;University of Colorado, Boulder
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12599569
    </Internal_Number>
    <TrialID>PACTR201406000609270
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Polymorphism of metabolisation and clinical implications
    </Public_title>
    <Scientific_title>Profile of Isoniazid Acetylation Phenotype in Rwandan healthy subjects and Tuberculosis patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>National University of Rwanda
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20130807
    </Date_registration3>
    <Date_registration>07/08/2013
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=609
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>16 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>80 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>02/01/2012
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single group: all participants receive same intervention throughout study,Non-randomised
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>Andre 
    </Contact_Firstname>
    <Contact_Lastname>Musemakweri
    </Contact_Lastname>
    <Contact_Address>University street
    </Contact_Address>
    <Contact_Email>amusemakweri@nur.ac.rw
    </Contact_Email>
    <Contact_Tel>+250788592150
    </Contact_Tel>
    <Contact_Affiliation>Dr/Butare university teaching hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Healthy individual&#x0D;&lt;br&gt;Volunteer&#x0D;&lt;br&gt;Tuberculosis patient&#x0D;&lt;br&gt;Naive on TB and HIV drugs&#x0D;&lt;br&gt;Inpatient
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: No pregnancy&#x0D;&lt;br&gt;No any medication 72 hours before
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Tuberculosis;Tuberculosis
    </Condition>
    <Intervention>;Healthy volunteers;TB Patients
    </Intervention>
    <Primary_outcome>Acetylator class: slow, intermediate, fast;Impact of Phenotype on clinical outcomes
    </Primary_outcome>
    <Source_Support>NUR research commission
    </Source_Support>
    <Ethics_review_status>Not approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;01/11/2011
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>National Ethics Committee;Butare Hospital Ethic committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone> +250787557273;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12599568
    </Internal_Number>
    <TrialID>PACTR201310000604277
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Acetylation phenotype and clinical implications in tuberculosis patients
    </Public_title>
    <Scientific_title>-	Profile of Isoniazid Acetylation Phenotype and Clinical Implications in Rwandan Healthy Subjects and Tuberculosis Patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>NUR
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20130729
    </Date_registration3>
    <Date_registration>29/07/2013
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=604
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>16 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>75 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/01/2011
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single group: all participants receive same intervention throughout study,Non-randomised
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>Andre
    </Contact_Firstname>
    <Contact_Lastname>Musemakweri
    </Contact_Lastname>
    <Contact_Address>University street
    </Contact_Address>
    <Contact_Email>amusemakweri@nur.ac.rw
    </Contact_Email>
    <Contact_Tel>+250788592150
    </Contact_Tel>
    <Contact_Affiliation>Physician/NUR CHUB
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Healthy &#x0D;&lt;br&gt;student&#x0D;&lt;br&gt;volunteer&#x0D;&lt;br&gt;Tuberculosis patient&#x0D;&lt;br&gt;Consult the University hospital&#x0D;&lt;br&gt;both sexes
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: pregnancy&#x0D;&lt;br&gt;under other treatment&#x0D;&lt;br&gt;less than 15 years&#x0D;&lt;br&gt;treated with ARVs
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Tuberculosis;Tuberculosis
    </Condition>
    <Intervention>;Healthy volunteers;Clinical outcomes
    </Intervention>
    <Primary_outcome>Acetylator class: slow, intermediate, fast
    </Primary_outcome>
    <Secondary_outcome>Impact of Phenotype on clinical outcomes
    </Secondary_outcome>
    <Source_Support>UE-ACP Edulink
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>10/03/2011
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>CHUB ethics committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4753754
    </Internal_Number>
    <TrialID>NCT02150655
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women
    </Public_title>
    <Scientific_title>Pilot Study Investigating Bacteria (Microbiota), Their By-products (Metabolome) and Environmental Toxins in Relation to Reproductive Health in Rwandan Women.
    </Scientific_title>
    <Acronym>RVMM
    </Acronym>
    <Primary_sponsor>Western University, Canada
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20130704
    </Date_registration3>
    <Date_registration>04/07/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT02150655
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>55 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>September 2012
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
    </Study_design>
    <Phase>Phase 0
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Gregor Dr Reid, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Western Ontario, Canada
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant women between the ages of 18 and 55.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  *Current infection of gonorrhoea, *Chlamydia, genital warts, *active genital herpes&#x0D;&lt;br&gt;             lesions, *active syphilis; *urinary tract infection including pyelonephritis (an&#x0D;&lt;br&gt;             ascending urinary tract infection); *receiving drug therapy that may affect the&#x0D;&lt;br&gt;             vaginal flora; *had unprotected sexual intercourse (vaginal or oral) within the past&#x0D;&lt;br&gt;             48 hours; *have used a vaginal douche, genital deodorant, or genital wipe products in&#x0D;&lt;br&gt;             the past 48 hours; *have taken any 'acidophilus' 'bifidobacteria' or probiotic health&#x0D;&lt;br&gt;             food supplements in the past 48 hours; *are menstruating at time of clinical visit.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Vulvovaginal Candidiasis;Bacterial Vaginosis
    </Condition>
    <Intervention>Biological: Lactobacillus GR-1 and Lactobacillus RC-14 oral capsules;Biological: Placebo
    </Intervention>
    <Primary_outcome>maintenance of healthy vaginal microbiota
    </Primary_outcome>
    <Secondary_outcome>Reduction of environmental toxins in blood by lactobacilli
    </Secondary_outcome>
    <Secondary_ID>102886
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>6629208
    </Internal_Number>
    <TrialID>NCT01836731
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Impact Evaluation of Community-Based Health Programs in Rwanda
    </Public_title>
    <Scientific_title>Health Impact Evaluation of the "Community-Based Environmental Health Promotion Programme" in Rwanda
    </Scientific_title>
    <Acronym>CBEHPP
    </Acronym>
    <Primary_sponsor>Georgetown University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20130416
    </Date_registration3>
    <Date_registration>16/04/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01836731
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>5 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 2013
    </Date_enrollement>
    <Target_size>8718
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda;Rwanda;Rwanda;Rwanda;Rwanda
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>James P Habyarimana, PhD;James P Habyarimana, PhD;James P Habyarimana, PhD;James P Habyarimana, PhD;James P Habyarimana, PhD
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>Georgetown University;Georgetown University;Georgetown University;Georgetown University;Georgetown University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -All households with children under 5 years in the study communities are eligible for&#x0D;&lt;br&gt;        socio-economic and health outcome evaluation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -All households are eligible to participate in the intervention. However, for the purposes&#x0D;&lt;br&gt;        of the study, households with no children under the age of 5 will not be selected for data&#x0D;&lt;br&gt;        collection purposes.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -All households with children under 5 years in the study communities are eligible for&#x0D;&lt;br&gt;        socio-economic and health outcome evaluation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -All households are eligible to participate in the intervention. However, for the purposes&#x0D;&lt;br&gt;        of the study, households with no children under the age of 5 will not be selected for data&#x0D;&lt;br&gt;        collection purposes.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -All households with children under 5 years in the study communities are eligible for&#x0D;&lt;br&gt;        socio-economic and health outcome evaluation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -All households are eligible to participate in the intervention. However, for the purposes&#x0D;&lt;br&gt;        of the study, households with no children under the age of 5 will not be selected for data&#x0D;&lt;br&gt;        collection purposes.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -All households with children under 5 years in the study communities are eligible for&#x0D;&lt;br&gt;        socio-economic and health outcome evaluation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -All households are eligible to participate in the intervention. However, for the purposes&#x0D;&lt;br&gt;        of the study, households with no children under the age of 5 will not be selected for data&#x0D;&lt;br&gt;        collection purposes.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Diarrhea;Malaria;Diarrhea;Malaria;Diarrhea;Malaria;Diarrhea;Malaria
    </Condition>
    <Intervention>Behavioral: Classic Intervention;Behavioral: Minimum Intervention;Behavioral: Classic Intervention;Behavioral: Minimum Intervention;Behavioral: Classic Intervention;Behavioral: Minimum Intervention;Behavioral: Classic Intervention;Behavioral: Minimum Intervention
    </Intervention>
    <Primary_outcome>Incidence of Diarrhea;Incidence of Diarrhea;Incidence of Diarrhea
    </Primary_outcome>
    <Secondary_outcome>Impact of CBEHPP on height-for-age in children under-5 years;Impact of CBEHPP on weight-for-age in children under-5 years;Impact of CBEHPP on drinking water quality;Impact of CBEHPP on incidence of malaria;Impact of CBEHPP on individual contribution to public goods game;Impact of CBEHPP on administratively verified cases of diarrhea;Impact of CBEHPP on administratively verified cases of pneumonia and severe pneunomia
    </Secondary_outcome>
    <Secondary_ID>CBEHPP
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National University, Rwanda;New York University;London School of Hygiene and Tropical Medicine;Innovations for Poverty Action;Bill and Melinda Gates Foundation;Emory University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4733210
    </Internal_Number>
    <TrialID>NCT01882777
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Evaluation of a Project to Distribute Water Filters and Cookstoves in Western Rwanda
    </Public_title>
    <Scientific_title>ASSESSING THE IMPACT OF WATER FILTERS AND IMPROVED COOK STOVES ON DRINKING WATER QUALITY AND INDOOR AIR POLUTION: A RANDOMISED CONTROLED TRIAL IN RWANDA
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>London School of Hygiene and Tropical Medicine
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20130222
    </Date_registration3>
    <Date_registration>22/02/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01882777
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>September 2012
    </Date_enrollement>
    <Target_size>566
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All households in three selected villages&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  None&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Faecal Contamination of Household Drinking Water (Environmental Outcome)
    </Condition>
    <Intervention>Behavioral: Household drinking water filters and cookstoves
    </Intervention>
    <Primary_outcome>Thermotolerant coliforms in household drinking water
    </Primary_outcome>
    <Secondary_outcome>Particulate matters 2.5 mg/m3 (PM2.5) concentrations;Adherence - use of water filters and cookstoves
    </Secondary_outcome>
    <Secondary_ID>6239
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>DelAgua Health and Development;Portland State University;University of Colorado, Boulder;University of Zurich;Rwanda Ministry of Health
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4736185
    </Internal_Number>
    <TrialID>NCT01921608
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Safety Study of the PrePex Device for Non-Surgical Adult Male Circumcision During Phased in National Implementation in an Effort to Prevent the Spread of HIV
    </Public_title>
    <Scientific_title>One-Arm, Open Label, Prospective Safety Study of the PrePex Device for Non-Surgical Adult Male Circumcision During Phased in National Implementation in an Effort to Prevent the Spread of HIV.
    </Scientific_title>
    <Acronym>RMC-07
    </Acronym>
    <Primary_sponsor>Ministry of Health, Rwanda
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20130217
    </Date_registration3>
    <Date_registration>17/02/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01921608
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>49 Years
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>January 2013
    </Date_enrollement>
    <Target_size>1001
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Vincent Mutabazi, M.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Rwanda Ministry of Health
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ages - 21 to 49 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject wants to be circumcised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncircumcised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to understand the study procedures and requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to abstain sexual intercourse for 6 weeks post device removal&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to abstain from masturbation for 2 weeks post device removal&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to return to the health care facility for follow-up visits (or as instructed)&#x0D;&lt;br&gt;             after his circumcision for a period of 1 week post removal (2 weeks total)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject able to comprehend and freely give informed consent for participation in this&#x0D;&lt;br&gt;             study and is considered by the investigator to have good compliance for the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject agrees to anonymous video and photographs of the procedure and follow up&#x0D;&lt;br&gt;             visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active genital infection, anatomic abnormality or other condition, which in the&#x0D;&lt;br&gt;             opinion of the investigator prevents the subject from undergoing a circumcision&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject with the following diseases/conditions: phimosis, paraphimosis, warts under&#x0D;&lt;br&gt;             the prepuce, torn or tight frenulum, narrow prepuce, hypospadias, epispadias&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known bleeding / coagulation abnormality, uncontrolled diabetes, by questionnaire&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject who have an abnormal penile anatomy or any penile diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject that to the opinion of the investigator is not a good candidate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject does not agree to anonymous video and photographs of the procedure and follow&#x0D;&lt;br&gt;             up visits&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Male Circumcision
    </Condition>
    <Intervention>Device: PrePex™ device
    </Intervention>
    <Primary_outcome>To assess the safety of scaling up Voluntary Medical Male Circumcision (VMMC) with the PrePex device by assessing the rate of moderate and severe AEs and allowing the program to continue with passive surveillance
    </Primary_outcome>
    <Secondary_ID>RMC-07
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4823409
    </Internal_Number>
    <TrialID>NCT01796613
    </TrialID>
    <Last_Refreshed_on>23 March 2015
    </Last_Refreshed_on>
    <Public_title>Safety and Acceptability of Vaginal Rings That Protect Women From Unintended Pregnancy
    </Public_title>
    <Scientific_title>Safety and Acceptability of Vaginal Rings That Protect Women From Unintended Pregnancy
    </Scientific_title>
    <Acronym>Ring-Plus
    </Acronym>
    <Primary_sponsor>Institute of Tropical Medicine, Belgium
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20130214
    </Date_registration3>
    <Date_registration>14/02/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01796613
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>35 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>June 2013
    </Date_enrollement>
    <Target_size>120
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Tania Crucitti, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Institute of Tropical Medicine, Belgium
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able and willing to give informed consent/assent, according to national guidelines&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Female who self-reports to be sexually active (meaning at least one penetrative&#x0D;&lt;br&gt;             vaginal coital act per month for the last 3 months prior to screening)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Between 18 to 35 years old, inclusive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently in good physical and mental health&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Interested in initiating hormonal contraception&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able and willing to participate in the study as required by the protocol, this&#x0D;&lt;br&gt;             includes willing to undergo HIV testing and use a NuvaRing®&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV negative at screening as confirmed by rapid HIV testing&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently using a modern contraceptive method other than barrier methods&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of a hormonal contraceptive method in the three months prior to the screening&#x0D;&lt;br&gt;             visit&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently using antimicrobial medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant on urine pregnancy test&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of cardiovascular disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of hysterectomy or genital tract surgery (including cervical polypectomy,&#x0D;&lt;br&gt;             dilatation and curettage, hysteroscopy, or laparoscopy) in the three months prior to&#x0D;&lt;br&gt;             the screening visit&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of complications with hormonal contraception or with contra indications for&#x0D;&lt;br&gt;             the use of hormonal contraceptives such as:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  History or known predisposition for venous thrombosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  History of migraine with focal neurological symptoms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Diabetes mellitus with vascular involvement&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  History of pancreatitis or severe hepatic disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Known or suspected hypersensitivity to any of the excipients of NuvaRing®&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding,&#x0D;&lt;br&gt;             incontinence or urge incontinence, diagnosed chronic and/or recurrent vulvovaginal&#x0D;&lt;br&gt;             candidiasis, urethral obstruction&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participating in other clinical studies involving investigational products&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently breastfeeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently a smoker&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Contraception
    </Condition>
    <Intervention>Device: Vaginal Ring - intermittent regimen;Device: Vaginal Ring - continuous regimen
    </Intervention>
    <Primary_outcome>vaginal bacterial counts
    </Primary_outcome>
    <Secondary_outcome>Incidence of adverse and serious adverse experiences;Changes in phenotype of bacterial vaginosis-related bacteria;Presence or absence of a biofilm on the contraceptive vaginal rings (CVRs);Changes in inflammatory cytokines concentrations in Cervicovaginal lavage (CVLs)
    </Secondary_outcome>
    <Secondary_ID>ITMC0313
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Rinda Ubuzima;University of Liverpool
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>5090751
    </Internal_Number>
    <TrialID>NCT01705990
    </TrialID>
    <Last_Refreshed_on>7 September 2015
    </Last_Refreshed_on>
    <Public_title>Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected Volunteers
    </Public_title>
    <Scientific_title>A Phase I Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety and Immunogenicity of a Sendai HIV Vaccine SeV-G(NP) Given Intranasally and Ad35-GRIN Administered Intramuscularly in Prime-Boost Regimens in HIV-Uninfected, Healthy Adult Volunteers
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>International AIDS Vaccine Initiative
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20121010
    </Date_registration3>
    <Date_registration>10/10/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01705990
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>50 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>March 2013
    </Date_enrollement>
    <Target_size>65
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
    </Study_design>
    <Phase>Phase 1
    </Phase>
    <Countries>Kenya;Rwanda;United Kingdom;Kenya;Rwanda;United Kingdom
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  healthy male or female adults,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  18 to 50 years of age (21 to 50 years of age for volunteers in Rwanda),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  who do not report high-risk behaviour for HIV infection,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  who are available for the duration of the trial,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  who are willing to undergo HIV testing,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  use an effective method of contraception, and&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  who, in the opinion of the principal investigator or designee, understand the study&#x0D;&lt;br&gt;             and who provide written informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  confirmed HIV infection,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pregnancy and lactation,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  significant acute or chronic disease,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  clinically significant laboratory abnormalities,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  recent vaccination or receipt of a blood product,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  previous receipt of an HIV vaccine, and&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  previous severe local or systemic reactions to vaccination or history of severe&#x0D;&lt;br&gt;             allergic reactions.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV Infections
    </Condition>
    <Intervention>Biological: SeV-G(NP) (0.2mL, 2x10^7 CIU);Biological: SeV-G(NP) (0.2mL, 2x10^8 CIU);Biological: Ad35-GRIN (0.5mL)
    </Intervention>
    <Primary_outcome>Number of participants with adverse events as a measure of safety and tolerability
    </Primary_outcome>
    <Secondary_outcome>Shedding;Immunogenicity
    </Secondary_outcome>
    <Secondary_ID>IAVI S001
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10218889
    </Internal_Number>
    <TrialID>NCT01618058
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Observational Study of HIV Infection in Participants of Seroconvert During Dapivirine Vaginal Ring Trials
    </Public_title>
    <Scientific_title>A Long-Term Observational Cohort Study of HIV Infection in Participants Who Seroconvert After Enrolment in Dapivirine Vaginal Ring Trials
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>International Partnership for Microbicides, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120608
    </Date_registration3>
    <Date_registration>08/06/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01618058
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>45 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>October 4, 2012
    </Date_enrollement>
    <Target_size>151
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Rwanda;South Africa;Rwanda;South Africa
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Linda-Gail Bekker
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Desmond Tutu HIV Centre
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Recent HIV seroconversion during participation in IPM 027, according to the HIV&#x0D;&lt;br&gt;             testing algorithm of that trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability and willingness to provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willingness to give the research centre permission to share information with the&#x0D;&lt;br&gt;             primary health care provider (PHCP), and willingness to sign approved site-specific&#x0D;&lt;br&gt;             documentation to facilitate such sharing.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any condition that, in the opinion of the Investigator, would preclude provision of&#x0D;&lt;br&gt;             informed consent, make participation in the study unsafe, complicate interpretation of&#x0D;&lt;br&gt;             study outcome data, or otherwise interfere with achieving the study objectives.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV Infections
    </Condition>
    <Intervention>Drug: No Investigational Product
    </Intervention>
    <Primary_outcome>To identify HIV drug resistant mutations following recent seroconversion in plasma and vaginal secretions and change in resistant mutations over time in participants previously exposed to an ARV-based microbicide or a placebo.
    </Primary_outcome>
    <Secondary_ID>IPM 007
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>5268695
    </Internal_Number>
    <TrialID>NCT01594359
    </TrialID>
    <Last_Refreshed_on>14 December 2015
    </Last_Refreshed_on>
    <Public_title>Nutrition Study of Effect of High Iron Beans on Iron Status
    </Public_title>
    <Scientific_title>Efficacy of Iron Biofortified Beans in Improving the Iron Status of Rwandan Adolescent Girls: A Randomized Control Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Swiss Federal Institute of Technology
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120503
    </Date_registration3>
    <Date_registration>03/05/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01594359
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>12 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>August 2012
    </Date_enrollement>
    <Target_size>300
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Richard F. Hurrell, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Zurich
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-pregnant adolescent subjects of reproductive age with low iron stores with or&#x0D;&lt;br&gt;             without mild anemia, who are otherwise healthy, will be enrolled in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant, lactating, severe anemia, low BMI would be excluded&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Iron Deficiency
    </Condition>
    <Intervention>Other: Biofortified beans;Other: BEAN
    </Intervention>
    <Primary_outcome>Improved iron status
    </Primary_outcome>
    <Secondary_outcome>Improved physical and cognitive performance
    </Secondary_outcome>
    <Secondary_ID>Project #8209
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>HarvestPlus
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12366811
    </Internal_Number>
    <TrialID>NCT01539226
    </TrialID>
    <Last_Refreshed_on>27 June 2022
    </Last_Refreshed_on>
    <Public_title>Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women
    </Public_title>
    <Scientific_title>A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>International Partnership for Microbicides, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120221
    </Date_registration3>
    <Date_registration>21/02/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01539226
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>45 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>March 27, 2012
    </Date_enrollement>
    <Target_size>1950
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>South Africa;Uganda;South Africa;Uganda;Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Annalene Nel
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>IPM
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women &gt; 18 and &lt; 45 years of age, at screening, who can provide informed consent;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Available for all visits and consent to follow all procedures scheduled for the trial;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Self-reported sexually active (defined as an average of at least one penetrative&#x0D;&lt;br&gt;             penile-vaginal coital act per month for the last 3 months prior to screening);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV-negative as determined by the HIV algorithm applied at screening and enrolment;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  On a stable form of contraception as defined within section 5.4 and willing to&#x0D;&lt;br&gt;             continue on stable contraception for the duration of the clinical trial, unless&#x0D;&lt;br&gt;             post-menopausal or surgically sterilised;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Asymptomatic for genital infections at the time of enrolment (if a woman is diagnosed&#x0D;&lt;br&gt;             with any clinically significant curable STI, she must have initiated treatment at&#x0D;&lt;br&gt;             least 1 week prior to enrolment and have completed the full course of treatment);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to provide adequate locator information for trial retention purposes and be&#x0D;&lt;br&gt;             reachable per local standard procedures (e.g., by home visit or telephone; or via&#x0D;&lt;br&gt;             family or close neighbour contacts); confidentiality to be maintained;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to refrain from participation in another research trial using drugs, vaccines,&#x0D;&lt;br&gt;             medical devices, microbicides or oral pre-exposure prophylaxis investigational drugs&#x0D;&lt;br&gt;             for the duration of the IPM 027 trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently pregnant or last pregnancy within 3 months prior to screening or intends to&#x0D;&lt;br&gt;             become pregnant during trial participation;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently breast-feeding;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-therapeutic injection drug use in the 12 months prior to screening;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participated in another research trial using drugs, medical devices, microbicides or&#x0D;&lt;br&gt;             oral pre-exposure prophylaxis agents within 60 days prior to screening;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previously participated or currently participating in any HIV vaccine trial;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Untreated, clinically significant urogenital infections , e.g., urinary tract, or&#x0D;&lt;br&gt;             other sexually transmitted infections, or other gynaecological symptoms within 1 week&#x0D;&lt;br&gt;             prior to enrolment;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has a Grade 2 or higher pelvic examination finding, according to the Division of AIDS&#x0D;&lt;br&gt;             Table for Grading the Severity of Adult and Pediatric Adverse Events; Addendum 1&#x0D;&lt;br&gt;             Female Genital Grading Table for Use in Microbicide Studies;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding,&#x0D;&lt;br&gt;             diagnosed chronic and/or recurrent vulvovaginal candidiasis, urethral obstruction,&#x0D;&lt;br&gt;             incontinence or urge incontinence;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any gynaecological surgery within 90 days prior to screening;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any Grade 1 or higher baseline aspartate aminotransferase (AST), alanine transaminase&#x0D;&lt;br&gt;             (ALT), or platelet count, and any Grade 2 or higher baseline haematology, chemistry or&#x0D;&lt;br&gt;             urinalysis laboratory value according to the Division of AIDS Table for Grading the&#x0D;&lt;br&gt;             Severity of Adult and Pediatric Adverse Events;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of&#x0D;&lt;br&gt;             sensitivity/allergy to latex or a silicone elastomer;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any history of diabetes mellitus and chronic use of oral corticosteroid therapy; and&#x0D;&lt;br&gt;             any uncontrolled serious chronic or progressive disease;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cervical cytology at screening that requires cryotherapy, biopsy or treatment (other&#x0D;&lt;br&gt;             than for infection). Women with Grade 1 cervical cytology findings can be enrolled&#x0D;&lt;br&gt;             upon completion of the initial phase of evaluation if no current treatment is&#x0D;&lt;br&gt;             indicated (based on local standard of care for management of abnormal cervical&#x0D;&lt;br&gt;             cytology);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any condition(s) that, in the opinion of the investigator, might put the participant&#x0D;&lt;br&gt;             at risk, or interfere with the trial objectives or the participant's adherence to&#x0D;&lt;br&gt;             trial requirements.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV Infections
    </Condition>
    <Intervention>Combination Product: Placebo Vaginal Ring;Combination Product: Dapivirine Vaginal Ring, 25 mg
    </Intervention>
    <Primary_outcome>The primary endpoint is HIV-1 seroconversion as measured by rapid and specialised laboratory testing according to comprehensive HIV testing alorithm. Endpoint confirmation of HIV infection is by Western blot.;All adverse events
    </Primary_outcome>
    <Secondary_outcome>The incidence rate of HIV-2 seroconversion;;The incidence of curable STIs;The incidence of pregnancy in each trial arm over the IP use period;;The proportion of women who report adherence to the use of the vaginal ring inserted once every 4 weeks over the trial period;;The proportion of women who report the use of the vaginal ring as acceptable;;The proportion of participants with HIV-1 drug resistance mutations among participants who acquire HIV-1.
    </Secondary_outcome>
    <Secondary_ID>IPM 027
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4705581
    </Internal_Number>
    <TrialID>NCT01521273
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Iron Absorption From Biofortified Beans With Different Levels of Phytic Acid
    </Public_title>
    <Scientific_title>A Multiple Meal Study to Evaluate the Role of Phytic Acid From Beans on Human Iron Absorption
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Swiss Federal Institute of Technology
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120125
    </Date_registration3>
    <Date_registration>25/01/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01521273
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>35 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>March 2012
    </Date_enrollement>
    <Target_size>25
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Richard Hurrell, Prof. Dr.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Swiss Federal Institute of Technology
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-pregnant, non-lactating women&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Between 18 and 40 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Below 65kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Metabolic, chronic and gastro-intestinal disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Long-term medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Blood donation within 6 month before the study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Enrichment of Blood
    </Condition>
    <Intervention>Other: Bean varieties
    </Intervention>
    <Primary_outcome>The impact of different bean phytic acid concentrations on iron absorption measured by stable iron isotope techniques
    </Primary_outcome>
    <Secondary_ID>Rwa3
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4704688
    </Internal_Number>
    <TrialID>NCT01509573
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Pilot Feasibility Trial of the Family Strengthening Intervention in Rwanda (FSI-R)
    </Public_title>
    <Scientific_title>Family-Based Prevention of Mental Health Problems in HIV/AIDS-Affected Children (R34MH084679-01A1)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Harvard School of Public Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20111222
    </Date_registration3>
    <Date_registration>22/12/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01509573
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>July 2011
    </Date_enrollement>
    <Target_size>82
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Theresa S Betancourt, ScD, MA
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Associate Professor, Harvard School of Public Health
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion criteria: All participants must be HIV/AIDS-affected (i.e., having an HIV+&#x0D;&lt;br&gt;        family member, including those who have died). We will select single and dual caregiver&#x0D;&lt;br&gt;        families to reflect population dynamics in the area. Caregivers must be at least 18 years&#x0D;&lt;br&gt;        of age (the age of majority in Rwanda), must live in the same household as the children,&#x0D;&lt;br&gt;        and must be the child's legal guardian. Legal guardians may be aunts, uncles,&#x0D;&lt;br&gt;        grandparents, or foster parents. Caregivers must be willing to discuss HIV/AIDS with&#x0D;&lt;br&gt;        school-aged children in the family.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria: Potential participants will be excluded if they do not live in the&#x0D;&lt;br&gt;        Rwinkwavu catchment area. Untreated mental illness or active suicidal ideation/attempts in&#x0D;&lt;br&gt;        the family also constitutes exclusion criteria (mental health treatment for these problems&#x0D;&lt;br&gt;        may occur in conjunction with the FSI). HIV-positive children are ineligible for the study&#x0D;&lt;br&gt;        if their HIV status has not been disclosed to them. Exclusion criteria also include lack&#x0D;&lt;br&gt;        of caregiver willingness to discuss HIV/AIDS with school-aged children in the family.&#x0D;&lt;br&gt;        Youth-headed households will be excluded due to concerns about youth caregivers' capacity&#x0D;&lt;br&gt;        to participate in the FSI in addition to other caretaking duties.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Depressive Symptoms;Anxiety;Parenting
    </Condition>
    <Intervention>Behavioral: Family Strengthening Intervention in Rwanda (FSI-R)
    </Intervention>
    <Primary_outcome>Change from Baseline in Mental Health of Children and Caregivers
    </Primary_outcome>
    <Secondary_ID>RPCGA-FSI-15440
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Partners In Health;Harvard University;Children's Hospital Boston
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4703725
    </Internal_Number>
    <TrialID>NCT01496989
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers
    </Public_title>
    <Scientific_title>A Phase 1 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate Safety and Immunogenicity of a Multiantigen HIV (HIV-MAG) pDNA Vaccine With or Without Human IL-12 pDNA GENEVAX® IL-12) and Ad35-GRIN/ENV Vaccine in HIV-Uninfected, Healthy Volunteers
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>International AIDS Vaccine Initiative
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20111219
    </Date_registration3>
    <Date_registration>19/12/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01496989
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>50 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>December 2011
    </Date_enrollement>
    <Target_size>75
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
    </Study_design>
    <Phase>Phase 1
    </Phase>
    <Countries>Kenya;Rwanda;Uganda;Kenya;Rwanda;Uganda
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  healthy male or female adults,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  18 to 50 years of age (21 to 50 years of age for volunteers in Rwanda),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  who do not report high-risk behaviour for HIV infection,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  who are available for the duration of the trial,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  who are willing to undergo HIV testing,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  use an effective method of contraception, and&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  who, in the opinion of the principal investigator or designee, understand the study&#x0D;&lt;br&gt;             and who provide written informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Principal exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  confirmed HIV infection,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pregnancy and lactation,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  significant acute or chronic disease,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  clinically significant laboratory abnormalities,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  recent vaccination or receipt of a blood product,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  previous receipt of an HIV vaccine, and&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  previous severe local or systemic reactions to vaccination or history of severe&#x0D;&lt;br&gt;             allergic reactions.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV Infections
    </Condition>
    <Intervention>Biological: HIV-MAG (3,000mcg);Biological: GENEVAX® IL-12 (100mcg);Biological: GENEVAX® IL-12 (1000mcg);Biological: Ad35-GRIN/ENV
    </Intervention>
    <Primary_outcome>Number of participants with adverse events as a measure of safety and tolerability
    </Primary_outcome>
    <Secondary_outcome>Immunogenicity
    </Secondary_outcome>
    <Secondary_ID>IAVI B004
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Profectus Biosciences, Inc.;Ichor Medical Systems Incorporated
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4698959
    </Internal_Number>
    <TrialID>NCT01434628
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Cohort Field Study to Assess the Safety and Efficacy of the PrePex Device for Non-Surgical Circumcision When Performed by Nurses
    </Public_title>
    <Scientific_title>One Arm, Open Label, Prospective, Cohort Field Study to Assess the Safety and Efficacy of the PrePex Device for Non-Surgical Circumcision When Performed by Nurses in Resource Limited Settings for HIV Prevention
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Ministry of Health, Rwanda
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20110910
    </Date_registration3>
    <Date_registration>10/09/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01434628
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>54 Years
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>July 2011
    </Date_enrollement>
    <Target_size>590
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Vincent Mutabazi, M.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>TRAC Plus
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ages 21 - 54 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject wants to be circumcised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncircumcised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to understand the study procedures and requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to abstain sexual intercourse and to keep caution not directly rub the cut&#x0D;&lt;br&gt;             area if masturbating, for 8 weeks.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to return to the health care facility for follow-up visits (or as instructed)&#x0D;&lt;br&gt;             after his circumcision for a period of 7 weeks post removal (8 weeks total).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject able to comprehend and freely give informed consent for participation in this&#x0D;&lt;br&gt;             study and is considered by the investigator to have good compliance for the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject agrees to anonymous video and photographs of the procedure and follow up&#x0D;&lt;br&gt;             visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active genital infection, anatomic abnormality or other condition, which in the&#x0D;&lt;br&gt;             opinion of the investigator prevents the subject from undergoing a circumcision&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject with the following diseases/conditions: phimosis, paraphimosis, warts under&#x0D;&lt;br&gt;             the prepuce, torn or tight frenulum, narrow prepuce, hypospadias,epispadias&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known bleeding / coagulation abnormality, uncontrolled diabetes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject who have an abnormal penile anatomy or any penile diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject that to the opinion of the investigator is not a good candidate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject does not agree to anonymous video and photographs of the procedure and follow&#x0D;&lt;br&gt;             up visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Refusal to take HIV test&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Male Circumcision;HIV Prevention
    </Condition>
    <Intervention>Device: PrePex™ device
    </Intervention>
    <Primary_outcome>To assess the safety of the PrePex device when circumcision is performed by nurses
    </Primary_outcome>
    <Secondary_outcome>Evaluating the cost of PrePex circumcision procedure;To evaluate the PrePex training needs;Assessing ideal messaging for scale up sensitization, to include:
    </Secondary_outcome>
    <Secondary_ID>RMC-03
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4698151
    </Internal_Number>
    <TrialID>NCT01424046
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Health Care for Type 1 Diabetes in Developing World
    </Public_title>
    <Scientific_title>Evaluation of Differing Type 1 Diabetes Regimens in Youth in the Developing World
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Pittsburgh
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20110824
    </Date_registration3>
    <Date_registration>24/08/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01424046
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>1 Year
    </Inclusion_agemin>
    <Inclusion_agemax>24 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>May 2011
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Trevor J Orchard, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Pittsburgh
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Type 1 diabetes being treated by the Association Rwandese des Diabetiques&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Resident of Rwanda&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  life expectancy less than three years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  requiring additional diabetes therapy beyond the scope of the trial&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Type 1 Diabetes
    </Condition>
    <Intervention>Drug: basal insulin glargine;Drug: standard therapy
    </Intervention>
    <Primary_outcome>HbA1c
    </Primary_outcome>
    <Secondary_outcome>Microalbuminuria
    </Secondary_outcome>
    <Secondary_ID>RC4DK090809;RC4 pitt 1
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National University, Rwanda;Association Rwandaise des Diabetiques
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4696412
    </Internal_Number>
    <TrialID>NCT01401335
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>HIV Prevention and Care of Psychological Trauma in Vulnerable Rwandan Youth
    </Public_title>
    <Scientific_title>A PILOT STUDY Integrating HIV Prevention and Care With Treatment of Psychological Trauma in Vulnerable Rwandan Youth: A Community-based Pilot Intervention
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Stanford University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20110719
    </Date_registration3>
    <Date_registration>19/07/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01401335
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>25 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>October 2009
    </Date_enrollement>
    <Target_size>120
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States;Rwanda;United States;Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Andrew R Zolopa
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Stanford University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  100 orphans/vulnerable youth aged 15 to 25 will be recruited through their&#x0D;&lt;br&gt;             participation at the day care center, on a voluntary basis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age less than 15 or greater than 25 and not participating in the day care center&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Acquired Immunodeficiency Syndrome;Stress Disorders, Post-Traumatic
    </Condition>
    <Intervention>Behavioral: Questionnaires
    </Intervention>
    <Primary_outcome>psychosocial interventions
    </Primary_outcome>
    <Secondary_outcome>HIV treatment adherence and medical follow-up adherence questionnaires
    </Secondary_outcome>
    <Secondary_ID>IRB# 17289;SU-12082010-7279
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Ministry of Health, Rwanda
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>8757194
    </Internal_Number>
    <TrialID>ACTRN12611000493943
    </TrialID>
    <Last_Refreshed_on>13 January 2020
    </Last_Refreshed_on>
    <Public_title>An Evaluation of the World Health Organization Trauma Care Checklist
    </Public_title>
    <Scientific_title>Evaluation of Health Care Worker Behavior Change in response to a Trauma Care Checklist Programme intervention Before and After study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>World Health Organization
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20110511
    </Date_registration3>
    <Date_registration>11/05/2011
    </Date_registration>
    <Source_Register>ANZCTR
    </Source_Register>
    <web_address>https://anzctr.org.au/ACTRN12611000493943.aspx
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>No limit
    </Inclusion_agemin>
    <Inclusion_agemax>No limit
    </Inclusion_agemax>
    <Inclusion_gender>Both males and females
    </Inclusion_gender>
    <Date_enrollement>12/10/2010
    </Date_enrollement>
    <Target_size>3200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Purpose: Educational / counselling / training; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Efficacy;
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Australia;Viet Nam;Canada;Colombia;Cameroon;Rwanda;India;Thailand
    </Countries>
    <Inclusion_Criteria>Inclusion criteria: Health care workers treating severely injured patients during the first hour of their admission to the emergency room
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Health care workers who do not wish to participate in the study
    </Exclusion_Criteria>
    <Condition>Resuscitation of severely injured patients by health care workers in the emergency room; &lt;br&gt;Resuscitation of severely injured patients by health care workers in the emergency room;Public Health - Health promotion/education
    </Condition>
    <Intervention>Trauma Care Checklist to be used by the health care worker during the first one hour of resuscitation for severely injured patients who present to the emergency room. The purpose of the checklist is to help remind healthcare workers of certain key items in the initial resuscitation that should be completed for all severely injured patients. Health care workers will be assessed for a period of time before checklist implementation and after checklist implementation based on a stepped wedge intervention design.
    </Intervention>
    <Primary_outcome>Adherence to items on the checklist by health care workers as measured by observation and chart review.[During the resuscitation of severely injured patients health care workers will be observed both before and after checklist implementation. The before period for each site will be between 4 and 6 months and the after period will be between 6 and 8 months.];morbidity of patients being treated by health care workers will be measured by chart review at the time of patient discharge.[morbidity of patients being treated by health care workers will be measured by chart review at the time of patient discharge both before and after checklist implementation. The before period for each site will be between 4 and 6 months and the after period will be between 6 and 8 months.]
    </Primary_outcome>
    <Secondary_outcome>mortality of patients being treated by health care workers measured by chart review at time time of patient discharge.[mortality of patients being treated by health care workers measured by chart review at time time of patient discharge  both before and after checklist implementation. The before period for each site will be between 4 and 6 months and the after period will be between 6 and 8 months.]
    </Secondary_outcome>
    <Secondary_ID>Nil
    </Secondary_ID>
    <Source_Support>Second Assist;AO Foundation
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>World Health Organization
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4691546
    </Internal_Number>
    <TrialID>NCT01337570
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa
    </Public_title>
    <Scientific_title>A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Phase III Safety and Efficacy Trial of a Vaginal Matrix Ring With Dapivirine for the Prevention of HIV-1 Infection in Women
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>International Partnership for Microbicides, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20110413
    </Date_registration3>
    <Date_registration>13/04/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01337570
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>40 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>July 2011
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Malawi;Rwanda;South Africa;Zimbabwe;Malawi;Rwanda;South Africa;Zimbabwe
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Annalene Nel
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>IPM
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women &gt;18 and &lt;40 years of age who can provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Available for all visits and consent to follow all procedures scheduled for the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Generally healthy and self-reported sexually active (defined as an average of at&#x0D;&lt;br&gt;             least one penetrative penile vaginal coital act per month for the last 3 months prior&#x0D;&lt;br&gt;             to enrolment)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV-negative as determined by the HIV algorithm applied at screening and enrolment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  On a stable form of contraception as defined within section 5.4 and willing to&#x0D;&lt;br&gt;             continue on stable contraception for the duration of the clinical trial;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Asymptomatic for genital infections at the time of enrolment (if a woman is diagnosed&#x0D;&lt;br&gt;             with any clinically significant treatable STI, she must have initiated treatment at&#x0D;&lt;br&gt;             least 1 week prior to enrolment and have completed the full course of treatment)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to answer questions about adherence, sexual behaviour, vaginal practices and&#x0D;&lt;br&gt;             ring acceptability;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to provide adequate locator information for trial retention purposes and be&#x0D;&lt;br&gt;             reachable per local standard procedures (e.g., by home visit or telephone; or via&#x0D;&lt;br&gt;             family or close neighbour contacts [confidentiality to be maintained])&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to refrain from participation in another research trial using drugs,&#x0D;&lt;br&gt;             vaccines, medical devices, microbicides or oral pre-exposure prophylaxis&#x0D;&lt;br&gt;             investigational drugs for the duration of the IPM 009A trial;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In the absence of the use of exogenous hormone(s), have a self-reported regular&#x0D;&lt;br&gt;             menstrual cycle defined as having a minimum of 21 days and a maximum of 35 days&#x0D;&lt;br&gt;             between menses;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to refrain from use of vaginal products or objects including spermicides,&#x0D;&lt;br&gt;             tampons, female condoms, cotton wool, rags, diaphragms, cervical caps (or any other&#x0D;&lt;br&gt;             vaginal barrier method), douches and drying agents within 14 days from enrolment and&#x0D;&lt;br&gt;             for the duration of the trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently pregnant or last pregnancy within 3 months prior to screening;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently breast-feeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participated in another research trial using drugs, medical devices, microbicides or&#x0D;&lt;br&gt;             oral pre-exposure prophylaxis agents within 60 days prior to screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previously participated or currently participating in any HIV vaccine trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Untreated, clinically significant urogenital infections (either symptomatic or&#x0D;&lt;br&gt;             asymptomatic), e.g., urinary tract or other sexually transmitted infections, or other&#x0D;&lt;br&gt;             gynaecological symptoms within 1 week prior to enrolment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding,&#x0D;&lt;br&gt;             urethral obstruction, incontinence or urge incontinence&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any gynaecological surgery within 90 days prior to enrolment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any Grade 3 or 4 baseline haematology, chemistry or urinalysis laboratory value&#x0D;&lt;br&gt;             according to the DAIDS Table for Grading Adverse Experiences, or clinically&#x0D;&lt;br&gt;             significant Grade 2 findings&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of&#x0D;&lt;br&gt;             sensitivity/allergy to latex or a silicone elastomer&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any history of diabetes mellitus and chronic use of oral steroid therapy and any&#x0D;&lt;br&gt;             uncontrolled serious chronic or progressive disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cervical cytology at screening that requires cryotherapy, biopsy, treatment (other&#x0D;&lt;br&gt;             than for infection), or further evaluation [this includes any findings of atypical&#x0D;&lt;br&gt;             squamous cells of undetermined significance (ASCUS)]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any condition(s) that, in the opinion of the investigator, might put the participant&#x0D;&lt;br&gt;             at risk, or interfere with the trial objectives, or adherence to trial requirements&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV Infections
    </Condition>
    <Intervention>Other: Dapivirine;Other: Placebo;Drug: Dapivirine
    </Intervention>
    <Primary_outcome>Efficacy as determined by the proportion of women in each arm HIV-1 seroconversion rate per person-years of product use, measured at the end of the investigational product use period.;Safety as determined by grade 3 and 4 AE's, clinically significant grade 2 laboratory findings (based on DAIDS grading) and all serious AE's.
    </Primary_outcome>
    <Secondary_outcome>Adherence to the protocol-specific product regimen as determined by self-reported diary cards and questionnaires.;The incidence of curable STI's or pregnancy as determined by STI testing and pregnancy testing.
    </Secondary_outcome>
    <Secondary_ID>IPM 009A
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>6500412
    </Internal_Number>
    <TrialID>NCT01339429
    </TrialID>
    <Last_Refreshed_on>19 October 2017
    </Last_Refreshed_on>
    <Public_title>Simplified Negative Pressure Wound Therapy
    </Public_title>
    <Scientific_title>Evaluation of the Performance and Safety of a Simplified Negative Pressure Wound Therapy Device
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Brigham and Women's Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20110328
    </Date_registration3>
    <Date_registration>28/03/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01339429
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>14 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 2011
    </Date_enrollement>
    <Target_size>41
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design/>
    <Phase>Phase 1
    </Phase>
    <Countries>Rwanda;Rwanda;Rwanda;Rwanda
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Robert Riviello, M.D., M.P.H.;Robert Riviello, M.D., M.P.H.;Robert Riviello, M.D., M.P.H.;Robert Riviello, M.D., M.P.H.
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>Brigham and Women's Hospital;Brigham and Women's Hospital;Brigham and Women's Hospital;Brigham and Women's Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  open wound appropriate for NPWT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  wound size greater than 2 cm2 and less than 150 cm2&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  adequate adjacent intact skin for application of sNPWT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  adequate contour of wound location for application of sNPWT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patient is expected to tolerate change of the NPWT dressing with the chosen analgesia&#x0D;&lt;br&gt;             and sedation plan by the treating physician&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  the patient is expected to remain clinically stable for the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  the patient is to remain hospitalized for the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patient or their legal representative is willing and able to sign an IRB-approved&#x0D;&lt;br&gt;             informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patient less than 21 years old is willing to sign an approved assent form if able to&#x0D;&lt;br&gt;             sign&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  exposed blood vessels&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ischemic wound&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  wound with necrotic tissue requiring further debridement at the time of enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  acute osteomyelitis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  malignancy in the wound&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  latex or rubber containing product sensitivity&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  open wound appropriate for NPWT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  wound size greater than 2 cm2 and less than 150 cm2&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  adequate adjacent intact skin for application of sNPWT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  adequate contour of wound location for application of sNPWT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patient is expected to tolerate change of the NPWT dressing with the chosen analgesia&#x0D;&lt;br&gt;             and sedation plan by the treating physician&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  the patient is expected to remain clinically stable for the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  the patient is to remain hospitalized for the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patient or their legal representative is willing and able to sign an IRB-approved&#x0D;&lt;br&gt;             informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patient less than 21 years old is willing to sign an approved assent form if able to&#x0D;&lt;br&gt;             sign&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  exposed blood vessels&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ischemic wound&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  wound with necrotic tissue requiring further debridement at the time of enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  acute osteomyelitis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  malignancy in the wound&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  latex or rubber containing product sensitivity&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  open wound appropriate for NPWT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  wound size greater than 2 cm2 and less than 150 cm2&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  adequate adjacent intact skin for application of sNPWT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  adequate contour of wound location for application of sNPWT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patient is expected to tolerate change of the NPWT dressing with the chosen analgesia&#x0D;&lt;br&gt;             and sedation plan by the treating physician&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  the patient is expected to remain clinically stable for the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  the patient is to remain hospitalized for the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patient or their legal representative is willing and able to sign an IRB-approved&#x0D;&lt;br&gt;             informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patient less than 21 years old is willing to sign an approved assent form if able to&#x0D;&lt;br&gt;             sign&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  exposed blood vessels&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ischemic wound&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  wound with necrotic tissue requiring further debridement at the time of enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  acute osteomyelitis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  malignancy in the wound&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  latex or rubber containing product sensitivity&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  open wound appropriate for NPWT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  wound size greater than 2 cm2 and less than 150 cm2&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  adequate adjacent intact skin for application of sNPWT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  adequate contour of wound location for application of sNPWT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patient is expected to tolerate change of the NPWT dressing with the chosen analgesia&#x0D;&lt;br&gt;             and sedation plan by the treating physician&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  the patient is expected to remain clinically stable for the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  the patient is to remain hospitalized for the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patient or their legal representative is willing and able to sign an IRB-approved&#x0D;&lt;br&gt;             informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patient less than 21 years old is willing to sign an approved assent form if able to&#x0D;&lt;br&gt;             sign&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  exposed blood vessels&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ischemic wound&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  wound with necrotic tissue requiring further debridement at the time of enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  acute osteomyelitis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  malignancy in the wound&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  latex or rubber containing product sensitivity&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Wounds;Wounds;Wounds;Wounds
    </Condition>
    <Intervention>Device: simplified negative pressure wound therapy device (Wound Pump device);Device: simplified negative pressure wound therapy device (Wound Pump device);Device: simplified negative pressure wound therapy device (Wound Pump device);Device: simplified negative pressure wound therapy device (Wound Pump device)
    </Intervention>
    <Primary_outcome>Maintenance of Negative Pressure;Maintenance of Negative Pressure
    </Primary_outcome>
    <Secondary_outcome>Number of Participants With Serious Adverse Events
    </Secondary_outcome>
    <Secondary_ID>2010-P-002279/1
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Center for Integration of Medicine &amp; Innovative Technology;Fogarty International Clinical Research Scholarship
    </Secondary_Sponsor>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>20/05/2015
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT01339429
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4687472
    </Internal_Number>
    <TrialID>NCT01284088
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Comparing the PrePex™ Device to Surgical Circumcision for Rapid Scale Up of Male Circumcision in Resource Limited Setting
    </Public_title>
    <Scientific_title>A Prospective, Randomized, Open Label, Trial Comparing the PrePex™ Device to Surgical Circumcision for Rapid Scale Up of Male Circumcision in Resource Limited Settings
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Ministry of Health, Rwanda
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20110124
    </Date_registration3>
    <Date_registration>24/01/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01284088
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>54 Years
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>January 2011
    </Date_enrollement>
    <Target_size>217
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Agnes Binagwaho, M.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Ministry of Health, Rwanda
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ages 21 - 54 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject wants to be circumcised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncircumcised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to be circumcised by any of the study methods, PrePex™ or Surgical as will be&#x0D;&lt;br&gt;             determined randomly&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to understand the study procedures and requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to abstain sexual intercourse and to keep caution not directly rub the cut&#x0D;&lt;br&gt;             area if masturbating, for 8 weeks post removal (9 weeks total).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to return to the health care facility for follow-up visits (or as instructed)&#x0D;&lt;br&gt;             after his circumcision that may take up to 8 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject able to comprehend and freely give informed consent for participation in this&#x0D;&lt;br&gt;             study and is considered by the investigator to have good compliance for the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active genital infection, anatomic abnormality or other condition, which in the&#x0D;&lt;br&gt;             opinion of the investigator prevents the subject from undergoing a circumcision&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject with the following diseases/conditions: phimosis, paraphimosis, warts under&#x0D;&lt;br&gt;             the prepuce, torn or tight frenulum, narrow prepuce, hypospadias,epispadias&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known bleeding/coagulation abnormality, uncontrolled diabetes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject who have an abnormal penile anatomy or any penile diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject that to the opinion of the investigator is not a good candidate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject that refuse to have an HIV test&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject does not agree to anonymous video and photographs of the procedure and follow&#x0D;&lt;br&gt;             up.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV
    </Condition>
    <Intervention>Device: PrePex™ device for adult male circumcision;Procedure: Surgical circumcision
    </Intervention>
    <Primary_outcome>The study's primary goal is to compare the PrePex™ circumcision procedure with one of the approved WHO methods of surgical circumcision.
    </Primary_outcome>
    <Secondary_outcome>Measured circumcision preparation time.;Pain assessment at key time points;Clinical adverse event rates;Patient satisfaction;Time to complete healing
    </Secondary_outcome>
    <Secondary_ID>RMC-01
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4690801
    </Internal_Number>
    <TrialID>NCT01327755
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Rwanda Selenium Supplementation Clinical Trial
    </Public_title>
    <Scientific_title>Effect of Selenium Supplementation on CD4 + Cell Recovery, Viral Suppression, Morbidity and Quality of Life of HIV Infected Patients in Rwanda: a Prospective, Double-Blinded, Placebo-Controlled Trial
    </Scientific_title>
    <Acronym>RSST
    </Acronym>
    <Primary_sponsor>The Canadian College of Naturopathic Medicine
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20110111
    </Date_registration3>
    <Date_registration>11/01/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01327755
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>February 2011
    </Date_enrollement>
    <Target_size>300
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Julius K Kamwesiga, MD MPH(cand);Don Warren, BSc ND DHANP
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Rwanda Selenium Supplementation Clinical Trial;Global Benefit Canada
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients &gt; or = 21 years at enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Confirmed HIV positive with a CD4 range between 400 and 650 mm3&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV+ patients willing to participate in the study and who provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pre-antiretroviral therapy (Pre-ART) at enrollment in study (not yet initiated ART)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to practice barrier method of birth control at all times&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients intending to be transferred out of the clinic catchment area before study&#x0D;&lt;br&gt;             ends&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients scheduled to start ART&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Moribund patients&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant women&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unable or not wanting to commit to barrier method of birth control&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV
    </Condition>
    <Intervention>Dietary Supplement: Selenium;Other: Placebo
    </Intervention>
    <Primary_outcome>CD4 count
    </Primary_outcome>
    <Secondary_outcome>viral load;Occurrence of opportunistic infections;Incidence of antiretroviral therapy (ART)initiation
    </Secondary_outcome>
    <Secondary_ID>RCT-32122010
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Global Benefit Canada;University of Ottawa;Wilfrid Laurier University;Kibagabaga District Hospital;Kinyinya Health Centre
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>6499314
    </Internal_Number>
    <TrialID>NCT01258049
    </TrialID>
    <Last_Refreshed_on>19 October 2017
    </Last_Refreshed_on>
    <Public_title>Superiority of ArTiMist Versus Quinine in Children With Severe Malaria
    </Public_title>
    <Scientific_title>A Phase III, Randomised, Open Labelled, Active Controlled, Multi Centre, Superiority Trial of ArTiMist™ Versus Intravenous Quinine in Children With Severe or Complicated Falciparum Malaria, or Uncomplicated Falciparum Malaria With Gastrointestinal Complications.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Proto Pharma Ltd
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20101209
    </Date_registration3>
    <Date_registration>09/12/2010
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01258049
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 2010
    </Date_enrollement>
    <Target_size>151
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design/>
    <Phase>Phase 3
    </Phase>
    <Countries>Burkina Faso;Ghana;Rwanda;Burkina Faso;Ghana;Rwanda;Burkina Faso;Ghana;Rwanda;Burkina Faso;Ghana;Rwanda;Burkina Faso;Ghana;Rwanda;Burkina Faso;Ghana;Rwanda;Burkina Faso;Ghana;Rwanda;Burkina Faso;Ghana;Rwanda
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Daryl Bendel, MBChB MFPM;Daryl Bendel, MBChB MFPM;Daryl Bendel, MBChB MFPM;Daryl Bendel, MBChB MFPM
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>Xidea Solutions Limited;Xidea Solutions Limited;Xidea Solutions Limited;Xidea Solutions Limited
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. The patient's legally acceptable representative has provided informed consent and the&#x0D;&lt;br&gt;             patient has assented (where relevant) to participation in the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. The patient is a child that weighs between 5.00 kg and 15.00 kg inclusive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. The patient has falciparum malaria as evidenced by thick or thin blood smears of = 500&#x0D;&lt;br&gt;             P Falciparum per mcl (patients with mixed infections may be included provided = 500 P&#x0D;&lt;br&gt;             Falciparum per mcl)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. The patient has either:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  severe or complicated falciparum malaria as determined by the investigator based&#x0D;&lt;br&gt;                  on the WHO criteria for severity, and/or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  uncomplicated falciparum malaria but is unable to tolerate oral medication as a&#x0D;&lt;br&gt;                  result of gastrointestinal complications such as vomiting or diarrhoea.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. The patient's legally acceptable representative does not provide informed consent for&#x0D;&lt;br&gt;             participation, or the child if capable, does not assent to participation in the trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Ability to tolerate oral therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patient has received any antimalarial therapy within the 7 days prior to first study&#x0D;&lt;br&gt;             drug administration.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient has evidence of significant co-infections (this does not include mixed&#x0D;&lt;br&gt;             Plasmodium infections).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patient has a contraindication, allergy or is otherwise intolerant to either&#x0D;&lt;br&gt;             artemether or quinine .&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. The patient's legally acceptable representative has provided informed consent and the&#x0D;&lt;br&gt;             patient has assented (where relevant) to participation in the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. The patient is a child that weighs between 5.00 kg and 15.00 kg inclusive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. The patient has falciparum malaria as evidenced by thick or thin blood smears of = 500&#x0D;&lt;br&gt;             P Falciparum per mcl (patients with mixed infections may be included provided = 500 P&#x0D;&lt;br&gt;             Falciparum per mcl)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. The patient has either:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  severe or complicated falciparum malaria as determined by the investigator based&#x0D;&lt;br&gt;                  on the WHO criteria for severity, and/or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  uncomplicated falciparum malaria but is unable to tolerate oral medication as a&#x0D;&lt;br&gt;                  result of gastrointestinal complications such as vomiting or diarrhoea.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. The patient's legally acceptable representative does not provide informed consent for&#x0D;&lt;br&gt;             participation, or the child if capable, does not assent to participation in the trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Ability to tolerate oral therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patient has received any antimalarial therapy within the 7 days prior to first study&#x0D;&lt;br&gt;             drug administration.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient has evidence of significant co-infections (this does not include mixed&#x0D;&lt;br&gt;             Plasmodium infections).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patient has a contraindication, allergy or is otherwise intolerant to either&#x0D;&lt;br&gt;             artemether or quinine .&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. The patient's legally acceptable representative has provided informed consent and the&#x0D;&lt;br&gt;             patient has assented (where relevant) to participation in the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. The patient is a child that weighs between 5.00 kg and 15.00 kg inclusive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. The patient has falciparum malaria as evidenced by thick or thin blood smears of = 500&#x0D;&lt;br&gt;             P Falciparum per mcl (patients with mixed infections may be included provided = 500 P&#x0D;&lt;br&gt;             Falciparum per mcl)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. The patient has either:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  severe or complicated falciparum malaria as determined by the investigator based&#x0D;&lt;br&gt;                  on the WHO criteria for severity, and/or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  uncomplicated falciparum malaria but is unable to tolerate oral medication as a&#x0D;&lt;br&gt;                  result of gastrointestinal complications such as vomiting or diarrhoea.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. The patient's legally acceptable representative does not provide informed consent for&#x0D;&lt;br&gt;             participation, or the child if capable, does not assent to participation in the trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Ability to tolerate oral therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patient has received any antimalarial therapy within the 7 days prior to first study&#x0D;&lt;br&gt;             drug administration.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient has evidence of significant co-infections (this does not include mixed&#x0D;&lt;br&gt;             Plasmodium infections).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patient has a contraindication, allergy or is otherwise intolerant to either&#x0D;&lt;br&gt;             artemether or quinine .&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. The patient's legally acceptable representative has provided informed consent and the&#x0D;&lt;br&gt;             patient has assented (where relevant) to participation in the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. The patient is a child that weighs between 5.00 kg and 15.00 kg inclusive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. The patient has falciparum malaria as evidenced by thick or thin blood smears of = 500&#x0D;&lt;br&gt;             P Falciparum per mcl (patients with mixed infections may be included provided = 500 P&#x0D;&lt;br&gt;             Falciparum per mcl)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. The patient has either:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  severe or complicated falciparum malaria as determined by the investigator based&#x0D;&lt;br&gt;                  on the WHO criteria for severity, and/or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  uncomplicated falciparum malaria but is unable to tolerate oral medication as a&#x0D;&lt;br&gt;                  result of gastrointestinal complications such as vomiting or diarrhoea.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. The patient's legally acceptable representative does not provide informed consent for&#x0D;&lt;br&gt;             participation, or the child if capable, does not assent to participation in the trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Ability to tolerate oral therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patient has received any antimalarial therapy within the 7 days prior to first study&#x0D;&lt;br&gt;             drug administration.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient has evidence of significant co-infections (this does not include mixed&#x0D;&lt;br&gt;             Plasmodium infections).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patient has a contraindication, allergy or is otherwise intolerant to either&#x0D;&lt;br&gt;             artemether or quinine .&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Plasmodium Falciparum Malaria;Plasmodium Falciparum Malaria;Plasmodium Falciparum Malaria;Plasmodium Falciparum Malaria
    </Condition>
    <Intervention>Drug: Artemether Sublingual Spray;Drug: Quinine;Drug: Artemether Sublingual Spray;Drug: Quinine;Drug: Artemether Sublingual Spray;Drug: Quinine;Drug: Artemether Sublingual Spray;Drug: Quinine
    </Intervention>
    <Primary_outcome>Parasitological Success (MITT);Parasitological Success (PP);Parasitological Success (MITT);Parasitological Success (PP)
    </Primary_outcome>
    <Secondary_outcome>Parasite Clearance Time (PCT) [MITT Population];PCT 90 [MITT Population];PCT 50 [MITT Population];PRR 24 [MITT Population];PRR 12 [MITT Population];Fever Clearance Time (FCT);Complete Cure Rate;Early Treatment Failure;Late Clinical Failure;Late Parasitological Failure;Time to Return to Full Consciousness;Time to Return to Normal Per os Status;Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events, of Possible, Probably and Definite Causalities;Number of Deaths or Neurological Sequelae at Day 28
    </Secondary_outcome>
    <Secondary_ID>ART004
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>28/02/2014
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT01258049
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4530293
    </Internal_Number>
    <TrialID>ISRCTN91805477
    </TrialID>
    <Last_Refreshed_on>13 January 2015
    </Last_Refreshed_on>
    <Public_title>Coartem or Coarnate for uncomplicated malaria and parasite carriage in Rwanda
    </Public_title>
    <Scientific_title>An open labeled randomised trial of Coartem vs. Co-Arinate for uncomplicated malaria and parasite carriage in Rwanda                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>INTERACT - Centre for Poverty related Communicable Diseases (CPCD) (Rwanda)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20101025
    </Date_registration3>
    <Date_registration>25/10/2010
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN91805477
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Not Specified
    </Inclusion_gender>
    <Date_enrollement>15/09/2010
    </Date_enrollement>
    <Target_size>900
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Open label randomised controlled trial (Prevention)
    </Study_design>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: 1. Either sex, age &gt; 6 months&lt;br&gt;2. Simple malaria
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Severe malaria
    </Exclusion_Criteria>
    <Condition>Malaria &lt;br&gt;Infections and Infestations &lt;br&gt;Unspecified malaria
    </Condition>
    <Intervention>Patients will be randomised to receive &lt;br&gt;&lt;br&gt;1. Coartem (arthemeter lumifantrine)&lt;br&gt;5-14 kg 20 mg arthemeter+120 mg lumefantrine 2/day for 3 days&lt;br&gt;15-24 kg: 40 mg arthemeter+ 240 mg lumefantrine 2/day for 3 days&lt;br&gt;25-34 kg: 60 mg arthemeter+360 mg lumefantrine 2/day for 3 days&lt;br&gt;34+ kg: 80 mg arthemeter + 480 mg lumefantirne 2/day for 3 days&lt;br&gt;&lt;br&gt;2. Co-arinate (artesunate + sulfamethoxypyrazine + pyrimethamine)&lt;br&gt;5-14 kg: 50 mg artesunate+125mg sulfamethoxypyrazine+6.25mg pyrimethamine (t=0 and12 and  24 hrs later)&lt;br&gt;15-25 kg: 100 mg artesunate+250mg sulfamethoxypyrazine+12.5 mg pyrimethamine (t=0 and 12 and 24 hrs later)&lt;br&gt;25-34 kg: 150 mg artesunate+ 375 mg sulfamethoxypyrazine+ 18.75 mg pyrimethamine (t=0 and 12 and 24 hrs later)&lt;br&gt;35+ kg: 200 mg artesunate+500 mg sulfamethoxypyrazine+25 mg pyrimethamine  (t=0 and 12 and 24 hrs later)&lt;br&gt;&lt;br&gt;All drugs will be given orally. Follow-up of all participants will be at day 0, day 1, day 7, day 14, day 21, day 28, day 35 and day 42.
    </Intervention>
    <Primary_outcome>Parasite clearance as per WHO guidelines:&lt;br&gt;Full parasitological an clinical responses after 42 days of follow-up as measured by microscopy examination. At every follow-up visit a microscopy slide will be examined for parasites and counted against 200 whole blood count (WBC).
    </Primary_outcome>
    <Secondary_outcome>Gametocyte carriage: &lt;br&gt;At day 0,day 1, day 7 and day 14 blood samples (50 ul on filter paper) will be collected for molecular analysis of gametocytes. After nucleic acid extraction analysis will be done with NASBA and results will be expressed as gametocytes/ul
    </Secondary_outcome>
    <Secondary_ID>No.187/RNEC/2010
    </Secondary_ID>
    <Source_Support>INTERACT (Rwanda)
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4682199
    </Internal_Number>
    <TrialID>NCT01215149
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults
    </Public_title>
    <Scientific_title>A Phase 1 Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Safety and Immunogenicity of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adult Volunteers
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>International AIDS Vaccine Initiative
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20101004
    </Date_registration3>
    <Date_registration>04/10/2010
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01215149
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>50 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>October 2010
    </Date_enrollement>
    <Target_size>218
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
    </Study_design>
    <Phase>Phase 1
    </Phase>
    <Countries>United States;Kenya;Rwanda;South Africa;United States;Kenya;Rwanda;South Africa
    </Countries>
    <Contact_Firstname> ; ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Lindsey Baden, MD;Gaudensia Mutua, MB ChB, MPH;Etienne Karita, MD, M.Sc., MSPH;Linda-Gail Bekker, MD;Glenda Gray, MBBCH, FCPaeds(SA);Liesl Page-Shipp
    </Contact_Lastname>
    <Contact_Email>;;;;;
    </Contact_Email>
    <Contact_Tel>;;;;;
    </Contact_Tel>
    <Contact_Affiliation>Brigham and Women's Hospital, Boston, MA, USA;Kenya AIDS Vaccine Initiative, Kangemi, Kenya;Projet San Francisco;Desmond Tutu HIV Foundation-Emavundleni Research Center;Perinatal HIV Research Unit;Aurum Institute
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Healthy male or female, as assessed by a medical history, physical exam, and&#x0D;&lt;br&gt;             laboratory tests;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  At least 18 years of age on the day of screening and has not reached his/her 51st&#x0D;&lt;br&gt;             birthday on the day of first vaccination;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to comply with the requirements of the protocol and available for follow-up&#x0D;&lt;br&gt;             for the planned duration of the study;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In the opinion of the Principal Investigator or designee, and based on Assessment of&#x0D;&lt;br&gt;             Informed Consent Understanding (AOU) results, has understood the information provided&#x0D;&lt;br&gt;             and potential risks linked to vaccination and participation in the trial; written&#x0D;&lt;br&gt;             informed consent will be provided by the volunteer before any study-related&#x0D;&lt;br&gt;             procedures are performed;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to undergo HIV testing, risk reduction counselling, receive HIV test results&#x0D;&lt;br&gt;             and committed to maintaining low risk behaviour for the trial duration as defined by&#x0D;&lt;br&gt;             the protocol;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If a female of childbearing potential, willing to use an effective non-barrier method&#x0D;&lt;br&gt;             of contraception (oral or injectable hormonal contraceptive; intrauterine device&#x0D;&lt;br&gt;             [IUD]) from screening until at least 4 months after the last study vaccination;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Assessed by the clinic staff as being at "low risk" for HIV infection on the basis of&#x0D;&lt;br&gt;             sexual behaviours within the 12 months prior to enrolment;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All female volunteers must be willing to undergo pregnancy tests at time points&#x0D;&lt;br&gt;             indicated in the protocol and must test negative prior to each study vaccination;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All sexually active males (unless anatomically sterile) must be willing to use an&#x0D;&lt;br&gt;             effective method of contraception (such as consistent condom use) from the day of&#x0D;&lt;br&gt;             first vaccination until at least 4 months after the last vaccination;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to forgo donations of blood or any other tissues during the study and, for&#x0D;&lt;br&gt;             those who test HIV positive due to trial vaccination (vaccine-induced HIV&#x0D;&lt;br&gt;             seropositivity), until the anti-HIV antibody titers become undetectable.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Confirmed HIV-1 or HIV-2 infection;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any clinically relevant abnormality on history or examination including history of&#x0D;&lt;br&gt;             immunodeficiency or autoimmune disease; use of systemic corticosteroids (the use of&#x0D;&lt;br&gt;             topical or inhaled steroids is permitted); immunosuppressive, anticancer,&#x0D;&lt;br&gt;             antituberculosis or other medications considered significant by the investigator&#x0D;&lt;br&gt;             within the previous 6 months;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any clinically significant acute or chronic medical condition that is considered&#x0D;&lt;br&gt;             progressive, or in the opinion of the investigator, makes the volunteer unsuitable&#x0D;&lt;br&gt;             for participation in the study;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Reported risky behaviour for HIV infection within 12 months prior to vaccination, as&#x0D;&lt;br&gt;             defined by the protocol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If female, pregnant or planning a pregnancy within 4 months after last vaccination;&#x0D;&lt;br&gt;             or lactating;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Asthma requiring high-dose oral or inhaled corticosteroids;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fever &gt; 100.4° F/38.0° C within 72 hours prior to vaccine administration;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Bleeding disorder that was diagnosed by a physician (e.g., factor deficiency,&#x0D;&lt;br&gt;             coagulopathy or platelet disorder that requires special precautions) (Note: A&#x0D;&lt;br&gt;             volunteer who states that he or she has easy bruising or bleeding, but does not have&#x0D;&lt;br&gt;             a formal diagnosis and has IM injections and blood draws without any adverse&#x0D;&lt;br&gt;             experience is eligible);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of splenectomy;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any abnormal laboratory parameters as defined by the protocol;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Receipt of live-attenuated vaccine within the previous 60 days or planned receipt&#x0D;&lt;br&gt;             within 60 days after vaccination with Investigational Product (within 14 days for&#x0D;&lt;br&gt;             live attenuated influenza vaccine [LAIV]); or receipt of other vaccine (e.g.,&#x0D;&lt;br&gt;             influenza, pneumococcal), allergy treatment with antigen injections or tuberculin&#x0D;&lt;br&gt;             skin test within the previous 14 days or planned receipt within 14 days after&#x0D;&lt;br&gt;             vaccination with Investigational Product;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Receipt of blood transfusion or blood-derived products within the previous 3 months;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in another clinical trial of an Investigational Product currently,&#x0D;&lt;br&gt;             within the previous 3 months or expected participation during this study;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Receipt of another investigational HIV vaccine candidate (Note: receipt of an HIV&#x0D;&lt;br&gt;             vaccine control or placebo will not exclude a volunteer from participation if&#x0D;&lt;br&gt;             documentation is available and the Medical Monitor gives approval);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of severe local or systemic reactogenicity to vaccines (e.g., anaphylaxis,&#x0D;&lt;br&gt;             respiratory difficulty, angioedema);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Confirmed diagnosis of active hepatitis B, hepatitis C or active syphilis;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Seizure disorder: A participant who has had a seizure in the last 3 years is&#x0D;&lt;br&gt;             excluded. (Not excluded: a participant with a history of seizures who has neither&#x0D;&lt;br&gt;             required medications nor had a seizure for 3 years.);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychiatric condition that precludes compliance with the protocol. Specifically&#x0D;&lt;br&gt;             excluded are persons with psychoses within the past 3 years, ongoing risk for&#x0D;&lt;br&gt;             suicide, or history of suicide attempt or gesture within the past 3 years.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV Infections
    </Condition>
    <Intervention>Biological: Ad35-ENV vaccine;Biological: Ad26.ENVA.01 vaccine;Biological: Placebo Control
    </Intervention>
    <Primary_outcome>Number of Participants with Adverse Events as a Measure of Safety and Tolerability
    </Primary_outcome>
    <Secondary_outcome>Immunogenicity
    </Secondary_outcome>
    <Secondary_ID>IAVI B003/ IPCAVD-004
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>HIV Vaccine Trials Network;National Institute of Allergy and Infectious Diseases (NIAID);Beth Israel Deaconess Medical Center;Ragon Institute of MGH, MIT and Harvard
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4681906
    </Internal_Number>
    <TrialID>NCT01211327
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda
    </Public_title>
    <Scientific_title>Topical Cyclosporine in the Treatment of Vernal Keratoconjunctivitis in a Rwandan Eye Clinic; a Prospective Randomized Double-masked Clinical Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University Hospital, Ghent
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20100928
    </Date_registration3>
    <Date_registration>28/09/2010
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01211327
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>July 2008
    </Date_enrollement>
    <Target_size>366
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Philippe Kesteleyn, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University Hospital, Ghent
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        - at least 5 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  being pregnant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  suffering from any other infectious or inflammatory ocular pathology&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  using topical/ systemic corticosteroids, antihistamines, non-steroidal&#x0D;&lt;br&gt;             anti-inflammatory drugs or immunosuppressives 2 weeks prior to the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  been treated with steroid injection 6 months prior to the study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Vernal Keratoconjunctivitis
    </Condition>
    <Intervention>Drug: Cyclosporine A;Drug: Dexamethasone
    </Intervention>
    <Primary_outcome>Difference in score for symptoms and clinical signs between treatment arms
    </Primary_outcome>
    <Secondary_outcome>Speed of symptom/sign reduction;Safety and tolerance of the test medication
    </Secondary_outcome>
    <Secondary_ID>UZ Ghent 003
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Funds for Research in Ophthalmology (FRO) of Belgium;Novartis
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4677251
    </Internal_Number>
    <TrialID>NCT01150370
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>A Pivotal Study to Assess the Safety and Efficacy of The PrePex System, a Male Circumcision Device and Methodology for Rapid Scale up of Painless and Bloodless National Circumcision Programs, in Urban and Remote Rural Settings
    </Public_title>
    <Scientific_title>A Pivotal Study to Assess the Safety and Efficacy of The PrePex System, a Male Circumcision Device and Methodology for Rapid Scale up of Painless and Bloodless National Circumcision Programs, in Urban and Remote Rural Settings
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Ministry of Health, Rwanda
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20100623
    </Date_registration3>
    <Date_registration>23/06/2010
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01150370
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>54 Years
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>June 2010
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Dr. Jean Paul Bitega, M.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Kanombe Military Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male of ages 18 - 54 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject wants to be circumcised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncircumcised&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV sero-negative Agrees to undergo measurements of width of the penis at different&#x0D;&lt;br&gt;             areas in flaccid status&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to understand the study procedures and requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agrees to abstain sexual intercourse and to keep caution not directly rub the cut&#x0D;&lt;br&gt;             area if masturbating, until the end of the follow-up that may take up to 6 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject able to comprehend and freely give informed consent for participation in this&#x0D;&lt;br&gt;             study and is considered by the investigator to have good compliance for the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active genital infection, anatomic abnormality or other condition, which in the&#x0D;&lt;br&gt;             opinion of the investigator prevents the subject from undergoing a circumcision&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV sero-positive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject with the following diseases: phimosis, paraphimosis, warts under the prepuce,&#x0D;&lt;br&gt;             torn or tight frenulum, narrow prepuce, hypospadias&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diabetes mellitus&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject who have an abnormal penile anatomy or any penile diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject that to the opinion of the investigator is not a good candidate&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Male Circumcision;HIV Prevention;HIV Infections
    </Condition>
    <Intervention>Device: The PrePex a novel device for adult male circumcision
    </Intervention>
    <Primary_outcome>The efficacy and safety of The PrePex System for adult male circumcision in Rwanda
    </Primary_outcome>
    <Secondary_outcome>Operational scalability to mass scale up program;satisfaction &amp; acceptability of patients;Guidelines for utility in scale up mass circumcision program;compliance with post procedure instructions
    </Secondary_outcome>
    <Secondary_ID>CMT-01
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Ministry of Defence, Rwanda
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>7813364
    </Internal_Number>
    <TrialID>ISRCTN24907704
    </TrialID>
    <Last_Refreshed_on>1 April 2019
    </Last_Refreshed_on>
    <Public_title>The Millennium Villages Project (MVP): Integrating the delivery of health and development interventions and assessing the impact on child survival in sub-Saharan Africa
    </Public_title>
    <Scientific_title>A pair-matched community intervention trial to assess the impact of an integrated health and development intervention on child survival and the Millennium Development Goals (MDG) in 10 sub-Saharan African countries                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>United Nations Development Program (UNDP) - Regional Bureau for Africa (RBA)
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20100603
    </Date_registration3>
    <Date_registration>03/06/2010
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN24907704
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/06/2006
    </Date_enrollement>
    <Target_size>6000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Pair-matched community intervention trial (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Ethiopia;Ghana;Kenya;Malawi;Mali;Nigeria;Rwanda;Senegal;Tanzania;Uganda
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                Resident in a Millennium Village Cluster and informed consent to undergo periodic assessments. Selection of comparison villages is based on village-level parameters with the potential to influence child mortality and related MDG outcomes including:&lt;br&gt;                1. agro-ecological zone&lt;br&gt;                2. accessibility (distance to tar roads and markets)&lt;br&gt;                3. principal livelihood strategies&lt;br&gt;                4. crop types&lt;br&gt;                5. levels of electrification&lt;br&gt;                6. numbers of clinics and schools&lt;br&gt;                7. presence of other development projects in the area&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Does not meet inclusion criteria
    </Exclusion_Criteria>
    <Condition>Child mortality, Millennium Development Goals &lt;br&gt;Not Applicable
    </Condition>
    <Intervention>The Millennium Villages Project involves the coordinated and simultaneous delivery of a package of proven interventions in health, agriculture, infrastructure and education at a projected annual cost of US$110 per capita.
    </Intervention>
    <Primary_outcome>Under 5 mortality rate, measured at baseline, after 3 years and after 5 years of intervention exposure
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Proportion of under 5s who are:&lt;br&gt;                1.1. Stunted (low height for age Z-score)&lt;br&gt;                1.2. Wasted (low weight for height Z-score)&lt;br&gt;                1.3. Underweight (low weight for age Z-score)&lt;br&gt;                2. Duration of breastfeeding&lt;br&gt;                3. Age at introduction of complementary feeding&lt;br&gt;                4. Proportion of under 5?s with diarrhoea in past 2 weeks&lt;br&gt;                5. Proportion of under 5?s with diarrhoea in past 2 weeks who receive ORS&lt;br&gt;                6. Proportion under 1s immunized against measles&lt;br&gt;                7. Proportion of under 5s treated for pneumonia&lt;br&gt;                8. Prevalence of malaria among under 5s&lt;br&gt;                9. Proportion of under 5s with a fever in the past 2 weeks who receive appropriate anti-malarial treatment&lt;br&gt;                10. Proportion of under 5s sleeping under Long lasting insecticide treated bed-nets&lt;br&gt;                11. Proportion of pregnant women who received an HIV test&lt;br&gt;                12. Proportion of newborns receiving a post-natal check in the first week of life&lt;br&gt;                13. Proportion of women who receive at least 4 ante-natal care (ANC) visits&lt;br&gt;                14. Proportion of births attended by skilled health personnel&lt;br&gt;                15. Survival rate to last grade of primary education&lt;br&gt;                16. Asset based wealth index&lt;br&gt;                17. Proportion of households reporting not enough food for 1 of past 12 months&lt;br&gt;                18. Proportion of the population using an improved drinking water source&lt;br&gt;                19. Proportion of the population using an improved sanitation source&lt;br&gt;                Outcomes will be measured at baseline, after 3 years and after 5 years of intervention exposure&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;NCT01125618;N/A
    </Secondary_ID>
    <Source_Support>United Nations Development Program (UNDP) - Regional Bureau for Africa (RBA) (UNDP CU08-8798)
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1990
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>
                    Columbia University Institutional Review Board approved on 30/01/2005 (ref: AAAA8202). The latest ethical review was approved on 17/04/2009.
                    Approval has also been received from all host-country IRBs
                
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_completed>01/06/2012
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>5670684
    </Internal_Number>
    <TrialID>NCT01127204
    </TrialID>
    <Last_Refreshed_on>8 August 2016
    </Last_Refreshed_on>
    <Public_title>Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age
    </Public_title>
    <Scientific_title>Randomized Phase 3 Trial to Evaluate Two Simplified Antiretroviral Treatment Strategies in HIV Infected Children, Treated by Antiretroviral Triple Therapy Before One Year of Age, in Virological Success in Africa (Burkina Faso, Côte d'Ivoire, Rwanda)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20100519
    </Date_registration3>
    <Date_registration>19/05/2010
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01127204
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>3 Months
    </Inclusion_agemin>
    <Inclusion_agemax>12 Months
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>June 2011
    </Date_enrollement>
    <Target_size>161
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Burkina Faso;Côte D'Ivoire;Burkina Faso;Côte D'Ivoire;Rwanda
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Marguerite Timite-Konan;Jules Mugabo;Nicolas Meda
    </Contact_Lastname>
    <Contact_Email>;;
    </Contact_Email>
    <Contact_Tel>;;
    </Contact_Tel>
    <Contact_Affiliation>Service de pédiatrie - CHU Yopougon - Abidjan, Côte d'Ivoire;Center for Infectious Desease Control - Kigali, Rwanda;Université de Ouagadougou - Ouagadougou, Burkina Faso
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria for antiretroviral treatment initiation:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  infant follow-up in one of the trial site&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV-1 infection diagnose by RT PCR after 6 weeks of life&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age between 3 and 12 month at the antiretroviral treatment initiation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  naive of antiretrovirals except if received for the prevention of mother to child HIV&#x0D;&lt;br&gt;             transmission&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HB&gt;=7 g/dl, neutrophiles&gt;750/mm3, creatinin&lt;3xULN, TGO and TGP&lt;3xULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  signed informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria for antiretroviral treatment initiation:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV-2 infection or HIV-1/HIV-2 co-infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known intolerance to one of the trial treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HB&lt;7 g/dl, neutrophiles&lt;750/mm3, creatinin&gt;3xULN, TGO or TGP&gt;3xULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria for randomisation at 12 months in the simplification phase:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age 24 months at most&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  virological success define as 2 consecutive indetectable HIV RNA measured by RT PCR&#x0D;&lt;br&gt;             at least 3 months apart.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria for randomisation at 12 months in the simplification phase:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  virological failure after the first 12 months of antiretroviral treatment&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV Infections
    </Condition>
    <Intervention>Drug: AZT-3TC-LPV/r twice a day;Drug: ABC-3TC-EFV once a day
    </Intervention>
    <Primary_outcome>Initial therapeutic cohort: Virological success;Randomised simplification phase: Virological success
    </Primary_outcome>
    <Secondary_outcome>Virological success;Immunological response;Antiretroviral and cotrimoxazol pharmacokinetic parameters;Tolerance;Adherence;Resistance to antiretroviral
    </Secondary_outcome>
    <Secondary_ID>IP.2007.33011.002;ANRS 12206 MONOD
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>European and Developing Countries Clinical Trials Partnership (EDCTP);Public Research Centre Health, Luxembourg;Ministry of Foreign Affairs, Luxembourg;University of Ouagadougou, Burkina Faso;Programme national,ANRS,Coopération française-Côte d'Ivoire (PAC-CI), Côte d'Ivoire;Ministry of Health, Rwanda;Institut National de la Santé Et de la Recherche Médicale, France;University of Bordeaux;Institut de Sante Publique, d'Epidémiologie et de Développement;Université Montpellier;University of Paris 5 - Rene Descartes;Queen Fabiola Children's University Hospital
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>6616715
    </Internal_Number>
    <TrialID>NCT01125618
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Millennium Villages Project in Sub-Saharan Africa
    </Public_title>
    <Scientific_title>A Pair-matched Community Intervention Trial to Assess the Impact of an Integrated Health and Development Intervention on Child Survival and the Millennium Development Goals in 10 Sub- Saharan African Countries
    </Scientific_title>
    <Acronym>MVP
    </Acronym>
    <Primary_sponsor>Columbia University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20100512
    </Date_registration3>
    <Date_registration>12/05/2010
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01125618
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2005
    </Date_enrollement>
    <Target_size>65000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Factorial Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Ethiopia;Ghana;Kenya;Malawi;Mali;Nigeria;Rwanda;Senegal;Tanzania;Uganda;Ethiopia;Ghana;Kenya;Malawi;Mali;Nigeria;Rwanda;Senegal;Tanzania;Uganda;Ethiopia;Ghana;Kenya;Malawi;Mali;Nigeria;Rwanda;Senegal;Tanzania;Uganda;Ethiopia;Ghana;Kenya;Malawi;Mali;Nigeria;Rwanda;Senegal;Tanzania;Uganda;Ethiopia;Ghana;Kenya;Malawi;Mali;Nigeria;Rwanda;Senegal;Tanzania;Uganda;Ethiopia;Ghana;Kenya;Malawi;Mali;Nigeria;Rwanda;Senegal;Tanzania;Uganda;Ethiopia;Ghana;Kenya;Malawi;Mali;Nigeria;Rwanda;Senegal;Tanzania;Uganda;Ethiopia;Ghana;Kenya;Malawi;Mali;Nigeria;Rwanda;Senegal;Tanzania;Uganda;Ethiopia;Ghana;Kenya;Malawi;Mali;Nigeria;Rwanda;Senegal;Tanzania;Uganda;Ethiopia;Ghana;Kenya;Malawi;Mali;Nigeria;Rwanda;Senegal;Tanzania;Uganda
    </Countries>
    <Contact_Firstname> ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Jeffrey Sachs, PhD;Pedro Sanchez, PhD;Cheryl Palm, PhD;Sonia Sachs, MD, PhD;Jeffrey Sachs, PhD;Pedro Sanchez, PhD;Cheryl Palm, PhD;Sonia Sachs, MD, PhD;Jeffrey Sachs, PhD;Pedro Sanchez, PhD;Cheryl Palm, PhD;Sonia Sachs, MD, PhD;Jeffrey Sachs, PhD;Pedro Sanchez, PhD;Cheryl Palm, PhD;Sonia Sachs, MD, PhD;Jeffrey Sachs, PhD;Pedro Sanchez, PhD;Cheryl Palm, PhD;Sonia Sachs, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;;;;;;;;;;;;;;;;;;;
    </Contact_Email>
    <Contact_Tel>;;;;;;;;;;;;;;;;;;;
    </Contact_Tel>
    <Contact_Affiliation>The Earth Institute, Columbia University;The Earth Institute, Columbia University;The Earth Institute, Columbia University;Director of Health, The Earth Institute, Columbia University;The Earth Institute, Columbia University;The Earth Institute, Columbia University;The Earth Institute, Columbia University;Director of Health, The Earth Institute, Columbia University;The Earth Institute, Columbia University;The Earth Institute, Columbia University;The Earth Institute, Columbia University;Director of Health, The Earth Institute, Columbia University;The Earth Institute, Columbia University;The Earth Institute, Columbia University;The Earth Institute, Columbia University;Director of Health, The Earth Institute, Columbia University;The Earth Institute, Columbia University;The Earth Institute, Columbia University;The Earth Institute, Columbia University;Director of Health, The Earth Institute, Columbia University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Resident in a Millennium Village and consenting to periodic assessments&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Those not consenting to participate&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Resident in a Millennium Village and consenting to periodic assessments&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Those not consenting to participate&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Resident in a Millennium Village and consenting to periodic assessments&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Those not consenting to participate&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Resident in a Millennium Village and consenting to periodic assessments&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Those not consenting to participate&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Child Survival;Child Survival;Child Survival;Child Survival
    </Condition>
    <Intervention>Other: Health and development intervention package;Other: Routine services;Other: Health and development intervention package;Other: Routine services;Other: Health and development intervention package;Other: Routine services;Other: Health and development intervention package;Other: Routine services
    </Intervention>
    <Primary_outcome>Child Mortality Rate;Child Mortality Rate;Child Mortality Rate
    </Primary_outcome>
    <Secondary_outcome>Prevalence of Stunting;Prevalence of Diarrhea;Prevalence of Malaria;Prevalence of antenatal care;Survival rate to last grade of primary education (School Quality);Prevalence of improved sanitation utilization;Duration or breast feeding (Child feeding practices);Age of introduction of complementary feeding (Child feeding practices);Prevalence of bed net utilization;Prevalence of malaria treatment;Prevalence of measles immunization;Prevalence of diarrhea management;Prevalence of pneumonia management;Prevalence of newborn care;Proportion of pregnant women who received and HIV test;Prevalence of food insecurity;Institutional delivery rate;Prevalence of underweight;Prevalence of wasting;Prevalence of low mid-upper arm circumference;Household Asset Index (Household poverty);Prevalence of improved water source utilization
    </Secondary_outcome>
    <Secondary_ID>AAAA8202
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>United Nations;Bill and Melinda Gates Foundation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4674581
    </Internal_Number>
    <TrialID>NCT01115361
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Postpartum Family Planning Service Through Enhanced Family Planning in Immunization Services
    </Public_title>
    <Scientific_title>Improving Access to and Uptake of Postpartum Family Planning Service Through Enhanced Family Planning in Immunization Services
    </Scientific_title>
    <Acronym>PPFP-IZ
    </Acronym>
    <Primary_sponsor>FHI 360
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20100428
    </Date_registration3>
    <Date_registration>28/04/2010
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01115361
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>February 2010
    </Date_enrollement>
    <Target_size>800
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Lisa S Dulli, PhD, MHS;Steve Sortijas, MPH;Fidèle Ngabo, MD, MPH
    </Contact_Lastname>
    <Contact_Email>;;
    </Contact_Email>
    <Contact_Tel>;;
    </Contact_Tel>
    <Contact_Affiliation>FHI 360;FHI 360;Rwanda Ministry of Health
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Clients:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  adult women, aged 21 years and older, or married women ages 18 to 20 who have&#x0D;&lt;br&gt;             achieved legal majority status by emancipation due to marriage,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  bring their infants between the ages 6-12 months to immunization services at study&#x0D;&lt;br&gt;             sites&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Providers:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  all health care providers who currently provide immunization services to infants&#x0D;&lt;br&gt;             and/or family planning services within the selected facilities.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Contraception
    </Condition>
    <Intervention>Behavioral: Family planning for postpartum women
    </Intervention>
    <Primary_outcome>Use of a modern contraceptive method among postpartum women
    </Primary_outcome>
    <Secondary_ID>890028
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Ministry of Health, Rwanda
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4671201
    </Internal_Number>
    <TrialID>NCT01071174
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>A Safety Study of Dapivirine Vaginal Ring in Africa
    </Public_title>
    <Scientific_title>A Double-Blind, Randomized, Placebo-Controlled Phase I/II Study to Evaluate the Safety of an Intravaginal Matrix Ring With Dapivirine in Healthy, HIV-Negative Women.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>International Partnership for Microbicides, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20100217
    </Date_registration3>
    <Date_registration>17/02/2010
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01071174
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>40 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>April 2010
    </Date_enrollement>
    <Target_size>280
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
    </Study_design>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Countries>Kenya;Malawi;South Africa;Tanzania;Kenya;Malawi;Rwanda;South Africa;Tanzania;Zambia
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Dr Annalene Nel
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>IPM
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women between 18 and 40 years of age inclusive who can provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Available for all visits and consent to follow all procedures scheduled for the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Healthy and self-reported sexually active&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV-negative&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  On a stable form of contraception and willing to continue OR have undergone surgical&#x0D;&lt;br&gt;             sterilization at least 3 months prior to enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In the absence of the use of exogenous hormone(s), have a self-reported regular&#x0D;&lt;br&gt;             menstrual cycle defined as having a minimum of 21 days and a maximum of 35 days&#x0D;&lt;br&gt;             between menses&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Upon pelvic/speculum examination and colposcopy at the time of enrolment, the cervix&#x0D;&lt;br&gt;             and vagina appear normal as determined by the investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Asymptomatic for genital infections at the time of enrolment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to refrain from use of vaginal products or objects within 14 days from&#x0D;&lt;br&gt;             enrollment and for the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to answer to acceptability, adherence and behavioural assessments throughout&#x0D;&lt;br&gt;             the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to refrain from participation in any other research study for the duration of&#x0D;&lt;br&gt;             their participation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to provide adequate locator information for study retention purposes and be&#x0D;&lt;br&gt;             reachable per local standard procedures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently pregnant or last pregnancy within 3 months prior to enrolment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently breast-feeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participated in any other research study within 60 days prior to screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previously participated in any HIV vaccine study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Untreated urogenital infections within 2 weeks prior to enrolment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of any abnormal physical finding on the vulva, vaginal walls or cervix&#x0D;&lt;br&gt;             during pelvic/speculum examination and/or colposcopy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding,&#x0D;&lt;br&gt;             or urethral obstruction, incontinence or urge incontinence&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pap smear result at screening that requires cryotherapy, biopsy, treatment or further&#x0D;&lt;br&gt;             evaluation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any Grade 2, 3 or 4 baseline (screening) haematology, chemistry or urinalysis&#x0D;&lt;br&gt;             laboratory abnormality according to the DAIDS Table for Grading Adverse Events&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any abnormal bleeding per vagina, bleeding per vagina during or following vaginal&#x0D;&lt;br&gt;             intercourse, or gynaecologic surgery within 90 days prior to enrolment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of&#x0D;&lt;br&gt;             sensitivity/allergy to latex or silicone elastomer&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any serious acute, chronic or progressive disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any condition(s) that, in the opinion of the investigator, might interfere with&#x0D;&lt;br&gt;             adherence to study requirements or evaluation of the study objectives&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV Infections
    </Condition>
    <Intervention>Other: Dapivirine;Other: Placebo
    </Intervention>
    <Primary_outcome>Safety as determined by the proportion of women in each arm experiencing protocol-specified events, including AEs, laboratory abnormalities, cervico-vaginal abnormalities, abnormal vaginal flora/pH during the study.
    </Primary_outcome>
    <Secondary_outcome>Acceptability of the product determined by questionnaire.;Adherence to the protocol-specific product regimen as determined by self-report and clinician observation at each study visit.
    </Secondary_outcome>
    <Secondary_ID>IPM 015
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4671003
    </Internal_Number>
    <TrialID>NCT01068574
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Evaluation of the Basic Assessment of Severity of Illness in Children (BASIC) Scale
    </Public_title>
    <Scientific_title>Evaluation of the BASIC Scale (Basic Assessment of Severity of Illness in Children): A Simple Triage Tool for Resource-limited Settings
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Brigham and Women's Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20100212
    </Date_registration3>
    <Date_registration>12/02/2010
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01068574
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>2 Months
    </Inclusion_agemin>
    <Inclusion_agemax>5 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>January 2010
    </Date_enrollement>
    <Target_size>2500
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational Model: Cohort, Time Perspective: Prospective
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Peter Drobac, MD;Peter Drobac, MD
    </Contact_Lastname>
    <Contact_Email>pdrobac@partners.org;pdrobac@partners.org
    </Contact_Email>
    <Contact_Tel>857-776-7114;857-776-7114
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Child aged two months to five years presenting routine or urgent care in an&#x0D;&lt;br&gt;             ambulatory facility&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  None&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Acute Illness
    </Condition>
    <Intervention>Other: BASIC Score (Observational)
    </Intervention>
    <Secondary_ID>2009P002546
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Partners In Health;Thrasher Research Fund;Ministry of Health, Rwanda
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>6496222
    </Internal_Number>
    <TrialID>NCT01047436
    </TrialID>
    <Last_Refreshed_on>19 October 2017
    </Last_Refreshed_on>
    <Public_title>Efficacy of ArTiMist™ in Children
    </Public_title>
    <Scientific_title>An Open Label Randomised Comparative Trial to Establish the Efficacy of 3 mg/kg ArTiMist™ When Compared to Intravenous Quinine in Children With Severe or Complicated Falciparum Malaria, or Uncomplicated Falciparum Malaria With Gastrointestinal Complications
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Proto Pharma Ltd
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20100108
    </Date_registration3>
    <Date_registration>08/01/2010
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01047436
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 2009
    </Date_enrollement>
    <Target_size>31
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design/>
    <Phase>Phase 2
    </Phase>
    <Countries>Rwanda;Rwanda;Rwanda;Rwanda
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Daryl Bendel, MBChB MBA Dip Pharm Med MFPM;Daryl Bendel, MBChB MBA Dip Pharm Med MFPM;Daryl Bendel, MBChB MBA Dip Pharm Med MFPM;Daryl Bendel, MBChB MBA Dip Pharm Med MFPM
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>Xidea Solutions Limited;Xidea Solutions Limited;Xidea Solutions Limited;Xidea Solutions Limited
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. The patient's parent or attendant relative has provided informed consent and the&#x0D;&lt;br&gt;             patient has assented (where relevant) to participation in the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. The patient is a child that weighs between 5 and 15 kg (kilogram)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. The patient has falciparum malaria as evidenced by&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Thick or thin blood smears of &gt; 500 P falciparum per mcl (microlitre)(patients&#x0D;&lt;br&gt;                  with mixed infections may be included provided &gt;500 P Falciparum /mcl) and /or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Positive RDT (rapid diagnostic test)for malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. The patient has either&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. severe or complicated malaria as determined by the Investigator based on the WHO&#x0D;&lt;br&gt;                  criteria for severity, or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. the patient has uncomplicated malaria but is unable to tolerate oral medication&#x0D;&lt;br&gt;                  as a result of gastrointestinal complications such as vomiting or diarrhoea.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Attending relative or parent does not provide informed consent for participation, or&#x0D;&lt;br&gt;             the child if capable does not assent to participation in the trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Ability to tolerate oral therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patient has received any treatment with an artemisinin or quinine in the last 24 hours&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient has evidence of significant co-infections (this does not include mixed&#x0D;&lt;br&gt;             Plasmodium infections).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patient is allergic or intolerant to artemisinins.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. The patient's parent or attendant relative has provided informed consent and the&#x0D;&lt;br&gt;             patient has assented (where relevant) to participation in the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. The patient is a child that weighs between 5 and 15 kg (kilogram)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. The patient has falciparum malaria as evidenced by&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Thick or thin blood smears of &gt; 500 P falciparum per mcl (microlitre)(patients&#x0D;&lt;br&gt;                  with mixed infections may be included provided &gt;500 P Falciparum /mcl) and /or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Positive RDT (rapid diagnostic test)for malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. The patient has either&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. severe or complicated malaria as determined by the Investigator based on the WHO&#x0D;&lt;br&gt;                  criteria for severity, or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. the patient has uncomplicated malaria but is unable to tolerate oral medication&#x0D;&lt;br&gt;                  as a result of gastrointestinal complications such as vomiting or diarrhoea.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Attending relative or parent does not provide informed consent for participation, or&#x0D;&lt;br&gt;             the child if capable does not assent to participation in the trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Ability to tolerate oral therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patient has received any treatment with an artemisinin or quinine in the last 24 hours&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient has evidence of significant co-infections (this does not include mixed&#x0D;&lt;br&gt;             Plasmodium infections).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patient is allergic or intolerant to artemisinins.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. The patient's parent or attendant relative has provided informed consent and the&#x0D;&lt;br&gt;             patient has assented (where relevant) to participation in the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. The patient is a child that weighs between 5 and 15 kg (kilogram)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. The patient has falciparum malaria as evidenced by&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Thick or thin blood smears of &gt; 500 P falciparum per mcl (microlitre)(patients&#x0D;&lt;br&gt;                  with mixed infections may be included provided &gt;500 P Falciparum /mcl) and /or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Positive RDT (rapid diagnostic test)for malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. The patient has either&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. severe or complicated malaria as determined by the Investigator based on the WHO&#x0D;&lt;br&gt;                  criteria for severity, or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. the patient has uncomplicated malaria but is unable to tolerate oral medication&#x0D;&lt;br&gt;                  as a result of gastrointestinal complications such as vomiting or diarrhoea.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Attending relative or parent does not provide informed consent for participation, or&#x0D;&lt;br&gt;             the child if capable does not assent to participation in the trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Ability to tolerate oral therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patient has received any treatment with an artemisinin or quinine in the last 24 hours&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient has evidence of significant co-infections (this does not include mixed&#x0D;&lt;br&gt;             Plasmodium infections).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patient is allergic or intolerant to artemisinins.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. The patient's parent or attendant relative has provided informed consent and the&#x0D;&lt;br&gt;             patient has assented (where relevant) to participation in the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. The patient is a child that weighs between 5 and 15 kg (kilogram)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. The patient has falciparum malaria as evidenced by&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Thick or thin blood smears of &gt; 500 P falciparum per mcl (microlitre)(patients&#x0D;&lt;br&gt;                  with mixed infections may be included provided &gt;500 P Falciparum /mcl) and /or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Positive RDT (rapid diagnostic test)for malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. The patient has either&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. severe or complicated malaria as determined by the Investigator based on the WHO&#x0D;&lt;br&gt;                  criteria for severity, or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. the patient has uncomplicated malaria but is unable to tolerate oral medication&#x0D;&lt;br&gt;                  as a result of gastrointestinal complications such as vomiting or diarrhoea.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Attending relative or parent does not provide informed consent for participation, or&#x0D;&lt;br&gt;             the child if capable does not assent to participation in the trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Ability to tolerate oral therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patient has received any treatment with an artemisinin or quinine in the last 24 hours&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient has evidence of significant co-infections (this does not include mixed&#x0D;&lt;br&gt;             Plasmodium infections).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patient is allergic or intolerant to artemisinins.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Falciparum Malaria;Falciparum Malaria;Falciparum Malaria;Falciparum Malaria
    </Condition>
    <Intervention>Drug: Quinine;Drug: Artemether;Drug: Quinine;Drug: Artemether;Drug: Quinine;Drug: Artemether;Drug: Quinine;Drug: Artemether
    </Intervention>
    <Primary_outcome>Parasitological Success Defined as a Reduction in Parasite Count of = 90% of Baseline at 24 Hours After the First Dose;Time for Parasite Count to Fall by 90% PCT(90);Time for Parasite Count to Fall by 50% PCT(50);Parasitological Success Defined as a Reduction in Parasite Count of = 90% of Baseline at 24 Hours After the First Dose;Time for Parasite Count to Fall by 90% PCT(90);Time for Parasite Count to Fall by 50% PCT(50)
    </Primary_outcome>
    <Secondary_outcome>Parasite Clearance Time;Parasite Reduction Ratio (PRR) at 24 h (Hours) After the First Dose;Parasite Reduction Ratio (PRR) at 12 Hours After the First Dose
    </Secondary_outcome>
    <Secondary_ID>ART003
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Xidea Solutions Limited
    </Secondary_Sponsor>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>14/01/2011
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT01047436
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11627402
    </Internal_Number>
    <TrialID>CTRI/2009/091/000531
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Phase II trial of dispersible fixed dose combination of arterolane (RBx 11160) maleate and piperaquine phosphate in pediatric patients with acute uncomplicated Plasmodium falciparum malaria

    </Public_title>
    <Scientific_title>A Phase II, Multicentric, Open label study to assess the antimalarial efficacy and safety of fixed dose combination dispersible tablets of arterolane (RBx 11160) maleate and piperaquine phosphate in pediatric patients with acute uncomplicated Plasmodium falciparum Malaria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Ranbaxy Laboratories Limited
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20091223
    </Date_registration3>
    <Date_registration>23-12-2009
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=734
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>22-07-2010
    </Date_enrollement>
    <Target_size>120
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single Arm Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>India;Cote d'Ivoire;Rwanda
    </Countries>
    <Contact_Firstname>Dr Nilanjan Saha
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Ranbaxy Laboratories Limited.R&amp;D IV,  Plot No. 77-B, Sector 18, IFFCO Road,Udyog Vihar Industrial Area 
    </Contact_Address>
    <Contact_Email>nilanjan.saha@ranbaxy.com
    </Contact_Email>
    <Contact_Tel>91-124-4194340
    </Contact_Tel>
    <Contact_Affiliation>Head-Clinical Pharmacology and Development
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients must fulfill the following inclusion criteria to be eligible for enrollment into the study: &lt;br/ &gt;&lt;br&gt; &lt;br/ &gt;&lt;br&gt;1.	Children of either gender aged between 6 months to 12 years, both inclusive. &lt;br/ &gt;&lt;br&gt;2.	Minimum body weight of 5 kg.  &lt;br/ &gt;&lt;br&gt;3.	Able to take drugs under study by the oral route   &lt;br/ &gt;&lt;br&gt;4.	Absence of severe malnutrition (defined as a child whose weight-for-height is below -3 standard deviation or less than 70% of the median of the NCHS/ WHO normalized reference values or who has symmetrical oedema involving at least the feet4,5 ) &lt;br/ &gt;&lt;br&gt;5.	Minimum Hemoglobin (Hb) level of  &gt; 8 gm/dL. &lt;br/ &gt;&lt;br&gt;6.	Presence of acute symptomatic uncomplicated malaria with a diagnosis confirmed by a positive blood smear with asexual forms of P. falciparum parasites only. &lt;br/ &gt;&lt;br&gt;7.	Initial parasite densities appropriate for inclusion will be between 1,000 and 100,000 asexual parasites/ÂµL blood (both inclusive). &lt;br/ &gt;&lt;br&gt;8.	Presence of fever (axillary temperature â?¥ 37.5 Â°C) or a history of fever in the past 24 hours. &lt;br/ &gt;&lt;br&gt;9.	Written informed consent, provided by parent/guardian in accordance with local practice. If parent/ guardian is unable to provide informed consent in writing, a thumbprint to indicate consent in the presence of at least one witness is acceptable.  &lt;br/ &gt;&lt;br&gt;10.	Willingness and ability to comply with the study protocol for the duration of the study. &lt;br/ &gt;&lt;br&gt;11.	Patient resides within a reasonable distance of the investigational site, so that attendance of all study visits and follow-up by medical staff are logistically feasible. &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: If any of the following conditions apply, the patient should not be enrolled in the study.&lt;br&gt;&lt;br&gt;1.Known allergy to artesunate, artemether, artemisinin derived products, piperaquine or any other related drug.&lt;br&gt;2.Infants with a history of hyperbilirubinemia during the neonatal period &lt;br&gt;3.Use of concomitant medications that may induce haemolysis or haemolytic anaemia from the World Health Organization (WHO) list of essential drugs &lt;br&gt;4.Evidence of any concomitant infection at the time of presentation (including P. vivax, P. ovale and P. malariae) &lt;br&gt;5.Any other underlying disease that may compromise the diagnosis and the evaluation of the response to the study medication (including clinical symptoms of immunosuppression, tuberculosis, bacterial infection; cardiac or pulmonary disease)&lt;br&gt;6.Ongoing prophylaxis with drugs having antimalarial activity such as cotrimoxazole for the prevention of Pneumocystis carini pneumonia in children born to HIV+ women.  &lt;br&gt;7.Patients with severe malaria as per WHO criteria 2003.&lt;br&gt;8.Presence of general danger signs of severe malaria among children &amp;lt;5 years old (as per WHO) &lt;br&gt;9.Female patients between the age group of 8 to 12 years (both inclusive) who are pregnant at screening. The selection of the candidate for pregnancy screening test would be as per the judgement of the Investigator. &lt;br&gt;10.Female patients between the age group of 8 to 12 years (both inclusive) who are lactating at the time of screening.&lt;br&gt;11.Any antimalarial treatment during 1 month prior to screening, as assessed by medical history&lt;br&gt;12.Participation in any investigational drug study during the 30 days prior to screening.&lt;br&gt;13.Electrocardiogram (ECG) abnormalities with clinical significance or relevance that require urgent management. These abnormalities include QTc interval &amp;gt; 450 msec at screening and cardiac conduction disorders, with the exception of right bundle branch block.&lt;br&gt;14.Gastrointestinal dysfunction that could alter absorption or motility (e.g., diarrhea defined as &amp;gt; 3 episodes of watery stools in the previous 24 hours or patients who have had 3 episodes of vomiting within 24 hours prior to screening).&lt;br&gt;15.Patients with known significant renal or hepatic impairment indicated by the following laboratory evaluations at screening:&lt;br&gt;Serum creatinine &amp;gt; 1.5 &amp;times; upper limit of normal (ULN).&lt;br&gt;Aspartate transaminase &amp;gt; 2.5 &amp;times; ULN.&lt;br&gt;Alanine transaminase &amp;gt; 2.5 &amp;times; ULN.&lt;br&gt;Serum bilirubin &amp;gt; 3 mg/dL. &lt;br&gt;16.Patients who have had a splenectomy as confirmed by history or clinical examination.&lt;br&gt;17.Patients with known history of human immunodeficiency virus (HIV) infection or other immunosuppressive disorders.&lt;br&gt;18.Evidence of clinically significant cardiovascular, pulmonary, metabolic, gastrointestinal, neurological, or endocrine diseases, malignancy, or other abnormalities (other than the indication being studied).&lt;br&gt;19.Patients who have epilepsy or a history of convulsions.
    </Exclusion_Criteria>
    <Condition>Health Condition 1: null- Acute uncomplicated Plasmodium falciparum malaria

    </Condition>
    <Intervention>Intervention1: Fixed dose combination of dispersible tablets of arterolane maleate and piperaquine phosphate: Each dispersible tablet consists of arterolane maleate 37.5 mg and PQP 187.5 mg in a fixed dose combination. The study drug will be administered as a single daily dose for 3 consecutive days. Number of tablets in a single dose will be provided according to age categories of the patients&lt;br&gt;&lt;br&gt;One tablet for 6 months to less than 2 years, two tablets for 2 years to less than 6 years and three tablets for &lt;br&gt;6 years to equal to 12 years. &lt;br&gt;&lt;br&gt;Control Intervention1: NIL: NIL&lt;br&gt;
    </Intervention>
    <Primary_outcome>â?¢	To estimate the Day 28 PCR corrected Adequate Clinical and Parasitological Response (ACPR) of three dose regimen of fixed dose combination (FDC) dispersible tablets of arterolane maleate and PQPTimepoint: Day 28
    </Primary_outcome>
    <Secondary_outcome>Cure rate (ACPR) on Day 42.  &lt;br/ &gt;&lt;br&gt;PCT. &lt;br/ &gt;&lt;br&gt;FCT. &lt;br/ &gt;&lt;br&gt;Proportion of patients with PCR-uncorrected ACPR on Day 28. &lt;br/ &gt;&lt;br&gt;Gametocyte count on Days 0, 7 (Â±1), 14(Â±1), 21(Â±2)  28(Â±2), 35(Â±2) and 42 (Â±2) &lt;br/ &gt;&lt;br&gt;PK parameters of  arterolane and piperaquine: Cmax, Tmax, AUC, Cl/ F, Vd/F, t1/2 and additional PK model dependant parameters &lt;br/ &gt;&lt;br&gt;Incidence of adverse events or clinically significant changes in laboratory parameters, physical examination, ECG, or vital signs. &lt;br/ &gt;&lt;br&gt; &lt;br/ &gt;&lt;br&gt;Timepoint: Days 0, 7 (Â±1), 14(Â±1), 21(Â±2)  28(Â±2), 35(Â±2) and 42 (Â±2)
    </Secondary_outcome>
    <Secondary_ID>R11160082001
    </Secondary_ID>
    <Source_Support>Ranbaxy Laboratories Limited, 
India

    </Source_Support>
    <Secondary_Sponsor>DST Govt of India
    </Secondary_Sponsor>
    <Ethics_review_status>Approved;Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>13/07/2012;23/04/2012;08/01/2010;31/07/2008;16/12/2009
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Center Hospitalier Universitaire De Kigali;Comitte National DEthique Et De La Recherche Ivory Coast;Institutional Ethics Committee, Ispat General Hospital, Rourkela;Institutional Ethics Committee, National Institute of Malaria Research (NIMR), Delhi;Intitutional Ethics Committe, Tata Main Hospital, Jamshedpur
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4659592
    </Internal_Number>
    <TrialID>NCT00917891
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>An Expanded Safety Study of Dapivirine Gel 4759 in Africa
    </Public_title>
    <Scientific_title>A Double-blind, Randomized, Placebo-Controlled Phase I/II Study to Evaluate the Safety and Acceptability of Dapivirine Gel 4759, 0.05%, 2.5g, a Vaginal Microbicide, Conducted Using Daily Monitored Adherence in Healthy, HIV-Negative Women.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>International Partnership for Microbicides, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20090608
    </Date_registration3>
    <Date_registration>08/06/2009
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00917891
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>40 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>November 2009
    </Date_enrollement>
    <Target_size>280
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention
    </Study_design>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Countries>Kenya;Malawi;Rwanda;South Africa;Tanzania;Kenya;Malawi;Rwanda;South Africa;Tanzania
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Dr Annalene Nel
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>IPM
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Women 18 to 40 years of age inclusive who can give written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Available for all visits and consent to follow all procedures scheduled for the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Agree to daily application of gel and monitoring as per Daily Monitored Adherence&#x0D;&lt;br&gt;             (DMA) method&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Healthy and self-reported sexually active&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. HIV-negative as determined by a HIV rapid test at time of enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. On a stable form of contraception  and willing to continue on this stable method of&#x0D;&lt;br&gt;             contraception, OR, Have undergone surgical sterilisation at least 3 months prior to&#x0D;&lt;br&gt;             enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. In the absence of the use of exogenous hormone(s), have a self-reported regular&#x0D;&lt;br&gt;             menstrual cycle defined as having a minimum of 21 days and a maximum of 36 days&#x0D;&lt;br&gt;             between menses&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Upon pelvic/speculum examination and colposcopy at the time of enrollment, the cervix&#x0D;&lt;br&gt;             and vagina appear normal as determined by the investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Asymptomatic for genital infections at the time of enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Willing to refrain from use of vaginal products or objects within 14 days prior to&#x0D;&lt;br&gt;             enrollment and for the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Willing to answer acceptability and adherence questionnaires throughout the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Willing to refrain from participation in any other research study for the duration of&#x0D;&lt;br&gt;             this study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Willing to provide adequate locator information for study retention purposes and be&#x0D;&lt;br&gt;             reachable per local standard procedures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Currently pregnant or last pregnancy outcome within 3 months prior to enrolment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Currently breast-feeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Participated in any other research study within 60 days prior to screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Previously participated in any HIV vaccine study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Untreated urogenital infections (either symptomatic or asymptomatic) within 2 weeks&#x0D;&lt;br&gt;             prior to enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Presence of abnormal physical finding on the vulva, vaginal walls or cervix during&#x0D;&lt;br&gt;             pelvic/speculum examination and/or colposcopy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding,&#x0D;&lt;br&gt;             urethral obstruction&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Pap smear result at screening that requires cryotherapy, biopsy, treatment (other&#x0D;&lt;br&gt;             than for infection), or further evaluation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Any Grade 2, 3 or 4 baseline haematology, chemistry or urinalysis laboratory&#x0D;&lt;br&gt;             abnormality according to the DAIDS Table for Grading Adverse Experiences&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Unexplained, undiagnosed abnormal bleeding per vagina, bleeding per vagina during or&#x0D;&lt;br&gt;             following vaginal intercourse, or gynaecologic surgery within 90 days prior to&#x0D;&lt;br&gt;             enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of&#x0D;&lt;br&gt;             sensitivity/allergy to latex&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Any serious acute, chronic or progressive disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Any condition(s) that, in the opinion of the investigator, might interfere with&#x0D;&lt;br&gt;             adherence to study requirements or evaluation of the study objectives&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV Infections;Acquired Immunodeficiency Syndrome
    </Condition>
    <Intervention>Drug: dapivirine;Drug: placebo
    </Intervention>
    <Primary_outcome>Gynaecological examinations, including pelvic/speculum examination and colposcopy, and laboratory STI testing.;Safety laboratory tests;Adverse event/serious adverse event reports
    </Primary_outcome>
    <Secondary_outcome>Questionnaires concerning acceptability and adherence to daily use of vaginal gel.;Documentation of adherence to the DMA method including the Applicator Collection Checklist, focus groups and male interviews.
    </Secondary_outcome>
    <Secondary_ID>IPM 014A
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4659593
    </Internal_Number>
    <TrialID>NCT00917904
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>An Expanded Safety Study of Dapivirine Gel 4789 in Africa
    </Public_title>
    <Scientific_title>A Double-blind, Randomized, Placebo-Controlled Phase I/II Study to Evaluate the Safety and Acceptability of Dapivirine Gel 4789, 0.05%, 2.5g, a Vaginal Microbicide, Conducted Using Daily Monitored Adherence in Healthy, HIV-Negative Women.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>International Partnership for Microbicides, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20090608
    </Date_registration3>
    <Date_registration>08/06/2009
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00917904
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>40 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>July 2009
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention
    </Study_design>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Countries>South Africa;Kenya;Malawi;Rwanda;Tanzania
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Dr Annalene Nel
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>IPM
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Women 18 to 40 years of age inclusive who can give written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Available for all visits and consent to follow all procedures scheduled for the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Agree to daily application of gel and monitoring as per Daily Monitored Adherence&#x0D;&lt;br&gt;             (DMA) method&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Healthy and self-reported sexually active&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. HIV-negative as determined by a HIV rapid test at time of enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. On a stable form of contraception  and willing to continue on this stable method of&#x0D;&lt;br&gt;             contraception, OR, Have undergone surgical sterilisation at least 3 months prior to&#x0D;&lt;br&gt;             enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. In the absence of the use of exogenous hormone(s), have a self-reported regular&#x0D;&lt;br&gt;             menstrual cycle defined as having a minimum of 21 days and a maximum of 36 days&#x0D;&lt;br&gt;             between menses&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Upon pelvic/speculum examination and colposcopy at the time of enrollment, the cervix&#x0D;&lt;br&gt;             and vagina appear normal as determined by the investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Asymptomatic for genital infections at the time of enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Willing to refrain from use of vaginal products or objects within 14 days prior to&#x0D;&lt;br&gt;             enrollment and for the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Willing to answer acceptability and adherence questionnaires throughout the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Willing to refrain from participation in any other research study for the duration of&#x0D;&lt;br&gt;             this study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Willing to provide adequate locator information for study retention purposes and be&#x0D;&lt;br&gt;             reachable per local standard procedures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Currently pregnant or last pregnancy outcome within 3 months prior to enrolment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Currently breast-feeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Participated in any other research study within 60 days prior to screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Previously participated in any HIV vaccine study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Untreated urogenital infections (either symptomatic or asymptomatic) within 2 weeks&#x0D;&lt;br&gt;             prior to enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Presence of abnormal physical finding on the vulva, vaginal walls or cervix during&#x0D;&lt;br&gt;             pelvic/speculum examination and/or colposcopy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding,&#x0D;&lt;br&gt;             urethral obstruction&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Pap smear result at screening that requires cryotherapy, biopsy, treatment (other&#x0D;&lt;br&gt;             than for infection), or further evaluation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Any Grade 2, 3 or 4 baseline haematology, chemistry or urinalysis laboratory&#x0D;&lt;br&gt;             abnormality according to the DAIDS Table for Grading Adverse Experiences&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Unexplained, undiagnosed abnormal bleeding per vagina, bleeding per vagina during or&#x0D;&lt;br&gt;             following vaginal intercourse, or gynaecologic surgery within 90 days prior to&#x0D;&lt;br&gt;             enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of&#x0D;&lt;br&gt;             sensitivity/allergy to latex&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Any serious acute, chronic or progressive disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Any condition(s) that, in the opinion of the investigator, might interfere with&#x0D;&lt;br&gt;             adherence to study requirements or evaluation of the study objectives&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV Infections;Acquired Immunodeficiency Syndrome;Healthy
    </Condition>
    <Intervention>Drug: dapivirine;Drug: placebo
    </Intervention>
    <Primary_outcome>Gynaecological examinations, including pelvic/speculum examination and colposcopy, and laboratory STI testing.;Safety laboratory tests;Adverse event/serious adverse event reports
    </Primary_outcome>
    <Secondary_outcome>Questionnaires concerning acceptability and adherence to daily use of vaginal gel.;Documentation of adherence to the DMA method including the Applicator Collection Checklist, focus groups and male interviews.
    </Secondary_outcome>
    <Secondary_ID>IPM 014B
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>12599342
    </Internal_Number>
    <TrialID>PACTR2009010000911750
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>4 ACT for uncomplicated malaria in African children
    </Public_title>
    <Scientific_title>Evaluation of 4 Artemisinin-Based Combinations for Treating Uncomplicated Malaria in African Children                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>Institute Tropical Medicine
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20081110
    </Date_registration3>
    <Date_registration>10/11/2008
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=91
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>28/08/2007
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Block randomisation of variable size. ,Sealed opaque envelopes
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Zambia;Rwanda;Uganda;Burkina Faso;Nigeria;Gabon;Mozambique;Uganda
    </Countries>
    <Contact_Firstname>Raffaella
    </Contact_Firstname>
    <Contact_Lastname>Ravinetto
    </Contact_Lastname>
    <Contact_Address>Nationalestraat 155
    </Contact_Address>
    <Contact_Email>rravinetto@itg.be
    </Contact_Email>
    <Contact_Tel>32 3 247 6625
    </Contact_Tel>
    <Contact_Affiliation>Head Clinical Trial Unit
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Weight &gt; 5 kg;&#x0D;&lt;br&gt;2. Monoinfection with P. falciparum and a parasitaemia of 2,000-200,000 asexual parasites per µl; &#x0D;&lt;br&gt;3. Fever (axillary temperature ³37.5 °C) or history of fever in the preceding 24 hours;&#x0D;&lt;br&gt;4. Haemoglobin value more or equal to 7.0 g/dl; &#x0D;&lt;br&gt;5. Signed informed consent by the parents or guardians; &#x0D;&lt;br&gt;6. Parents' or guardians' willingness and ability to comply with the study protocol for the duration of the trial
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Participation in any other investigational drug study (antimalarial&#x0D;&lt;br&gt;or others) during the previous 30 days&#x0D;&lt;br&gt;2. Known hypersensitivity to the study drugs&#x0D;&lt;br&gt;3. Severe malaria&#x0D;&lt;br&gt;4. Danger signs: not able to drink or breast-feed, vomiting (&gt; twice in&#x0D;&lt;br&gt;24hours), recent history of convulsions (&gt;1 in 24h), unconscious state, unable to sit or stand;&#x0D;&lt;br&gt;5. Presence of intercurrent illness or any condition (cardiac, renal, hepatic diseases) which would place the subject at undue risk or interfere with the results of the study, including known G6PD deficiency&#x0D;&lt;br&gt;6. Severe malnutrition (defined as weight for height &lt;70% of the median&#x0D;&lt;br&gt;NCHS/WHO reference)&#x0D;&lt;br&gt;7. Ongoing prophylaxis with drugs having antimalarial activity such as cotrimoxazole for the prevention of Pneumocisti carini pneumonia in children born to HIV+ women &#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Malaria;Malaria
    </Condition>
    <Intervention>;artemether-lumefantrine;dihydroartemisinin-piperaquine;Chlorproguanil-dapsone-artesunate;amodiaquine-artesunate
    </Intervention>
    <Primary_outcome>PCR adjusted treatment failure up to day 28 (TF28A): all early failures before day 14 plus the recurrent parasitaemias detected at day 14 or later and classified by genotyping as recrudescence;PCR unadjusted treatment failure (TF28U): all treatment failures detected during the active follow up, regardless of genotyping
    </Primary_outcome>
    <Source_Support>EDCTP;EDCTP;MMV;MMV
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>16/10/2006
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Comite voor Medische Ethiek, Universitair Ziekenhuis Antwerpen
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4632078
    </Internal_Number>
    <TrialID>NCT00553956
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>A Randomized Controlled Clinical Trial With Orphans and Widows Who Experienced the Rwandan Genocide
    </Public_title>
    <Scientific_title>Phase 1:Epidemiological Study of PTSD and Comorbid Disorders in Widows and Orphans Who Experienced the Rwandan Genocide Phase 2: A Randomized Controlled Clinical Trial With Orphans and Widows Who Experienced the Genocide Carried Out by Trained Local Psychologists -NET/IPT Versus Waiting List-
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Konstanz
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20071105
    </Date_registration3>
    <Date_registration>05/11/2007
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00553956
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>17 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>August 2007
    </Date_enrollement>
    <Target_size>150
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 1
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Susanne Schaal;Susanne Schaal, Dr.;Jean-Pierre Dusingizemungu, Prof.
    </Contact_Lastname>
    <Contact_Email>;Susanne.Schaal@gmx.de;dusingize@yahoo.fr
    </Contact_Email>
    <Contact_Tel>;0049-(0)7531-880;
    </Contact_Tel>
    <Contact_Affiliation>University of Konstanz;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  widows and orphans&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  confrontation of the Rwandan genocide&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  clinical diagnosis of PTSD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  mental retardation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  psychotic symptoms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  current drug or alcohol&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Posttraumatic Stress Disorder;Depression;Prolonged Grief Disorder
    </Condition>
    <Intervention>Behavioral: Narrative Exposure Therapy/Interpersonal Psychotherapy
    </Intervention>
    <Primary_outcome>Symptoms of PTSD, depression, prolonged grief disorder
    </Primary_outcome>
    <Secondary_ID>NET_IPT
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>German Research Foundation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4626862
    </Internal_Number>
    <TrialID>NCT00484900
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria
    </Public_title>
    <Scientific_title>Open Randomized Multi-Centre Trial, Comparing Artesunate-Sulfamethoxypyrazine-Pyrimethamine FDC Over 3 Days, Artesunate-Sulfamethoxypyrazine-Pyrimethamine FDC Over 48 Hours and Artemether-Lumefantrine FDC Over 3 Days on P. Falciparum Malaria
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Dafra Pharma
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20070608
    </Date_registration3>
    <Date_registration>08/06/2007
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00484900
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>May 2006
    </Date_enrollement>
    <Target_size>1390
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Cameroon;Mali;Rwanda;Sudan;Cameroon;Mali;Rwanda;Sudan
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Issaka Sagara, Dr;Wilfred F Mbacham, Dr;Ishag A Adam, Dr;Stephen Rulisa, Dr
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>University of Bamako, Mali;University Yaoundé, Cameroon;University of Khartoum, Sudan;Kigali Central University  Hospital, Rwanda
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age at least 6 months,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  weight at least 5 kg,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  residing in one of the four countries (Mali, Cameroon, Sudan, Rwanda),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  able to receive oral treatment,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  having an axillary body temperature of more than 37,5 degrees Celsius or history of&#x0D;&lt;br&gt;             fever within the proceeding 24 hours,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  suffering from a mono specific P. falciparum infection with a parasite density&#x0D;&lt;br&gt;             between 2000 and 200000 asexual forms per micro litre of blood.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  presence of severe or complicated malaria (WHO 2000),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe concomitant pathology or one that needs a medical follow-up incompatible with&#x0D;&lt;br&gt;             the study,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  allergic to one of the drugs involved in this study,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pregnant (reported pregnancy, detected clinically or with the ß HCG test),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  use of one of the anti-malaria drugs involved in this study during 28 days preceding&#x0D;&lt;br&gt;             inclusion.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Plasmodium Falciparum Malaria
    </Condition>
    <Intervention>Drug: Co-Arinate FDC;Drug: Coartem
    </Intervention>
    <Primary_outcome>PCR corrected Adequate Clinical and Parasitological Response;Early treatment failure;Late clinical failure;Late parasitological failure
    </Primary_outcome>
    <Secondary_outcome>Parasitic clearance;Fever clearance;Parasitological re-infection;Gametocyte carriage;Safety - Adverse events;Haemoglobin levels;Clinical and biological tolerance (Haemogram + Lever tests)
    </Secondary_outcome>
    <Secondary_ID>2005/57/01
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4625110
    </Internal_Number>
    <TrialID>NCT00461578
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Tolerability and Efficacy of CD+A Compared to AQ+SP for the Treatment of P.Falciparum Malaria in Rwandan Children
    </Public_title>
    <Scientific_title>Open Study on the Tolerability and Efficacy of the Combination Chlorproguanil-Dapsone+Artesunate Compared to Amodiaquine+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria in Rwandan Children
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>London School of Hygiene and Tropical Medicine
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20070416
    </Date_registration3>
    <Date_registration>16/04/2007
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00461578
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>12 Months
    </Inclusion_agemin>
    <Inclusion_agemax>59 Months
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>April 2005
    </Date_enrollement>
    <Target_size>800
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Umberto d'Alessandro, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>ITM
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 12-59 months;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Weight =5 kg;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Monoinfection with P. falciparum;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parasite density between 2,000-200,000/µL;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fever (axillary body temperature =&gt;37.5C) or history of fever in the preceding 24&#x0D;&lt;br&gt;             hours;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Packed Cell Volume (PCV) &gt;21%.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe malaria;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mixed malaria infection;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any other concomitant illness or underlying disease;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known allergy to the study drugs being used in this trial;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clear history of adequate antimalarial treatment in the previous 72 hours.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria
    </Condition>
    <Intervention>Drug: Chlorproguanil-dapsone + artesunate
    </Intervention>
    <Primary_outcome>Incidence of microscopically and genotypically confirmed recrudescent infections in the different treatment groups by day 28
    </Primary_outcome>
    <Secondary_outcome>Parasite clearance;Fever clearance;Occurrence of adverse events
    </Secondary_outcome>
    <Secondary_ID>CDA/RWD/2006
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institute of Tropical Medicine, Belgium
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4619993
    </Internal_Number>
    <TrialID>NCT00393679
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children
    </Public_title>
    <Scientific_title>Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Institute of Tropical Medicine, Belgium
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20061027
    </Date_registration3>
    <Date_registration>27/10/2006
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00393679
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>59 Months
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>July 2007
    </Date_enrollement>
    <Target_size>4112
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Burkina Faso;Gabon;Mozambique;Nigeria;Rwanda;Uganda;Zambia;Burkina Faso;Gabon;Mozambique;Nigeria;Rwanda;Uganda;Zambia
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>UmbertoC D'Alessandro, MD MsC PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Institute of Tropical Medicine, Antwerp
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Males and Females aged between 6 months and 59 months inclusive. In the sites where&#x0D;&lt;br&gt;             CDA is tested all recruited children will be aged between 12 months and 59 months&#x0D;&lt;br&gt;             inclusive (this arm was discontinued on 17th February 2008). This criterion applies&#x0D;&lt;br&gt;             only for the recruitment in the first follow up. For the second follow up, children&#x0D;&lt;br&gt;             having been included in the first follow up are eligible, regardless of their age.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Body weight of 5 Kg and above.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Microscopically confirmed, monoinfection of Plasmodium falciparum (parasitaemia =&#x0D;&lt;br&gt;             2,000/µL to 200,000/µL).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fever (axillary temperature at = 37.5°C) or history of fever in the previous 24&#x0D;&lt;br&gt;             hours.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Haemoglobin value =  7.0 g/dl;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signed (or thumb-printed whenever parents/guardians are illiterate) informed consent&#x0D;&lt;br&gt;             by the parents or guardians. Note the informed consent will be asked only at&#x0D;&lt;br&gt;             recruitment and will cover the whole period of the study, including second active&#x0D;&lt;br&gt;             follow up and passive case detection.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parents' or guardians' willingness and ability to comply with the study protocol for&#x0D;&lt;br&gt;             the duration of the trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in any other investigational drug study (antimalarial or others) during&#x0D;&lt;br&gt;             the previous 30 days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known hypersensitivity to the study drugs.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe malaria.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Danger signs: not able to drink or breast-feed, vomiting (&gt; twice in 24hours), recent&#x0D;&lt;br&gt;             history of convulsions (&gt;1 in 24h), unconscious state, unable to sit or stand.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of intercurrent illness or any condition (cardiac, renal, hepatic diseases)&#x0D;&lt;br&gt;             which in the judgement of the investigator would place the subject at undue risk or&#x0D;&lt;br&gt;             interfere with the results of the study, including known G6PD deficiency.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe malnutrition (defined as weight for height &lt;70% of the median NCHS/WHO&#x0D;&lt;br&gt;             reference).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ongoing prophylaxis with drugs having antimalarial activity such as cotrimoxazole for&#x0D;&lt;br&gt;             the prevention of Pneumocystis carinii pneumonia in children born to HIV+ women.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Fever;Malaria
    </Condition>
    <Intervention>Drug: amodiaquine-artesunate (ASAQ);Drug: dihydroartemisinin-piperaquine (DHAPQ);Drug: artemether-lumefantrine (AL);Drug: Lapdap (Chlorproguanil-Dapsone) + artesunate (AS)
    </Intervention>
    <Primary_outcome>PCR unadjusted treatment failure (TF28U): all treatment failures detected during the active follow up, regardless of genotyping.;PCR adjusted treatment failure up to day 28 (TF28A): all early failures before day 14 plus the recurrent parasitaemias detected at day 14 or later and classified by genotyping as recrudescence.
    </Primary_outcome>
    <Secondary_outcome>PCR unadjusted treatment failure up to day 63 (TF63U): TF28U plus all cases of recurrent parasitaemia (symptomatic or asymptomatic) detected between day 29 and day 63 by passive follow up, regardless of genotyping;PCR adjusted treatment failure for the whole period of passive surveillance (TFAPS): TF28A plus all episodes of recurrent parasitaemia identified as recrudescence by genotyping.;Fever clearance time.;Asexual parasite clearance time.;Gametocytaemia (prevalence and density) at day 7, 14, 21 and 28 after treatment (for both active follow-ups);;Hb changes day 3, 7, 14 and 28 (first and second follow up);;Clinical malaria after first active follow-up;;Clinical malaria after second active follow-up;;TF second clinical episode (D28 and D63);;Changes in the frequency of mutations in the dihydrofolate reductase (DHFR) gene at day 0 first follow-up and day re-appearance of parasitaemia (for patients treated with CDA - NOTE that CDA arm was discontinued on 17.02.2008).;Safety profiles including significant changes in relevant laboratory values.
    </Secondary_outcome>
    <Secondary_ID>IRB Antwerp: 6/40/187;4 ABC
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Liverpool School of Tropical Medicine;East African Network for Monitoring Antimalarial Treatment;Centre Muraz;University of Calabar;Tropical Diseases Research Centre, Zambia;University Hospital Tuebingen;Albert Schweitzer Hospital;Uganda Malaria Surveillance Project;Mbarara University of Science and Technology;Ministry of Health, Rwanda;University of Barcelona;Centro de Investigacao em Saude de Manhica
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4618405
    </Internal_Number>
    <TrialID>NCT00372632
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>IPT of Malaria With SP in Different Zones of Drug Resistance in Rwanda
    </Public_title>
    <Scientific_title>Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in Different Zones of Drug Resistance in Rwanda
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Institute of Tropical Medicine, Belgium
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20060905
    </Date_registration3>
    <Date_registration>05/09/2006
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00372632
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>50 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>December 2005
    </Date_enrollement>
    <Target_size>1717
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Umberto D'Alessandro, MD,MSc, PHD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Institute of Tropical Medicine, Antwerp
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Pregnant women between 16-28 weeks of gestation;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Residence within the catchment's area of the health facility;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Willing to deliver at the health facility;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Willing to ; adhere to all requirements of the study;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Willing to provide written informed consent;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Aged 21 years and above&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Severe anemia (Hb &lt; 6 g/dL)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. History of allergic reactions to sulfa drugs;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Taking other sulfa drugs as CTX;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. History of known pregnancy complications (e.g. breech presentation, severe&#x0D;&lt;br&gt;             pre-eclampsia, prior caesarian section);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. History or presence of major illnesses likely to influence pregnancy outcome&#x0D;&lt;br&gt;             including diabetes mellitus, severe renal or heart disease, or active tuberculosis,&#x0D;&lt;br&gt;             prior to randomization;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Any significant illness that requires hospitalization;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Intent to move out of the study catchment's area before delivery or deliver at&#x0D;&lt;br&gt;             relative's home out of the catchment's area;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Prior enrollment in the study or concurrent enrollment in another study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Non HIV Infected Pregnant Women
    </Condition>
    <Intervention>Drug: Sulfadoxine-Pyrimethamine;Drug: placebo
    </Intervention>
    <Primary_outcome>malaria infection will be defined as the presence of asexual stage parasites on thick smears made with maternal side placental blood and Maternal peripheral blood
    </Primary_outcome>
    <Secondary_outcome>LBW = birth weight &lt;2,500 grams;Premature delivery = delivery prior to 37 weeks gestation;Spontaneous miscarriage = any spontaneous abortion before the end of gestation;Stillbirth;Cord blood parasitaemia = presence of asexual stage parasites in thick smears;Neonatal death = infant death within the first 28 days of life;Maternal anemia = Hb &lt;11.0 g/dL;Maternal severe anemia = Hb &lt;6 g/dL;Symptomatic maternal malaria infection = axillary temperature 37.5°C and asexual parasitaemia;Severe maternal adverse reactions to SP = severe cutaneous reactions (e.g., erythema multiform, Stevens-Johnson syndrome, or toxic epidermal necrolysis)
    </Secondary_outcome>
    <Secondary_ID>05 34 5 520
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4615170
    </Internal_Number>
    <TrialID>NCT00329134
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Investigation of the Efficacy of Quinine Sulphate Administered Via Taste-Masked Pellets to Children With Falciparum Malaria
    </Public_title>
    <Scientific_title>Investigation of the Efficacy of Quinine Sulphate Administered Via Taste-Masked Pellets to Children With Falciparum Malaria
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University Ghent
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20060522
    </Date_registration3>
    <Date_registration>22/05/2006
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00329134
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>59 Months
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>July 2006
    </Date_enrollement>
    <Target_size>56
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Rwanda
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Luc Van Bortel, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University Hospital, Ghent
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Malaria (falciparium malaria, uncomplicated)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria
    </Condition>
    <Intervention>Drug: Administration of quinine sulphate taste-masked pellets
    </Intervention>
    <Primary_outcome>Clocktime when child has had no fever for minimal 48h (&lt; 37,5°C);Parasitemy
    </Primary_outcome>
    <Secondary_outcome>Plasma concentration of quinine at day 4 between first and second administration
    </Secondary_outcome>
    <Secondary_ID>2006/177
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4613247
    </Internal_Number>
    <TrialID>NCT00303576
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel
    </Public_title>
    <Scientific_title>A Phase I/II Double-Blind, Randomized Study of the Safety, Tolerability and Systemic Absorption of TMC120 Vaginal Microbicide Gel and Matching Placebo in Healthy HIV-Negative Women.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>International Partnership for Microbicides, Inc.
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20060315
    </Date_registration3>
    <Date_registration>15/03/2006
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00303576
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>50 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>October 2005
    </Date_enrollement>
    <Target_size>112
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
    </Study_design>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Countries>Rwanda;South Africa;Tanzania;Rwanda;South Africa;Tanzania
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Zeda Rosenberg, ScD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>IPM
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV-negative&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to participate and sign an informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to be tested for HIV, use an experimental vaginal gel, and to be randomized&#x0D;&lt;br&gt;             to a study group that includes the possibility of being assigned to a placebo group.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to use two forms of contraception during the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to undergo pelvic examinations with colposcopy and photographic documentation&#x0D;&lt;br&gt;             according to the protocol throughout the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a regular menstrual cycle defined as having a minimum of 21 days and a maximum&#x0D;&lt;br&gt;             of 36 days between menses.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to abstain from using any vaginal product (other than the study product or&#x0D;&lt;br&gt;             placebo).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to be sexually abstinent from randomization until completion of Day 7&#x0D;&lt;br&gt;             evaluations.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently pregnant or breast-feeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically detectable genital abnormality on the vulva, vaginal walls or cervix.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Laboratory confirmed gonorrhea, chlamydia, trichomonas, syphilis, or vaginal&#x0D;&lt;br&gt;             candidiasis or clinically diagnosed genital ulcer disease or active HSV-2 lesions.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Breakthrough bleeding or gynecologic surgery within 60 days prior to randomization.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Symptomatic bacterial vaginosis and unwilling to undergo treatment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women who require treatment for tuberculosis (TB) within 21 days prior to&#x0D;&lt;br&gt;             randomization.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV Infections
    </Condition>
    <Intervention>Drug: dapivirine (TMC120) vaginal gel
    </Intervention>
    <Primary_outcome>Local and systemic safety and tolerability.
    </Primary_outcome>
    <Secondary_ID>IPM003
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>10200107
    </Internal_Number>
    <TrialID>NCT00194519
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission
    </Public_title>
    <Scientific_title>Phase III Randomized Placebo-Controlled Trial of HSV-2 Suppression to Prevent HIV Transmission Among HIV-Discordant Couples
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Washington
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20050913
    </Date_registration3>
    <Date_registration>13/09/2005
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00194519
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 2004
    </Date_enrollement>
    <Target_size>3408
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Botswana;Kenya;Rwanda;South Africa;Tanzania;Uganda;Zambia;Botswana;Kenya;Rwanda;South Africa;Tanzania;Uganda;Zambia
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Connie Celum, MD, MPH;Jairam Lingappa, MD, PhD,;Anna Wald, MD, MPH
    </Contact_Lastname>
    <Contact_Email>;;
    </Contact_Email>
    <Contact_Tel>;;
    </Contact_Tel>
    <Contact_Affiliation>University of Washington;University of Washington;University of Washington
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Potential index (HIV-infected) participants must meet the following criteria (by&#x0D;&lt;br&gt;        self-report, unless otherwise indicated) in order to be eligible for inclusion in the&#x0D;&lt;br&gt;        study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Of legal age to provide independent informed consent for research per local&#x0D;&lt;br&gt;             regulations and guidelines.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able and willing to provide written informed consent to be screened for and to take&#x0D;&lt;br&gt;             part in the study. (Note: Index participants who are not willing to provide genital&#x0D;&lt;br&gt;             tract specimens for HIV viral load quantitation, but are willing to undergo all other&#x0D;&lt;br&gt;             study procedures, will be considered eligible for inclusion in the study.)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Part of a heterosexual couple in which one partner meets the study eligibility&#x0D;&lt;br&gt;             criteria for index participants and the other partner meets the study eligibility&#x0D;&lt;br&gt;             criteria for partner participants. Couples are defined as partners who are sexually&#x0D;&lt;br&gt;             active and plan to remain in the relationship for at least one year. Each site will&#x0D;&lt;br&gt;             develop appropriate criteria for determining whether a couple is likely to remain in&#x0D;&lt;br&gt;             the relationship (i.e., married, duration of partnership, cohabitation, have&#x0D;&lt;br&gt;             children).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has had vaginal intercourse with the partner participant at least three times in the&#x0D;&lt;br&gt;             last three months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Plans to maintain his/her relationship with the partner participant for the next 24&#x0D;&lt;br&gt;             months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV-infected based on positive EIA.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HSV-2-seropositive based on the Focus HSV-2 EIA (performed by study staff) with an&#x0D;&lt;br&gt;             index ratio of at least 3.5 or if Focus EIA IN 1.1-3.4, confirmed by HSV-2 WB dot-blot&#x0D;&lt;br&gt;             performed at the UW.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  CD4 cell count (performed by study staff) of at least 250 cells/mm3.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No history of any clinical AIDS-defining diagnoses.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able and willing to provide adequate locator information for study retention purposes,&#x0D;&lt;br&gt;             as defined by local standard operating procedures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Potential partner (HIV-uninfected at enrollment) participants must meet the following&#x0D;&lt;br&gt;        criteria (by self-report, unless otherwise indicated) in order to be eligible for inclusion&#x0D;&lt;br&gt;        in the study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Of legal age to provide independent informed consent for research per local&#x0D;&lt;br&gt;             regulations and guidelines.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able and willing to provide written informed consent to be screened for and to take&#x0D;&lt;br&gt;             part in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Part of a heterosexual couple in which one partner meets the study eligibility&#x0D;&lt;br&gt;             criteria for index participants and the other partner meets the study eligibility&#x0D;&lt;br&gt;             criteria for partner participants.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has had vaginal intercourse with the study partner at least three times in the last&#x0D;&lt;br&gt;             three months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Plans to maintain his/her relationship with the index participant for the next 24&#x0D;&lt;br&gt;             months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV-uninfected based on negative HIV EIA tests.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able and willing to provide adequate locator information for study retention purposes,&#x0D;&lt;br&gt;             as defined by local standard operating procedures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Potential index (HIV-infected) participants who meet any of the following criteria (by&#x0D;&lt;br&gt;        self-report, unless otherwise indicated) will be excluded from the study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of combination antiretroviral therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known history of adverse reaction to acyclovir.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known history of persistent genital ulcers unresponsive to episodic acyclovir therapy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known plans to re-locate or travel away from the study site for more than two&#x0D;&lt;br&gt;             consecutive months during the next 24 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant, based on participant self-report or urine testing performed by study staff.&#x0D;&lt;br&gt;             (Note: Self-reported pregnancy is adequate for exclusion from the study. A documented&#x0D;&lt;br&gt;             negative test performed by study staff is required for inclusion.)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Potential partner participants who meet any of the following criteria (by self-report,&#x0D;&lt;br&gt;        unless otherwise indicated) will be excluded from the study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has had sexual intercourse with a partner other than the index participant in the last&#x0D;&lt;br&gt;             two months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known plans to re-locate or travel away from the study site for more than two&#x0D;&lt;br&gt;             consecutive months during the next 24 months.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV Infection;Herpes Simplex, Genital;Sexually Transmitted Diseases
    </Condition>
    <Intervention>Drug: Generic acyclovir;Drug: Placebo
    </Intervention>
    <Primary_outcome>Sequence-verified HIV-transmission from index to partner participant
    </Primary_outcome>
    <Secondary_outcome>Measure effect of viral load, gender and other factors on HIV transmission;Assess adherence to acyclovir suppressive therapy;Assess effect of twice daily acyclovir on the frequency of genital ulcers;Assess effect of twice daily acyclovir on plasma HIV viral load;Assess effects of twice daily acyclovir on the sexual behaviors;Assess host immunologic and virologic determinants of HIV transmission
    </Secondary_outcome>
    <Secondary_ID>Gates Foundation Grant #26469;STUDY00000867
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Bill and Melinda Gates Foundation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>4534502
    </Internal_Number>
    <TrialID>ISRCTN50258054
    </TrialID>
    <Last_Refreshed_on>13 January 2015
    </Last_Refreshed_on>
    <Public_title>The Africa Quinine versus Artesunate in Severe Malaria Trial
    </Public_title>
    <Scientific_title>The AQUAMAT trial:  An open label randomised comparison of injectable artesunate and quinine in children with severe falciparum malaria in Africa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>University of Oxford (UK)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20050722
    </Date_registration3>
    <Date_registration>22/07/2005
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN50258054
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>08/10/2005
    </Date_enrollement>
    <Target_size>5300
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomised controlled trial (Treatment)
    </Study_design>
    <Countries>Congo, Democratic Republic;Gambia;Ghana;Kenya;Mozambique;Nigeria;Rwanda;Tanzania;Uganda
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: 1. OptiMal malaria rapid test positive, and &lt;br&gt;2. Treating physician considers patient to have severe malaria
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patient has received more than or equal to 24 hours of effective treatment with quinine or an artemisinin derivative, or&lt;br&gt;2. Patient has a known allergy to quinine or an artemisinin derivative
    </Exclusion_Criteria>
    <Condition>Malaria &lt;br&gt;Infections and Infestations &lt;br&gt;Malaria
    </Condition>
    <Intervention>Please note that as of 01/09/10 this trial has reached its target sample size and recruitment has been closed. The trial is now in follow-up. &lt;br&gt;&lt;br&gt;Current information as of 26/01/2009:&lt;br&gt;Patients are randomised to treatment with either intravenous (i.v.) or intramuscular (i.m.) artesunate or i.v. or i.m. quinine.  &lt;br&gt;&lt;br&gt;Initial information at time of registration:&lt;br&gt;In two of the study sites intramuscular artesunate will be compared with intramuscular quinine. In two other study sites the comparison will be between intravenous artesunate and intravenous quinine.
    </Intervention>
    <Primary_outcome>In-hospital mortality
    </Primary_outcome>
    <Secondary_outcome>Current information as of 20/04/2010:&lt;br&gt;1. Neurological sequelae at day 28 after discharge from the hospital&lt;br&gt;2. Combined in-hospital mortality and neurological sequelae at day 28 after discharge from the hospital&lt;br&gt;&lt;br&gt;Initial information at time of registration:&lt;br&gt;1. Neurological sequelae&lt;br&gt;2. Recovery times:&lt;br&gt;2.1. To localise pain&lt;br&gt;2.2. To speak&lt;br&gt;2.3. To sit unsupported&lt;br&gt;2.4. To eat or breast feed, and &lt;br&gt;2.5. To discharge from hospital&lt;br&gt;&lt;br&gt;Assessed at discharge.
    </Secondary_outcome>
    <Secondary_ID>076908
    </Secondary_ID>
    <Source_Support>The Wellcome Trust (UK) (grant ref: 076908)
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:27:58</Export_date>
    <Internal_Number>11572391
    </Internal_Number>
    <TrialID>NCT00124007
    </TrialID>
    <Last_Refreshed_on>8 November 2021
    </Last_Refreshed_on>
    <Public_title>Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults
    </Public_title>
    <Scientific_title>A Phase I, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by Recombinant, Multiclade HIV-1 Adenoviral Vector Vaccine or the Multiclade HIV-1 Adenoviral Vector Vaccine Alone in Healthy Adult Volunteers Not Infected With HIV
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20050722
    </Date_registration3>
    <Date_registration>22/07/2005
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00124007
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>50 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 2005
    </Date_enrollement>
    <Target_size>114
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Diagnostic. Masking: Double. 
    </Study_design>
    <Phase>Phase 1
    </Phase>
    <Countries>Kenya;Rwanda;Kenya;Rwanda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Job Bwayo, MD, PhD;Etienne Karita, MD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Kenya AIDS Vaccine Initiative, University of Nairobi;Project San Francisco
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to follow all the requirements of the study and available for follow-up for&#x0D;&lt;br&gt;             the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have understanding of the study and provide written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to undergo HIV testing and counseling and willing to receive HIV test results&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to use acceptable forms of contraception&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV infected&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hepatitis B virus infected&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hepatitis C virus infected&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active or untreated syphilis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participated in high-risk behavior for HIV infection within 6 months prior to study&#x0D;&lt;br&gt;             entry. More information on this criterion can be found in the protocol.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any clinically significant abnormality in history or upon examination (e.g.,&#x0D;&lt;br&gt;             immunodeficiency or autoimmune disease; use of systemic corticosteroids,&#x0D;&lt;br&gt;             immunosuppressive, antiviral, anticancer, or other medications considered significant&#x0D;&lt;br&gt;             by the investigator) within 6 months prior to study entry&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any clinically significant acute or chronic medical condition that, in the opinion of&#x0D;&lt;br&gt;             the investigator, would make the volunteer unsuitable for the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Live attenuated vaccines within 30 days prior to study entry OR plan to receive a live&#x0D;&lt;br&gt;             attenuated vaccine within 60 days after vaccination in this study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subunit or killed vaccines within 14 days prior to study entry OR plan to receive a&#x0D;&lt;br&gt;             subunit or killed vaccine within 14 days after vaccination in this study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Blood transfusion or blood products within 120 days prior to study entry&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Immunoglobulin within 60 days prior to study entry&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in another investigational product clinical trial in the 3 months prior&#x0D;&lt;br&gt;             to study entry OR expected to participate in another investigational trial during this&#x0D;&lt;br&gt;             study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any other investigational HIV vaccine at any time&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of severe local or systemic reactogenicity to vaccines or history of severe&#x0D;&lt;br&gt;             allergic reactions&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major psychiatric illness, including any history of schizophrenia or severe psychosis,&#x0D;&lt;br&gt;             bipolar disorder requiring therapy, or suicide attempt or suicidal thoughts within the&#x0D;&lt;br&gt;             3 years prior to study entry&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncontrolled hypertension&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant, breastfeeding, or plan to become pregnant&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV Infections
    </Condition>
    <Intervention>Biological: VRC-HIVADV014-00-VP;Biological: VRC-HIVDNA016-00-VP
    </Intervention>
    <Primary_outcome>Local reactogenicity signs and symptoms;systemic reactogenicity signs and symptoms;laboratory measures of safety;adverse and serious adverse experiences
    </Primary_outcome>
    <Secondary_outcome>Proportion of volunteers who have HIV-1 specific T-cell responses quantified by intracellular cytokine staining (ICS; both CD4+ and CD8+) and ELISPOT and magnitude of the responses;proportion of volunteers with HIV-1 specific antibodies and magnitude of the response;proportion of volunteers with increase in antibodies to rAd5;impact of pre-existing immunity to rAd5 on immunogenicity;proportion of volunteers who test "false positive" on standard HIV testing algorithm.
    </Secondary_outcome>
    <Secondary_ID>10380;IAVI V001
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>
</Trials_downloaded_from_ICTRP>